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Summary 
This thesis was an observational study to retrospectively examine the prevalence 
and incidence of DR and its associated risk factors from two screening services 
(Wales and Johannesburg, South Africa) in order to determine safe screening 
intervals in persons without evidence of DR at initial screening based on digital 
photography.  Between 2005 and 2009 a total of 135,152 persons with diabetes 
over 12 years of age in Wales were screened.  However, a total of 43,759 persons 
were excluded from analysis as they did not have their type of diabetes recorded 
(29,807) or where it was recorded it was outside of the pre-specified age at 
diagnosis of diabetes range of ≥30 years for type 2 DM and <30 years for type 1 DM 
(13,952).  In the Centre for Diabetes and Endocrinology, Johannesburg, South 
Africa a smaller population of 5,565 were screened between 2001-2010.  A total of 
50 persons were excluded from this analysis as they had a type of diabetes 
recorded other than type 1 DM or type 2 DM. Therefore,  data from 91,393 (86,390 
T2DM, 5,003 T1DM) persons from the Wales screening service  and 5,515 (3,978 
T2DM, 1,537 T1DM from South Africa, were analysed.   
 
In Wales, the prevalence of any DR was 31.0%, background DR (BDR) 26.6% and 
referable DR (RDR) 4.4% in T2DM at baseline.  The prevalence was higher in 
T1DM at 56.2%, 39.8% and 16.4% respectively.  Increased duration of diabetes 
was independently associated with increased prevalence and incidence of any DR, 
BDR and RDR for T2DM and T1DM as well as treatment modality in T2DM.  The 
four year cumulative incidence of RDR was 1.6% for T2DM and 5.6% for T1DM.    
 
At the Centre for Diabetes and Endocrinology Johannesburg the prevalence of any 
DR was 21.6%, BDR 14.8% and RDR 6.7% in T2DM at first screening and higher at 
36.9%, 27.2% and 9.7% respectively for T1DM.  Glycaemic control (HbA1c) and 
duration of diabetes were significantly associated with the prevalence and incidence 
of any DR, BDR and RDR in both T2DM and T1DM.  Ethnicity and hypertension 
were also risk factors.  The seven year cumulative incidence of RDR was 4.7% for 
T2DM and 5.0% for T1DM. 
 
Risk factor analysis indicated that the screening intervals could be extended beyond 
annual based on type of diabetes, duration of diabetes, HbA1c, ethnicity, 
hypertension and treatment modality in T2DM.  This analysis adds to an increasing 
evidence base for considering extending the screening intervals beyond annually for 
those at low risk with no DR at initial screening. 
 
Limitations of this study included the need to exclude a high number of persons in 
order to ensure the quality of the data; the numbers lost to follow up (meaning all 
results from 3 years should be interpreted with caution) and the fact that the visual 
impairment and blindness within the programmes could not necessarily all be 
attributed to DR as recordings of other lesions were not included in the datasets.
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1.1 Introduction 
Diabetes mellitus (diabetes) results in considerable morbidity and premature 
mortality, and is estimated to involve 387 million people worldwide in 2014, with a 
possible further 46% remaining undiagnosed.(Same 1993, Wild et al. 2004, Al-
Rubeaan 2010, International Diabetes Federation 2014)  These figures are 
predicted to rise to 592 million people worldwide by 2035 due to a number of factors 
including an increased life expectancy, obesity, reduced physical fitness, 
urbanisation and improved detection.(International Diabetes Federation 2014)  
Diabetes is a chronic metabolic disease characterised by hyperglycaemia that 
results from defects in insulin secretion, absolute or relative and/or insulin 
action.(American Diabetes Association 2014)  The range of pathogenic processes 
involved include the autoimmune destruction of pancreatic β cells with insulin 
deficiency and abnormalities in carbohydrate, fat and protein metabolism, resulting 
in resistance to insulin action.  The majority of diabetes falls into two broad 
categories: type I diabetes which is caused by an absolute deficiency of insulin 
secretion, and type 2 diabetes caused by a combination of resistance to insulin 
action and an inadequate compensatory insulin secretion response.  The majority of 
persons with diabetes (~90%) will have type 2 diabetes.  There are also other types 
of diabetes which are either secondary to diseases of the exocrine pancreas, and 
drug or chemically induced; or to other causes such as either to genetic defects in 
β-cell function and insulin action and gestational diabetes, which is diagnosed 
during pregnancy and is not clearly diabetes.(American Diabetes Association 2013) 
 
Diabetes has profound effects on the structure and function of many tissues and 
organs in the body.  Complications of diabetes include macrovascular disease - 
cardiovascular disease such as stroke, myocardial infarction and peripheral 
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vascular disease, and microvascular disease including diabetic retinopathy (DR), 
diabetic neuropathy and diabetic kidney disease (diabetic nephropathy).(Holt et al. 
2010)  The prevalence of these complications is strongly related to the type and 
duration of diabetes and glycaemic control.  Other risk factors for these 
complications include hypertension, dyslipidaemia and treatment modality.  The 
increasing global population, increasing age and predicted rise in the proportion of 
adults with diabetes will inevitably be accompanied by an increase in diabetic 
complications.   
 
Diabetes is a major public health problem and the incidence of blindness is 2-3 
times greater in persons with diabetes when compared with the non-diabetic 
population.(Hayward et al. 2002, Zhang et al. 2008)  DR is the most common 
microvascular complication of diabetes and was until recently regarded as the most 
prevalent cause of visual impairment in the working age population in developed 
countries.(Heng et al. 2012)  However, a recent report has indicated that in the UK, 
DR has been overtaken by inherited retinal conditions as the leading cause of 
blindness in the working age group which the authors suggested was possibly a 
result of DR screening programmes and improved diabetes care.(Liew et al. 2014)  
Globally, it is estimated that there are 93 million people with DR, 17 million with 
proliferative DR (PDR), 21 million with macular oedema and 28 million with sight-
threatening DR.(Yau et al. 2012)  Visual loss and blindness due to diabetes is 
essentially preventable in the vast majority of people, through optimal treatment of 
diabetes, hypertension and hypercholesterolemia and the implementation of 
screening to detect treatable DR.   
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1.2 Diabetic retinopathy 
Our understanding of the pathophysiological mechanisms underlying the 
development of DR is constantly evolving.(Ciulla et al. 2003, Antonetti et al. 2006, 
Curtis et al. 2009)  Overall, diabetic microvascular complications are caused by 
prolonged exposure to high glucose levels.(Giacco F et al. 2010)  The extent of 
tissue damage is also determined by genetic determinants of individual 
susceptibility and by the presence of such independent accelerating factors as 
hypertension and dyslipidaemia.  Chronic exposure to hyperglycaemia and other 
causal risk factors (hypertension) is believed to initiate a cascade of biochemical 
and physiological changes that ultimately lead to neuro-vascular damage and 
consequently retinal dysfunction,(Cheung et al. 2010) (Figure 1.2.1). 
 
Figure 1.2.1: Physico-chemical mechanisms in the evolution of DR. Reproduced 
with permission from (Gibbins 1999) 
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PROTEIN GLYCOSYLATION (A.G.E. PRODUCTION)POLYOL ACCUMULATION FREE RADICAL PRODUCTION
PERICYTE DEPLETION BASEMENT MEMBRANE CHANGES
ENDOTHELIAL PROLIFERATION AND DAMAGE  (    VEGF/VPF) 
CAPILLARY DILATION, FRAGILITYCAPILLARY CLOSURE
INCREASED COAGULATION FACTORS
LOCALISED  ISCHAEMIA
RETINAL INFARCTION (cws)
ANGIOGENIC FACTORS
(GH, IGF-1, VEGF/VPF)
LACTIC ACID
VENOUS DILATION, BEADING
CAPILLARY LEAKAGE
IRMA
NEOVASCULARISATION
HAEMORRHAGE
RETINAL OEDEMA
EXUDATIVE & OEDEMATOUS
MACULOPATHY
MICROANEURISMS
PRERETINAL, VITREOUS
HAEMORRHAGE
FIBROSIS
RETINAL DETATCHMENT
NEW  VESSELS
ISCHAEMIC 
MACULOPATHY
VISUAL LOSS
HYPERLIPIDAEMIA
EXUDATES
 
 
1.2.1  Natural history of diabetic retinopathy 
DR is considered to be the result of changes in the retinal vasculature  and the 
neuroretina.(Kohner 1993)  The retina consists of 95% neural tissue and 5% 
vascular tissue (Figure 1.2.2).(Antonetti et al. 2012)  It is primarily concerned with 
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the retinal capillaries and effects the entire neurosensory unit (which consists of 
astrocytes, Muller cells, amacrine and ganglion cells).  Histologically, the earliest 
vascular changes are usually a decrease in the number of capillary pericytes and a 
thickening of the basement membrane.  These occur long before any clinically 
visible lesions develop.  
 
Figure 1.2.2: The neurovascular unit of the retina (Antonetti et al. 2012)
Vasculature 5% 
Neural 95%  
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1.2.1.1 Neurovascular unit 
Changes in the neuroretina may occur even before the onset of microvascular 
changes.(Lieth et al. 2000, Antonetti et al. 2006)  Most retinal neurons and glial cells 
are altered and are progressively impaired with worsening DR.  Figures 1.2.3A&B 
illustrates the disruption of the neurovascular unit due to diabetes.  Additional 
alterations include biochemical defects, such as impaired control of glutamate 
metabolism, which is the major neurotransmitter,(Gowda et al. 2011) as well as loss 
of synaptic activity and dendrites,(Gastinger et al. 2008, VanGuilder et al. 2008) 
apoptosis of neurons primarily in the ganglion-cell and inner nuclear layers,(Barber 
et al. 1998) and activations of microglial cells that may protect the inner retina from 
injury but also contribute to the inflammatory response.(Zeng et al. 2008)  These 
findings suggest that DR represents a sensory neuropathy that affects the retinal 
parenchyma, not dissimilar to peripheral diabetic neuropathy.(Cheung et al. 2010, 
Antonetti et al. 2012)   
 
There is evidence that the disruption of the neuroretina caused by diabetes leads to 
changes in electroretinograms (ERG),(Lovasik et al. 1993) resulting in altered dark 
adaption (Henson et al. 1979) and reduced contrast and colour sensitivity.(Della 
Sala et al. 1985, Kurtenbach et al. 1994, Lieth et al. 2000, Kurtenbach et al. 2006)  
These changes have been shown to occur well before any first visible signs of DR.  
The relationship between the neural and vascular units of the retina in the 
pathogenesis of DR remains to be clarified. .(Antonetti et al. 2012)  However, more 
recently the neurosensory retina can be observed by slit-lamp biomicroscopy and 
insight into the relationship between the retinal neurovascular unit could be 
achieved by the undertaking of a prospective assessment of diabetic patients using 
clinical and state-of-the-art functional and imaging technologies.
6 
 
Figure 1.2.3: Retinal neurovascular Unit (Antonetti et al. 2012) A) normal, B) 
diabetes 
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1.2.2.2 Microvascular changes 
Pericytes are an important constituent of the wall of retinal microvasculature with 
contractile properties to control vessel calibre and therefore blood flow. (Kohner 
1993)  Figure 1.2.4 shows the location of pericytes within capillaries.  The loss of 
pericytes, creating ghost cells, are followed by the loss of capillary endothelial cells.  
Apoptosis, or programmed cell death, is thought to account for the disappearance of 
both cell types and is caused by hyperglycaemia due to variety of mechanisms e.g. 
Sorbitol etc.  The loss of pericytes means the vessels become rigid, with increased 
blood flow,(Kohner 1993) the endothelium of the vessel wall is damaged by the 
increased shear stress.  Destruction of the endothelial cells and increased 
basement membrane thickness, eventually leads to a breakdown of the blood-retina 
barrier, increasing the permeability of vessel walls to proteins and other substances.  
Thickening of the basement membrane is mainly a consequence of hyperglycaemia 
and/or a consequence of the accumulation of advanced glycosylation end products 
(AGEs).(Jennings 1992, Tooke 1992, Roy et al. 1994) 
 
Figure 1.2.4: Location of pericytes within capillaries (Hamilton et al. 2010) 
 
Form A) rings of smooth muscle encircle arterioles, while pericytes send processes along 
and around capillaries, without fully covering the vessel. B) Pericytes are located outside the 
endothelial cells and are separate from them and the parenchyma by a layer of basal 
lamina. In the parenchyma, astrocyte end-feet and neuronal terminals are closely associated 
with the capillary.(Hamilton et al. 2010) 
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Microaneurysms are the first feature of DR to become visible on clinical 
examination.  Figures 1.2.5 and 1.2.6 show a trypsin digest of a microaneurysm and 
retinal image of microaneurysms respectively.  However, even before these are 
clinically apparent, many more may be seen on fluorescein angiography 
accompanied by small areas of non-perfusion (Figures 1.2.6 and 1.2.7 ).  The 
response to non-perfusion in some capillaries results in dilation of others and when 
this is localised (as most often occurs) a microaneurysm is formed (small dot 
lesion),(Kohner 1993) and are lined with endothelium which has increased 
permeability. 
 
Figure 1.2.5: Trypsin digest images of the formation of a microaneurysm 
(Bernardino et al. 2006) 
 
Figure 1.2.6: Retinal images showing microaneurysms on the retina (arrows) 
(www.itoozhiayurveda.in) 
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Figure 1.2.7: Fluorescein angiogram with microaneurysms fluorescing (Goatman 
1997) 
 
 
Increasing numbers of microaneurysms are often associated with retinal 
haemorrhages, which may be superficial and flame shaped, or deeper and more 
rounded lesions (‘blot’) and with small hard exudates, which are an accumulation of 
plasma lipoprotein.(Cunha-Vaz 2010)  Large blot haemorrhages tend to form at the 
interface of the perfused and ischaemic areas of the retina (Figure 1.2.8 and 1.2.9).   
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Figure 1.2.8: Diagram of the location of the different types of retinal haemorrhages 
within the layers of the retina. Reproduced from (www.ophthobook.com 2007) 
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Figure 1.2.9: Retinal image showing retinal haemorrhages (www.joneseye.com 
2013) 
 
 
 
Exudates composed of lipid material develop and appear as yellow deposits often 
larger than the microaneurysms.  They have a distinctive yellow shiny appearance 
(Figure 1.2.10).  Their origin is thought to be leaky capillary blood vessels and 
microaneurysms in the retina.  They may be transient and reabsorbed by the retina, 
though they tend to increase in total number over time.(Kohner 1991)   
 
Figure 1.2.10: Digital retinal photographs of exudates (www.imgarcade.com) 
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As ischaemia increases, the number of haemorrhages increase and evidence of 
focal ischaemia in the form of Cotton Wool Spots (CWS) may appear which are 
infarctions of the retinal nerve fibre layer (Figure 1.2.11).   
 
Figure 1.2.11: Retinal images showing CWS a) digital image and b) a fluorescein 
angiogram of the same images showing the CWS as areas of non perfusion 
(www.quizlet.com) 
  a)       b) 
 
 
CWS and haemorrhages may be present in ischaemic retinal conditions other than 
DR, but in the presence of microaneurysms are considered to be part of the process 
of DR.(Early Treatment Diabetic Retinopathy Study Research Group 1991c)  Intra-
Retinal Microvascular Abnormalities (IRMAs), i.e. dilation of the retinal capillary bed, 
can form in what appear to be avascular areas of the retina (Figure 1.2.12).  These 
IRMAs may represent the earliest form of neovascularisation.(Early Treatment 
Diabetic Retinopathy Study Research Group 1991c)   
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Figure 1.2.12: Digital image depicting IRMA's  
 
 
Abnormalities may also be observed in the larger blood vessels.  The venules may 
develop segments which are dilated alternating with segments that are constricted 
resembling beading (Figure 1.2.13).  Duplication of veins may also develop so that 
there appear to be parallel veins in some areas (reduplication) (Figure 1.2.14).(Early 
Treatment Diabetic Retinopathy Study Research Group 1991c) 
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Figure 1.2.13: Retinal image depicting venous beading (Hall 2011) 
 
 
Figure 1.2.14: Close up retinal image showing venous loop/reduplication 
(www.imagebank.asrs.org) 
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New vessels usually develop from the veins in the retinal periphery (new vessels 
elsewhere, NVE) or on the optic disc (new vessels on the disc, NVD) (Figure 
1.2.15).  The location of the new vessels determine the prognosis in terms of visual 
outcome.(Kohner 1991)  When they occur at the disc, more than 50% of affected 
eyes may become blind within 5 years, compared with less than one third when new 
vessels are located away from the disc.  They arise generally, although not 
exclusively when there are large areas of avascular retina in the vicinity. (Davis 
1992)  They later develop more characteristic frond-like patterns.  
 
Figure 1.2.15: Growth of A) NVD(www.imagebank.asrs.org), B) NVE 
(www.eyecasualty.co.uk) 
A) 
 
B) 
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Evidence from the DRS showed that certain features of new vessels and vitreous 
and pre-retinal haemorrhage conferred a greater likelihood of severe visual loss if 
untreated.(Diabetic Retinopathy Study Research Group 1981a)  These features 
were termed ‘high risk characteristics' (HRCs) (Figure 1.2.16).   
 
Figure 1.2.16: DRS high risk characteristics 
1. NVD > 25% of disc area, +/- Vitreous Haemorrhage, Pre-retinal 
Haemorrhage 
2. NVD < 25% of disc area, + Vitreous Haemorrhage and/or  
Pre-retinal Haemorrhage  
3. NVE > 50% disc area in size 
 
The new vessels usually develop a fibrous sheath covering and break through the 
internal limiting membrane when they become attached to the posterior surface of 
the vitreous, which they use as a scaffold on which they continue to grow.  The 
retracting vitreous often pulls on the vessels causing haemorrhage.  The 
development and progression of DR maybe asymptomatic up to  this stage (unless 
maculopathy has also developed), and symptoms only occur if these new vessels 
bleed causing vision to become obscured.  The new vessels themselves do not 
cause any visual symptoms, it is the bleeding from the new vessels that are 
responsible for the visual loss. 
 
Bleeding at this stage may initially produce 'boat shaped' haemorrhages if limited to 
the pre-retinal space (Figure 1.2.17), or vitreous haemorrhage with sudden visual 
loss if more generalised.  Early vitreous haemorrhages may be small, with only 
transient visual loss, but may be an indication of impending major haemorrhage.  
Small haemorrhages may clear within a few weeks, but large ones may never clear, 
or do so very slowly.(Davis 1992)  Without treatment, it has been demonstrated that 
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approximately one third of patients will be blind in both eyes within one year of their 
first vitreous haemorrhage, and only 14% of patients will have good vision within five 
years of developing new vessels.(Caird et al. 1968) 
 
Figure 1.2.17: Pre-retinal haemorrhage (www.ucdenver.edu) 
 
 
Fibrous tissue accompanying new vessels can exert traction on the retina, either 
due to its own contraction, or secondary to posterior vitreous detachment (Figure 
1.2.18).(Davis 1992)  Traction or retinal detachment normally involves the posterior 
pole and hence the macular area and will cause a decrease or distortion in vision.  It 
is uncommon for spontaneous regression to occur at this stage.  The visual loss 
related to these fibro-vascular abnormalities is usually sudden and unexpected
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Figure 1.2.18: Fibrous tissue with traction  
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In some subjects, especially where ischaemia is a major feature, new vessels and 
fibrosis may also occur on the iris (rubeosis iridis), and in the angle of the anterior 
chamber (Figure 1.2.19).  The resulting obstruction to normal drainage of aqueous 
fluid gives rise to painful glaucoma, which, if untreated, rapidly leads to 
blindness.(Kohner 1991) 
 
Figure 1.2.19: Rubeosis iridis  
 
 
1.2.1.4 Maculopathy 
Diabetic maculopathy is defined as DR within one disc diameter (DD) of the centre 
of the fovea.(Chowdhury et al. 2002)  There are two aspects of maculopathy, 
oedema where lipoproteins accumulate within the retina and ischaemia where there 
is a closure of perifoveal capillaries.  Macular oedema may be focal or diffuse 
(Figure 1.2.20).  Focal macular oedema is characterised by an increase in retinal 
thickening due to leakage from microaneurysms which are frequently associated 
with hard exudates.(Cunha-Vaz 2010)  Diffuse macular oedema is caused by 
leakage from abnormally dilated capillaries, arterioles and venules in the macular 
area, and sometimes associated with cystic lesions, but with less visible focal 
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vascular damage and fewer hard exudates.(Chowdhury et al. 2002)  Table 1.2.1 
describes the principle features of each type of maculopathy.  
 
 Figure 1.2.20: Retinal images depicting the diabetic macular oedema A) Focal 
(Ober et al. 2009) B) Diffuse  
A)           
 
B) 
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Table 1.2.1 Categories of maculopathy 
 
 
 
 
Oedematous 
Focal Localised areas of retinal thickening associated 
with focal leakage of individual microaneurysms or 
clusters of microaneurysms or dilated capillaries 
(Bhagat et al. 2009) 
Diffuse/cystoid More generalised and chronic form of oedema, 
with widespread macular leakage and pooling of 
dye in cystic spaces (Bhagat et al. 2009) 
Ischaemic Ischaemic Microaneurysms and haemorrhages with a small 
amount of capillary nonperfusion evident with 
fluorescein angiography.  Varying oedema is 
present ranging from mild to cystoid in 
appearance. 
Diabetic maculopathy may be central involving or non-central involving as well as tractional 
due to vitreo-retinal pathology or non-tractional (intraretinal).(The Royal College of 
Ophthalmologists 2012) 
 
Maculopathy and the visual distortion and decreased visual acuity associated with 
oedema (clinically significant macular oedema [CSMO] is defined in Figure 1.2.21). 
Maculopathy can occur in the presence of microaneurysms, haemorrhages, CWS, 
IRMA, and venous changes.(Klein et al. 2003)  The associated visual loss is 
progressive.  Without treatment about one third of affected eyes may be expected to 
become blind within five to seven years.(British Multicentre Study Group 1983, Early 
Treatment Diabetic Retinopathy Research Study Group 1985) 
 
Figure 1.2.21: Definition of clinically significant macular oedema (Early Treatment 
Diabetic Retinopathy Research Study Group 1985): 
 Retinal thickening within 500µm of the centre of the fovea 
 Hard exudates within 500µm of the centre of the fovea with adjacent retinal 
thickening 
 Retinal thickening 1DD or larger in size located within 1 DD of the fovea. 
 
1.2.2 Classification of diabetic retinopathy 
The need for a classification of DR, to allow the evaluation of treatment and natural 
progression was recognised long ago.  Early classifications were disadvantaged by 
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the need for detailed and time consuming fundal drawings to complete a full 
evaluation.(Lee et al. 1966)  The arrival of reliable retinal photography in 1955 
facilitated the availability of standard photographs with which an individual’s eyes 
could be compared.  The Hammersmith classification was one of the first to use this 
method.(Oakley et al. 1967)  Five types of lesion were recognised: microaneurysm 
and haemorrhage, exudate, new vessels, venous irregularities and proliferation.  
These lesions were graded on a scale from 1 to 5 depending on severity.  Macular 
involvement was not identified separately and CWS were ignored.  This initial 
classification was limited, but the use of standard photographs and lesion grading 
was firmly established.  
 
The first internationally recognised classification of DR was established in 1968, i.e. 
the Airlie House classification.(Davis et al. 1969)  Fifteen clinical features and two 
assessments one based on fluorescein angiography and one including seven 
standard colour photographs were each graded as ‘absent’ (0), ‘mild to moderate’ 
(1), and ‘moderate to severe’ (2).  The features assessed in the Airlie classification 
are detailed in Table 1.2.2.  
 
23 
 
Table 1.2.2 : Features of the Airlie House classification of diabetic retinopathy 
Grading category Features 
Non-proliferative HM and/or MA 
EX 
‘Soft exudates’ (CWS) 
Venous abnormalities 
Intraretinal microvascular abnormalities 
(IRMA) 
Retinal oedema at the macula 
Findings on fluorescein angiography Arteriovenous phase (15-25 seconds): 
IRMA and MA 
Late phase (3-5 minutes): Dye leakage 
Proliferative Neovascularisation within 1 disc diameter of 
disc 
Neovascularisation areas other than disc 
Fibrous proliferation within 1 disc diameter 
of disc 
Fibrous proliferation areas other than disc 
Plane of proliferation 
Retinal elevation 
Vitreous haemorrhage Pre-retinal haemorrhage 
Vitreous haemorrhage 
History of vitreous haemorrhage 
HM - haemorrhage; MA - microaneurysm; EX - exudates; CWS - cotton wool spots;  
 
An additional 3 standard photographs were made available for those wanting to 
further grade CWS, NVE and fibrous proliferation.  Macular oedema was recognised 
as an important separate feature, though not linked to the presence of exudates.  
 
Most subsequent classifications of DR have been adapted from the Airlie House 
classification.  The first major modification was published in 1981 following evidence 
of the DRS study.(Diabetic Retinopathy Study Research Group 1981c, a)  The 
needs of the Early Treatment Diabetic Retinopathy Study (ETDRS) Research Group 
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resulted in further expansion, with more emphasis being placed on early changes 
and lesions at and around the macula, particularly macular oedema.   
 
However, the Airlie House and ETDRS classifications were overly complex, being 
designed to assess in detail the effectiveness of treatment for DR.  However, this 
rendered them unwieldy as tools for the classification of DR in clinical practice.  The 
principles of the DRS classification were used by the Wisconsin Epidemiologic 
Study of Diabetic Retinopathy (WESDR) in a clinical grading system for assessing 
progression of DR in persons with type 1 diabetes in 1984.(Klein et al. 1984a)  The 
patient's final DR grade was determined either as the DR level in the worst eye, or 
as the level in each eye, which proved to be more sensitive in detecting 
progression.  An important feature of this study was the recognition that the 
presence of some lesions, particularly CWS and IRMA, conferred a higher risk of 
progression to PDR (50% and 61% respectively over six years compared all 
persons with type 1 diabetes of 44%).  
 
Over the next 2 years, various amendments to this classification were 
published.(Klein et al. 1984a, Davis et al. 1985, Early Treatment Diabetic 
Retinopathy Study Research Group 1991b)  The assessment of DR level for an 
individual evolved from being based on individual fields,(Klein et al. 1984a) through 
to assessment by ‘worse eye only’ or 'worse eye emphasised’ to a 'median DR level' 
per subject in the KROC study.(Davis et al. 1985)  
 
The completion of the ETDRS allowed a more detailed assessment of the severity 
of DR and risk of progression to PDR to be made, though risk factors for the 
development of macular oedema were not assessed.(Early Treatment Diabetic 
Retinopathy Study Research Group 1991c)  The resulting ETDRS final DR severity 
scale provided 13 levels of severity per eye, based on seven field 30 stereoscopic 
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photographs.  It was derived from the lesion-based interim ETDRS scale,(Early 
Treatment Diabetic Retinopathy Study Research Group 1991b) and incorporated 
the principles of both the WESDR and KROC systems, being numerically based 
with the grade of DR progressing from 10 (no retinopathy) to 85 (advanced vitreous 
haemorrhage).  A summary of the ETDRS final grading scale is reproduced in Table 
1.2.7. 
 
Table 1.2.3 : ETDRS Final Retinopathy Severity Scale 
Level Severity Definition 
10 DR absent MA and other characteristics absent 
14 DR questionable EX, CWS or IRMA definite; MA absent 
15 DR questionable HM definite; MA absent 
20 Microaneurysms only MA definite; other characteristics absent 
35 Mild NPDR Venous loops  D/1 
CWS, IRMA, or VB = Q 
HM present 
EX  D/1 
CWS  D/1 
43 Moderate NPDR HM/MA = M/4-5 or IRMA = D/1-3 (NOT both) 
47 Moderately Severe NPDR Both Level 43 characteristics and/or one (only) of 
the following: 
IRMA = D/4-5 
HM/MA = S/2-3 
VB = D/1 
53 Severe NPDR  2 of the 3 level 47 characteristics 
HM/MA  S/4-5 
IRMA  M/1 
VB  D/2-3 
61 Mild PDR FPD or FPE present with NVD and NVE absent; 
 or NVE = D 
65 Moderate PDR 1)  NVE  M/1 or NVD = D; and VH and PRH = A or 
Q 
2) VH or PRH = D and NVE < M/1 and NVD absent 
71 High Risk PDR 1) VH or PRH  M/1 
2)  NVE  M/1 and VH or PRH  D/1 
3) NVD = D and VH or PRH  D/1 
4) NVD  M 
75 High risk PDR NVD  M and VH or PRH  D/1 
81 Advanced PDR: fundus partly 
obscured, centre of macula 
attached 
NVD cannot grade, or NVD < D and NVE = cannot 
grade in  1 field and absent in all others; and 
retinal detachment at centre of macula < D 
85 Advanced PDR: posterior 
fundus obscured or centre of 
macula detached 
VH = VS in fields 1 and 2; or retinal detachment at 
centre of macula = D 
90 Ungradeable even as levels 81 
or 85 
 
Notes: 
Levels 14 and 15 are not considered separate steps, but pooled with level 10 or 20 
Levels 35 and above require the presence of MA. 
Abbreviations: 
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DR = Diabetic retinopathy; NPDR = Non-proliferative DR; PDR = proliferative DR; MA = 
Microaneurysm; HM = Haemorrhage; EX = Hard Exudate; CWS = Cotton wool spot (soft 
exudate); IRMA = Intraretinal Microvascular abnormality; VB = venous beading; FPD = 
fibrous proliferations at disc; FPE = fibrous proliferations elsewhere; NVD = New vessels at 
the disc; NVE = New vessels elsewhere (> 1 disc diameter from disc); VH = vitreous 
haemorrhage; PRH = preretinal haemorrhage. 
Severity Grades:  
Q = Questionable; D = Definite; M = Moderate; S = Severe; VS = Very severe. 
Number of fields (out of 7) in which lesions appear follow after ‘/’. 
Examples: CWS  M/2-3 means Soft exudates of equal to or greater than moderate severity 
compared with standard photographs present in 2 to 3 fields; VB = Q means venous 
beading questionable. 
 
 
As well as the classification of DR being updated following evidence from clinical 
trials and population studies, the number of fields required for the assessment of DR 
were also assessed.  The WESDR group recognised that seven field stereo 
photography was time consuming and not always possible in routine clinical 
practice, and assessed the sensitivity of employing fewer 30 fields in 1989.(Moss et 
al. 1989)  Use of standard fields one and two (macular centre and nasal) gave an 
agreement of 80% in determining all eight levels of DR (Figure 1.2.22).  If the eight 
levels were reduced to 4, corresponding with no DR (level 10), mild non proliferative 
DR (NPDR) (levels 15 -20), moderate to severe NPDR (levels 30 -40) and PDR 
(levels 60 -70), agreement was 85% for standard fields one and two.  The addition 
of two further fields (three and four, or four and five) increased agreement up to 
91% for eight levels of DR and 95% for four levels.  Addition of temporal fields 
(three and four) increased particularly the detection of new vessels, vitreous 
haemorrhage and pre-retinal haemorrhage.  
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Figure 1.2.22: Seven standard retinal fields (www.revophth.com) 
 
Area 1 corresponds to a disc centred image; Area 2 - macular centred; Area 3 - Macular 
centred; Area 4 - Superior temporal; Area 5 - inferior temporal; Area 6 - superior nasal; Area 
7 - inferior temporal 
 
The use of fewer standard fields was a feature of the epidemiology and prevention 
of diabetes (EURODIAB) study of complications in persons with type 1 
diabetes.(Stephenson et al. 1994)  This study used a grading system based on two 
45 field colour retinal transparencies.(Aldington et al. 1995)  The macular centred 
field was positioned so that the centre of the optic disc was at the nasal end of the 
horizontal meridian of the field of view, and the nasal/disc field positioned so that the 
medial edge of the optic disc was 1 disc diameter (DD) in from the temporal edge of 
the field on the horizontal meridian (Figure 1.2.23).   
28 
 
Figure 1.2.23: Two standard retinal fields A) macular centred and B) nasal  
A)          B) 
r centred  
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This gave access to an area of retina of approximately 80 horizontally and 45 
vertically.  In comparison, the seven standard retinal fields obtained with the 30 
retinal camera provide a field of view of approximately 75 horizontally and 70 
vertically, with more emphasis on the area temporal to the macula, and also the 
inferior and superior nasal areas.  The total area of retina covered by the two 45 
fields approximates to that obtained by four 30 fields because of variations in 
overlap.  The EURODIAB grading system based on lesion counts and comparison 
with standard photographs.  Lesion counts were then translated into a 6 level 
grading system detailed in table 1.2.4 
 
Table 1.2.4 : EURODIAB retinopathy grading system 
Level Retinopathy features 
Level 0 No Retinopathy 
Level 1 Minimal non-proliferative retinopathy: 
HM/MA = grade 2-3 in 1 or 2 fields and/or EX grade 2-4 in 1 or 2 fields 
Level 2 Moderate non-proliferative retinopathy: 
HM/MA grade 4 in only 1 field, OR 
HM/MA grade 2-3 in 1 or 2 fields PLUS: 
CWS grade 2-3 in 1 or 2 fields and/or 
IRMA grade 2 in 1 or 2 fields and/or 
VB grade 2 in 1 or 2 fields 
Level 3 Severe non-proliferative retinopathy (pre-proliferative): 
HM/MA grade 4 in both fields, OR 
HM/MA grade 2-4 in 1 or 2 fields PLUS: 
CWS grade 4 in 1 or 2 fields and/or 
IRMA grade 2 in 1 or 2 fields and/or 
VB grade 3 in 1 or 2 fields 
Level 4 Photocoagulated: 
Scars of photocoagulation in any field 
Level 5 Proliferative retinopathy: 
ANY OF: NVD, NVE, 
Fibrous proliferation, disc or elsewhere 
Pre-retinal haemorrhage 
Vitreous haemorrhage 
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HM - haemorrhage; MA - microaneurysm; CWS - cotton wool spot; IRMA - intra-retinal 
microvascular anomaly; VB - venous beading; NVD - New vessels on the optic disc; NVE - 
new vessels elsewhere; EX - exudates 
 
1.2.4.1 Classification of diabetic retinopathy for the purpose of 
screening 
For use in a clinical, rather than a research setting, the EURODIAB classification 
was used to define a set of recommendations for screening for DR.(Kohner et al. 
1990)  These were agreed by members of a working party on DR, held at the 
Hammersmith Hospital in London in 1990 under the auspices of the St. Vincent 
declaration.  These clinical categories are detailed in Table 1.2.5. 
 
This latter system was used to derive the grading system used by the Welsh 
Community study of DR (WCSDR).(Gibbins 1999)  This was then later further 
modified and used in the first pilot regional screening programme in Wales, the Bro-
Taf DR Service (Bro-Taf DRS),(Bouhaimed et al. 2008) and in the beginning of the 
Welsh National screening programme - Diabetic Retinopathy Screening Service for 
Wales (DRSSW).  A further revision was made in 2005 in conjunction with the All 
Wales Ophthalmology Group to provide the current grading system employed by the 
DRSSW.  Table 1.2.6 details the changes that occurred from WCDRS to the Bro-
Taf DRS and finally the DRSSW grading systems.  All grading systems for DR 
recognise that the presence and quantity of certain features may confer a greater 
degree of risk of progression of disease, and are intended to allow appropriate 
classification, permitting timely intervention in order to prevent visual loss. 
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Table 1.2.5 : European field guide book screening categories and recommendations 
For review in screening clinic in 6 -12 months: 
Mild Non-proliferative retinopathy: - CWS in small numbers not associated with 
pre-proliferative lesions. 
- Occasional haemorrhages and/or 
microaneurysms and hard exudates not 
within 1 disc diameter of the macular area. 
- Drusen may sometimes be confused with 
hard exudates. Drusen, if not associated with 
other signs of age related macular 
degeneration, are not considered important. 
Lesions to be referred as soon as possible for assessment by an ophthalmologist: 
Non-proliferative retinopathy without macular 
involvement: 
- Large circinate or plaque hard exudates 
within the major temporal vascular arcades. 
Non-proliferative retinopathy with macular 
involvement: 
- Reduced visual acuity not corrected by 
pinhole (suggestive of macular oedema) 
- Haemorrhages and/or hard exudates within 
one disc diameter of the macula, with or 
without visual loss 
Pre-proliferative retinopathy: - Venous irregularities (beading, 
reduplication, loops), 
- and/or multiple haemorrhages 
- and/or multiple CWS 
- and/or intraretinal microvascular 
abnormalities 
Sight threatening retinopathy, requiring immediate referral: 
Proliferative retinopathy: - New vessels on the optic disc or elsewhere 
in the retina 
- Preretinal haemorrhage 
- Fibrous tissue 
Advanced diabetic eye disease: - Vitreous haemorrhage 
- and/or fibrous tissue 
- and/or recent retinal detachment 
- and/or rubeosis iridis 
CWS - cotton wool spots
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Table 1.2.6: Comparison of the WCDRS, Bro Taff DRS and DRSSW standard grading protocols. 
WCDRS grading Bro-Taf DRS grading DRSSW grading 
0 NoDR 0 No DR R0 No DR 
1 Non- PDR (mild) 
Occasional Hms and/or Mas 
Hard exudate not within 1dd of 
macular centre 
1 CWS not associated with PPDR 
lesions 
1 Minimal NPDR 
≤ 5 Mas > 1 DD from fovea and/or 
1 Hm > 1 DD from fovea 
R1.1 Mild BDR 
< 5 Mas > 1 DD from fovea  
< 4 Hms > 1 DD from fovea 
3 Mas < 1 DD from fovea 
≤ 3 MA < 1 DD from fovea with VA better than 
6/12 
exudates > 2 DD from fovea ±CWS (< 5) 
2a Non-PDR (moderate) without macular 
involvement 
Large Circinate or plaque hard 
exudates within temporal arcades but 
not <1DD from macula centre 
 
2a Mild NPDR 
> 5 Mas  
≤ 2 Ma < 1 DD from fovea and/or 
≥ 2 Hm > 1 DD from fovea and/or 
Ex outside arcades and/or 
≤ 5 CWS 
Questionable IRMA 
R1.2 Moderate BDR 
≥ 5 MAs > 1 DD from fovea  
≥ 4 < 8 HMs > 1DD from fovea  
> 3 MAs < 1 DD from fovea with VA > 6/12 
Circinate or grouped exudates > 2 DD from 
fovea but within arcades 
Questionable IRMA only in the presence of 
MA/HM  2b  Non-PDR (moderate) with macular 
involvement 
Hm and/or hard exudates  within 
temporal arcades <1DD from macula 
centre 
2b Mild NPDR 
Features of 2a and 
> 2Ma < 1DD from fovea and/or 
Ex within arcade >1 DD from fovea 
2c Mild NPDR 
Circinate Ex within arcade > 1 DD from fovea 
3 PPDR 
Venous irregularities 
And/or multiple Hms 
And/or CWS 
And/or IRMA 
3a Moderate NPDR 
> 5 CWS 
Multiple Hm 
R2 Severe BDR (PPDR) 
≥ 8 blot haemorrhages per eye (superior and 
inferior hemi-fields) 
Venous irregularities, beading, reduplication, 
venous loops (but not on their own) 
Definite IRMA 
±CWS (but not CWS on their own) 
3b Severe NPDR 
Venous irregularities (beading, loops, 
reduplication) 
Definite IRMA 
4 PDR 
New Vessels on disc or elsewhere 
Pre-retinal Hm 
4 PDR 
New vessels on disc (NVD) and/or 
New vessels elsewhere (NVE) and/or 
R3 PDR/ADED 
New vessels on disc (NVD) 
New vessels elsewhere (NVE) 
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WCDRS grading Bro-Taf DRS grading DRSSW grading 
 And/or fibrous tissue  Pre-retinal Hm and/or 
Fibrous tissue 
 Pre-retinal haemorrhage 
Vitreous haemorrhage 
Pre-retinal fibrosis 
Traction retinal detachment 
5 Advanced diabetic eye disease 
Vitreous Hm 
And/or fibrous tissue 
And/or retinal detachment 
And/or rubeosis iridis 
5 Advanced diabetic eye disease 
Vitreous Hm and/or 
Fibrosis/Traction and/or 
Retinal detachment (recent) 
  
6 Presence of photocoagulation from 
previous treatment 
7 Findings that observer finds difficult to 
interpret with reasonable certainty 
  Maculopathy Maculopathy 
 M1 Hm < 1DD from fovea and/or 
Ex < 1 DD from fovea 
MO No Maculopathy 
M2 Possible CSMO (VA < 6/12) M1 
 
 
Possible Maculopathy 
Exudates < 2 DD >1DD from fovea 
> 3 Mas <1 DD from fovea with VA < 6/12 
Hm < 2DD from fovea 
 
M2 Definite Maculopathy 
Exudates < 1 DD from fovea 
Retinal thickness changes < 1 DD from  
Table 1.2.6 continued 
Hm - haemorrhage; Ma - microaneurysm; Ex - exudate; CSMO - clinically significant macular oedema; DD - disc diameter; VA - visual acuity; NVE - new 
vessels on elsewhere; NVD - new vessels on the optic disc; BDR - background diabetic retinopathy; PPDR - pre-proliferative diabetic retinopathy; proliferative 
diabetic retinopathy; CWS - cotton wool spots; IRMA - intra-retinal microvascular abnormality
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1.3 Epidemiology of diabetic retinopathy  
It has been known for some time that estimates of prevalence and incidence of DR 
differ between type 1 and type 2 diabetes and that they are dependent on duration 
of diabetes and glycaemic control along with other risk factors including 
hypertension and dyslipidaemia.(Bodansky et al. 1982, Klein et al. 1985)  
Historically they also vary between different time periods of data collection, due to 
changes in classification of both diabetes and DR, and different methods of 
detection of DR employed such as  ophthalmoscopy direct/indirect, biomicroscopy, 
fluorescein angiography and photography using Polaroid, 35mm film or digital 
images.  When comparing prevalence and incidence estimates hospital based clinic 
vs. community difference should also be taken into account.  Community based 
programmes, such as DR screening in the UK, may underestimate the prevalence 
of sight-threatening DR due to the exclusion of persons who are under the care of a 
hospital eye service for DR reasons and therefore not subjected to screening.  In 
contrast hospital based (ophthalmology) clinics may over-estimate the prevalence of 
sight-threatening DR for a particular population. 
 
1.3.1 Prevalence and incidence of diabetic retinopathy 
Prevalence is a measure of the frequency of disease within a population at a 
particular time.  Whereas, incidence is defined as the number of new cases of a 
disease occurring over a defined period of time.  
 
Much of the data regarding the prevalence and incidence of DR originates from the 
WESDR.(Klein et al. 1984b, c)  In this extensive study, a large group of persons 
with diabetes living in South Wisconsin, USA were followed for more than 25 years.  
The subjects were divided into two groups; those with an age at diagnosis of 
diabetes less than 30 years (younger onset group), taken to be almost exclusively 
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persons with type 1 diabetes (n=996), and those with an age at diagnosis of 30 
years or more (older onset group), predominantly persons with type 2 diabetes 
(n=1,370).  The latter group were subdivided into those taking insulin (n=674) and 
those on other forms of treatment such as diet with or without oral hypoglycaemic 
agents (OHAs) (n=696).  DR assessment was based on the ETDRS adaption of the 
Airlie House grading system,(Early Treatment Diabetic Retinopathy Study Research 
Group 1991b) with seven standard stereoscopic colour fundus photographs taken 
per eye following mydriasis. 
 
The prevalence of any DR in the younger onset group was 71%,(Klein et al. 1984b) 
and in the older onset group using insulin was similar at 70%, whilst in those not 
using insulin the prevalence was 39%.(Klein et al. 1984c)  In the younger onset 
group 23% had PDR,(Klein et al. 1984b) and in the older onset group those using 
insulin PDR occurred in 14%, and those not using insulin PDR was present in 
3%.(Klein et al. 1984c)  Macular oedema occurred in 6% of the younger onset 
group,(Klein et al. 1984b) 11% of the older onset group using insulin and 4% in 
those not using insulin.(Klein et al. 1984c)  The data  suggested a link between the 
types of diabetes and the severity of DR seen, with PDR more prevalent in the 
younger onset or type 1 group and macular oedema in the older onset or type 2 
group.   
 
In the WESDR the overall incidence of any DR was 40.3% over a four year 
period.(Klein et al. 2003)  In the younger onset group the 4 year cumulative 
incidence of any DR was 59.0%,(Klein et al. 1989b) and for the older onset group 
was 47.4% in those using insulin and 34.4% in those not using insulin.(Klein et al. 
1989a)  Further follow up of the younger onset group indicated that almost all 
developed any DR after 14 years and the cumulative incidence of PDR was 
37.0%.(Klein et al. 1998)  The ten year incidence of macular oedema was 20.1% for 
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the younger onset group and 25.4% for older onset group on insulin therapy and 
13.9% in those not using insulin.(Klein et al. 1995)  Comparative figures for CSMO 
were 13.6%, 17.6% and 9.2% respectively.  Since this landmark epidemiologic 
study, changes in the classification of diabetes and DR and the advances made in 
diabetes treatment may mean that these prevalence and incidence rates may not be 
relevant today.(Klein et al. 2009, Wong et al. 2009) 
 
A systematic review carried out in 2004 identified a total of 153 publication reporting 
prevalence data and 70 providing incidence figures for DR, PDR and maculopathy 
in type 1, type 2 diabetes or mixed cohorts.(Williams et al. 2004)  The overall 
prevalence estimates for DR reported were very broad ranging from 0-84.0% in 
persons with type 1 diabetes in the USA, 33.6-36.7% in the UK, and 10.8-68.3% in 
Scandinavian countries.  In persons with type 2 diabetes the prevalence estimates 
for DR ranged from 7-55.0% in the USA, 21.0-52.0% in the UK and 18.8-65.9% in 
Scandinavia.  The incidence of DR in persons with type 1 diabetes ranged from 
33.0% to 89.3% over 2 and 10 years respectively in the USA, and 9.0%-56.0% over 
5 and 7 years respectively in Europe.  For type 2 diabetes it was 66.9% over 10 
years in USA, and 22.0% over 6 years in the UK. 
 
A more recent systematic review performed a pooled individual participant meta-
analysis from 35 studies with a total of 22,898 participants, utilising retinal 
photographs with the aim of providing worldwide estimates for the prevalence of 
DR.(Yau et al. 2012)  They estimated the prevalence of any DR at 77.0% and 
32.0% in type 1 and type 2 diabetes aged 20-79 years, respectively.  In type 1 
diabetes the prevalence of PDR was 32.0% and for maculopathy 3.0% compared to 
14.0% and 6.0% for type 2 diabetes respectively.  These estimates were reasonably 
similar to those recorded earlier for the WESDR.(Klein et al. 1984b, c) 
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Both the prevalence and incidence of DR are influenced not only by type of diabetes 
but also duration of diabetes, glycaemic and blood pressure control, dyslipidaemia, 
the use of insulin, and possibly by ethnicity as well as other factors such as age, 
gender, pregnancy and genetic makeup.(Stewart et al. 1993) 
 
1.3.2 Putative risk factors for diabetic retinopathy 
1.3.2.1 Duration of diabetes 
In almost all epidemiologic studies of DR the duration of diabetes is the most 
important characteristic associated with increased risk.  Although not a causal factor 
in a way that is informative about the disease mechanisms itself, nevertheless it is 
an important consistent feature of most chronic complications seen in people with 
diabetes.(Klein et al. 2003)  After 20 years of diabetes 80% of persons with type 1 
diabetes will have developed DR and 50% sight-threatening DR.  Whereas in 
persons with type 2 diabetes 50% will develop DR and 10% sight-threatening DR.  
Figure 1.3.1 shows how the prevalence of any DR and PDR and Figure 1.3.2 how 
CSMO increased with increasing duration of diabetes in the WESDR study.(Klein et 
al. 1984b, c)   
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Figure 1.3.1: Prevalence of any DR and PDR (Klein et al. 1984b, c) 
 
Figure 1.3.2: Prevalence of CSMO (Klein et al. 1984b, c) 
 
 
The strength and time course of this relationship differs between those subjects with 
type 1 and type 2 diabetes.  However, duration of disease in type 2 diabetes is often 
inaccurate due to the asymptomatic nature of the disease early on, therefore the 
exact age at onset is often unknown leaving the time course difficult to estimate in 
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this group.(Klein et al. 2003)  Two studies have estimated, using the presence and 
severity of DR as a marker, that the onset of diabetes in those with type 2 diabetes 
may occur between four and seven years prior to diagnosis.(Harris et al. 1992, 
Porta M et al. 2014)   
 
1.3.2.2 Glycaemic control 
There is a wealth of evidence that poor glycaemic control of diabetes increases the 
risk of the development and progression of DR in both type 1 and type 2 
diabetes.(Engerman et al. 1977, Pirart 1978, Ballard et al. 1986, Nathan et al. 1986, 
Klein et al. 1988, 1989b, a, Brinchmann-Hansen et al. 1992, Davis et al. 1998)  Two 
landmark clinical trials the Diabetes Control and Complications Trial (DCCT) and the 
United Kingdom Prospective Diabetes Study (UKPDS) showed that achieving near 
normo-glycaemia delays both the onset and retards the progression of DR.(The 
Diabetes Control and Complications Trial Research Group 1993, UK Prospective 
Diabetes Study group 1998b, c)  
 
In the primary prevention group (those without DR at baseline) of the DCCT, in type 
1 diabetes conducted over a mean 6.5 years follow up period the frequency of 
progression of DR was reduced by 76% in the intensive treatment group compared 
to the usual care group.(The Diabetes Control and Complications Trial Research 
Group 1993)  In the secondary prevention group the corresponding risk reduction 
was 54% (Figure 1.3.3).  The long term follow up 10 years of this study group has 
demonstrated a residual protective effect on DR of this early tight control despite 
subsequent comparable glycaemic control (metabolic memory).(White et al. 2010, 
Aiello et al. 2014)  However, there are some persons with poor glycaemic and blood 
pressure control who never develop DR even over prolonged periods of time, whilst 
other will develop DR despite good control of risk factors.  In the Medalist study 50% 
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of older persons did not develop DR despite having type 1 diabetes for over 50 
years.(Keenan et al. 2007) 
 
Figure 1.3.3: Cumulative incidence of DR in persons with type 1 diabetes receiving 
intensive or convention therapy in the DCCT trial A) Primary prevention cohort, B) 
secondary prevention cohort (The Diabetes Control and Complications Trial 
Research Group 1993) 
 
 
The UKPDS included persons with type 2 DM showed that a reduction of mean 
HbA1c from 7.9% to 7.0% over 9 years was associated with a 21.0% reduction in the 
risk of progression of retinopathy over 10 years.(UK Prospective diabetes study 
group 1998c)  Similar reductions in risk were observed for obese subjects treated 
with metformin rather than sulphonylureas or insulin, indicating that it was the 
reduction in glycaemia rather than the type of treatment that was of significance.(UK 
Prospective Diabetes Study group 1998b)  Long term follow up of the UKPDS has 
also shown that despite early loss of glycaemic difference, there was a continued 
reduction in microvascular risk during 10 years of post trial follow up referred to as 
the legacy effect.(Holman et al. 2008a) 
 
The Steno-2 trial was a target driven, intensified, multifactorial intervention of 
modifiable risk factors compared to conventional treatments in persons with type 2 
diabetes and microalbuminuria.(Gaede et al. 2003)  The intensive therapy 
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intervention included; a dietary intake of fat <30% and saturated fatty acid <10% of 
the daily energy intake, light-moderate exercise 30 minutes 3-5 times per week, 
prescription of an ACE inhibitor or an angiotensin II-receptor antagonist irrespective 
of blood pressure level, a vitamin-mineral supplement, aspirin, oral hyperglycaemic 
agents (OHA) was added HbA1c <6.5% could not be maintained after 3 months, if 
HbA1c >7.0% despite maximal doses of OHAs then insulin therapy was initiated, 
raised fasting serum cholesterol levels were treated with statins and 
hypertriglyceridaemia was treated with fibrates.  The study found a 57% reduction in 
risk of DR for persons in the intensive treatment group over an 8 year period.  The 
action to control cardiovascular risk factors in diabetes (ACCORD) trial assessed 
the effects of intensive glycaemic control, lipid control and intensive hypertensive 
therapy on cardiovascular events and the progression of DR.(ACCORD study group 
et al. 2010)  Intensive glycaemic control was found to significantly reduced the risk 
of progression of DR after 4 years.   
 
There have however, been two trials, the action in diabetes and vascular disease: 
Preterax and Diamicron MR controlled evaluation trial (ADVANCE) and Veterans 
affairs diabetes trial (VDAT) trials, involving persons with type 2 diabetes that have 
reported no significant reduction in the incidence or progression of DR following 
intensive glycaemic control.  The ADVANCE trial looked at the effects of blood 
pressure lowering and intensive glycaemic control (targeting a HbA1c ≤6.5% in 
persons with type 2 diabetes over a period of 4.1 years.(Beulens et al. 2009)  There 
was a borderline significant reduction in the risk of microaneurysms, exudates and 
macular oedema associated with intensive glycaemic control.  The authors 
concluded that a longer follow up period and a greater number of patients were 
required for intensive glycaemic control to result in significant risk reductions in DR.  
The VDAT trial examined the effects of lowering HbA1c levels by 1.5% in veterans 
with type 2 diabetes over a median follow up period of 5.6 years.(Duckworth et al. 
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2009)  The study reported a non-significant trend towards an increased incidence in 
severity of DR in the standard therapy group. 
 
1.3.2.3 Blood pressure 
Although there is some inconsistency in the evidence it is generally accepted that 
hypertension is an independent and important risk factor for the development of 
microvascular complications in diabetes.(Knowler et al. 1980, Klein et al. 1984b, 
Ballard et al. 1986, Klein et al. 1995)  The UKPDS and appropriate blood pressure 
control in diabetes (ABCD) trials demonstrated the importance of hypertension as a 
risk factor for micro- and macro-vascular complications in type 2 diabetes.(Schrier et 
al. 1996, Kohner et al. 1998, UK Prospective diabetes study group 1998a, Estacio 
et al. 2000, Schrier et al. 2002)  However the more recent ACCORD and ADVANCE 
trials did not find a beneficial effect of lowering blood pressure on DR.(Beulens et al. 
2009, ACCORD study group et al. 2010) 
 
In the UKPDS study severity of DR was related to both systolic and diastolic blood 
pressure at entry into the study.(Kohner et al. 1998)  Over nine years, a reduction in 
mean blood pressure from 154/87 mm Hg to 144/82 mmHg resulted in a 34% lower 
risk of progression of DR and a 47% lower risk of significant reduction in visual 
acuity.(UK Prospective diabetes study group 1998a)  For each 10mmHg decrease 
in mean systolic blood pressure there was a 13% reduction in the incidence of DR 
with no apparent threshold.  However, these benefits were not sustained post trial 
once the differences in blood pressure between the groups were lost 2 years after 
the end of the trial.(Holman et al. 2008b)  The results of the ABCD showed over a 5 
year follow up period there was no difference between the intensive and moderate 
control groups with regards to progression of DR.(Schrier et al. 1996, Estacio et al. 
2000, Schrier et al. 2002)  This trial may suggest the possibility of a threshold effect 
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below which only minimal efficacy for reducing the risk of progression of DR is 
achieved by further reductions in blood pressure. 
 
The more recent ADVANCE and ACCORD trials however, could not confirm the 
influence of blood pressure lowering on progression of DR.(ADVANCE 
Collaborative Group 2007, ACCORD study group et al. 2010)  The UKPDS trial had 
higher baseline and achieved a greater reduction in blood pressure values than 
either ADVANCE or ACCORD.  Therefore leaving investigators to postulate that 
blood pressure control was more effective in poorly controlled hypertension or that a 
longer follow up time was required to observe the effects on DR progression at 
lower levels of blood pressure. 
 
Recent studies have focused on the renin-angiotension system (RAS).  The 
EUCLID controlled trial of Lisinopril (an angiotensin convertase enzyme [ACE] 
inhibitor) showed a significant reduction in the progression of DR.(Chaturvedi et al. 
1998)  The diabetic retinopathy Candesartan trials (DIRECT) (tested the efficacy of 
Candesartan an angiotensin receptor blocker on DR) found that Candesartan 
reduced the incidence of DR by 18% but did not significantly affect its 
progression,(Chaturvedi et al. 2008, Sjolie et al. 2008) in persons with type 1 
diabetes.  However, regression of early DR was shown in persons with type 2 
diabetes.(Sjolie et al. 2008)  These studies have also found that the use of ACE 
inhibitors or angiotension II receptor blockers have effects beyond that of blood 
pressure control as progression of DR was reduced even in those normotensive 
persons.(Lingam et al. 2013)  This may be due to ACE inhibitors having a direct 
effect on the eye as some studies have shown that ACE is produced locally by 
vascular endothelial cells which may affect retinal flow and vascular 
structure.(Chaturvedi et al. 1998) 
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1.3.2.4 Lipids 
If the effects of blood pressure control on the incidence and progression of DR have 
been inconsistent in clinical trials, then the impact of lipid control have been even 
more inconsistent.  The EURODIAB study, identified triglyceride levels as a 
significant risk factor for moderate and severe non PDR (NPDR) and PDR 
(standardised relative risks (RR) 1.4, 1.3 and 1.6 respectively).(Sjolie et al. 1997)  
Evidence from the earlier ETDRS indicated that elevated triglycerides were an 
independent risk factor for the development of high risk PDR. (Davis et al. 1998)  
Elevated total cholesterol and low density lipoprotein cholesterol (LDL-cholesterol) 
levels were also seen to be associated with twice the risk of having hard exudates 
at entry into the study and about one and a half times the risk of developing hard 
exudates during the study, whereas other lipoprotein fractions and triglycerides 
were not.(Davis et al. 1998)  In the WESDR study in persons using insulin 
(irrespective of age at onset) higher total serum cholesterol was associated with 
increased odds of having retinal hard exudates.(Klein et al. 1999)  However, there 
was no relationship between total cholesterol and high density lipoprotein-
cholesterol (HDL-cholesterol) with DR or with hard exudates in the older onset age 
group not using insulin.(Klein et al. 1991)  The STENO-2 study found a 67% 
significant reduction in DR in the intensive intervention group involving multiple risk 
factors, including glycaemic control, blood pressure, cholesterol and 
microalbuminuria over 4 years, which was sustained at 8 years.(Gaede et al. 1999, 
Gaede et al. 2003)  However these findings have not been universally 
consistent.(Duncan et al. 1968, Sjolie et al. 1997, Colhoun et al. 2004, Thomason et 
al. 2004)   
 
The use of fibrates have been shown to have a beneficial effect on retinal exudates 
(Harrold et al. 1969, Dorne 1977, Rencova et al. 1992, Freyberger et al. 1994, 
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Keech et al. 2007, ACCORD study group et al. 2010, Morgan et al. 2013) and 
macular oedema.(Cullen et al. 1964, Duncan et al. 1968)  The Fenofibrate 
Intervention and Event Lowering in Diabetes study (FIELD) reported that persons 
with type 2 diabetes treated with fenofibrate, in addition to therapies for 
hyperglycaemia and other risk factors for DR, were less likely to need laser therapy 
than controls.(Keech et al. 2005)  There was also less progression of pre-existing 
DR with fenofibrate.  However, in persons without pre-existing DR there was no 
significant reduction in the progression to DR.(Keech et al. 2007)  This was also 
confirmed in the ACCORD eye study which aimed to determine whether any one of 
three interventions in the main ACCORD trial being intensive glycaemic therapy, the 
addition of fenofibrate to a statin and intensive blood pressure therapy reduced the 
risk of development or progression of DR compared to standard 
treatments.(ACCORD study group et al. 2010)  However a retrospective matched 
cohort study found that treatment with fibrates was associated with a 20% reduction 
in the rate of first onset DR.(Morgan et al. 2013)  This reduction in the onset of DR 
did not appear to be attributable to the lipid lowering effects of fibrates.  Other non-
lipid-related mechanisms that may explain the effect of fibrates on DR are the anti-
inflammatory and antioxidant properties of fibrates.(Poynter et al. 1998, Delerive et 
al. 1999)  Fenofibrate acid has also been reported to prevent the disruption of the 
retinal pigment epithelium cells and prevent the increased breakdown of the blood-
brain capillary barrier and downregulation of vascular endothelial growth factor 
(VEGF).(Meissner M et al. 2004, Trudeau K et al. 2011, Villarroel M et al. 2011)  In 
addition fibrates possess neuroprotective properties.(Bordet R et al. 2006) 
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1.3.2.5 Other risk factors  
Ethnicity 
Ethnic origin differences in the prevalence of DR have been a focal point of interest 
in recent research.(Cheung et al. 2010)  Prevalence of DR and ethnic origin 
associations with the presence of any DR and also severe/referable stages of DR 
have previously been reported to be higher in non-Caucasian persons when 
compared with Caucasians.(West et al. 1982, Ross et al. 2007, Stolk et al. 2008, 
Raymond et al. 2009)  However, while variability in frequency may reflect true 
differences in prevalence; lack of uniformity in study designs, protocols for 
examination and documentation may explain some of the differences.(Klein et al. 
2003)  There may also be differences in environmental and genetic risk factors as 
well as other covariates that may have a marked impact on frequency. 
 
Pregnancy 
Pregnancy may accelerate the incidence and progression of DR.  Pregnancy was 
found to be independently associated with the progression of DR in both the 
WESDR and the DCCT.(Klein et al. 1990, The Diabetes Control and Complications 
Trial Research Group 2000).  Several factors related to metabolic changes 
(hyperglycaemia), type of diabetes (duration of diabetes prior to conception, 
baseline DR status), pregnancy itself (hypervolaemia and hypercoagulation, 
impaired retinal autoregulation) and complications of pregnancy (pre-eclampsia) all 
seem to play an important role in the progression of DR during pregnancy.(Kaaja et 
al. 2007)  However, unless DR has progressed to pre-proliferative DR (PPDR) or 
PDR stages pregnancy seems to have no long term detrimental effects with regards 
to progression.  It has been suggested that fundal examinations be conducted in 
pregnant women with diabetes in the first trimester and then once every 3 months 
following the initial examination and importantly 3 months post-natal. 
47 
 
Genetics 
It seems likely that both genetic and environmental confounders exist for the 
development of DR, especially in light of the evidence that some persons with short 
duration of diabetes and good glycaemic control still develop DR and some with 
long duration and hyperglycaemia do not.(Nathan 1993, The Diabetes Control and 
Complications Trial Research Group 1993)  There was also some evidence 
indicating significant correlations between the severity of DR in family members 
from the DCCT study and others, (The Diabetes Control and Complications Trial 
Research Group 1997, Alcolado 1998) and increased risks in siblings of affected 
persons.(Leslie et al. 1982)  Heritability has been estimated to be as high as 27% 
for DR and 52% for PDR.(Looker et al. 2007, Hietala et al. 2008)  However, 
currently our understanding of the relationship between genetics of DR is limited.  It 
is thought that current studies assessing genome wide associations offer greater 
promise in our understanding the genetic architecture of DR susceptibility.(Liew et 
al. 2009, Cho et al. 2014) 
 
1.4 Treatment of diabetic retinopathy 
As discussed in section 1.3 above, tight glycaemic and blood pressure control are 
the cornerstones in the primary prevention of DR with some evidence of benefits 
with the use of fibrates.(Mohamed et al. 2007)  Currently treatment once DR is 
established is by photocoagulation for selected cases of severe NPDR and PDR 
and vitrectomy if DR continues to worsen despite adequate photocoagulation 
treatment.  There is also the recent addition of anti-VEGF treatment for CSMO with 
some benefits seen for PDR. 
 
Diabetes emerged as a leading cause of vision loss by 1968, therefore clinicians 
attempted to develop the tools and means to preserve vision.  Some of these were 
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invasive such as partial pituitary ablation but there were complications related to 
hypopituitarism, which included death.(Antonetti et al. 2012)  Other attempts were 
as simple as one aspirin per day.  Therefore prognosis for vision during this time 
was poor.  Pan retinal photocoagulation was first used to treat retinal disease in the 
1950s, and is now an established technique for treating severe NPDR and 
PDR.(Kapany et al. 1963, Meyer-Schwickerath 1967)  Randomised controlled trials 
in the 1960s, 1970s and 1980s confirmed the benefit of laser photocoagulation in 
the treatment of DR and maculopathy to prevent vision loss.(Diabetic Retinopathy 
Study Research Group 1976, 1981a, b, British Multicentre Study Group 1984, Early 
Treatment Diabetic Retinopathy Study Research Group 1991a)  The best response 
was observed in early PDR, whereas  advanced neovascularisation and gliosis 
showed little improvement.  However photocoagulation is a destructive process 
burning the retina and thereby destroying the cells and vision and so should not be 
used too early in the course of the development of DR. 
 
Removal of all or part of the vitreous by pars plana vitrectomy was first advocated in 
the early 1970s.(Machemer et al. 1972)  Evidence from trials have demonstrated 
that vitrectomy performed in eyes with good visual acuity and early evidence of 
traction detachment had good preservation of vision in 73% of cases.(Shea 1983, 
Diabetic Retinopathy Vitrectomy Study Research Group 1985)  In the Diabetic 
Retinopathy Vitrectomy Study (DRVS) significant benefit was seen only in persons 
with type 1 diabetes and not in type 2 diabetes.(Diabetic Retinopathy Vitrectomy 
Study Research Group 1985)   
 
Further clinical trials in the 1980s evaluated the benefit of laser treatment in 
maculopathy.(British Multicentre Study Group 1983, Early Treatment Diabetic 
Retinopathy Research Study Group 1985)  They found that significant visual loss in 
treated eyes was approximately half that in untreated eyes.  Eyes showing evidence 
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of CSMO were particularly likely to benefit, and the presence of CSMO was an 
indication for focal treatment even if visual acuity was normal.   
 
In 1999, intravitreal injections of corticosteroids (triamcinolone acetonide) were 
proposed as a treatment for diabetic macular oedema.  A treatment thought to be 
effective for its anti-inflammatory properties and as it was demonstrated to inhibit 
the expression of the VEGF gene.(Nauck et al. 1998)  Initial findings from studies of 
intravitreal triamcinolone acetonide (IVTA) were positive showing improvements in 
retinal thickness and visual acuity.(Martidis et al. 2002, Jonas et al. 2003)  However 
these improvements appear to be short term.(Bressler et al. 2009, Rudnisky et al. 
2009, Yilmaz et al. 2009, Elman et al. 2011, Jampol et al. 2014)  The adverse effect 
of IVTA most commonly reported was raised intraocular pressure, additionally 
cataract formation or progression, endophthalmitis and retinal detachment have 
been reported.(Yilmaz et al. 2009) 
 
In 2006 attention turned to the use of intravitreal injections of anti-VEGF 
medications.(Jampol et al. 2014)  Anti-VEGF agents have to be injected directly into 
the vitreous body at regular intervals.  There are currently four anti-VEGF drugs 
available for the treatment of diabetic macular oedema that have been extensively 
investigated: pegaptanib, bevacizumab, ranibizumab and aflibercept.  Clinical trials 
have indicated that vision can be improved with repeated injections.(Cunningham et 
al. 2005, Massin et al. 2010, Michaelides et al. 2010)  Use of bevacizumab and 
ranibizumab have been shown to improve visual acuity by an average of one to two 
lines on a Snellen chart, with an improvement of 3 lines or more in 25% to 30% of 
people, and the loss of visual acuity decreased by one third.(Arevalo et al. 2007, 
Massin et al. 2010, Michaelides et al. 2010)  Pegaptanib improved visual acuity by 
approximately one line.(Cunningham et al. 2005)  Some studies have also shown 
beneficial effects of the use of intravitreal bevacizumab in conjunction with 
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photocoagulation on PDR as well as prior to vitrectomy.(Tonello et al. 2008, 
Ahmadieh et al. 2009, Cho et al. 2009)  The use of intravitreal bevacizumab 
resulted in a greater reduction in active leaking new vessels, and preventing visual 
dysfunction and foveal thickening and rapid resolution of vitreous haemorrhage.  
The use of intravitreal bevacizumab prior to pars plana vitrectomy prevented re-
bleeding and accelerated postoperative vitreous clear up.  However, intravitreal 
injection of anti-VEGF therapies have systemic and ocular adverse risks the most 
damaging of which is infectious endophalmitis.  Other ocular risks are inflammation, 
rhegmatogenous retinal detachment, raised intraocular pressure, and subretinal 
haemorrhage.(Ghasemi Falavarjani et al. 2013)  Despite the adverse risks, the need 
for monthly injections and related costs, anti-VEGF therapies are slowly becoming 
the preferred therapy for CSMO.  NICE guidelines recommends their use if the 
central retinal thickness is ≥ 400 microns and they are also currently under 
investigation for use in PDR with or without laser.(NICE 2013)  
 
Other treatments for DR currently being investigated involve the blockage of RAS 
system, (Chaturvedi et al. 2008, Sjolie et al. 2008) and the use of protein kinase-C 
(PKC) inhibitors, (PKC-DRS study group 2005, Aiello et al. 2006, Aiello et al. 2007) 
which have shown some positive results.  However, further investigation into these 
new therapies is required before they are recommended for use in the treatment of 
DR. 
  
1.5 Detection of diabetic retinopathy  
1.5.1 History of the ophthalmoscope and retinal photography 
The retina was first visualised in 1704 by Jean Mery who saw the retinal vessels in 
the fundus after placing a cat under water.(Keeler 2003)  Jan Purkinje then used his 
myopic glasses to reflect candle light placed behind a dog to visualise the fundus in 
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1825.  In 1846 William Cumming published his findings that every eye could be 
visualised if the light source directed towards the subjects eye and the observers 
line of sight were coincident.(Cumming 1846)  In 1851 Hermann Von Helmholtz 
invented the first ophthalmoscope (Figure 1.5.1).(Keeler 2003)  The 
ophthalmoscope underwent many design changes during the 19th and 20th century 
and by 1913 Edward Landolt reported that over 200 models had been produced. 
 
Figure 1.5.1: a) Early Helmholtz ophthalmoscope (www.college-optometrists.org) 
(1851), b) modern day Keeler direct ophthalmoscope (www.keeler.co.uk) 
a)      b)  
 
 
Two years after the first ophthalmoscope was developed Reute invented the indirect 
ophthalmoscope, which allowed a wider stereoscopic view of the fundus.(Avanced 
retinal imaging laboratory 2014)  This allowed the periphery of the retina to be 
viewed even through slightly hazy media (Figure 1.5.2).  The golden age of 
ophthalmology became evident following these first two inventions with the 
discovery of pigment retinopathy and detachment of the retina in 1853, DR, retinal 
vein occlusions and glaucoma in 1855, hypertensive retinopathy in 1856, syphilitic 
retinitis in 1858 and embolism of the central retinal vein in 1859. 
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Figure 1.5.2: a) first indirect ophthalmoscope, b) modern day indirect 
ophthalmoscope. (www.nyee.edu) 
a)      b) 
  
 
The first photographs of the retina were obtained from a rabbit, and were produced 
in 1862 by Dr Noyes.(Van Cader 1978).  The photographs were captured using 
Frederic Scott Archer's wet plate method of coating glass plates with a photographic 
surface.  It was another 20 years before anyone attempted to photograph a human 
subject.  This was achieved by Jackson and Weber in 1886, using a small camera 
attached to the head of a patient and an ophthalmoscopic mirror placed at 45o to the 
camera lens, which deflected light from a source placed near the ear of the patient.  
However, due to constriction of the pupil after the flash of light, the lack of colour 
and a large central artefact associated with retinal photography, ophthalmic artists 
were employed to produce accurate drawings of the retina.  In 1871, the wet plate 
was replaced with a plate that could be used dry, the photographic emulsion 
developed by Dr Maddox.  In 1907, Dimmer published the first ever atlas of fundus 
photography using a fundus camera that was so large and expensive only one was 
ever built by Zeiss (Figure 1.5.3) (Same 1993). 
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Figure 1.5.3: Dimmer-Zeiss fundus camera (www.opsweb.org) 
 
 
The first widely used camera, the Zeiss-Nordenson, was created in 1925 designed 
by Dr Nordenson with the Zeiss company (Figure 1.5.4).  The camera had a 10o 
field of view and required a 0.5 second exposure with colour film.  In the mid 1920s 
35mm rolled film was produced for the camera.  This nitrate film ended the need for 
fragile glass plates.  In 1929, Bedell published his atlas of stereo fundus 
photographs, the same year colour fundus photography was attempted.(Same 
1993)  Between 1931 and 1950 retinal photography gained favour, however slow 
film and long shutter speeds meant obtaining quality images was difficult.  In 1955 
the Zeiss-Littmann camera was produced which was a fully adapted fundus camera 
with electronic flash, better optics and an affordable price, imaging the central 30o 
pole of the retina.   
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Figure 1.5.4: Zeiss-Nordenson fundus camera (www.museumofvision.org) 
 
 
In the 1970s, Nikon developed the first wide angle fundus camera at 45o.  Fundus 
cameras in use today feature variable wide angle lenses ranging from 15o to the full 
fundus view (from pole to pole).  In the 1990s Polaroid film began being used to 
record retinal images.  In the 1980s non-mydriatic 45° cameras were introduced in 
the UK originally using 35mm film followed by Polaroid film and now digital imaging.   
 
1.5.2 Methods of screening for diabetic retinopathy 
There are several methods currently available for visualising the retina, including 
direct ophthalmoscopy, fundus photography, slit lamp biomicroscopy and 
fluorescein angiography.  Fluorescein angiography is held as the gold standard for 
detecting DR, however there are side effects to fluorescein making it less desirable 
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for general population screening.  Deciding on the best method for screening has 
been the subject of much debate.  Direct ophthalmoscopy with mydriasis was 
shown to have a sensitivity of 65% when used by ophthalmologists, 33-66% general 
practitioners and 48-83% optometrists, (Harding et al. 1995, Owens et al. 1998, 
Younis et al. 2002) falling short of the >80% sensitivity for detecting DR 
recommended by the Exeter standards.(British Diabetic Association 1997)  Indirect 
ophthalmoscopy using slit lamp biomicroscopy and Volk lenses by ophthalmologists 
and optometrists had a sensitivity of 91% and specificity of 95% for the detection of 
sight-threatening DR.(Moss et al. 1985, Kleinstein et al. 1987)  The widespread 
availability was an advantage for this method of detection however, slit lamp 
biomicroscopy requires considerable skill and the procedure could be time-
consuming.  The National Screening Committee (NSC) also had concerns with this 
method for use in screening programmes as quality assurance would be difficult to 
assess.(Garvican et al. 2000) 
 
In comparison with direct ophthalmoscopy, retinal photography by non-mydriatic 
cameras with mydriasis has been shown to have adequate sensitivity at >80%, 
therefore meeting the Exeter standards for screening.  Non-mydriatic and mydriatic 
photography was compared by Moss in 1985 with equivalent agreement between 
the methods (82.5% and 86.5% respectively).(Moss et al. 1985)  However, non-
mydriatic photography without mydriasis has been shown to be less sensitive mainly 
due to the pupillary constriction of the second eye following flash photography in the 
first.(Younis et al. 2002)  Therefore, retinal photography with non-mydriatic cameras 
following dilation was the recommended method for screening in the UK.(Garvican 
et al. 2000, The National Screening committee 2000) 
 
Earlier debates regarding the method of screening has been the use of Polaroid vs. 
35mm film.  Advantages of Polaroid film were the availability of an immediate image 
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allowing discussion with the patient at the time of appointment.  However Polaroid 
film was found to have poor resolution, could fade, was expensive, difficult to store 
and easy to loose from patient files.(Taylor 1996)  35mm film was found to have a 
much higher resolution but the films took several days to develop.  Both of these 
media have now been overtaken with the advancement of digital photography which 
was found to be comparable with 35mm in sensitivity and specificity for detecting 
sight-threatening DR.(Li et al. 2010b)  Even compression of the images did not 
compromise gradeablity.(Li et al. 2010a)   
 
Digital photography has several advantages over its predecessors.  In comparison 
to direct and indirect ophthalmoscopy there is the creation of a permanent record, 
reduced time requirements and a lower skill level to achieve similar levels of 
sensitivity and specificity.  In comparison to Polaroid and 35 mm film there are fewer 
storage issues and less chance of the images fading or being destroyed.  Also the 
advances in computer technology allow for easier manipulation of images and 
therefore easier grading, storage and analysis.  Camera based screening with 
digital storage of images is the preferred option for screening.(Garvican et al. 2000) 
 
Following the introduction of digital imaging and the continuing debate over the 
number of fields required to adequately classify DR, recent advancements have 
included the development of widefield scanning laser ophthalmoscopy and optical 
coherence tomography,(Virgili et al. 2007, Wilson P J et al. 2010, Wessel et al. 
2012, Prescott et al. 2014) which maybe incorporated into screening in the future.
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1.5.3 Screening for diabetic retinopathy 
Screening is defined as “the process of examining a group of people for the 
presence of a disease” (Wilson et al. 1968) with its prerequisites being: 
 The disease must appear in a defined population 
 The population must be identifiable 
 The disease must present a health problem 
 There must be effective treatment for the disease 
 Screening must be cost effective and improve quality of life (Kohner 1993) 
 
As photocoagulation is an effective treatment for PDR especially when applied in 
the early stages of PDR when it remains asymptomatic, widespread screening for 
DR has been advocated.  In 1989, the St. Vincent Declaration (International 
Diabetes Federation 1990) identified strategies for the control of chronic diseases in 
developed countries.  The key five year targets for diabetes were 'to elaborate, 
initiate and evaluate comprehensive programmes for detection and control of 
diabetes and its complications' and to 'implement effective measures to reduce new 
blindness due to diabetes by one third or more', among other directives relating to 
cardiovascular disease, renal disease and amputations.   
 
A protocol for screening for DR and a field guide for those involved in screening in 
Europe was published in 1991.(Retinopathy Working Party 1991)  It stated that the 
cost of organising nation-wide screening was substantially lower than the costs 
involved in late and often unsuccessful treatment and supportive care for people 
who had become blind.   
 
Screening in the UK remained patchy throughout the 1990s and in those areas 
where screening was taking place different methods were in use (direct 
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ophthalmoscopy by physicians/GPs, community or hospital based retinal 
photography and ophthalmoscopic examination by optometrists).(Younis et al. 
2002)  The methods used were dictated by several factors including local policy, 
historical activity and funding issues.   
 
Thompson et al surveyed health authorities between 1994-95, whilst Bagga et al 
surveyed diabetologists in 1996 to find out if they had a policy on screening for DR 
and if they were purchasing screening services.(Bagga et al. 1998, Thompson et al. 
1999) They concluded that DR screening was in a period of transition and that 
whilst the St Vincent declaration had served as an important catalyst for change in 
the UK the direction in which service provision was developing was less clear.   
In 1999 the Royal College of Ophthalmologists together with Diabetes UK, 
developed plans for a national screening programme in England, Wales, Scotland 
and Northern Ireland to combat the adhoc nature in which they had been set up 
historically.(Garvican et al. 2000)  The National Service Framework (NSF) for 
diabetes was published in 2001 for England and in 2002 for Wales.(Department of 
Health 2001a, Welsh Assembly Government 2002)  Both documents set out key 
directives necessary to raise the standards of care for diabetes.  One of the key 
recommendations for DR was the need for regular surveillance of adults with 
diabetes and early laser treatment of those identified with sight-threatening DR, 
which would then reduce the incidence of visual impairment and blindness in 
persons with diabetes.  In conjunction with the NSF, the NSC and the National 
Institute for Clinical Excellence (NICE) published guidelines and recommendations 
for the preservation of sight in persons with diabetes. (Department of Health 2001b, 
National Institute for Clinical Excellence 2002)  The primary objective was to identify 
all undiagnosed sight-threatening DR and facilitate timely onwards referral to 
hospital eye services (HES). The secondary objective was to identify the presence 
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of any DR so that improvements in glycaemic control, hypertension and 
dyslipidaemia could be implemented where necessary. 
 
1.5.4 Screening intervals for diabetic retinopathy 
Annual screening was recommended by the clinical standards advisory group on 
standards of care for people with diabetes,(Grewing et al. 1994) by the then British 
Diabetic Association (BDA, now Diabetes UK) specialist workgroup on visual 
handicap,(Kohner et al. 1996) and in guidelines for DR issued by the Royal College 
of Ophthalmologists.(Royal college of Ophthalmologists 2005)  This 
recommendation was made based on expert opinions, as there was no evidence 
from clinical trials or observational studies on which to base this recommendation.  
The annual timescale also fitted with the annual review for people with diabetes 
conducted in general practice.  However, it was at the time proposed that this 
situation would be re-evaluated when established screening programmes had 
additional data available.  Although screening for DR has been shown to be cost 
effective, DR screening programmes are expensive.(Javitt et al. 1989, James et al. 
2000)  In these times of increasing healthcare expenditure, all services are under 
increased pressure to be as cost effective as possible, with prudent healthcare 
being very much promoted in Wales.(1000 lives improvement service in Public 
Health Wales 2014)  Extending the screening interval in those at low risk could 
improve the cost effectiveness of DR screening programmes (Rein et al. 2011, 
Chalk et al. 2012) and meet the principle of prudent healthcare of 'delivering the 
best-evidence based treatment and services to the most appropriate level, based on 
individual need.'(1000 lives improvement service in Public Health Wales 2014) 
 
There is evidence from small screening programmes in the UK, Iceland, Italy, 
Sweden and Denmark that extending the screening interval in persons without DR 
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is safe (Younis et al. 2003a, Younis et al. 2003b, Olafsdottir et al. 2007, Agardh et 
al. 2011, Aspelund et al. 2011, Jones et al. 2012, Looker et al. 2013, Porta et al. 
2013, Stratton et al. 2013) and cost-effective.(Chalk et al. 2012)   
 
In the UK, Younis et al demonstrated that screening intervals could safely be 
extended to once every five years in persons with type 2 diabetes and type 1 
diabetes without evidence of DR.(Younis et al. 2003a, Younis et al. 2003b)  
However, a maximum screening interval of once every 2-3 years was recommended 
due to a possible fall in compliance if screening intervals were overly long.  Jones et 
al also demonstrated that the incidence of referable DR (RDR) and PDR in persons 
with type 2 diabetes without evidence of DR was sufficiently low to allow extension 
of the screening interval beyond annual, although they stopped short of 
recommending a screening interval.(Jones et al. 2012)  Stratton et al suggested that 
the risk of developing sight-threatening DR is different even among persons without 
DR at first screening.(Stratton et al. 2013)  They, therefore suggested that the DR 
results from two sequential annual screening visits should be combined to 
determine the level of risk and inform the screening intervals.  Looker et al also 
suggested that a screening interval of once every two years could be appropriate for 
persons without evidence of DR at two consecutive screening events, resulting in a 
40% reduction in people screened.(Looker et al. 2013)  In addition the four nations 
in the UK are expected to report to the NSC on findings from a research project 
combining datasets from 4 screening programmes in England, as well as the 
National screening programmes in Wales, Scotland and Northern Ireland.(Four 
Nations Study Group 2013)   
 
In Denmark, Aspelund et al used a mathematical algorithm to set screening 
intervals for each person based on clinical risk factors such as diabetes type, 
duration of diabetes, glucose control, blood pressure and the level of DR.(Aspelund 
61 
 
et al. 2011)  The conclusions of this study were that the same results were achieved 
through individualised screening as annual screening with 59% fewer examinations.  
In Iceland screening intervals for persons without DR have been extended to 
biennial, and over a 10 year period no person experienced a delay in treatment of 
DR.(Olafsdottir et al. 2007)  On detection of DR annual screening is reinstituted.  
Whilst in Sweden, screening intervals have been extended to triennial for persons 
with type 2 diabetes, under good glycaemic control (6.4%±1.4), with a short duration 
of diabetes (6 years) and without DR.(Agardh et al. 2011)  At the three year follow 
up screening no person had developed PDR and only three people had developed 
macular oedema, however only one person required treatment.  Porta et al in Italy 
has recommended biennial screening in all persons without DR.(Porta et al. 2013)  
They also suggested the possibility of further stratifying the screening interval as 
persons using insulin with a long duration diabetes (≥10 years) progressed more 
rapidly to RDR than those not using insulin with a shorter duration of diabetes.  
Evidence from large scale screening programmes and populations with access to 
more putative risk factors than screening programmes routinely collect prior to this 
study however, is lacking.(Thomas et al. 2012) 
 
1.6 Aims and Objectives of this Thesis 
The aim of my study was to determine the epidemiology of DR in Wales, UK based 
on the National Diabetic Retinopathy Screening Service for Wales (DRSSW).  
Therefore the prevalence and incidence of DR was estimated and the limited 
putative risk factors collected by the DRSSW were assessed for their association 
with the development and or progression of DR.  The screening interval for DR in 
Wales is currently annual for all persons with diabetes.  Therefore this thesis aimed 
to determine whether annual screening was necessary in persons with diabetes 
without DR at screening, or if a longer screening interval could be safely introduced.   
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In addition the prevalence and incidence of DR was also assessed in a population 
undergoing screening within a private diabetes management programme in 
Johannesburg, South Africa.  This second data set provided a unique opportunity to 
assess additional putative risk factors and their association with the development of 
DR over a longer period of time, but in a small sized population.  It also provided an 
opportunity to assess whether annual screening for DR in persons with diabetes but 
without evidence of DR was necessary in other ethnically diverse populations.  
 
This study addresses these issues by retrospective analysis of the DRSSW and the 
centre for diabetes and endocrinology (CDE) in Johannesburg, South Africa 
databases.  The DRSSW is a national screening programme providing a large 
database, whilst the CDE is a smaller diabetes management programme providing 
data on a much wider range of putative risk factors.  As assessment of visual acuity 
forms part of the screening procedures an additional aim of this thesis was to 
assess the level of visual impairment and blindness within both the DRSSW and 
CDE. 
 
  
 
 
Chapter 2 
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2.1 Diabetic retinopathy screening  
2.1.1 Screening methods  
Several methods including direct and indirect ophthalmoscopy and retinal 
photography have been used to visualise the retina to permit the detection and 
assessment of DR.  Direct ophthalmoscopy has been shown not to have adequate 
sensitivity (49%) for screening for DR.(Sussman et al. 1982)  Indirect 
ophthalmoscopy with slip lamp biomicroscopy has been shown to have adequate 
sensitivities (96%) and specificities (93%) for screening however, the method 
required considerable skill and training.(Sussman et al. 1982, Garvican et al. 2000)  
Retinal photography with images captured on 35mm film by a specially trained 
technician was proven to have higher sensitivities and equivalent specificities 
compared to direct ophthalmoscopy performed by an experienced ophthalmologist 
(sensitivity 89% vs. 65% and specificity 86% vs. 97%).(Harding et al. 1995)  Retinal 
photography (35mm film) also has the added benefits of a permanent record, 
beneficial for quality assurance.   
 
Initially retinal photography for screening purposes was captured using Polaroid 
images.  The benefit of this was that the image was available immediately, however 
the images were often lost from patient's records and would degrade over time.  In 
contrast 35mm film provided better quality images,(Jones et al. 1988) with a higher 
resolution over Polaroid, with the benefits of not degrading.  However, the time 
taken to develop 35 mm film at approximately 5 days to allow grading was a distinct 
disadvantage and also did not allow images to be shared with patients at the time of 
appointment.  Studies assessing the performance of 35mm film vs. Polaroid have 
demonstrated that using 35mm film had a better detection of DR lesions.(Pardhan 
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et al. 1991)  In more recent years the advent of digital cameras has allowed 
improved storage of images with the added benefit of the image being immediately 
available and also providing the possibility of image enhancement and analysis.  
Studies have shown close agreement (weighted kappa 0.88) between digital images 
and 35mm film,(George et al. 1998, Henricsson et al. 2000) and improved detection 
of DR and sight-threatening DR compared to Polaroid images.(Ryder et al. 1998) 
 
2.1.2 Screening for DR in Wales, UK 
During the early 1990s, there were many different methods of screening in 
operation in England and Wales including ophthalmoscopy and retinal photography 
(Polaroid and 35 mm film).(Younis et al. 2002)  The Welsh community diabetic 
retinopathy study (WCDRS), funded by the department of health, set out to compare 
the different methods of screening i.e. direct ophthalmoscopy versus retinal 
photography (two 45° field Polaroid film or 35mm colour film transparencies) 
following mydriasis at general practice (GP) locations.(Gibbins et al. 1998, Owens et 
al. 1998, Gibbins 1999)  The study recruited 644 persons with diabetes from four 
GPs in Wales who subsequently attended two screening sessions, over a three year 
period.  A validated grading system for DR was used, which was derived by the 
European (St. Vincent) DR working group.(Kohner et al. 1990)  Clinical 
ophthalmoscopy was performed by both GPs and optometrists whilst the retinal 
images were assessed by a diabetologist in addition to the GPs and optometrists.  
 
In this community setting, retinal photography was shown to be a more sensitive 
screening technique for detecting sight-threatening DR than direct ophthalmoscopy 
with sensitivities ranging from 87.3% to 97.1% for 35mm or Polaroid film vs. 67.1% 
to 82.2% for ophthalmoscopy and specificities of 82.7% to 87.4% vs. 88.5% to 
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93.8% respectively.(Gibbins et al. 1998)  It was apparent that, whoever acted as 
assessor (GP or community optometrist or specialist optometrist), the use of 35mm 
retinal photographs improved sensitivity for the detection of sight-threatening DR by 
between 10% and 20% compared to ophthalmoscopy (GP 79.2% vs. 62.6%, 
community optometrist 73.9% vs. 88.2% and specialist optometrist 69.9% vs. 86.1% 
respectively).  This observation had also been demonstrated in other previous 
studies.(Buxton et al. 1991, Peters et al. 1993, Harding et al. 1995)   
 
In addition, the WCDRS also demonstrated that it was possible to organise an 
effective mobile screening service for DR in a community setting, involving three 
regional health authorities in South Wales.  Through the close co-operation between 
different health care sectors, with the then 'high' prevalence rate of known diabetes 
at 2.1%, there was a high attendance rate (84.3%) at screening sessions.(Gibbins 
et al. 1989, Owens et al. 1998, Gibbins 1999) 
 
Following the WCDRS a pilot regional mobile DR screening programme was 
commissioned in 1998 by the Bro-Taf Regional Health Authority in South Wales.  
This initial Bro-Taf DRSS proved that community based mobile screening could be 
provided on an annual basis for a population of approximately 19,000 persons with 
diabetes within the regions of Cardiff, Rhondda Cynon Taf, Merthyr Cynon and Vale 
of Glamorgan.  Subsequently in 2002, following the success of the Bro-Taf regional 
screening programme, the National DRSSW was commissioned by the Welsh 
government to meet one of the objectives of the National Service Frameworks for 
Diabetes in Wales.(Welsh Assembly Government 2002) 
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2.1.2.1 Diabetic retinopathy screening service for Wales, UK 
In 2003, the DRSSW moved into its permanent base at Treforest, just outside 
Cardiff,(Figure 2.1.1) and began screening for DR in the areas of Gwynedd, Ynys 
Mon and Blaenau Gwent in addition to the Bro Taf region in its first year of 
operation.  Satellite centres were then opened in Caernarfon (North Wales) and 
Carmarthen (West Wales) (Figure 2.1.1)   
 
Figure 2.1.1: DRSSW main base in Treforest, South Wales and location of satellite 
centres 
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The DRSSW had centralised administration and retinal grading at the Treforest 
base as well as hosting local photography teams (consisting of a photographer and 
a health care assistant [HCA]) for screening in South Wales (Figure 2.1.2).  The two 
satellite centres provide a base for the North and West Wales photography teams.  
The DRSSW is a community based mobile screening service using both bespoke 
vans to transport equipment for screening to approximately 240 clinic venues (GP 
surgeries, hospital and community venues) as well two large dedicated screening 
vans to facilitate screening in remote locations or where access to adequate NHS 
facilities is difficult (Figure 2.1.3).  In 2006, screening became available to the last 
remaining region of Wales i.e. Monmouth and all 100,000 eligible persons (at that 
time) were offered a screening appointment by the end of 2006.  Therefore 
screening for DR for all 162,291 eligible persons (numbers correct in May 2012) 
with diabetes in Wales has been provided by the DRSSW since 2006. 
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Figure 2.1.2: DRSSW main base in Treforest, South Wales A) administration department B) grading department during the study period 2005-
2009 
A) 
Administration :Scheduling staff (10) Call and recall 
system – ‘robust’ 
Appointment letters dispatched : 
Location and date choices 
Two appointments only given 
Attendance/DNA list sent to GP 
Calls per day 300-500 
01.12.06-28.02.07  ~20,000 calls 
Results sent to : Patient, GP, Diabetologist & 
Ophthalmologist 
Administration:  
Appointments staff  
69 
 
Figure 2.1.2 B: continued 
Diabetic Retinopathy Graders (16) 
Chief Grader (1) 
Senior Grader (1) - Myself 
Graders (14)   
 
Training schedule : 
6 week initiation course 
18 month to final grade level 
Diploma in Retinal Screening (C & G) 
Quality Assurance QA : 
Monthly 
Professional body : 
British Association of Retinal 
Screeners (BARS) 
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Figure 2.1.3: Two modes of mobile screening, 1) small vans to transport equipment 
to clinics and 2) the dedicated mobile screening unit. 
 
 
Organisation of screening 
The procedure for screening was initiated following referral predominantly from 
primary care (GPs), but also from secondary care (hospital based services).  All 
persons registered with a GP in Wales with diabetes aged 12 years and over were 
entitled to be referred to the DRSSW.  Exclusions from screening included those 
under the age of 12 years, under the care of hospital eye service for DR, registered 
blind and without the perception of light in both eyes, medical reasons as 
determined by the persons GP or clinical director of the DRSSW for reasons such 
as terminal illness or where screening may cause harm etc and those who did not 
wish to participate in screening.  Referrals were required to contain demographic 
details including: name, address, date of birth, date of diagnosis of diabetes, type of 
diabetes and current diabetes treatment. Unfortunately very often the information 
received from primary care was incomplete (see section 2.2.1 for details).  The 
1) 
2) 
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procedures involving registration call and recall of persons for screening at the 
DRSSW are illustrated in Figure 2.1.4. 
Figure 2.1.4 The Registration, call and recall process.   
 
Key: DNA - Did not attend appointment; HES - Hospital eye services; STDR - Sight-
threatening DR; DR - Diabetic retinopathy; GP - General practitioner; NSTDR - Non sight-
threatening DR; *Exclusion from screening decided by persons GP. 
 
The DR screening clinics were organised by administrators at the Treforest base 
who would send out appointments, and later dispatched the results to the patients, 
GPs, and where applicable the hospital based clinicians (at diabetic clinics).  Once 
the location and timing of the screening clinics were confirmed, the photography 
teams, would be assigned to each clinic.  At the clinics, a HCA would confirm the 
personal details, take a brief eye health history and obtain consent for each of the 
following: instillation of mydriatic eye drops, photography (lens and retina), grading 
and the use of the images for teaching and research.  The HCA then tested the 
current/habitual  visual acuity using a 3 meter illuminated Snellen chart, (with or 
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without the use of distance glasses). If this was worse than 6/9 a pinhole visual 
acuity measurement was then undertaken, followed by the administration of 
mydriatic eye drops (1.0% tropicamide).  After approximately 15-20 minutes, to 
allow for pupil dilation, digital retinal images were taken by the photographer.  Two 
standard 45° retinal images (one macular and one nasal field) per eye were taken 
(Figure 2.1.5).  
Figure 2.1.5: Example of  2 x 45˚ retinal images (macula centred and nasal) taken 
per eye as standard by the DRSSW 
 
 
Additional images were captured during the appointment if the photographer felt 
more information was required, such as a better view of peripheral lesions or 
external images, if images were of poor quality.  All images were then stored on the 
photographer’s laptop and downloaded onto the main server in Treforest at the end 
of each day/or week depending on the photographers schedule and location.  
Images were transmitted across secure NHS lines from the remote centres to the 
server at Treforest.  All images are retained on the central server at Treforest for a 
minimum of eight years. 
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Training 
All staff within the DRSSW participate in an initial 6 week internal training 
programme consisting of: lectures on diabetes, epidemiology, pathophysiology and 
the natural history of diabetic retinopathy, the anatomy of the eye, an introduction to 
the grading process, an introduction to retinal photography as well as administrative 
matters such as standard operating procedures.  Once the generic (6 week) training 
programme is complete staff undergo further intensive departmental training.  The 
further training involves a shadowing process: where photographers attended clinics 
and graders and administrators observed senior team members in base.  
Photographers receive an intensive course on camera use and maintenance and 
must complete a portfolio of 50 patients before being allowed to take reduced clinics 
alone.  Graders undergo an 18 month training process with monthly quality 
assurance.  Once quality assurance confirmed staff were competent to grade 
images without lesions they move up to the next level of the grading protocol until at 
the end of the 18 month training process they are competent to refer cases into 
ophthalmology and participate in secondary grading.  All staff are also required to 
complete the City and Guilds diploma in retinal screening. 
 
2.1.2.2 Evolution of Grading 
The grading process 2003-2008 
The DRSSW was launched in 2002, and utilised the same grading process as the 
Bro-Taf DRSS.  The process involved checking the images in order to prioritise 
those images with sight-threatening conditions.  These cases were seen first by the 
central grading staff so that if necessary, appointments could be arranged at the 
nearest HES as soon as possible.  In some cases where HRC were present, 
images were graded and referred to HES the same day.  All other retinal images 
were graded in date order.  The grader would perform a full disease assessment 
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firstly of the right eye followed by the left eye using the DRSSW grading protocol, 
this initial grading would constitute the primary grading event.  Following primary 
grading all images with disease identified (DR and other lesions), 10% of images 
without DR and ungradeable images underwent a secondary grading event.  
Secondary grading was carried out by a more senior grading team member where 
the grading was either finalised, or sent for tertiary grading.  The tertiary grading 
event was conducted by an ophthalmologist, or the Clinical Director of the DRSSW 
for cases of sight threatening lesions such as PPDR or worse, or where 
maculopathy or other eye disease were present.  This grading process for the 
period of 2003-2008 is represented in figure 2.1.6. 
Figure 2.1.6: Grading process 2003-2008  
 
Stable R2, M1, M2 consists of lesions which have either been seen in HES previously and 
determined to be stable or when current images were compared to previous images lesions 
were determined to be unchanged 
Primary grading 
Secondary grading 
Hospital eye service Annual rescreen 
90% of normal 
patient image 
sets (R0 M0) 
All image sets with DR R1, R2 
R3 M1 and M2 and 10% of 
normal image sets (R0 M0) 
and ungradeable images 
R2, R3, M1 and M2 and 
other eye disease 
R0, R1, M0 
Urgent referrals R3 M2 
Tertiary grading 
R2, R3, M2 and other 
eye disease 
?Stable? 
R2, M1 
M2 
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The grading process 2008 to the present day 
The grading process was amended in 2008, to include an arbitration grading stage 
(Figure 2.1.7).  Primary grading still involved a full disease assessment, with all 
screen positive cases and 10% of all screen negative cases being sent for 
secondary grading.  Any disagreements between primary and secondary grading 
then undergo arbitration grading, by a more senior grader.  Referral for tertiary 
grading occurs for the same reasons as previously mentioned.  All ungradeable 
images are second graded and then referred to HES for further assessment.   
Figure 2.1.7: Grading process 2008 to the present day  
 
Stable R2, M1, M2 consists of lesions which have either been seen in HES previously and 
determined to be stable or when current images were compared to previous images lesions 
were determined to be unchanged. 
 
Primary grading 
Secondary grading 
Arbitration grade 
Hospital eye service Annual rescreen 
90% of normal 
patient image 
sets (R0 M0) 
All image sets with DR R1, R2 
R3 M1 and M2 and 10% of 
normal image sets (R0 M0) 
Agreement between 
first and second 
grades of R0, R1, 
and M0 
Disagreement over grades 
and or referral 
requirements 
R2, R3, M1, M2 and 
other eye disease 
R0, R1, M0 
Agreed R2, R3, 
M2 
Urgent referrals R3 M2 
Tertiary grading 
Other eye disease, R2, 
R3, M1, M2 
?Stable?R2, 
M1,M2 
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Outcome of grading  
Outcomes of grading were rescreen in 12 months, rescreen in 3 months (in the case 
of technical failures) or refer to HES. If the outcome was refer to HES the timescales 
were as follows:  routine 3-6 months, soon 4-6 weeks, urgent 2-4 weeks and 
emergency within 2 weeks. The outcome was dependant on the final grade of DR 
and is detailed in Table 2.1.2. 
Table 2.1.2: Grading outcomes from the DRSSW 
DR grading Meaning of grade Outcome 
R0 MO No DR  
 
Routine 12 month rescreen 
R1.1 M0 Minimal BDR  
R1.2 M0 Moderate BDR  
R1.1 M1 Mild BDR with possible maculopathy  
R1.2 M1 Moderate BDR with possible 
maculopathy 
 
R2 M0 PPDR  
R2 M1 PPDR 
R1.1 M2 Minimal BDR with definite 
maculopathy  
Routine/soon referral to HES 
 
R1.2 M2 Moderate BDR with definite 
maculopathy  
R2 M2 PPDR with definite maculopathy  Soon referral to HES 
R3 M0 PDR   
Urgent referral to HES R3 M1 PDR  
R1/2/3 M2 Any DR with exudative maculopathy 
and signs of oedema 
 
R3 M0/1/2 PDR with/without maculopathy but 
pre-retinal or vitreous Hm present 
Emergency referral to HES 
No DR - no diabetic retinopathy; BDR - background diabetic retinopathy; PPDR - pre-
proliferative diabetic retinopathy; PDR - proliferative diabetic retinopathy; Hm - 
haemorrhage; HES - hospital eye service 
 
2.1.2.3 Quality assurance  
All departments at the DRSSW i.e. administration, photography and grading are 
subject to internal quality assurance (QA).  There was regular monthly monitoring of 
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the call/recall system, validation of GP lists, monitoring of the quality of images 
taken by photographers as well as monitoring of the graders’ competence (Table 
2.1.3).  All internal QA systems are ongoing and supported by continuous training.   
 
Table 2.1.3: Grading monthly QA form 
 Primary grader 
Se
co
n
da
ry
 
gr
ad
e
r 
 R0 R1.1 R1.2 R2 R3 
R0      
R1.1      
R1.2      
R2      
R3      
Blue denotes complete agreement between primary and secondary graders; above/below 
would indicate under or over grading by primary grader; sensitivities, specificities and 
positive predictive values are calculated based on this cross tabulation 
 
External Quality Assurance (EQA) of the DRSSW is provided by the UK National 
Diabetic Eye Screening Programme with visits taking place once every three years.  
The EQA team consisted of a member from public health, a clinical lead 
(ophthalmologist, diabetologist, optometrist), a programme manager and a 
screening/grading reviewer.  The visits assessed the programme based on whether 
or not it is meeting the minimum clinical standards.  
 
2.1.3 Screening for DR in South Africa 
Outside the UK screening for DR has been adopted using a variety of different 
models of delivery and sophistication depending on the availability of 
ophthalmologists, the technology for screening and funding.(Klein et al. 1985, 
Kristinsson et al. 1995, Agardh et al. 2011, Murthy et al. 2012, Olafsdottir et al. 
78 
 
2013)  However, many countries remain without screening or have limited and 
rudimentary programmes available.  This is especially true of developing nations 
where there are other pressures on their scarce financial resources. (Vashist et al. 
2011, Khandekar 2012, Murthy et al. 2012, Burgess et al. 2013, Ramasamy et al. 
2013) 
 
In South Africa, screening for DR at the primary care level is almost 
nonexistent,(Seggie 2014) despite guidelines recommending annual screening 
since 2002, and the country joining the World Health Organisation (WHO) and 
International Agency for the Prevention of Blindness (IAPB) vision 2020 
programme.(Department of Health 2002)  Where it does exist it is conducted on an 
adhoc and opportunistic basis by a range of healthcare workers.(Cook et al. 2014)  
Although previous feasibility studies found that screening could increase fundal 
examinations by 42%, approximately 40% of those screened would require referral 
to already overstretched ophthalmology departments.(Mash et al. 2007) 
 
2.1.3.1 Centre for Diabetes and Endocrinology, Johannesburg 
South Africa 
Whilst screening for DR in the public sector in South Africa still faces many 
challenges, a diabetes management programme with annual screening for DR has 
been operational in the private sector since 1994, by the Centre for Diabetes and 
Endocrinology (CDE), Johannesburg (Figure 2.1.8).(Distiller et al. 2010)  The CDE 
has a network of 262 smaller centres providing care to urban, rural and under-
developed communities in South Africa.  The programme is paid for by medical aid 
schemes and has more 18,000 persons with diabetes registered.  The centre 
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utilises a trained multidisciplinary team of healthcare workers, including doctors 
specifically trained in diabetes management. 
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Figure 2.1.8 Map of South Africa 
 
 
The CDE operates a diabetes management programme for the treatment and 
management of diabetes, and prevention of its complications.  All persons with 
diabetes enrolled in the programme are entitled to a minimum standard of care as 
set out in Table 2.1.4.(Distiller et al. 2010)  
 
All affiliated centres use a customized internet-based clinical management 
programme, which stores all patient contacts, findings, medication dispensed and 
laboratory results.(Distiller et al. 2010)  This facility is used to check patient and 
centre compliance with the adopted ‘Minimum Care Guidelines’.  In addition, there is 
a full-time medical practitioner who conducts an ongoing peer review and audit of 
the centres annually.   
 
Address: 81 Central street, 
Houghton 2198 
Johannesburg 
South Africa 
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Table 2.1.4: Minimum care standards within the CDE for persons with diabetes 
Service Description  Frequency  
Consultations: 
Doctor  
 
x 2 annually 
Nurse educator x 2 annually 
Nutritionist x1 annually 
Podiatrist x 1 annually (screening) 
DR screening  x 1 annually 
Exercise physiologist If required 
Clinical psychologist  If required 
Laboratory tests HbA1c x 2 annually (minimum) 
Lipid profile  x 1 annually (minimum) 
Renal function, microalbuminuria, eGFR x 1 annually (minimum) 
Full blood count 
Blood Pressure 
x 1 annually (minimum) 
x 2 annually 
24-h emergency line for community 
management of 
diabetes emergencies and advice 
24 ⁄ 7 ⁄ 365 
 
All diabetes medications 
and monitoring equipment 
As prescribed 
Insulin  As prescribed 
Oral glucose-lowering agents  As prescribed 
Blood glucose meters and test strips  As prescribed 
Glucagon hypoglycaemia kit (insulin 
therapy_ 
replaced 
on use ⁄ expiry) 
Ketone test strips (type 1 diabetes) replaced 
on use ⁄ expiry) 
Syringes, needles, lancets  As prescribed 
Risk assumption for the 
costs of hospital admission 
Acute diabetes emergencies only 
 
eGFR - estimated glomerular filtration rate  ; 24-h - 24 hour; DR - diabetic retinopathy 
 
The HbA1c assays are undertaken at one of four locally available commercial 
laboratories.  The method used involves high-performance liquid chromatography, 
and the reference normal ranges for all laboratories were the same at 4.8–6.0%.  
Non-fasting lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol and 
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triglycerides) are analysed by enzymatic methods using automated 
techniques.(Distiller et al. 2010)  For any person, the same laboratory is used for 
follow-up purpose.   
 
2.1.3.2 Screening for DR within the CDE 
All persons with diabetes attending the CDE undergo routine digital retinal 
photography performed at the time of their first visit and annually thereafter.  Digital 
retinal photography is conducted in a darkened room using a non-mydriatic (NM) 
digital camera (Canon CR6–45NM) capturing one 45˚ macular centred image per 
eye without the use of mydriasis.  The photography is undertaken by one of two 
trained technicians, one of whom was a diabetes nurse educator.  All retinal images 
were graded at the time by a physician according to the CDE's own grading 
protocol.  Table 2.1.5 compares the South African and DRSSW grading protocols.   
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Table 2.1.5: DRSSW and South Africa's grading protocols 
DRSSW South Africa 
Grade Interpretation Grade Interpretation 
R0 No DR 0 No DR 
R1.1 Mild BDR 
< 5 Mas > 1 DD from fovea  
< 4 Hms > 1 DD from fovea 
3 Mas < 1 DD from fovea 
exudates > 2 DD from fovea with or 
without CWS (< 5) 
1 < 5 Ma / Hm 
R1.2 Moderate BDR 
≥ 5 Mas > 1 DD from fovea  
≥ 4 < 8 Hms > 1DD from fovea  per 
eye 
> 3 Mas < 1 DD from fovea with VA > 
6/12 
Circinate or grouped Ex > 2 DD from 
fovea but within arcades 
Questionable IRMA only in the 
presence of Ma/Hm 
2 > 5 Ma / Hm 
3 Grade 2 plus hard Ex 
4 Grade 3 plus deep Hm 
R2 Severe BDR (PPDR/NPDR) 
≥ 8 blot Hm per eye  
Venous irregularities, beading, 
reduplication, venous loops (but not 
on their own) 
Definite IRMA 
with or without CWS (but not CWS 
on their own) 
5 Grade 4 plus CWS or IRMA or venous 
beading 
R3 PDR/ADED 
NVD 
NVE 
Pre-retinal Hm 
Vitreous Hm 
Pre-retinal fibrosis 
Traction retinal detachment 
6 Neovascularisation 
Pre-retinal Hm &/ vitreous Hm 
7 Retinal detachment / rubeosis iridis 
8 not assessable due to small pupils / 
dense cataracts etc. 
9 not gradable/ lesions not due to DR 
10 blind due to DR 
Maculopathy 
M0 No Maculopathy present if hard exudates are within 1DD of the 
macula 
M1 Possible Maculopathy 
Ex < 2 DD >1DD from fovea 
> 3 Mas <1 DD from fovea with VA 
worse then 6/12 
Hm < 2DD from fovea with VA worse 
then 6/12 
M2 Definite Maculopathy 
Ex <1dd from fovea 
No DR - no diabetic retinopathy; BDR - background diabetic retinopathy; PPDR - pre-proliferative 
diabetic retinopathy; PDR - proliferative diabetic retinopathy; ADED - advanced diabetic eye 
disease; NPDR - non-proliferative diabetic retinopathy; Ma - microaneurysm; Hm - haemorrhage; 
Ex - exudate; IRMA - intra-retinal microvascular abnormalities; CWS - cotton wool spots; DD - disc 
diameter; 
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2.2 Data cleaning 
2.2.1 Diabetic retinopathy screening service for Wales DRSSW 
For the purpose of this study information for the time period 2005 to 2009 was 
extracted from the DRSSW database by the software company Digital Healthcare.  
Although the DRSSW had been operational since 2003, during 2004 there was a 
slight change in grading protocol.  Therefore only screening events taking place 
post 2005 were utilised for this study as the quality of the data prior to 2005 was 
uncertain.  All data analysis was conducted in SPSS version 16 and Excel 2007. 
 
During the data cleaning and validation process several inconsistencies in the data 
were noted.  These included unrecorded, or even changes in type of diabetes over 
time, unrecorded date of diagnosis of diabetes, as well as an 'unrealistic' age at 
diagnosis of diabetes for the type of diabetes recorded e.g. 50% of persons with a 
diagnosis of type 1 diabetes had an age at diagnosis of 30 years or more.  Whilst it 
is known that type 1 diabetes can manifest later on these cases are generally 
considered to be exceptions and need to be confirmed by GPs.  Therefore, in order 
to ensure the integrity of the analysis a number of exclusion criteria were imposed 
on the dataset, resulting in 43,759 persons being excluded out of a total of 135,152.  
These exclusions were: 
 Type of diabetes not recorded, n=29,807 
 Type 1 diabetes with an age at diagnosis of 30 years or more, n=3,105, 
However 730 of these were retained in the study for reasons detailed below 
 Type 2 diabetes with an age at diagnosis of less than 30 years, n=10,847
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The cut off age of 30 years at diagnosis of diabetes was proposed as it has been 
used in previous large scale epidemiological studies and clinical trials.(Klein et al. 
1985, Kohner et al. 1998)  Of the 3,105 persons with type 1 diabetes and an age at 
diagnosis of ≥ 30 years, 1,412 (45.5%) did not have evidence of DR at first 
screening.  In order to minimise the number of persons with type 1 diabetes 
excluded from the analysis, the GPs were contacted and asked to confirm type of 
diabetes, and date of diagnosis of diabetes for these 1,412 persons.  This resulted 
in 51.7% (730) being confirmed as having type 1 diabetes by their GP with an age 
at diagnosis of ≥ 30 years and therefore included in the subsequent analysis.  
12.2% (172) were confirmed as having type 2 diabetes, whilst the remaining 36.1% 
(510) remained without a diagnosis of diabetes as the GP practice would not 
confirm type of diabetes over the telephone.  Those persons originally classified as 
type 1 diabetes and subsequently confirmed as type 2 diabetes by GPs were 
excluded from the analysis.   
 
2.2.2 Centre for diabetes and endocrinology, Johannesburg South 
Africa 
Data from the CDE in South Africa was stored on an access database and 
anonymised before being transferred to us.  All images were graded at the CDE by 
a physician in charge of the persons care using the CDE standardised grading 
protocol.  Due to the differences between the CDE and DRSSW protocols (Table 
2.1.5) it was necessary to re classify the images graded by the CDE as having DR 
according to the DRSSW protocol.  All images were independently reviewed and re-
graded by myself or one of two senior retinal graders using the DRSSW grading 
protocol.  All persons originally graded as having no DR were not re-graded as this 
level of grading was the same in the South African and DRSSW grading protocols.   
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A total of 1,895 people required re-classifying as they had evidence of DR on retinal 
images, however images for 183 people were not available for this process and 
were therefore excluded from the dataset.  Therefore 1,712 images were re-
classified using the DRSSW grading protocol and a random sample of 123 (7.2%) 
images (n=238 eyes) underwent secondary grading by a second grader blinded to 
the results of the first grader to check agreement. 
 
There was complete agreement between first and second grader for the grade of 
any DR in 75.2% (n=179 eyes) (Table 2.2.1) and maculopathy in 82.4% (n=196 
eyes) (Table 2.2.2).  Disagreement between the first and second grader occurred 
most commonly in retinopathy grades R1.2 and R2 with disagreement in 9.2% of 
cases or in 22 eyes.  For maculopathy grades the most common disagreements 
were between M1 and M2 in 8.0% or 19 eyes.  There were 2 cases were a large 
disagreement in grades occurred.  In the first a retinal vein occlusion was present in 
the left eye which resulted in the first grader providing a grade of R0 M0 and the 
second grader giving R3 M2.  As this finding was not due to DR or maculopathy the 
grade R0 M0 was retained.  In the second vascular collaterals were present on the 
optic disc of the left eye, the first grader gave a grade of R3 M0 and the second 
grader gave a grade of R1.2 M0.  Therefore, as the new vessels graded by the first 
grader were collaterals the second grader grades were retained.  The inter-observer 
agreement level as assessed by Cohen's Kappa score for DR was moderate at 
58.5% and substantial at 72% for maculopathy.  There was a very good level of 
sensitivity for both DR at 96.8% and maculopathy at 93.8%.  However, specificity 
was slightly below the Exeter standards for  DR at 61.9% for DR and maculopathy 
at 86.2%.(British Diabetic Association 1997)  Where the disagreements occurred an 
arbitration grade was performed, on a total of 59 eyes, by the author and was taken 
as the final grade.  
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Table 2.2.1: Level of agreement between the first and second grader for DR 
 Grader 2 
G
ra
de
r 
1 
 R0 R1.1 R1.2 R2 R3 Total 
R0 13 (5.5%) 3 (1.3%) 3 (1.3%) 1 (0.4%) 0 20 
R1.1 6 (2.5%) 17 (7.1%) 7 (2.9%) 0 0 30 
R1.2 2 (0.8%) 11 (4.6%) 120 (50.4%) 20 (8.4%) 0 153 
R2 0 0 2 (0.8%) 20 (8.4%) 1 (0.4%) 23 
R3 0 0 1 (0.4%) 2 (0.8%) 9 (3.8%) 12 
Total 21 31 133 43 10 238 
Kappa score 58.5%, sensitivity 96.8%, specificity 61.9% 
 
 
Table 2.2.2: Level of agreement between the first and second grader for 
maculopathy 
 Grader 2 
G
ra
de
r 
1 
 M0 M1 M2 Total 
M0 94 (39.5%) 5 (2.1%) 3 (1.3%) 102 
M1 11 (4.6%) 25 (10.5%) 1 (0.4%) 37 
M2 4 (1.7%) 18 (7.6%) 77 (32.4%) 99 
Total 109 48 81 238 
kappa score 72.0%, sensitivity 93.8%, specificity 86.2% 
 
2.3 Study populations 
2.3.1 Diabetic retinopathy screening service for Wales 
In Wales in 2012, the prevalence of diabetes was approximately 5.9% (2012).  
Around 8.4% of people with diabetes in Wales during the study period were 
ineligible for screening for a variety of reasons including: 1.5% medical 
conditions/co-morbidities, 0.2% registered blind, 0.2% under the age of 12 years 
and 6.5% already being under the care of an ophthalmologist for DR.  Therefore, 
91.6% of persons with diabetes were eligible for screening.  However, 
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approximately 20% failed to attend their DR screening appointments.  Only details 
on those persons who attended screening were available for analysis,  therefore, 
further analysis relating to missed appointments could not be undertaken.  If for 
instance a person attended their first appointment, missed the second but attended 
the third appointment then the first appointment became their first screening event 
and the third appointment their second screening event. 
 
From January 2005 to November 2009, 91,393 persons over the age of 12 years 
underwent screening for DR by the DRSSW and met the inclusion criteria stated in 
section 2.2.1 (Figure 2.3.1).  5.5% had type 1 diabetes and 94.5% had type 2 
diabetes.  Ethnicity data was not collected by the DRSSW at the time, and so was 
not available for analysis in this population.  However, the majority of persons in 
Wales are Caucasian (95.6%), with 2.3% Asian, 0.6% Black and 1.5% other or 
mixed ethnic groups.(Office of National Statistics 2012)   
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Figure 2.3.1: Flow chart of inclusions and exclusions  
 
2.3.2 Centre for diabetes and endocrinology Johannesburg, South 
Africa  
South Africa has a population of more than 50.6 million the majority of whom are 
indigenous Africans (79.5%) with approximately 9% Caucasian, 9% Mixed Race 
and 2.5% Indian/Asian.(U.S. Department of State 2011)  The prevalence of diabetes 
in South Africa has been estimated at 5-10%, amounting to 2.5-5.1 million 
people.(Mash et al. 2007)  Approximately 18,000 of these were under the care of 
one of the CDE centres.  Our study population came from the CDE centre based in 
Johannesburg.   
 
90 
The 5,565 subjects who had DR screening at the CDE in Johannesburg between 
2001 and 2010 represent only 0.1%-0.2% of the total population estimated with 
diabetes in South Africa.  The study population consisted of 71.2% Caucasians, 
12.7% Indigenous Africans, 12.3% Indian Asians and 3.8% of Mixed race.  As the 
majority of the population in South Africa are Indigenous African, the population 
attending the CDE in Johannesburg is therefore not representative of the total 
population of South Africa.  In the study population the majority of persons had type 
2 diabetes (71.5%) with 27.6% having type 1 diabetes.  The remaining 0.9% with 
other forms of diabetes such as LADA and pre-diabetes/ impaired glucose tolerance 
(IGT), were excluded from all analysis.  Subjects included in this analysis were 
classified as having type 1 (1,537) or type 2 (3,978) diabetes according to the 
American Diabetes Association classification of diabetes.(American Diabetes 
Association 2010)   
 
2.3.3 Classification of DR employed in the study 
Levels of DR were classified as no DR if no lesions were detected, any DR when at 
least one microaneurysm and/or a blot haemorrhage were detected, background 
DR (BDR), when microaneurysms or haemorrhages or exudates were present 
which did not require referral to HES i.e. DR grades R1.1, R1.2 and maculopathy 
grade M1.  RDR, included PPDR (R2), and PDR (R3) as well as exudative 
maculopathy (M2).  RDR is the level at which further assessment by an 
ophthalmologist at HES is deemed necessary for both the DRSSW and CDE 
populations.  Grades were per person and based on the grade provided for the 
worst eye. 
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2.3.4 Classification of visual impairment and blindness 
The classification of visual impairment and blindness is based on the best recorded 
level of visual acuity in the better seeing eye.  The definition of normal vision, visual 
impairment and blindness was taken from the World Health Organisations criteria 
(World Health Organisation 2010) shown in Table 2.3.1
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Table 2.3.1: Classification of normal vision, visual impairment and blindness from WHOs definition and as applied in this thesis. 
WHO 
classification 
   Study    
  Log mar Snellen   Log mar Snellen 
0 Mild or no visual 
impairment 
Equal to or better 
than 
0.3  6/18 Normal vision Equal to or 
better than 
0.60 3/12 
1 Moderate Visual 
impairment 
Worse than 0.3 6/18 Visual 
impairment 
 0.78 3/18 to 3/36 
2 Severe visual 
impairment 
Worse than 
Equal to or better 
than 
0.1 
1.3 
6/60, 
3/60 
3 Blindness Worse than 
Equal to or better 
than 
1.3, 
0.02 
3/60, 
CF 
Blindness Equal to or 
worse than 
1.3 3/60 or worse 
4 Blindness  better than or equal 
to light perception 
0.02 CF 
5 Blindness  No Light perception    
6 Undetermined or 
unspecified 
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2.5 Aims 
 To estimate the prevalence and incidence of DR within two distinct 
populations of persons undergoing systematic screening for the presence of 
DR based in Wales, UK, and Johannesburg, South Africa. 
 To investigate the risk factors associated with the prevalence and incidence 
of DR.   
 To investigate the incidence of referable DR within defined subgroups of 
persons with type 1 and type 2 diabetes in order to elucidate low risk groups, 
in which the screening interval could be safely extended.   
 To estimate the prevalence of visual impairment and blindness within the 
DRSSW and CDE programs. 
2.6 Statistical analysis 
Statistical analysis of the DRSSW and CDE datasets were conducted separately.  
Prevalence of any DR, BDR and RDR was determined at first screening and the 
incidence of any DR, BDR and RDR over the course of the study were calculated in 
persons without evidence of DR at first screening using survival functions obtained 
from Kaplan Meier analysis.  The continuous data throughout this thesis were 
summarised by mean ±standard deviation, (SD) when the data was normally 
distributed and by median and interquartile range (IQR) if not normally distributed.  
Normality was checked using q-q plots.  Categorical data were presented as total 
numbers (n) and percentage (%).  The Student's t-test was used to compare the 
means of two groups and analysis of variance (ANOVA) to compare the mean of 
more than two groups for normally distributed continuous data.  Whereas Mann-
Whitney U and Kruskal Wallis tests were used for non-normally distributed 
continuous variables.  Pearson chi-squared test was used for categorical data.  P 
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values of <0.05 were taken as statistically significant.  Although extensive numbers 
of tests were performed, they were used only as an indication of differences 
between sub-groups for the identification of possible important explanatory variables 
which, in conjunction with univariate regression methods, yield a smaller subset of 
variables for multivariable analysis.  Therefore, adjustment for multiple comparisons 
was not necessary.   
 
Regression modelling was used to identify important risk factors for the 
development of DR.  Where the data was cross-sectional, outcomes were modelled 
using logistic regression analysis.  Longitudinal data was modelled using survival 
analysis, by fitting Cox proportional hazards models.  All estimates were 
accompanied by 95% confidence intervals (95% CI). 
 
Logistic regression analyses used in this thesis are common in medical research 
and were used to assess risk factors for the presence or absence of DR.  Odds 
ratios with 95% CI were used to denote the likelihood of an event occurring.  An 
odds ratio equal to one occurs when the odds are the same in two groups and is 
equivalent to no association between the exposure and the disease.(Kirkwood et al. 
2003).  Odds ratios (OR) less than one are interpreted as the event being less likely 
to occur for an increase in the predictor variable, whereas odds ratios larger than 
one are interpreted as the event being more likely to occur. 
 
Survival analysis used allowed the exploration of the time to an event of interest and 
in this thesis was the time to the first occurrence of DR – any DR, background DR 
(BDR) and referable DR (RDR).(Benitez-Parejo et al. 2011)  The Kaplan-Meier 
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estimate was used as this method avoids the assumption that individuals lost to 
follow up are censored half way through the interval.  The hypothesis, that the ratio 
of the hazard functions between two groups are the same, was tested using the log-
rank test.   
 
Cox proportional hazards regression was used to estimate the effect of defined risk 
factors on the incidence of any DR, BDR and RDR i.e. age at diagnosis; duration of 
diabetes; treatment of type 2 diabetes and gender in the DRSSW population and 
age at diagnosis; duration of diabetes; gender; HbA1c and hypertension in the CDE 
population.  The proportional hazards model assumes that the ratio of the hazards 
comparing different exposure groups remains constant over time relative to the 
hazard.  The proportional hazard model is the most general of the regression 
models because it is not based on any assumptions concerning the nature or shape 
of the underlying survival distribution. (Kirkwood et al. 2003)  A key reason for the 
popularity of the Cox model is that even though the baseline hazard is not specified, 
good estimates of regression coefficients, hazard ratios and adjusted survival 
curves can be obtained for a wide variety of data situations.  Therefore, the Cox 
model is robust and its results would closely approximate the results for the correct 
parametric model.   
 
The variables available for analysis in the DRSSW population were age, gender, 
age at diagnosis of diabetes, duration of diabetes, type of diabetes and treatment of 
diabetes.  Within the CDE population the variables available for analysis were age, 
gender, age at diagnosis of diabetes, duration of diabetes, type of diabetes, 
ethnicity, HbA1c , the presence of hypertension, total cholesterol level, 
96 
 
albumin:creatinine ratio, use of ACE inhibitors and aspirin, and the patients smoking 
history. 
 
For regression models, continuous data, i.e. age at diagnosis, duration of diabetes, 
HbA1c etc, were categorised to avoid assumptions of linearity.  The groups were 
separated into tertiles or quartiles for type 1 and type 2 diabetes separately to 
ensure an equal distribution.  The variables were sub-grouped for each analysis and 
are detailed in table 2.6.1.  In this thesis all variables, both time-independent and 
time-dependent, were assessed at entry into both the DRSSW and CDE 
programmes and therefore treated as time-independent variables. 
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Table 2.6.1: Details of subgroups of continuous variables 
  T1DM  T2DM 
 DRSSW Chapter 3  
Duration of 
diabetes (years) 
 <10 years <5 years 
 10-19 years 5-9 years 
 ≥20 years ≥10 years 
Age at 
diagnosis 
(years) 
 <10 years ≤55 years 
 11-20 years 56-65 years 
 21-29 years ≥65 years 
 Chapter 4   
Duration of 
diabetes (years) 
 ≤10 years 
11-19 years 
≥20 years 
<5 years 
5-9 years 
≥10 years 
Age at 
diagnosis 
(years) 
 ≤10 years 
11-20 years 
>20 years 
30-49 years 
50-59 years 
60-69 years 
≥70 years 
 CDE chapter 5   
Total Chol 
(mmol/L) 
Low <5  <5  
High >5  >5  
ACR (mg/mmol) Low <3  <3 
High >3  >3 
HbA1c (%)  <7  <6.6  
 7.0 -7.9 6.6-7.4  
 8.0-8.9  7.5 -8.9  
 >9  >9  
Duration of 
diabetes (years) 
 <7  <3 
 7-15 3-8 (1,360) 
 >15  >8 (1,224) 
Age at 
diagnosis 
(years) 
 <14  <46 (1,403) 
 14-26  46-55 (1,265) 
 >26  >55 (1,286) 
 Chapter 6   
Total Chol 
(mmol/L) 
 ≤4.43 
4.44-5.38 
≥5.39 
<4.90 
≥4.90  
ACR (mg/mmol) Low 
High 
<3 
>3  
 
HbA1c (%)  ≤7.4  ≤6.7 
  7.41-8.9 6.71-7.8 
  >8.9 >7.8  
Duration of 
diabetes (years) 
 ≤5  
6-11 
≥12 
<5  
5-10  
>10  
Age at 
diagnosis 
(years) 
 ≤12 
13-22 
23-33 
≥34 
<45 
45-50 
51-60 
>60 
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3.1 Introduction 
DR continues to be an important microvascular complication in both type 1 and type 
2 diabetes.  Previous findings suggests that DR is evident in approximately 84% of 
persons with type 1 diabetes of 40 years duration and advanced DR in 
50%.(Hammes et al. 2011)  In contrast, about 12-19% (Looker et al. 2012, 
Olafsdottir et al. 2013) of persons with type 2 diabetes have some DR already at the 
time of diagnosis,(Kohner et al. 1998) with 4% developing PDR after 20 years or 
more of diabetes.(Olafsdottir et al. 2013)   
 
Wales currently has a population of approximately 3.1 million, predominantly 
Caucasian, with the majority situated in the industrial south (~60%) with the 
remainder of the country generally regarded as rural.(Welsh Government 2012)  In 
2003 the Welsh government commissioned the DRSSW, which became an all 
Wales service at the end of 2006 when it was in a position to offer DR screening 
appointments to all eligible persons in Wales (see Chapter 2).  In 2012 there were 
177,238 (5.9%) persons with diabetes in Wales known to the DRSSW of whom, 
162,291 (91.6%) were eligible for annual screening.  Approximately 8.4% of persons 
with diabetes in Wales were ineligible for screening for a variety of reasons 
including: medical (1.5%), blindness (0.2%), under the age of 12 years (0.2%) and 
being under the care of a HES (ophthalmology) (6.5%).  Therefore, 91.6% of 
persons with diabetes were eligible for screening, of whom approximately 20% 
unfortunately did not attend their allotted appointments. 
 
The prevalence of DR has previously been described for several 
populations,(Zhang et al. 2010, Yau et al. 2012) using different methods for the 
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detection and also differing criteria for classifying DR which accounts in part for the 
broad variations observed (Table 3.1.1).
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Table 3.1.1: Studies of the prevalence of DR worldwide. 
Study N Recruit
ment 
Inclusions Exclusions Other details Prevalence of DR 
WESDR 
1984(Klein 
et al. 
1984a) 
1,210 identified 
996 included 
 
 
1979-
1980 
<30 years using 
insulin eligible 
under 30 years 
at diagnosis of 
diabetes, 
confined to 
nursing, home, 
died, did not 
have diabetes, 
Moved and 
gestational 
diabetes 
 
7 standard 
stereoscopic 
colour fundus 
photographs per 
eye following 
mydriasis. 
Grading 
performed using 
the ETDRS 
adaption of the 
Airlie house 
classification 
No DR 29% 
Any DR 70% 
NSTDR 48% 
STDR 22% 
 
WESDR 
1984(Klein 
et al. 
1984b) 
5,431 identified 
1,780 included 
696 non-insulin users and 674 insulin 
users 
Random selection from each group 
included in the study 
576/2,341 duration of diabetes 0-4yrs 
579/2,465 duration of diabetes 5-14yrs 
All 625 duration of diabetes ≥15yrs 
Total included 1,780 
 
 
1979-
1980 
≥30 years at 
diagnosis of 
diabetes. 
diagnosis of 
diabetes by GP 
confirmed by 
random or 
postprandial 
glucose of at least 
200mg/dl 
(11.1mmol/l) or 
fasting glucose 
140mg/dl 
(7.8mmol/l) on 2 
occasions and 
residence in the 
area. 
Exclusions as 
above 
Photography and 
grading as above 
No DR 45.6% 
Non-insulin 60.9%, Insulin 
29.8% 
Any DR 54%, Non-insulin 
38.5%, insulin 70.1% 
NSTDR 44.8%, non- 
insulin 35.4%, insulin 
54.5% 
STDR 9.3% non- insulin 
3%, insulin 15.6% 
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Iceland 
1994(Kristi
nsson et al. 
1994a) 
298 identified 
205 included (~90% of type 1 population 
in Iceland) 
1989-
1990 
Type 1 diabetes some patient 
with type 1 
diabetes of 0-5 
years not yet 
referred to the 
clinic and some 
refuse to 
participate in 
screening. 
Retinal examines 
are performed by 
ophthalmologists 
specialising in the 
retina using 
biomicroscopy 
with slit lamp and 
indirect 
ophthalmoscope 
following dilation. 
Iceland National 
grading protocol 
Any DR 51.7% 
PDR 12.7% 
 
Iceland 
1994(Kristi
nsson et al. 
1994b) 
245 identified 
243 included (~1/5th of type 2 
population in Iceland) 
1989-
1990 
Type 2 diabetes  As above NDR 59% 
Any DR 41% 
PDR 7% 
DME10% 
 
Liverpool 
2002(Youni
s et al. 
2002) 
10,440 invited for screening 1,050 type 
1 diabetes and 9,390 type 2 diabetes 
831 type 1 diabetes and 7,231 type 2 
diabetes attended 
1991-
1999 
Type 1 diabetes 
with an age at 
diagnosis <30 
years with insulin 
dependence of 
>30 years with 
evidence of 
ketoacidosis 
Type 2 diabetes 
age at diagnosis 
≥30 years of 
<30years without 
insulin 
dependence. 
 
 
 
approximately 
800 pts under 
the care of 
ophthalmology 
2 cameras canon 
CR4-45NM or 
Topcon TRC 
50SX Images 
were 35mm film 
Grading protocol 
was an adaption 
of the ETDRS 
NoDR Type 1 53.2%  
type 2 72.5% 
Any DR Type 1 45.7% 
Type 2 25.3% 
STED Type 1 16.4% 
Type 2 6.0% 
PDR Type 1  3.7%  
Type 2 0.5% 
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Norwich 
2009(Misra 
et al. 2009) 
20,788 people 
205 possible type 1's included 
1990-
2006 
Type 2 diabetes Those under the 
care of 
ophthalmology 
and type 1 
diabetes 
Canon 45NM 
following 
mydriasis 
Images captured 
on colour 
transparency film 
followed by digital 
images Grading 
performed by 
diabetologist, 
then 
ophthalmologist 
and finally trained 
graders Grading 
used European 
guidelines and 
then NSC 
Any DR 25.3% 
STDR 0.6% 
STED 2.9% 
USA 
2010(Zhan
g et al. 
2010) 
6,797 interviewed 
1,006 included 795 previously 
diagnosed diabetes and 211 
undiagnosed. 
2005-
2008 
Diabetes defined 
as self-report of 
previous diagnosis 
by a clinician or 
HbA1c ≥6.5% 
People aged ≥40 
years 
 Canon CR6-
45NM 2 images 
per eye not 
dilated 
Graded using the 
Airlie House 
classification 
system (ETDRS) 
 
 
 
 
 
 
 
 
 
Any DR 28.5% 
VTDR 4.4% 
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Systematic 
review 
2012(Yau 
et al. 2012) 
35/58 identified studies included 
22,896 people 
1984-
2010 
  Prevalence 
figures provided 
for 18-21 studies 
with similar 
definitions and 
methodologies 
All studies used 
retinal 
photography 
Grading 
performed using 
ETDRS, AAO, 
EURODIAB, 
UKNSCG, 
21 Studies dilated 
pupils 4 
photographed 1 
eye only 
number of fields 
per eye taken 
were: 
single field: 6 
2 fields: 16 
3 fields: 2 
4 fields:2 
6 fields: 1 
7 fields: 7 
9 fields: 1 
Ranging from 30-
60° 
 
 
 
 
Any DR 35.36% 
PDR 7.24% 
DME 7.48% 
VTDR 11.72% 
104 
 
Looker 
2012 
(Looker et 
al. 2012) 
51,526 persons with newly diagnosed 
type 2 diabetes identified.  47,090 were 
screened by before the end 2010.  
43,523 had a gradeable result. 
Coverage approximately 99% of the 
total diabetic population in Scotland 
2005-
2008 
Those registered 
on Sci-dc 
database with type 
2 diabetes data 
was extracted up 
until end of 2010. 
Excluded those 
under the care of 
ophthalmology 
Single fields per 
eye without 
mydriasis if 
images were 
unassessable 
then slit lamp 
biomicroscopy 
used however this 
data was not 
available for 
analysis.  
(approximately 
1%). 
Any DR 19.3% 
RDR 1.9% 
R3/4 0.7% 
 
Prevalence of any DR in 
those screened within a 
year of diagnosis was 
18.3% RDR 1.6% and 
those screened more 
than 1 year after 
diagnosis was 20.5% and 
2.3% and more than 2 
years from diagnosis was 
20.7% and 2.7%. Within 3 
months of diagnosis was 
18.5% and 1.4%. 
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A systematic review by Yau et al (Yau et al. 2012) estimated the global prevalence 
of DR and determined the major associated risk factors in an individual participant 
analysis to by pooling a total 35 studies (22,896 people) with retinal photographs 
carried out between 1980 and 2008 in the USA, Australia, Europe and Asia.  These 
studies included used a variety of different methods and media to obtain and grade 
retinal photographs: 35mm film and digital images, through dilated and undilated 
pupils capturing between one and nine fields per eye with a small minority 
photographing one eye only, with grading utilising the ETDRS scale, the American 
Academy of Ophthalmology International clinical diabetic retinopathy disease 
severity scale, or the UK National Screening Committee guidelines.  The quoted 
overall prevalence of any DR in this analysis was 34.6% and vision threatening DR 
was 10.2%..  When confined to studies of similar methodologies the prevalence 
increased slightly to 35.4% (4,487/12,620) for any DR and 11.7% (1,481/12,710) 
vision threatening DR.   
 
Our study (Thomas et al. 2014) of the prevalence of DR represents the largest  
community based national DR screening programme using standardised and quality 
assured image capture and grading methodologies (see chapter 2). 
 
3.2 Aims  
The primary aim of this study was: 
 to determine the prevalence of any DR, BDR and RDR within the DRSSW 
based on each person's first screening visit 
The secondary aims of this study were 
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  to investigate the impact of the currently available putative risk factors 
(duration of diabetes, age, treatment of type 2 diabetes and gender) on the 
prevalence of any DR, BDR and RDR 
 to determine the prevalence of visual impairment and blindness within the 
DRSSW at first screening 
 to investigate the impact of risk factors (DR status, duration of diabetes and 
age at screening) on the prevalence of visual impairment or blindness 
 
3.3 Methods 
The methods of screening, data cleaning and statistical analysis reported in this 
chapter are all described in detail in Chapter 2.  In brief, the screening protocol 
included assessment of visual acuity (VA) using a 3 meter illuminated Snellen chart, 
followed by capture of 2x45° digital retinal images per eye (following mydriasis with 
1% tropicamide) with a non-mydriatic Canon DGi camera.  Grading was then 
performed by accredited retinal graders at a central grading centre using a standard 
grading protocol.   
 
The inclusion criteria for this study was: 1) diagnosis of type 1 diabetes and an age 
at diagnosis of <30 years on insulin therapy 2) diagnosis of type 2 diabetes and an 
age at diagnosis of ≥30 years.  In this chapter different variables (duration of 
diabetes, age at diagnosis of diabetes, treatment of type 2 diabetes and gender) 
were assessed for their relationship with the presence of any DR, BDR and RDR 
using binary univariate and backwards stepwise multivariate logistic regression 
analyses. 
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3.4 Results  
From January 2005 to November 2009, 135,152 persons with diabetes over the age 
of 12 years underwent their first screening for DR with the DRSSW.  However, 
32.4% (43,759) were not eligible for further analysis as they did not meet the stated 
inclusion criteria (see above section 3.3). Of those excluded 29,807 (22.1%) did not 
have the type of diabetes recorded on their referral form and 13,952 (10.3%) had an 
age at diagnosis outside the stated limits for both type 1 and type 2 diabetes. 
 
The remaining 67.6% (91,393) of the total population screened were eligible for 
inclusion of which 5.5% (5,003) had type 1 diabetes (T1DM) and 94.5% (86,390) 
had type 2 diabetes (T2DM).  Table 3.4.1 shows that those who were excluded from 
the analysis had a slightly longer duration of diabetes (10.5 vs 6.0) with more using 
insulin (28.0 vs 14.6) and a higher prevalence of DR (35.7 vs 32.3) especially RDR 
(7.1 vs 5.0) compared to those included in the analysis. 
 
The overall prevalence of DR in those included in the analysis was 32.3% with 
67.6% without any evidence of DR (Figure 3.4.1).  Of the persons with DR, 27.3% 
had BDR and 5.0% had RDR.  The RDR category consisted of 1.7% PPDR, 1.5% 
maculopathy, 1.1% PPDR with maculopathy, 0.4% PDR and 0.3% PDR with 
maculopathy (Table 3.4.1).  Additionally 2.0% of the population had ungradeable 
images (percentage excluded from the total with/without DR). 
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Table 3.4.1: Characteristics and prevalence of DR within the whole population 
undergoing screening in Wales and those included in the analysis. 
 Population excluded Population included 
N 43,759 91,393 
Age yrs mean (SD) 61.1 (15.4) 63.7 (13.7) 
Gender n (%):   
Male 23,568 (56.8) 51,211 (56.3) 
Female 17,939 (43.2) 39,703 (43.7) 
Age at diagnosis of diabetes yrs 
mean (SD) 
49.6 (18.2) 57.8 (15.1) 
Known duration of diabetes yrs 
mean (SD) 
10.5 (10.2) 6.0 (6.8) 
Treatment of diabetes n (%):   
Diet only 4,956 (27.5) 26,025 (28.8) 
OHA 8,012 (44.5) 51,071 (56.5) 
Insulin  5,042 (28.0) 13,229 (14.6) 
Ungradeable images 
% (95% CI) 
 2.0 (0.9, 0.2) 2.0 (1.9, 2.1) 
DR status: % (95% CI)   
No DR 64.3 (63.8, 64.7) 67.6 (67.3, 67.9) 
Any DR 35.7 (35.3, 36.2) 32.3 (32.0, 32.6) 
BDR 28.6 (28.2, 29.0) 27.3 (27.0, 27.6) 
PPDR only 2.2 (2.1, 2.4) 1.7 (1.6, 1.8) 
Maculopathy (with BDR) 2.0 (1.8, 2.1) 1.5 (1.5, 1.6) 
PPDR with maculopathy 1.6 (1.4, 1.7) 1.1 (1.0, 1.2) 
PDR only 0.8 (0.7, 0.9) 0.4 (0.4, 0.5) 
PDR with maculopathy 0.6 (0.5, 0.7) 0.3 (0.3, 0.3) 
RDR 7.1 (6.9, 7.4) 5.0 (4.9, 5.1) 
Key: yrs - years; SD – Standard deviation; n – number; OHA – oral hypoglycaemic agents; 
DR – diabetic retinopathy; 95 % CI – 95% confidence intervals; BDR – Background diabetic 
retinopathy; PPDR – pre-proliferative diabetic retinopathy; PDR – Proliferative diabetic 
retinopathy 
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Figure 3.4.1: Overall prevalence of DR in the study population 
 
No DR - No diabetic retinopathy; BDR - Background diabetic retinopathy; RDR - Referable 
diabetic retinopathy; PPDR - Pre-proliferative diabetic retinopathy; PDR - proliferative 
diabetic retinopathy 
 
 
3.4.1 Diabetic retinopathy 
3.4.1.1 T2DM 
3.4.1.1.1 Prevalence of DR  
The population of persons with T2DM (86,390) undergoing screening for the first 
time at the DRSSW had a mean age of 65.3 years, a known duration of diabetes  
(median) of 4 years and a mean age of 60.0 years at diagnosis of diabetes (Table 
3.4.2).  The majority of persons were male (56.4%), 30.5% were diet controlled, 
59.9% were receiving OHAs whilst 9.5% were on insulin therapy.  The prevalence of 
any DR was 31.0%, BDR was 26.6% and RDR was 4.4% (Figure 3.4.2). 
 
No DR 
68% 
BDR 
27% 
Maculopathy 
1% 
PPDR± 
maculopathy 
3% 
PDR± 
maculopathy 
1% 
RDR 
5% 
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Table 3.4.2: Characteristics and prevalence of DR in persons with T2DM 
undergoing screening for the first time at the DRSSW. 
 T2DM 
(n = 86,390) 
Age yrs mean (SD) 65.3 (11.7) 
Gender n (%): 
Male 
Female 
 
48,490 (56.4) 
37,446 (43.6) 
Known duration of diabetes yrs median (IQR) 4.0 (1.0-7.0) 
Treatment n (%): 
Diet only 
OHA 
Insulin 
 
26,025 (30.5) 
51,071 (59.9) 
8,226 (9.5) 
Age at diagnosis of diabetes mean yrs (SD) 60.0 (11.9) 
Ungradeable images % (95% CI) 2.1 (2.0, 2.2) 
DR status: % (95%CI) 
No DR 
Any DR 
BDR 
PPDR only 
Maculopathy (with BDR) 
PPDR with maculopathy 
PDR only 
PDR with maculopathy 
RDR 
 
69.0 (68.7, 69.3) 
31.0 (30.7, 31.3) 
26.6 (26.3, 26.9) 
1.5 (1.4, 1.6) 
1.4 (1.3, 1.5) 
0.97 (0.91, 1.04) 
0.31 (0.28, 0.35) 
0.23 (0.20, 0.27) 
4.4 (4.3, 4.5) 
n - number; yrs - years; SD - standard deviation; IQR - interquartile range; 95% CI - 95% 
confidence interval; BDR – background diabetic retinopathy; PPDR – pre-proliferative 
diabetic retinopathy; PDR - proliferative diabetic retinopathy 
 
Figure 3.4.2 Prevalence of DR in persons with T2DM 
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Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable 
diabetic retinopathy; PPDR - preproliferative diabetic retinopathy; PDR - proliferative DR 
 
3.4.1.1.2 Risk factors for DR 
Known duration of diabetes 
The median duration of diabetes for those noted to have any evidence of DR was 6 
years, similar to those with BDR i.e. 5 years duration, although those with evidence 
of RDR had a longer duration of diabetes at 10 years (Table 3.4.3).  Those persons 
without evidence of DR the median duration of diabetes was shorter at 3 years.  
These differences between those with any DR, BDR and RDR compared to those 
without DR were significant.  As expected due to the correlation with duration of 
diabetes age and age at diagnosis of diabetes were also significantly different for 
those with any DR, BDR and RDR compared to those without evidence of DR.
NDR 
69.0% 
BDR 
26.6% 
maculopathy 
1.4% 
PPDR± 
maculopathy 
2.5% 
PDR± 
maculopathy 
0.54% 
RDR 
4.4% 
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Table 3.4.3: Difference in characteristics for those persons with T2DM presenting without DR, with any DR, BDR or RDR 
 
 No DR 
(n = 58,674) 
Any DR 
(n = 26,216) 
P value 
No DR 
vs. any 
DR 
BDR 
(n = 22,482) 
RDR 
(n = 3,734) 
P value  
No DR vs. 
BDR and 
RDR 
Age yrs mean (SD) 64.6 (11.7) 66.3 (11.4) <0.001 66.5 (11.5) 65.1 (11.1) <0.001 
Sex: n (%) 
Male 
Female 
 
32,312 (55.4) 
26,020 (44.6) 
 
15,425 (59.1) 
10,684 (40.9) 
<0.001 
 
13,109 (58.6) 
9,271 (41.4) 
 
2,316 (62.1) 
1,413 (37.9) 
<0.001 
Duration of diabetes yrs 
median (IQ) 
3.0 (1.0-6.0) 6.0 (3.0-11.0) <0.001 5.0 (2.0-10.0) 
 
10.0 (5.0-15.0) <0.001 
Treatment of diabetes: n (%) 
Diet 
OHA 
Insulin 
 
20,384 (35.2) 
33,585 (57.9) 
4,012 (6.9) 
 
5,078 (19.6) 
16,446 (63.6) 
4,339 (16.8) 
<0.001 
 
4,730 (21.3) 
14,210 (64.1) 
3,232 (14.6) 
 
348 (9.4) 
2,236 (60.6) 
1,107 (30.0) 
<0.001 
Age at diagnosis of diabetes yrs mean 
(SD) 
60.3 (11.7) 58.7 (12.1) <0.001 59.3 (11.9) 54.7 (12.1) <0.001 
NDR – no diabetic retinopathy; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable diabetic retinopathy; yrs – years; 
SD – standard deviation; IQ – Interquartile range 
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The prevalence of DR increased with increasing known duration of diabetes (Figure 
3.4.3).  The prevalence of any DR increased from 22.0% in persons with diabetes 
for <5 years, to 34.0% in persons with diabetes for 5-9 years and 56.4% in persons 
with diabetes for ≥10 years.  The prevalence of BDR increased similarly to any DR 
from 20.0% to 30.0% and 43.3% respectively.  The prevalence of RDR increased by 
11.2% from 1.9% in those with a duration of diabetes for <5 years to 13.1% in those 
with diabetes for ≥10 years. 
 
Figure 3.4.3: Prevalence of diabetic retinopathy by duration of diabetes in persons 
with T2DM 
  
Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable 
diabetic retinopathy;  
 
 
Within the first two years of diagnosis of diabetes the prevalence of any DR and 
BDR was high at 20.3 and 18.6% respectively (Table 3.4.4).  Whereas the 
prevalence of RDR was low within the first two years from diagnosis of diabetes at 
1.7%.  After a known duration of diabetes of ≥10 years  half of those with diabetes 
had any DR (51.1%) 40.6% of which was BDR and 10.5% was RDR.  After having 
diabetes for ≥25 years  the prevalence of any DR was 68.5%, 47.3% of which was 
BDR and 21.2% was RDR. 
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Table 3.4.4: Percentage of any DR, BDR and RDR by increasing duration of 
diabetes in persons with T2DM. 
Known duration of 
diabetes (yrs) 
n Any DR 
% (95% CI) 
BDR 
% (95% CI) 
RDR 
% (95% CI) 
0-2 32,193 20.3 (19.9-20.7) 18.6 (18.2-19.1) 1.7 (1.5-1.8) 
3-4 16,208 25.3 (24.6-26.0) 22.8 (22.2-23.5) 2.5 (2.2-2.7) 
5-6 11,946 30.2 (29.4-31.0) 27.0 (26.2-27.8) 3.2 (2.9-3.6) 
7-8 6,902 37.6 (36.5-38.8) 32.7 (31.6-33.8) 4.9 (4.4-5.4) 
9-10 5,402 45.4 (44.1-46.8) 38.3 (37.0-39.6) 7.1 (6.5-7.8) 
11-12 3,479 51.1 (49.4-52.7) 40.6 (38.9-42.2) 10.5 (9.5-11.6) 
13-14 2,197 56.2 (54.1-58.3) 43.7 (41.6-45.8) 12.5 (11.2-14.0) 
15-16 2,062 61.1 (59.0-63.2) 45.5 (43.4-47.7) 15.6 (14.1-17.3) 
17-18 986 64.9 (61.9-67.8) 47.9 (44.8-51.0) 17.0 (14.8-19.5) 
19-20 996 65.6 (62.6-68.5) 48.0 (44.9-51.1) 17.6 (15.3-20.1) 
21-22 643 63.0 (59.2-66.6) 46.7 (42.8-50.5) 16.3 (13.7-19.4) 
23-24 364 67.0 (62.1-71.7) 45.9 (408-51.0) 21.2 (17.3-25.6) 
25-28 524 68.5 (64.4-72.3) 47.3 (43.1-51.6) 21.2 (17.9-24.9) 
29+ 533 67.4 (63.3-71.2) 49.2 (44.9-53.4) 18.2 (15.2-21.7) 
Key: yrs - years; n – total number of persons; Any DR – any diabetic retinopathy; BDR – 
background diabetic retinopathy; RDR – referable diabetic retinopathy;; 95% CI – 95% 
confidence interval 
 
In univariate logistic regression the presence of any DR was significantly associated 
with increasing known duration of diabetes i.e. known duration 5-9 years OR 1.83 
and known duration ≥10 years OR 4.52 compared to a known duration of <5 years 
(Table 3.4.5).  Similar associations were seen for the presence of BDR and known 
duration of diabetes i.e. 5-9 years OR 1.76, ≥10 years OR 3.81 compared to <5 
years.  The association of RDR with known duration of diabetes was even greater 
i.e. 5-9 years OR 2.49 and ≥10 years OR 11.96 compared to <5 years.   
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Table 3.4.5: Univariate logistic regression analysis for the risk factors associated 
with the presence of any DR, BDR and RDR in persons with T2DM 
 
yrs - years; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; 
RDR – referable diabetic retinopathy; OR - odds ratio; 95% CI - 95% confidence interval 
 
 
In multivariate logistic regression analysis after adjusting for age at diagnosis of 
diabetes, gender and treatment of diabetes, the risk of RDR was 1.9- fold higher 
when known duration of diabetes was 5-9 years and 7.4-fold higher when the known 
duration of diabetes was ≥10 years when compared to those with diabetes duration 
<5 years (Table 3.4.6). 
 
 Any DR 
OR (95%CI) 
BDR 
OR (95%CI) 
RDR 
OR (95%CI) 
Age at diagnosis 
of diabetes (yrs): 
≤55 (n=30,184) 
56-65 (n=26,912) 
≥66 (n=29,124) 
 
 
1.00 
0.82 (0.79, 0.85) 
0.75 (0.72, 0.77) 
 
 
1.00 
0.87 (0.85, 0.92) 
0.83 (0.80, 0.86) 
 
 
1.00 
0.53 (0.49, 0.57) 
0.38 (0.35, 0.41) 
Male 1.16 (1.13, 1.20) 1.14 (1.10, 1.17) 1.32 (1.23, 1.41) 
Duration of 
diabetes (yrs): 
<5 (n=49,390) 
5-9 (n=21,592) 
>/=10 (n=15,238) 
 
 
1.00 
1.83 (1.77, 1.90) 
4.59 (4.42, 4.77) 
 
 
1.00 
1.77 (1.71, 1.84) 
3.87 (3.71, 4.03) 
 
 
1.00 
2.50 (2.28, 2.75) 
12.14 (11.18, 13.19) 
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Table 3.4.6: Multivariate logistic regression analysis for the risk factors associated 
with the presence of any DR, BDR and RDR in persons with T2DM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
yrs - years; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; 
RDR – referable diabetic retinopathy; OR - odds ratio; 95% CI - 95% confidence interval 
 
Treatment of diabetes 
The prevalence of DR increased as treatment of diabetes advanced from diet only, 
to OHA and eventually insulin therapy (Figure 3.4.4).  The prevalence of BDR 
increased from 18.6% in persons treated by diet alone to 28.4% in those using 
OHAs and to 40.0% in those requiring the addition of insulin therapy.  The 
prevalence of RDR was low in those treated by diet alone at 1.4% but increased to 
4.5% in those requiring OHAs and 13.7% in persons on insulin therapy.  These 
differences were significant (Table 3.4.3 pg 108)  
 Any DR 
OR (95%CI) 
BDR 
OR (95%CI) 
RDR 
OR (95%CI) 
Age at diagnosis 
of diabetes (yrs): 
≤55 (n=30,184) 
56-65 (n=26,912) 
≥66 (n=29,124) 
 
 
1.00 
0.97 (0.94, 1.01) 
1.16 (1.12, 1.21) 
 
 
1.00 
1.01 (0.97, 1.06) 
1.20 (1.15, 1.25) 
 
 
1.00 
0.69 (0.63, 0.75) 
0.81 (0.74, 0.89) 
Male 1.17 (1.14, 1.21) 1.15 (1.11, 1.19) 1.30 (1.20, 1.39) 
Duration of 
diabetes (yrs): 
<5 (n=49,390) 
5-9 (n=21,592) 
>/=10 (n=15,238) 
 
 
1.00 
1.60 (1.54, 1.66) 
3.70 (3.55, 3.86) 
 
 
1.00 
1.58 (1.52, 1.64) 
3.27 (3.13, 3.42) 
 
 
1.00 
1.86 (1.69, 2.05) 
7.43 (6.80, 8.13) 
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Figure 3.4.4: Prevalence of DR by treatment of diabetes in persons with T2DM 
  
Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable 
diabetic retinopathy; UG - ungradeable 
 
 
The presence of any DR was significantly associated with OHA or insulin (OR 1.96, 
OR 4.34 respectively) therapy compared to diet alone (Table 3.4.7).  Similar 
associations were seen for the presence of BDR i.e. treatment with OHA OR 1.82 or 
insulin OR 3.47 compared to diet alone.  The presence of RDR was associated with 
the treatment of diabetes (OHA OR 3.90 and insulin OR 16.16 compared to diet 
alone).   
 
Table 3.4.7 Univariate logistic regression for treatment of diabetes 
 Any DR  
OR (95% CI) 
BDR 
OR (95% CI) 
RDR 
OR (95% CI) 
Treatment of 
diabetes: 
Diet 
OHA 
Insulin 
 
 
1.00 
1.97 (1.90, 2.04) 
4.65 (4.41, 4.91) 
 
 
1.00 
1.82 (1.76, 1.89) 
3.72 (3.51, 3.94) 
 
 
1.00 
3.90 (3.48, 4.37) 
17.32 (15.27, 19.63) 
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After adjusting for age at diagnosis, known duration of diabetes and gender persons 
on treatment with OHA and insulin therapies were at an increased risk of having any 
DR, BDR and RDR compared to those maintained on diet and lifestyle alone (Table 
3.4.8).  Those on treatment with OHA s had a 1.6- fold increased risk of having any 
DR, 1.5 fold increased risk of  BDR and a 2.7-fold increased risk of RDR.  Those on 
insulin therapy had an even greater risk at 2.7- and 2.4-fold for the presence of any 
DR and BDR respectively and a 6.9 fold increased risk of RDR. 
 
Figure 3.4.8 Multivariate logistic regression analysis for treatment of diabetes 
adjusted for age at diagnosis, known duration of diabetes and gender. 
 Any DR 
OR (95% CI) 
BDR 
OR (95% CI) 
RDR 
OR (95% CI) 
Treatment of 
diabetes 
Diet 
OHA 
Insulin 
 
 
1.00 
1.59 (1.53, 1.65) 
2.76 (2.60, 2.93) 
 
 
1.00 
1.52 (1.46, 1.58) 
2.41 (2.26, 2.56) 
 
 
1.00 
2.66 (2.36, 2.99) 
6.93 (6.05, 7.94) 
 
3.4.1.1.3 Summary of main findings  
 The prevalence of any DR was 31.0% in persons with T2DM, BDR was 26.6% 
and RDR was 4.4% at first screening event 
 The presence of any DR, BDR and RDR within two years of diagnosis of type 2 
diabetes was  20.3% 18.6% and 1.7% respectively increasing to 65.5%, 48.0% 
and 17.8% respectively after 20 years of known diabetes. 
 Multivariate analysis indicated that those with a known duration of 10 years or 
more had a 3.7-fold increased risk of any DR and a 7.4 fold increased risk of 
RDR compared to those with diabetes of less than 10 years after adjusting for 
age at diagnosis, gender and treatment of diabetes. 
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 In multivariate analysis those requiring insulin therapy were at a 2.8-fold 
increased risk of any DR and a 6.9-fold increased risk of RDR compared to 
those on diet alone, after adjustment for age at diagnosis, gender and duration 
of diabetes.  
 
 
3.4.1.2 T1DM 
3.4.1.2.1 Prevalence of DR  
The characteristics and prevalence of DR of persons with T1DM is included in Table 
3.4.9.  The mean age was 36.5 years; median duration of diabetes 13.0 years, and 
mean age at diagnosis of diabetes was 19.7 years.  The majority were male (54.7%) 
and all were receiving insulin therapy.  The prevalence of any DR was 56.3%, BDR 
39.8% and RDR 16.4% (Figure 3.4.5).  The category of RDR consisted of 4.2% 
maculopathy only, 8.1% PPDR with or without maculopathy and 4.1% PDR with or 
without maculopathy. 
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Table 3.4.9: Characteristics at first screening in persons with T1DM 
 T1DM 
(n = 5,003) 
Age mean yrs mean (SD) 36.5 (16.4) 
Gender n (%): 
Male 
Female 
 
2,721 (54.7) 
2,257 (45.3) 
Known duration of Diabetes yrs median (IQR) 13.0 (6.0-25.0) 
Insulin n (%) 5,003 (100) 
Age at diagnosis of diabetes yrs mean (SD) 19.7 (13.7) 
Unassessable images % (95%CI) 0.5 (0.3, 0.7) 
DR status: % (95%CI) 
No DR 
Any DR 
BDR 
PPDR only 
Maculopathy (with BDR) 
PPDR with maculopathy 
PDR only 
PDR with maculopathy 
RDR 
 
43.7 (42.4, 45.1) 
56.3 (54.9, 57.7) 
39.8 (38.4, 41.2) 
5.2 (4.6, 5.9) 
4.2 (3.7, 4.8) 
2.9 (2.5, 3.4) 
2.6 (2.2, 3.1) 
1.5 (1.2, 1.9) 
16.4 (15.4, 17.4) 
Key: yrs – years; SD – Standard deviation; n – number; IQR – Interquartile range; OHA – 
oral hypoglycaemic agents; DR – diabetic retinopathy; 95 % CI – 95% confidence intervals; 
BDR – Background diabetic retinopathy; PPDR – pre-proliferative diabetic retinopathy; PDR 
– Proliferative diabetic retinopathy 
 
Figure 3.4.5: Prevalence of DR in persons with T1DM
No DR - No diabetic retinopathy; BDR - Background diabetic retinopathy; RDR - Referable 
diabetic retinopathy; PPDR - Pre-proliferative diabetic retinopathy; PDR - proliferative 
diabetic retinopathy 
No DR 
43.7% 
BDR 
39.8% 
maculopathy 
4.2% 
PPDR± 
maculopathy 
8.1% 
PDR± 
maculopathy 
4.1% 
RDR 
16.4% 
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3.4.1.2.2 Risk factors and DR 
Duration of Diabetes 
The median duration of diabetes for those noted to have any DR was 21 years, 
similar to those with BDR at 19 years and RDR at 24 years (Table 3.4.10).  
However for those persons without evidence of DR the median duration of diabetes 
was shorter at 6 years.  The differences in duration of diabetes between those with 
any DR, BDR and RDR compared to those without DR were highly significant.  The 
mean age at diagnosis for those persons noted to have any DR on first screening 
was 15.5 years, which was similar to those presenting with BDR at 15.9 years and 
RDR at 14.6 years and were much younger than those present with the same in 
T2DM at 58.7, 59.3 and 54.7 years respectively.  Those presenting without any 
signs of DR were significantly older at diagnosis of diabetes with a mean age of 
25.2 years compared to those with any DR, BDR and RDR. .
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Table 3.4.10: Difference in characteristics for those persons with T1DM presenting without DR (NDR), any DR, BDR or RDR. 
 No DR 
(n = 2,181) 
Any DR 
(n = 2,802) 
P value No 
DR vs. any 
DR 
BDR 
(n = 1,983) 
RDR 
(n = 819) 
P value No 
DR vs. BDR 
and RDR 
Age yrs mean (SD) 34.6 (19.2) 37.9 (13.5) <0.001 37.3 (14.3) 39.3 (11.2) <0.001 
Sex: n (%)  
Male 
Female 
 
1,183 (54.5) 
988 (45.5) 
 
1,524 (54.7) 
1,264 (45.3) 
0.904  
1,015 (51.5) 
957 (46.5) 
 
509 (62.4) 
307 (37.5) 
<0.001 
Duration of diabetes yrs 
median (IQ) 
6.0 (3.0-12.0) 
 
21.0 (13.0-31.0) <0.001 19.0 (11.0-
30.0) 
24.0 (17.0-31.0) <0.001 
Age at diagnosis of 
diabetes yrs mean (SD) 
25.2 (17.2) 15.5 (7.9) <0.001 15.9 (7.9) 14.6 (7.8) <0.001 
yrs - years; No DR – no diabetic retinopathy; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable diabetic 
retinopathy; yrs – years; SD – standard deviation; IQ – Interquartile range
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The prevalence of DR increased with increasing duration of diabetes (Figure 3.4.6).  
The prevalence of any DR increased from 21.3% in persons with a duration of 
diabetes <10 years to 66.7% in those with a duration of 10-19 years and to 84.5% in 
those with a duration of ≥20 years.   
 
Figure 3.4.6: Prevalence of diabetic retinopathy by duration of diabetes in persons 
with T1DM 
  
NDR - No diabetic retinopathy; BDR - Background diabetic retinopathy; RDR - Referable 
diabetic retinopathy 
 
 
In persons with diabetes for less than 2 years the prevalence of any DR, BDR and 
RDR was 9.7% 9.0% and 0.7% respectively (Table 3.4.9).  This increased to 47.2% 
with any DR, 40.5% BDR and 6.7% RDR in those with diabetes for 9-10 years.  In 
those with diabetes for 19-20 years this was further increased to 78.5% with any 
DR, 46.4% BDR and 32.1% RDR.   
0 
10 
20 
30 
40 
50 
60 
70 
80 
90 
No 
DR 
Any 
DR 
BDR RDR No 
DR 
Any 
DR 
BDR RDR No 
DR 
Any 
DR 
BDR RDR 
<10 10-19 шϮϬ 
78.7 
21.3 19.6 
1.7 
33.2 
66.7 
49 
17.9 14.7 
84.5 
54.3 
31 
P
re
v
a
le
n
ce
 (
%
) 
Duration of diabetes (years) 
124 
 
Table 3.4.11: Percentage of any DR, BDR and RDR by increasing duration of 
T1DM. 
Duration of 
diabetes (yrs) 
n Any DR 
% (95% CI) 
BDR 
% (95% CI) 
RDR 
% (95% CI) 
0-2 588 9.7 (7.6-12.4) 9.0 (7.0-11.6) 0.68 (0.26-0.17) 
3-4 390 13.9 (10.8-17.6) 13.1 (10.1-16.8) 0.77 (0.26-2.2) 
5-6 389 20.6 (16.9-24.9) 19.5 (15.9-23.8) 1.0 (0.40-2.6) 
7-8 345 38.6 (33.6-43.8) 35.1 (30.2-40.3) 3.5 (2.0-6.0) 
9-10 343 47.2 (42.0-52.5) 40.5 (35.5-45.8) 6.7 (4.5-9.9) 
11-12 318 64.8 (59.4-69.8) 51.9 (46.4-57.3) 12.9 (9.7-17.0) 
13-14 273 70.0 (64.3-75.1) 50.2 (44.3-56.1) 19.8 (15.5-24.9) 
15-16 250 70.8 (64.9-76.1) 49.2 (43.1-55.4) 21.6 (17.0-27.1) 
17-18 213 74.2 (67.9-79.6) 49.8 (43.1-56.4) 24.4 (19.1-30.6) 
19-20 209 78.5 (72.4-83.5) 46.4 (39.8-53.2) 32.1 (26.1-38.7) 
21-22 174 82.8 (76.5-87.7) 54.6 (47.2-61.8) 28.2 (22.0-35.3) 
23-24 176 84.1 (78.0-88.8) 46.6 (39.4-54.0) 37.5 (30.7-44.9) 
25-28 322 88.2 (84.2-91.3) 51.2 (45.8-56.7) 37.0 (31.9-42.4) 
29+ 989 85.3 (83.0-87.4) 57.9 (54.8-61.0) 27.4 (24.7-30.3) 
Key yrs - years; n – total number of persons; Any DR – any diabetic retinopathy; BDR – 
background diabetic retinopathy; RDR – referable diabetic retinopathy; 95% CI – 95% 
confidence interval 
 
 
The prevalence of any DR was lower within the first 2 years of diagnosis in persons 
with T1DM compared to those with T2DM at 9.7% vs. 20.3% (Figure 3.4.7).  After a 
duration of diabetes of 6 years the prevalence of any DR in persons with T2DM 
increased at a more constant rate until a known duration of 18 years.  Following this 
the prevalence rate reached a plateaux.  In contrast the prevalence of any DR 
rapidly increased for those persons with T1DM until a duration of 12 years after 
which the prevalence of any DR continued to increase but at a  slower rate.  There 
was a low prevalence of RDR in both T2DM and T1DM during the first 6 years 
following the diagnosis of diabetes (3.2% vs. 1.0%).  After a duration of 6 years the 
prevalence of RDR increased for both T2DM and T1DM although the increase was 
more rapid for T1DM 
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Figure 3.4.7: Prevalence of DR in both persons with T2DM and T1DM. 
 
Duration of diabetes was stratified into tertiles for purposes of the logistic regression 
analysis which were: <10 years (reference), 10-19 years and ≥20 years.  The 
univariate logistic regression is represented in Table 3.4.12, the presence of any DR 
was seen to be significantly associated with increasing duration of diabetes: 10-19 
years (OR 7.4) and ≥20 years (OR 21.3) compared to <10 years diabetes duration.  
This was similar for the presence of BDR with duration of diabetes of 10-19 years 
(OR 5.9) and >20 years (OR 14.7).  This association was even stronger for the 
presence of RDR for those persons with duration of diabetes of 10-19 years (OR 
24.7) and those with diabetes  ≥20 years (OR 96.3) when compared to those with 
diabetes for <10 years.   
 
In the multivariate analysis following adjustment for age at diagnosis and gender, 
duration of diabetes remained strongly associated with the presence of any DR and 
BDR increasing further for RDR (Table 3.4.13).  Those persons with a duration of 
diabetes of 10-19 years had a 28.9-fold increased risk of RDR and those with 
diabetes for ≥20 years had a 100.8- fold increased risk compared to those with a 
duration of diabetes of <10 years.  
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Table 3.4.12: Univariate logistic regression analysis for the risk factors associated 
with the presence of any DR, BDR and RDR in persons with T1DM 
yrs - years; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; 
RDR – referable diabetic retinopathy; OR - odds ratio; n - number; 95% CI - 95% confidence 
interval 
 
Table 3.4.13: Multivariate logistic regression analysis for the risk factors associated 
with the presence of any DR, BDR and RDR in persons with T1DM 
yrs - years; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; 
RDR – referable diabetic retinopathy; OR - odds ratio; n - number; 95% CI - 95% confidence 
interval 
 
 Any DR 
OR (95%CI) 
BDR 
OR (95%CI) 
RDR 
OR (95%CI) 
Age at diagnosis 
of diabetes (yrs): 
≤10 (n=1,278) 
11-20 (n=1,711) 
≥21 (n=2,014) 
 
 
1.00 
0.97 (0.83, 1.13) 
0.40 (0.35, 0.47) 
 
 
1.00 
1.03 (0.87, 1.21) 
0.46 (0.39, 0.54) 
 
 
1.00 
0.85 (0.70, 1.04) 
0.30 (0.24, 0.37) 
Male 1.01 (0.90, 1.13) 0.88 (0.78, 1.00) 1.38 (1.17, 1.63) 
Duration of 
diabetes (yrs) 
<10 (n=1,876) 
10-19 (n=1,341) 
≥20 (n=1,786) 
 
 
1.00 
7.43 (6.34, 8.71) 
21.43 (18.04, 25.45) 
 
 
1.00 
5.92 (5.02, 6.99) 
14.84 (12.41, 17.73) 
 
 
1.00 
24.78 (16.88, 36.37) 
97.02 (66.35, 141.88) 
 Any DR 
OR (95%CI) 
BDR 
OR (95%CI) 
RDR 
OR (95%CI) 
Age at diagnosis 
of diabetes (yrs): 
≤10 (n=1,278) 
11-20 (n=1,711) 
≥21 (n=2,014) 
 
 
1.00 
1.33 (1.10, 1.60) 
0.54 (0.45, 0.64) 
 
 
1.00 
1.32 (1.09, 1.60) 
0.55 (0.46, 0.66) 
 
 
1.00 
1.34 (1.02, 1.76) 
0.40 (0.31, 0.52) 
Male 1.17 (1.02, 1.35) 1.09 (0.95, 1.27) 1.86 (1.50, 2.32) 
Duration of 
diabetes (yrs) 
<10 (n=1,876) 
10-19 (n=1,341) 
≥20 (n=1,786) 
 
 
1.00 
7.89 (6.69, 9.31) 
21.12 (17.71, 25.20) 
 
 
1.00 
6.28 (5.29, 7.47) 
14.93 (12.43, 17.93) 
 
 
1.00 
28.92 (19.52, 42.86) 
100.75 (68.27, 148.68) 
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3.4.1.2.3 Summary of main findings  
 In persons with T1DM at first screening the prevalence of any DR was 
56.2%, BDR 39.8% and RDR was 16.4% 
 After 20 years or more of diabetes 78.5% had evidence of DR and 32.1% 
RDR  
 After adjusting for age at diagnosis and gender those with T1DM for 20 
years or more had approximately a 20- fold increased risk of any DR and a 
100-fold increased risk of RDR compared to those with diabetes of less than 
10 years duration. 
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3.4.2 Visual acuity 
3.4.2.1 T2DM 
3.4.2.1.1 Prevalence of visual impairment and blindness  
The majority (93.0%) of persons had normal vision (better than 6/12) in their better 
eye at first screening (Figure 3.4.8).  6.6% had visual impairment (6/12-6/36) and 
0.4% were blind (6/60 or worse). 
 
Figure 3.4.8: Visual acuity in persons with T2DM at first screening
 
 
The prevalence of no DR decreased as visual acuity worsened (Figure 3.4.9), with 
the prevalence of no DR decreasing from 69% in those with normal vision to 57% in 
those with visual impairment and 51.1% in those who were blind. The prevalence of 
BDR remained similar across the levels of vision, whereas the prevalence of RDR 
and the number of ungradeable images increased with worsening vision.  The 
prevalence of RDR increased from 4% in those with normal vision to 7.5% in those 
with visual impairment and 10% in those who were categorised as blind.  The 
better than 6/12 
93.0% 
6/12 - 6/36 
6.6% 
6/60 or worse 
0.4% 
129 
 
frequency of ungradeable images increased from 1% in those with normal vision to 
7% and 17% in those with visual impairment and blindness respectively. 
 
Figure 3.4.9: Visual acuity by DR level in persons with T2DM 
 
Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable 
diabetic retinopathy; UG - ungradeable 
 
In those persons with a known duration of < 5 years the prevalence of normal vision 
was 58%, visual impairment was 47% and those categorised as blind was 43% 
(Figure 3.4.10).  In contrast the proportion of persons with a known duration of 
diabetes of ≥10 years 17% had normal vision, 27% visual impairment and 34% in 
those who were categorised as blind.   
 
 
Figure 3.4.10: Visual acuity by duration of diabetes in persons with T2DM 
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The number of persons with normal vision was evenly distributed across the 
different age groups (Figure 3.4.11).  Of those persons with visual impairment and 
blindness the majority were aged ≥70 years at screening (74% and 82% 
respectively). 
 
Figure 3.4.11: Prevalence of visual acuity by age 
  
Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable 
diabetic retinopathy; UG - ungradeable 
 
 
3.4.2.2 T1DM 
3.4.2.2.1 Prevalence of visual impairment and blindness 
The majority (97.0%) of persons had a habitual visual acuity (with or without 
spectacles or with pinhole correction if habitual vision was worse than 6/9) of better 
than 6/12 (normal vision) in their better seeing eye at their first screening event 
(Figure 3.4.12).  2.8% had a visual acuity of 6/12 - 6/36 (visual impairment) and 
0.1% had a visual acuity of 6/60 or worse (blind). 
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Figure 3.4.12: Visual acuity at first screening with the DRSSW in persons with T1DM 
  
 
The prevalence of no DR, BDR and RDR was similar in those with normal vision and those 
with visual impairment (Figure 3.4.13).  Surprisingly the prevalence of no DR increased from 
43.7% in those with normal vision to 71.4% in persons who were categorised as blind and 
therefore the low VA in this group was due to causes other than DR.  The prevalence of 
BDR and RDR decreased from 39.9% and 16.1%, respectively in those with normal vision to 
14.3% (for both BDR and RDR) in persons who were blind.  Therefore, the inference is that 
in the majority of persons who were categorised as blind the low VA was not caused 
primarily by DR.  The number of ungradeable images increased in those with visual 
impairment 3.6% (compared to those with normal vision 0.3%) but surprisingly decreased in 
those classified as blind 0%.  These results however, may be skewed by the small number 
of persons with visual impairment or blindness (n=145). 
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Figure 3.4.13: Visual acuity by the DR level  
 
 
The prevalence of normal visual acuity was evenly distributed across the pre-
defined categories of duration of diabetes (Figure 3.4.14).  The prevalence of visual 
impairment was highest in those with a duration of ≥20 years (46.4%) and blindness 
was highest in those with diabetes for 10-19 years (57.1%).   
 
Figure 3.4.14: Visual acuity by the duration of diabetes in persons with T1DM 
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There was an even distribution of age within the normal visual acuity category 
(Figure 3.4.15).  The majority of visual impairment (61.3%) and blindness (67.0%) 
occurred in persons aged 66 yrs or older. 
 
Figure 3.4.15: Prevalence of visual acuity by age in persons with T1DM 
 
Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable 
diabetic retinopathy; UG - ungradeable 
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 In persons with T1DM, the majority of those who were blind were for reasons 
other than DR.  However there were very few T1DM who were blind and 
therefore results need to be interpreted with caution. 
 
 
3.5 Discussion  
Direct comparison of prevalence rates for DR between studies is inherently difficult 
due to the changing classification of diabetes with time, different image capture, 
technologies, professionals and grading protocols as well as the differences 
between the populations studied.  The studies reporting prevalence rates for DR 
along with the different methodologies employed are summarised in Table 3.5.1 
(page 96).(Klein et al. 1984a, b, Kristinsson et al. 1994b, Kristinsson et al. 1994a, 
Younis et al. 2002, Misra et al. 2009, Zhang et al. 2010, Yau et al. 2012)  
 
In this community based study population the overall prevalence of any DR (T2DM 
and T1DM combined) was 32.4% which is similar to that reported for the US at 
32.8%,(Zhang et al. 2010) and only slightly lower than 34.6% reported by a more 
recent global review based on studies involving retinal imaging.(Yau et al. 2012)  In 
contrast, the overall prevalence of RDR in our study was 5.0%, of which 3.4% would 
be classed as sight-threatening DR which is lower than the 5.2% and 10.2% 
reported in the US (Zhang et al. 2010) and the global review respectively.(Yau et al. 
2012)  Both of these studies had differences in the ethnicity make up of their 
populations, with Zhang et al having an almost even distribution of non-Hispanic 
whites (26.4%), non-Hispanic blacks (38.8%) and Mexican Americans (34%) and 
Yau et al having a higher proportion of Caucasians (44.4%), and lower proportions 
of other ethnic groups Asians (30.9%), Hispanic (13.9%) and African American 
135 
 
(8.9%).  Whilst the DRSSW did not have information available on the ethnicity of its 
population, the population of Wales is mainly Caucasian (95.6%).(Office for National 
Statistics 2012)  Therefore, this difference in ethnicity of the different populations 
may offer an explanation for the lower prevalence of sight-threatening DR within the 
DRSSW especially as certain ethnic groups such as Asians and African populations 
have previously been shown to have an increased risk of sight-threatening DR when 
compared to Caucasians.(Ross et al. 2007, Stolk et al. 2008, Thomas et al. 2013)  
Distribution of risk factors may also contribute to these differences. 
 
In our study involving persons with T2DM the prevalence of any DR was 30.3%, 
lower than that reported in the WESDR at 46.6%,(Klein et al. 1984b) as well as in 
Iceland at 41.0%.(Kristinsson et al. 1994b)  In contrast some of the other UK 
screening programmes in Liverpool and Norwich, as well as the above mentioned 
global review, reported similar lower prevalence rates of DR in T2DM not dissimilar 
to ourselves at 25.3%, 25.3% and 25.2% respectively.(Younis et al. 2002, Misra et 
al. 2009, Yau et al. 2012)   
 
In persons with T1DM in our study the prevalence of any DR at 56.0%, which was 
lower than previously reported in both the WESDR at 70.3%,(Klein et al. 1984a) and 
the more recent global review at 77.3%,(Yau et al. 2012) but similar to that seen in 
Iceland at 53.5%, (Kristinsson et al. 1994a) and only slightly higher than in the 
Liverpool screening programme at 45.7%.(Younis et al. 2002)  The lower 
prevalence rates seen in this study compared to that reported in the WESDR study 
may be due to the reduction in prevalence of DR over time due to advances in 
diabetes care .(Vallance et al. 2008, Downie et al. 2011)   
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In our study the prevalence of RDR was 4.4% in persons with T2DM and 16.4% in 
persons with T1DM.  This was considerably lower compared to the recent global 
review at 6.9% in T2DM and 38.5% in T1DM. (Yau et al. 2012)  The Liverpool 
screening programme also reported a slightly higher prevalence of RDR in persons 
with T2DM at 6.0%, but a similar prevalence in persons with T1DM at 
16.4%,(Younis et al. 2002) and Iceland at 16.9%.(Kristinsson et al. 1994b)  In 
marked contrast the Norwich screening programme reported a very much lower 
prevalence of RDR in their T2DM population at 0.6%.(Misra et al. 2009)  The 
difference between our findings and that reported by the Norwich screening 
programme is likely to be due differences in the definition of RDR in our study and 
sight-threatening DR in theirs.  RDR includes PPDR or worse and/or exudative 
maculopathy whereas PPDR would be excluded from definition of sight-threatening 
DR and only treatable maculopathy included rather than all exudative 
maculopathies.(Misra et al. 2009)   
 
Of the risk factors available, increasing duration of diabetes was the most 
significantly associated with the presence of any DR, BDR and RDR both in T2DM 
and T1DM.  The odds ratios were much lower in T2DM compared to T1DM, 
however the stratification on the basis of duration of diabetes were different; for 
persons with T2DM the subgroups were <5, 5-9 and ≥10 years and for persons with 
T1DM the subgroups were <10, 10-19 and ≥20 years).  The risk of all grades of DR 
increased with duration of diabetes being particularly high in those with diabetes 
duration of >10 years for T2DM and >20 years for T1DM.  The duration of diabetes 
has been shown in almost all prevalence studies of DR to be the most important 
characteristic associated with an increased risk.(Klein et al. 2003)   
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In persons with T2DM the risk of all grades of DR, especially RDR, was 
considerably higher for those on insulin therapy.  However, this is could be an epi-
phenomenon with the need for insulin therapy reflecting a more advanced disease 
state, and not necessarily a direct cause of DR.(Thomas et al. 2014)  However, 
other studies have directly linked the use of insulin therapy with increased risk of 
DR.(Zhao et al. 2014)  In a meta-analysis of 7 cohort studies conducted in Europe 
(n=5), America (n=1) and China (n=1), between 1967 and 2010, including 19,107 
persons with T2DM, insulin use was found to be associated with DR.(Zhao et al. 
2014)  When the analysis was adjusted for duration of diabetes, insulin use was no 
longer associated with DR.  This demonstrates the inter-relationship between the 
different risk factors for DR for example, the younger age at diagnosis of diabetes, 
the longer the duration of diabetes and therefore, the greater chance of requiring 
insulin therapy.  However, some studies have identified a transient worsening of DR 
at the initiation or intensification of insulin therapy.(The Diabetes Control and 
Complications Trial Research Group 1998, Henricsson et al. 2002)  This may also 
be an indirect relationship via the improvement in glycaemic control, as rapid 
improvement has been shown to worsen DR with subsequent re-establishment of 
poor control apparently improving DR.(Dahl-Jorgensen et al. 1985, Chantelau et al. 
2003)   
 
There was a low level of visual impairment and blindness within the population 
undergoing screening in Wales, UK for both type of diabetes.  The reason for the 
low prevalence of blindness within the DRSSW is likely due to the services 
exclusion criteria which excludes persons who were blind in both eyes.  The reason 
for this exclusion from screening is due to difficulties they may have seeing and 
therefore following lights within the retinal cameras during photography or are under 
the care of HES.  Therefore these persons are not referred to the DRSSW by their 
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GP.  The prevalence of visual impairment and blindness were higher in persons with 
T2DM at 6.6% and 0.4% respectively compared to T1DM at 2.8% and 0.1% 
respectively.  This difference may be a reflection of the age difference between the 
populations, with those persons with T2DM being older (mean 65 years) than those 
with T1DM (mean 37 years), rather than due to a difference in the type of diabetes.  
Other studies have reported overall levels of visual impairment and blindness of 
2.9% and 0.5%,(Scanlon et al. 2008) 3.4% and 0.8%,(Broadbent et al. 1999) and 
3.4% and 0.4%,(Sivaprasad et al. 2012) respectively in their target populations 
undergoing screening and 2.8% and 0.8%,(Prasad et al. 2001) in a clinic population 
of persons with diabetes.  However, none of these studies reported visual acuity 
separately for type of diabetes. 
 
There was an increase in the proportion of ungradeable images in persons with 
visual impairment and blindness in both T2DM and T1DM.  Therefore visual 
impairment and blindness was probably related predominantly to other causes such 
as cataract or media opacities.  Information on other eye conditions found during the 
screening process was not available for analysis in this study and therefore this 
could not be confirmed.  The proportion of RDR in persons with T2DM increased 
from 4% in those with normal vision to 7.5% in those with visual impairment and 
10% in those who were blind.  In persons with T1DM RDR increased slightly in 
persons with visual impairment to 23.9% from 16.1% in persons with normal vision 
and then fell to 14.3% in persons who were blind.  However the number of persons 
with T1DM who were blind were small and the majority had ungradeable images.  
This is to be expected as DR is still a major a cause of blindness.(Bunce et al. 2008) 
 
There was also an increased risk of visual impairment and blindness associated 
with increased duration of diabetes in persons with T2DM.  This agrees with a 
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recent survey of US adults aged 20 years or more where duration of ≥10 years was 
a significant risk factor for non-refractive visual impairment.(Ko et al. 2012)  The 
majority of those persons considered visually impaired and blind were aged >70 
years in persons with T2DM (>70%) and ≥65 years in those with T1DM (>60%).  
This finding was not unexpected as conditions such as damage to the cornea, 
cloudy or less pliable lens, damage to the retina and optic disc and other 
pathologies such as age related macular degeneration are more prevalent in an 
aging population.(Zacks 2006) 
 
Limitations of this study were the exclusion of those persons with diabetes in Wales 
who were ineligible for screening (exclusions: under the age of 12 years, under the 
care of a HES and considered medically unfit for screening), non-compliance with 
screening and the exclusion of persons with incomplete or erroneous data (no 
recorded type of diabetes, type of diabetes or age at diagnosis of diabetes 
unrepresentative of the diagnosis).  Therefore, the true prevalence of DR, and 
especially sight-threatening DR, in Wales could be higher than that reported here for 
the defined population especially due to the exclusion of those under the care of 
HES.  Therefore we have investigated the prevalence of DR and especially sight-
threatening DR in persons under the care of the hospital eye services in Wales who 
have not been screened by the DRSSW.(Richards 2014)  This study has found that 
in 2012 there were 3,995 persons with diabetes under the care of HES in Wales that 
had not been screened by the DRSSW.  To date the audit has looked at 
approximately 51.5% (2,058) of these persons (predominately located in the South) 
and has found that 32.4% have no DR, 9.1% have BDR and 44.5% have RDR, a 
further 14% had no mention of DR in their medical records.  Adding these findings 
to the prevalence estimates in this chapter would give estimates of prevalence for 
Wales of 64.7% without DR, 26.9% with BDR and 6.2% RDR which is not very 
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dissimilar to the prevalence rates reported without the data from the HES.  The 
availability of only limited putative risk factors is another limitation, which will be 
addressed in future studies.   
 
Previous studies relating to the prevalence of DR have also had issues of 
ascertainment and non-compliance (Klein et al. 1984a, b, Kristinsson et al. 1994b, 
Kristinsson et al. 1994a, Younis et al. 2002, Misra et al. 2009, Zhang et al. 2010, 
Looker et al. 2012, Yau et al. 2012) and have incorporated inclusion criteria based 
on an age at diagnosis.  In Wales approximately 20% of persons entitled and invited 
to screening do not attend appointments, and therefore no information is available 
on the characteristics or DR level within this population.  However, the strengths of 
this study were its large population size (despite the exclusions), it is community 
based and involved systematic screening with standardised quality assured 
procedures and equipment for both photography and grading.  Importantly both 
graders and photographers are quality controlled to ensure a consistency across all 
procedures involved in the acquisition and grading of the retinal images. 
 
Our findings will provide policy makers additional information for planning future eye 
care services within our communities, with the proviso that the prevalence rate may 
be slightly underestimated as mentioned above.  The prevalence of DR observed re-
emphasises the need for continued systematic community based screening to 
prevent the loss of vision and blindness in this highly susceptible population.  The 
detection of RDR at an early stage is essential to ensure timely onward referral for 
further assessment and possible treatment with improved outcome.  Detection of 
BDR also provides an opportunity, where necessary, to improve glycaemic and 
blood pressure control and therefore help prevent the progression of DR.  For the 
first time in 5 decades, DR is no longer the leading cause of blind certification in 
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England and Wales, inferring that with improved care for diabetes and early 
detection of DR through screening, the incidence of blindness due to diabetes can 
be reduced.(Liew et al. 2014) 
 
3.5.1 Summary of main findings 
 The Overall prevalence of any DR was 32.3% with 27.3% BDR and 5.0% RDR 
 The prevalence of DR was lower in persons with T2DM (any DR 31.0%, BDR 
26.6% and RDR 4.4%) compared to those with T1DM (any DR 56.2%, BDR 
39.8% and RDR 16.4%) 
 Duration of diabetes was the strongest risk factor for the prevalence of DR in 
both T2DM and T1DM after adjusting for confounders.  However putative risk 
factors were limited in this dataset to age, gender, duration of diabetes and in 
T2DM treatment of diabetes. 
 The prevalence of visual impairment and blindness in both T2DM and T1DM 
populations was low at 6.6% and 0.4% respectively and 2.8% and 0.1% 
respectively. 
 These prevalence figures may slightly underestimate the true prevalence of  DR 
and especially sight-threatening DR but also visual impairment and blindness 
due to the exclusion criteria for screening adopted by the DRSSW and 
consequently the data available for analysis. 
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4.1  Introduction 
The primary aim of the DRSSW is to reduce the incidence of blindness due to DR, 
through regular screening in order to implement early interventions such as laser 
therapy and/or VEGF inhibitors to prevent blindness.  Secondly, the early detection 
of DR also allows preventative measures to be initiated in an attempt to delay the 
onset and progression to sight-threatening DR by ensuring good blood glucose and 
blood pressure control, and improving lipid levels if and when necessary.(Garvican 
et al. 2000, Harding et al. 2003)  The screening interval for DR programmes in the 
UK was initially set at yearly intervals based on the opinion of experts and stated in 
the National Guidelines and to concur with the annual review requirement for all 
persons with diabetes.(Garvican et al. 2000, Department of Health 2001)  The 
guidelines recognised that this initial screening interval would be reviewed after 
evidence was accumulated over a number of years.  This is under consideration by 
the NSC at the present time. 
 
Since systematic annual screening was introduced it has been suggested that 
annual screening is unnecessary for all persons with diabetes and that a stratified 
screening interval based on the level of risk would be more appropriate, safe and 
cost-effective.(Younis et al. 2003a, Younis et al. 2003b, Olafsdottir et al. 2007, 
Agardh et al. 2011, Aspelund et al. 2011, Chalk et al. 2012, Jones et al. 2012, 
Looker et al. 2013, Porta et al. 2013, Stratton et al. 2013)  However, opinions on this 
have differed with some arguing that overly long intervals may lead to difficulties in 
maintaining contact with patients and may lead to complacency and non-compliance 
in certain patients.(Fong et al. 2001)  Klein in 2003 stated that 'before adopting new 
guidelines for intervals for retinal examination in individuals with type 2 diabetes, 
effectiveness in achieving a significant reduction in vision loss from diabetes at least 
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similar to that achieved by routine yearly dilated-eye examinations should be 
demonstrated.'(Klein 2003) 
 
For this purpose data from a large regional or national programme is required, 
which was not available and had not been reported prior to this study.(Thomas et al. 
2012)  Therefore, to date the National guidelines for screening for DR have not 
changed the recommendations for screening intervals in the UK, which remain at 
annual.(Garvican et al. 2000, UK National Screening Commitee 2007, UK National 
Screening Committee 2009)  However, currently there is an ongoing Four Nations 
diabetic retinopathy screening intervals project which is analysing data from seven 
UK screening programmes including the national programmes in Wales, Scotland 
and Northern Ireland and four of the 84 regional programmes in England.(Four 
Nations Study Group 2013)  The study found that with the caveats that screening 
programmes have robust IT systems and quality assured grading that those 
persons with two consecutive negative annual screening events are at lowest risk of 
developing RDR and can therefore have subsequent screening intervals once every 
two-three years.  The group reported their findings to the National screening 
Committee in November 2014 who will make recommendations regarding changing 
or maintaining the current screening interval.   
 
4.2  Aims 
The primary aim of this chapter was to determine the possibility of safely extending 
the screening interval for DR in persons with diabetes without evidence of DR at 
initial screening as determined using 2 x 45 degree fields per eye following 
mydriasis (see Chapter 2).  In order to assess the question of  screening intervals 
the following aims were investigated: 
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 The cumulative incidence of any DR, BDR and RDR in persons with T2DM 
and T1DM over a four year period (2005-2009) and, 
 the risk factors associated with the incidence of any DR, BDR and RDR in 
both T2DM and T1DM over the study period (2005-2009). 
 
4.3  Methods 
All persons attending the DRSSW between 2005 and 2009 without evidence of DR 
at their first screening event who underwent at least one additional screening event, 
were included in the analysis.  
 
Details of the statistical methods used in this study are fully described in Chapter 2.  
In addition to the basic descriptive analyses used throughout, survival analyses; 
Kaplan Meier and Cox proportional hazards methods were also used in order to 
estimate the incidence of any DR, BDR and RDR as well as examine the impact of 
the limited number of putative risk factors, known to be associated with the 
development of DR, that were available for analysis.  The log rank test was used to 
assess differences between the Kaplan Meier curves with p<0.05 taken as 
significant.  Cox regression is presented as hazard ratios (HR) with 95% CI.  
Thereafter, incidence rates of RDR were calculated, in order to examine the effect 
stratifying screening intervals by the identified risk factors would have within this 
population.  For T2DM the stratification was based on treatment of diabetes divided 
as; diet alone, OHA or insulin and known duration of diabetes i.e.<5 years, 5-9 
years and ≥10 years.  For T1DM the stratification was based on duration of diabetes 
alone divided as ≤10 years, 11-19 years and ≥20 years.  The incidence of RDR was 
calculated for these groups to determine how many cases of RDR would be at risk 
of a delay in diagnosis of RDR if the screening interval were to be extended beyond 
one year, the current screening interval.  
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4.4  Results 
Of the 60,566 persons with diabetes without evidence of DR at initial screening 
85.1% (51,556) had at least 1 further screening event within the study period and 
were therefore included in the following analysis.  Among the reasons for not having 
a second screening event included: time between first screening and end of study 
being <12 months, cancellation of appointments, non-attendance due to death, ill-
health, unknown reasons and also when the patient changed their GP to one 
outside Wales.  Due to the anonymisation process this aspect could not be 
investigated further. 
 
4.4.1 T2DM  
4.4.1.1 Incidence of DR over a period of 4 years  
Of the 57,199 persons with T2DM without evidence of DR at the first screening 
event, 87.0% (49,763) had at least a second screening event within the 4 year study 
period.  13.0% (7,436) did not attend for further screening during the study period, 
6.0% (449) of whom were not eligible for a second screen, as this would have been 
within 12 months (first screen in 2009).  The remainder 94.0% (6,987) did not 
undergo repeat screening for unknown reasons.   
 
The demographic characteristics of those who did not have a second screening 
event despite being eligible compared with those included in the analysis are 
included in Table 4.4.1.  Those excluded from the analysis were significantly older 
by two years both at time of screening and at diagnosis of diabetes when compared 
to those retained in the study.   
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Table 4.4.1: Characteristics of those persons with T2DM who did or did not attend 
more than 1 screening event. 
Characteristics No repeat screening 
event (eligible) 
At least 1 further 
screening event 
P value 
n 6,987 49,763 
 
Age years mean (SD) 66.9 (13.5) 64.4 (11.3) <0.001 
Known duration of DM 
years median (IQR) 
3.0 (1.0-6.0) 3.0 (1.0-6.0) 0.026 
Age when DM diagnosed 
years mean (SD) 
62.3 (13.2) 60.2 (11.3) <0.001 
Gender: n (%) 
Male 
Female 
Unknown 
 
3,794 (54.3) 
3,175 (45.4) 
18 (0.3) 
 
27,529 (55.3) 
21,975 (44.2) 
259 (0.5) 
0.087 
Treatment for DM: n (%) 
Diet 
OHA 
Insulin 
Unknown 
 
2,684 (38.4) 
3,787(54.2) 
394 (5.6) 
122 (1.7) 
 
17,236 (34.6) 
29,049 (58.4) 
2,669 (5.4) 
809 (1.6) 
<0.001 
n – total numbers; SD – standard deviation; IQR – interquartile range; OHA – oral 
hyperglycaemic agents; n - number 
 
 
Of the 49,763 persons with at least two screening events 31,924 (64.2%) had a 
third, 10,615 (21.3%) a fourth, 767 (1.5%) a fifth and 3 (0.006) a sixth screening 
event during the four year study period (Figure 4.4.1).  Reasons for having more 
than four screening events within the four year study period would be technical 
failures with a 3 month recall or a re-referral from GP or optician.  The median (IQR) 
interval between the first and second screening event was 16 (13-20) months, 
second and third screening was 14 (12-17) months, third and fourth was 13 (12-14) 
months, fourth and fifth was 12 (11-13) months, and fifth and sixth was 12 (11-13) 
months.  Due to the high dropout rate the findings beyond the third screening event 
should be interpreted with caution. 
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Figure 4.4.1: Number of persons with T2DM at each screening event 
 
At their final screening event 73.9% remained without evidence of DR (Figure 4.4.2) 
and 26% (12,922) developed DR, which consisted of 25.3% (12,574) BDR and 
0.7% (348) RDR.  RDR comprised of 0.2% (107) PPDR, 0.4% (197) maculopathy, 
0.03% (16) PPDR plus maculopathy, 0.05% (25) PDR, and 0.006% (3) PDR with 
maculopathy.  In those who developed PDR (28), the duration of diabetes was less 
than 5 years in 19 persons (68%), 27 persons (96%) were on diet and oral therapy 
and only one subject was receiving insulin therapy.  67.9% (19) of PDR were 
detected at the second screening event with a mean screening interval of 1.7 (±0.8) 
years.  Those who developed PDR at their second screening event were older than 
the mean age of the total population at 69.4 (±9.0) years vs. 64.4 (±11.3), older at 
diagnosis of diabetes 65.5 (±9.5) years vs. 60.2 (±11.3) years and more were male 
68.4% vs. 55.3%.  However, the duration of diabetes (median 3.0 years, IQR 0,5) 
and proportions on insulin therapy (5.3%) were similar compared to the total 
population.  As the putative risk factors of known duration of diabetes and use of 
insulin therapy are not indicated in this small subset of patients, other risk factors 
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not available for analysis here such as poor glycaemic control, may be contributing 
to this rapid progression to PDR. 
 
Figure 4.4.2: Incidence of any DR, BDR and RDR over the four year study period in 
persons with T2DM 
 
No DR - no diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy; PPDR - preproliferative diabetic retinopathy; PDR - proliferative diabetic 
retinopathy 
 
 
The estimated annual and cumulative incidence (cases per 1,000 persons) of any 
DR, BDR and RDR are included in Table 4.4.2.  The annual incidence of DR was 
low at 8 cases for both any DR and BDR and no cases of RDR.  Between 2 and 4 
years following a negative screening event the annual incidence of DR increased at 
a relatively constant rate with an average of 145.7 cases of any DR, 143.3 cases of 
BDR and 8.7 cases of RDR (Figure 4.4.3a). The four year cumulative incidence of 
any DR, BDR and RDR was 445, 438 and 16 cases respectively (Figure 4.4.3b).   
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Table 4.4.2: Incidence of any DR, BDR and RDR during the four year study period 
in persons with T2DM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Incidence and cumulative incidence is per 1,000 persons, Any DR - any diabetic retinopathy; 
BDR - background diabetic retinopathy; RDR - referable diabetic retinopathy; n - number 
remaining at risk; 95% CI – 95% Confidence Interval; * more than 2 decimal places provided 
due to the very narrow confidence intervals;  
Time 
(years) 
Any DR 
n Annual 
Incidence 
Cum Incidence 
(95% CI) 
1 48,793 8.00 8.00 (7.9997-8.0003)* 
2 30,693 155.00 163.00 (162.99-163.01) 
3 16,110 123.00 286.00 (285.98-286.02) 
4 3,107 159.00 445.00 (444.84-445.16) 
Time 
(years) 
BDR 
n Annual 
Incidence 
Cum Incidence 
(95% CI) 
1 48,457 8.00 8.00 (7.9997-8.0003)* 
2 30,573 151.00 159.00 (158.99-159.01) 
3 15,026 122.00 281.00 (280.97-281.03) 
4 3,098 157.00 438.00 (437.84-438.16) 
Time 
(years) 
RDR 
n Annual 
Incidence 
Cum Incidence 
(95% CI) 
1 49,083 0.00 0 
2 35,436 3.00 3.00 (2.9998-3.0002) 
3 19,274 4.00 7.00 (6.9993-7.0007) 
4 4,351 9.00 16.00 (15.993-16.007) 
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Figure 4.4.3: a) Annual and b) cumulative incidence of Any DR, BDR and RDR in persons with T2DM.  
a)          b) 
 
 
Ann. inc. - annual incidence; Cum. inc. - Cumulative incidence; any DR - any diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy 
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4.4.1.2 Risk Factors for incident DR 
The baseline characteristics of the persons with T2DM are summarised in Table 
4.4.3 divided into four groups according to outcome, i.e. those who did not develop 
DR and those who developed either any DR, BDR or RDR.  Those who remained 
free of DR were slightly but significantly younger at first screening than those who 
developed any DR and BDR but older than those who developed RDR.  
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Table 4.4.3: Characteristics of persons with T2DM who developed DR and those who remained free of DR in persons with T2DM 
 Remain No DR 
(n = 36,841) 
Reference category 
Develop 
any DR 
(n = 12,922) 
P value 
No DR 
vs. any 
DR 
Develop  
BDR 
(n = 12,574) 
P value 
No DR vs. 
BDR 
Develop RDR 
(n = 348) 
P value 
No DR vs. 
RDR 
Age mean (SD) 64.2 (11.3) 64.9 (11.3) 0.002 65.0 (11.3) <0.001 62.9 (11.3) 0.005 
Known Duration 
of DM median 
(IQR) 
 
3.0 (1.0-5.0) 
 
4.0 (2.0-7.0) 
 
<0.001 
 
4.0 (2.0-7.0) 
<0.001 
 
4.0 (2.0-7.0) 
 
<0.001 
Age at diagnosis 
mean (SD) 
 
60.3 (11.3) 
 
59.8 (11.5) 
 
<0.001 
 
59.8 (11.5) 
 
<0.001 
 
57.3 (11.8) 
 
<0.001 
Gender: 
Male n (%) 
Female n (%) 
 
20,346 (55.5) 
16,316 (44.5) 
 
7,183 (55.9) 
5,659 (44.1) 
0.232 
 
6,988 (55.9) 
5,507 (44.1) 
0.403 
 
195 (56.2) 
152 (43.8) 
0.786 
Treatment of DM: 
Diet n (%) 
OHA n (%) 
Insulin n (%) 
 
13,918 (38.5) 
20,723 (57.3) 
1,555 (4.3) 
 
3,318 (26.0) 
8,326 (64.4) 
1,114 (8.6) 
<0.001 
 
3,246 (26.2) 
8,092 (65.2) 
1, 072 (8.6) 
<0.001 
 
72 (20.7) 
234 (67.2) 
42 (12.1) 
<0.001 
No DR - no diabetic retinopathy; any DR - any diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable diabetic retinopathy; SD - 
standard deviation; IQR - interquartile range; OHA - oral hyperglycaemic agents
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Known duration of T2DM 
Those who did not develop DR during the 4 year study period had a significantly 
shorter known duration of diabetes (3 years), compared to those who developed 
any DR (4 years), BDR (4 years) or RDR (4 years) (Table 4.4.3, page 149).  
Significant differences were seen in the survival curves for known duration of 
diabetes and the incidence of any DR, BDR and RDR over the study period (Figure 
4.4.4a-c).  Those with diabetes for ≥10 years had a greater likelihood of developing 
any DR , BDR and RDR compared to those with diabetes for <5 years, with 
differences between the survival curves evident from approximately 1.4 years 
onwards for the presence of any DR and BDR and 2.2 years for RDR.  After 
adjusting for age at diagnosis of diabetes, gender and treatment of diabetes, 
increasing known duration of diabetes increased the risk of any DR, BDR and RDR 
developing (Table 4.4.4, page 152).  Those with a known duration of diabetes of 
≥10 years had a 1.6-fold increased risk of developing any DR and BDR and a 1.5-
fold increased risk of developing RDR relative to those persons with a known 
duration of diabetes of <5 years. 
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Figure 4.4.4: Kaplan Meier survival curves for the development of DR and known duration of diabetes in persons with T2DM 
 
a)       b)      c) 
 
Key:    <5 years    5-9 years   ≥10 years 
 
 
 
<5 years 5-9 years ≥10 years 
 
1 year 2 years 3 years 4 years 1 year 2 years 3 years 4 years 1 year 2 years 3 years 4 years 
An
y 
D
R
 
Number of people 
remaining at risk 
31,901 19,968 9,698 1,951 11,732 7,589 3,784 789 5,160 3,136 1,592 367 
Number of cases 226 3,951 5,926 7,048 102 1,983 2,994 3,567 68 1,096 1,625 1,931 
BD
R
 Number of people 
remaining at risk 
31,725 19,908 9,674 1,945 11,630 7,553 3,768 787 5,102 3,112 1,584 366 
Number of cases 222 3,831 5,770 6,874 97 1,912 2,903 3,462 65 1,059 1,572 1,871 
R
D
R
 Number of people 
remaining at risk 
32,064 22,572 11,961 2,645 11,812 8,963 5,041 1,121 5,207 3,901 2,272 585 
Number of cases 4 79 124 166 3 35 64 101 1 19 43 59 
p<0.001 p<0.001 p<0.001 
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Table 4.4.4: Cox regression analysis for the development of any DR, BDR and RDR in persons with T2DM 
 Any DR (12,922) BDR (12,574) RDR (348) 
Crude hazard 
Ratio (95% CI) 
Adjusted hazard 
Ratio (95% CI) 
Crude hazard 
Ratio (95% CI) 
Adjusted hazard 
Ratio (95% CI) 
Crude hazard  
Ratio (95% CI) 
Adjusted hazard 
Ratio (95% CI) 
Age at diagnosis (years) 
30-49 (8,932) 
50-59 (14,430) 
60-69 (15,572) 
≥70 (10,829) 
 
1.00 
0.94 (0.89, 0.94) 
0.92 (0.87, 0.96) 
1.03 (0.98, 1.09) 
 
1.00 
0.97 (0.92, 1.02) 
1.00 (0.95, 1.06) 
1.25 (1.18, 1.32) 
 
1.00 
0.94 (0.90, 0.99) 
0.93 (0.88, 0.98) 
1.04 (0.99, 1.10) 
 
1.00 
0.98 (0.93, 1.03) 
1.02 (0.96, 1.03) 
1.26 (1.19, 1.33) 
 
1.00 
0.71 (0.54, 0.94) 
0.50 (0.37, 0.68) 
0.70 (0.51, 0.95) 
 
1.00 
0.75 (0.56, 0.98) 
0.57 (0.42, 0.77) 
0.89 (0.64, 1.23) 
Gender: Male (27,529) 1.02 (0.99, 1.06) 1.02 (0.99, 1.06) 1.02 (0.99, 1.06) 1.02 (0.99, 1.06) 1.03 (0.83, 1.27) 1.03 (0.83, 1.27) 
Known Duration of DM (years) 
< 5 (32,574) 
5-9 (11,922) 
≥10 (5,297) 
 
1.00 
1.32 (1.27, 1.38) 
1.69 (1.61, 1.78) 
 
1.00 
1.25 (1.20, 1.30) 
1.59 (1.51, 1.68) 
 
1.00 
1.33 (1.27, 1.38) 
1.69 (1.60, 1.77) 
 
1.00 
1.25 (1.19, 1.30) 
1.59 (1.51, 1.68) 
 
1.00 
1.47 (1.16, 1.87) 
1.84 (1.38, 2.47 
 
1.00 
1.31 (1.02, 1.67) 
1.52 (1.12, 2.06) 
Treatment for diabetes: 
Diet (17,236) 
OHA (29,049) 
Insulin (2,669) 
 
1.00 
1.39 (1.34, 1.45) 
2.09 (1.96, 2.24) 
 
1.00 
1.34 (1.29, 1.40) 
1.87 (1.74, 2.01) 
 
1.00 
1.39 (1.34, 1.45) 
2.09 (1.95, 2.24) 
 
1.00 
1.34 (1.28, 1.40) 
1.86 (1.73, 2.00) 
 
1.00 
1.66 (1.27, 2.16) 
3.06 (2.09, 4.47) 
 
1.00 
1.52 (1.16, 2.00) 
2.44 (1.63 3.65) 
Any DR - any diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable diabetic retinopathy; 95% CI - 95% confidence interval; DM - 
diabetes mellitus; OHA - oral hyperglycaemic agent
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Treatment of diabetes  
There were significantly more persons who were on diet treatment and less using 
OHAs and on insulin therapy in those who remained free from DR compared to 
those who developed any DR, BDR and RDR (Table 4.4.3, page 149).  There were 
also significant differences in the survival curves for the incidence of any DR, BDR 
and RDR and the three categories of treatment of diabetes (Figure 4.4.5).  Those 
who were on insulin therapy had a poorer prognosis for the development of any DR, 
BDR and RDR.  After adjusting for age at diagnosis of diabetes, duration of diabetes 
and gender those persons using insulin therapy were at a 1.9-fold increased risk of 
developing any DR or BDR and a 2.4-fold increased risk of developing RDR relative 
to those receiving diet (Table 4.4.4, page 152). 
 
157 
 
Figure 4.4.5: Kaplan Meier survival curves for the development of DR and known treatment of diabetes in persons with T2DM 
a)       b)       c) 
 
Key:     Diet    OHAs     Insulin 
 
 
Diet OHA Insulin 
 
1 year 2 years 3 years 4 years 1 year 2 years 3 years 4 years 1 year 2 years 3 years 4 years 
An
y 
D
R
 
Number of people 
remaining at risk 
16,907 10,342 4,867 982 28,527 18,424 9,316 1,935 2,599 1,597 840 181 
Number of cases 103 1,887 2,776 3,237 244 4,407 6,715 8,065 35 616 901 1,082 
BD
R
 Number of people 
remaining at risk 
16,837 10,315 4,854 980 28,302 18,346 9,287 1,929 2,558 1,582 890 180 
Number of cases 101 1,842 2,717 3,167 235 4,251 6,510 7,837 34 589 850 1,041 
R
D
R
 Number of people 
remaining at risk 
16,978 11,499 5,795 1,256 28,723 21,537 12,202 2,794 2,618 2,026 1,247 289 
Number of cases 2 36 53 68 6 85 151 218 0 12 27 40 
<0.001 <0.001 <0.001 
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4.4.1.3 Screening Intervals 
As known duration and type of treatment of diabetes were shown to be the most 
important putative risk factors for DR they were used to assess the cumulative 
incidence of RDR (cases per 1,000 persons) in order to examine the impact of 
varying the screening intervals (Figure 4.4.6).  
 
There were no cases of RDR within the first year following an initial negative 
screening event for any of the groups according to treatment and/or duration of 
diabetes.  Those persons treated by diet alone, with a known duration of diabetes of 
<5 years, had two and three year cumulative incidence of 3 and 5 cases 
respectively, compared to 3 and 6 cases for those using OHAs and 3 and 21 cases 
for those using insulin within the same duration group.  In those with a known 
duration of diabetes was 5-9 years the two and three year cumulative incidence of 
RDR was 2 cases at two years and no additional cases at three years for those diet 
treated, 4 and 9 cases for those on OHAs respectively and 3 and 12 cases for those 
on insulin therapy respectively.  If the known duration of diabetes was ≥10 years the 
2 and 3 year cumulative incidence of RDR was 1 and 3 cases respectively for those 
on diet alone, 3 and 9 cases for those using OHAs and 11 and 28 cases for those 
using insulin (a 9 times higher rate compared to those diet controlled).   
 
Screening intervals for persons with T2DM with a preceding negative screen could 
be increased to once every two years from annual, without putting anyone at an 
increased risk of a delayed diagnosis of RDR.  In those persons treating their 
diabetes through diet alone, if the screening interval was once every three years 
then 6 cases would be at risk of a delayed diagnosis of RDR.  In those persons 
treating their diabetes with OHAs a screening interval of once every three years 
would mean 10 cases were at risk of a delayed diagnosis of RDR, this could be 
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reduced to 7 cases if those who also had diabetes for ≥10 years remained on 
biennial screening.  In those persons on insulin therapy 15 cases would be at risk of 
a delayed diagnosis with screening once every three years.  However, if those with 
diabetes ≥10 years and using insulin remained on a biennial screening interval then 
the risk would reduce to 4 cases.  
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Figure 4.4.6: Cumulative incidence of RDR by known duration of diabetes and treatment of diabetes in persons with T2DM 
* incidence is cases per 1,000 persons; † number of years since first negative screening event
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Insulin 
Incidence of 
RDR*
Category Total 
n
RDR 
Cases
1† 2† 3† 4†
< 5 yrs + 
Diet
13943 64 0 3 5 11
5-9 yrs + 
Diet
2429 6 0 2 2 6
≥ 10 yrs + 
Diet
864 2 0 1 3 3
Incidence of 
RDR*
Category Total n RDR 
Cases
1† 2† 3† 4†
< 5 yrs + 
OHA
17292 109 0 3 6 13
5-9 yrs + 
OHA
8240 85 0 4 9 22
≥ 10 yrs + 
OHA
3517 40 0 3 9 22
Incidence of 
RDR*
Category Total n RDR 
Cases
1† 2† 3† 4†
<5 yrs + 
Insulin
787 7 0 1 3 21
5-9 yrs 
Insulin
1072 16 0 3 12 37
≥ 10 yrs + 
Insulin
810 19 0 11 28 42
Diet only 
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4.4.1.4 Summary of main findings 
 In a population of 49,763 persons with T2DM, without evidence of DR at the 
first screening event, 348 (0.7%) persons developed RDR over the four year 
study period of which 28 (0.06%) developed PDR (± maculopathy). 
 The four year cumulative incidence of any DR, BDR and RDR was 445, 438 
and 16 cases per 1,000 persons respectively. 
 Of the limited putative risk factors for DR available, known duration of 
diabetes and treatment modality were the most significant risk factors 
associated with the incidence of any DR, BDR and RDR after adjusting for 
age at diagnosis and gender. 
 If the screening interval was extended from annual to biennial then no one 
(one year incidence of RDR 0 cases per 1,000 persons) would be at an 
increased risk of a delay in diagnosis of RDR. 
 When the screening interval was stratified for persons with T2DM according 
to both duration of diabetes and treatment type it demonstrated that in 
addition to biennial screening: 
o Those persons on diet treatment only and those using OHA's with a 
duration of diabetes of <10 years could have a triennial screening 
interval with only 6 cases (for diet) and 7 cases (for OHAs) at risk of 
a delayed diagnosis of RDR. 
 
4.4.2 T1DM 
4.4.2.1 Incidence of DR over the four year study period 
Of the 2,177 persons with T1DM who did not have DR at first presentation 82.4% 
(1,796) had at least one further screening event within the defined study period.  Of 
those who did not have a repeat screening event (17.5%), 3.8% (14) were anyway 
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not eligible within the study period as the interval from the first screen this would 
have been <12 months.  The reasons the remaining 96.3% (367) who were eligible 
for a repeat screening event within the study but did not receive one could not be 
investigated further due to the anonymised nature of the data.  The baseline 
characteristics between those eligible but who did not receive any further screening 
within the study period and those who did are included in Table 4.4.5.   
 
Table 4.4.5: Characteristics of those persons with T1DM who did or did not attend 
more than 1 screening event. 
 
 Without a second 
screening event 
(n=367) 
With more than one 
screening event 
(n=1,796) 
P value 
Age years mean (SD) 37.1 (21.3) 34.1 (18.7) 0.014 
Gender n (%): 
Male 
Female 
Unknown 
 
203 (55.3) 
164 (44.7) 
0 
 
971 (54.1) 
818 (45.5) 
7 (0.4) 
0.716 
Duration of diabetes years 
median (IQR) 
6.0 (3.0-12.0) 6.0 (3.0-12.0) 0.649 
Age at diagnosis of diabetes 
years means (SD) 
27.4 (19.5) 24.8 (16.7) 0.017 
n – total number; SD – standard deviation; IQR - interquartile range;  
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During the study a total of 1,131 (63.0%) persons had a third screening event, 432 
(24.1%) a fourth and 32 (1.8%) a fifth screening event (Figure 4.4.7).  The time 
between the first and second screening event 16 months (14-21), second and third 
14 months (12-17), third to fourth 12 months (12-12) and fourth and fifth was 11.5 
months (11-12).  Due to the high dropout rate and small sample size findings 
beyound the third screening event should be interpreted with caution. 
 
Figure 4.4.7: Number of persons with T1DM at each screening event 
 
Of the 1,796 patients with T1DM without evidence of DR at first screening, 57.0% 
(1,023) remained free of DR at the end of the study (Figure 4.4.8).  43.0% (773) 
developed DR, comprising 40.6% (729) with BDR and 2.4% (44) RDR.  The RDR 
group included 27.3% (12) with PPDR, 6.8% (3) PDR, 50.0% (22) maculopathy and 
15.9% (7) PPDR with maculopathy.  Of those who developed RDR, 56.8% (25) had 
BDR detected at an earlier screening event prior to the development of RDR.  The 
three persons who developed PDR did so by their second screening event which 
was one, two and three years following their initial screening.  Those few who 
developed PDR were relatively young at diagnosis of diabetes as compared to the 
whole group with a mean age (SD) of 16.3 (9.3) years and a longer duration of 
diabetes median (IQ) 7.0 (5.0-8.0) years at the time of first screening. 
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Figure 4.4.8: Incident DR over four years in persons with T1DM 
 
No DR - no diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy; PPDR - preproliferative diabetic retinopathy; PDR - proliferative diabetic 
retinopathy; RDR - referable diabetic retinopathy 
 
 
 
The annual incidence (cases per 1000 persons) of any DR increased from 17 cases 
in the first year to 204 cases in the fourth year the majority of which were BDR (15 
to 204 cases).  The annual incidence of RDR increased from 1 case in the first year 
to 34 cases in the fourth year.  The four year cumulative incidence of any DR, BDR 
and RDR was 649, 635 and 56 cases respectively (Table 4.4.6)
No DR 
57.0% 
BDR 
40.6% 
PPDR 
0.7% 
Maculopathy 
1.2% 
PPDR + 
Maculopathy 
0.4% 
PDR 
0.2% RDR 
2.4% 
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Table 4.4.6: Incident DR during the four year study in persons with T1DM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable 
diabetic retinopathy; Time - time since first negative screen; n - number remaining at risk; Cum 
incidence – cumulative incidence; 95% CI – 95% confidence interval; 
Any DR 
Time 
(years) 
n Annual 
incidence 
Cum 
Incidence 
95% CI 
1 1,746 17.00 17.00 16.98, 17.02 
2 1,014 247.00 264.00 263.62, 264.38 
3 500 181.00 445.00 444.03, 445.97 
4 105 204.00 649.00 644.75, 653.25 
BDR 
Time 
(years) 
n Annual 
incidence 
Cum 
Incidence 
95% CI 
1 1,707 15.00 15.00 17.98, 15.01 
2 1,000 237.00 252.00 251.63, 252.37 
3 495 179.00 431.00 430.03, 431.97 
4 105 204.00 635.00 630.67, 639.33 
RDR 
Time 
(years) 
n Annual 
incidence 
Cum 
Incidence 
95% CI 
1 1,747 1.00 1.00 0.999, 1.001 
2 1,023 8.00 9.00 8.98, 9.01 
3 509 13.00 22.00 21.92, 22.08 
4 107 34.00 56.00 55.03, 56.97 
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4.4.2.2 Risk Factors for incident DR 
Those who did not develop DR were significantly younger at initial screening aged 
32.6 years compared to those who subsequently developed any DR and BDR, both 
36.2 years of age (Table 4.4.7).  Although those who developed RDR were older 
than those who remained without DR the difference did not reach significance.  This 
finding may be an anomaly due to the small number of persons who developed 
RDR.  Those who developed any DR, BDR and RDR were significantly older at 
diagnosis of diabetes compared to those who remained without DR throughout the 
study period. 
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Table 4.4.7: Differences in characteristics between those persons with T1DM who develop any DR, BDR and RDR and those who remain free 
of DR  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No DR – no diabetic retinopathy; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable diabetic retinopathy; n – total 
number; SD – standard deviation; IQR – Interquartile range; 
 Remain No DR 
(n=1,023) 
Develop Any 
DR (n=773) 
P value No 
DR Vs any 
DR 
Develop 
BDR (n=729) 
P value No 
DR Vs BDR 
Develop 
RDR (n=44) 
P value No 
DR Vs RDR 
Age years mean (SD) 32.6 (18.6) 36.2 (18.7) <0.001 36.2 (18.7) <0.001 36.7 (17.6) 0.148 
Gender n (%): 
Male 
Female 
Unknown 
 
580 (56.7) 
440 (43.0) 
3 (0.3) 
 
391(50.6) 
378 (48.9) 
4 (0.5) 
0.011 
 
376 (51.6) 
349 (47.9) 
4 (0.3) 
0.039 
 
15 (34.1) 
29 (65.9) 
0.003 
Duration of DM years 
median (IQR) 
4.0 (2.0-9.0) 8.0 (5.0-15.0) <0.001 8.0 (5.0-15.0) <0.001 6.0 (2.0-11.0) <0.001 
Age at diagnosis of DM 
years mean (SD) 
25.4 (16.8) 24.1 (16.6) 0.125 24.4 (16.8) 0.260 19.1 (11.4) 0.001 
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Duration of diabetes 
There was a significant difference in the duration of diabetes at initial screening 
between  those who remained free of DR and those who developed DR.  Those 
who remained free of DR had a shorter duration of diabetes of 4 years compared to 
those developing DR i.e. any DR and BDR 8 years and RDR 6 years (Table 4.4.7, 
page 164).   
 
Significant differences were evident in the survival curves for duration of diabetes 
and the incidence of any DR, BDR and RDR over the study period (Figure 4.4.9a-c).  
Those with a duration of diabetes of 11-19 years had similar survival curves to those 
with diabetes for ≥20 years, both representing a poorer prognosis for the 
development of any DR and BDR than those with diabetes for ≤10 years.  There 
was a clear separation in the survival curve for those with a duration of diabetes of 
≤10 years and those with a duration of diabetes >10 years after 1.2 years for those 
who developed any DR and BDR.  The survival curves for the incidence of RDR 
although statistically different appeared very similar over the main period of the 
study.  However, the number of people developing RDR were small and so should 
be interpreted with caution.   
 
After adjusting for age at diagnosis of diabetes and gender, increasing duration of 
diabetes remained the strongest risk factor which was associated with the incidence 
of any DR, BDR and RDR (Table 4.4.8, page 167).  Those with diabetes for >10 
years were at an increased risk compared to those with diabetes for ≤10 years with 
those with diabetes for 11-19 years had a 1.8-fold increased risk for the incidence of 
any DR and BDR and a 2.2-fold increased risk of RDR, those with diabetes for ≥20 
years had a 2.8-fold increased risk for the incidence of any DR, 1.8- for BDR and a 
2.4- for RDR.  
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Figure 4.4.9: Kaplan Meier survival curves for the time to the incidence of DR for the duration of diabetes 
a)       b)       c) 
 
Key:    ≤10 years   11-19 years   ≥20 years 
 
 
 
≤10 years 11-19 years ≥20 years 
 
1 year 2 years 3 years 4 years 1 year 2 years 3 years 4 years 1 year 2 years 3 years 4 years 
An
y 
D
R
 
Number of people 
remaining at risk 
1,258 755 371 76 290 151 72 17 198 108 57 12 
Number of cases 20 234 368 450 6 112 150 174 5 72 105 121 
BD
R
 Number of people 
remaining at risk 
1,238 746 350 76 280 148 70 17 189 106 57 12 
Number of cases 19 222 368 429 4 103 140 162 3 63 94 110 
R
D
R
 Number of people 
remaining at risk 
1,271 909 508 121 298 227 141 30 202 164 119 28 
Number of cases 1 5 11 19 0 5 9 12 0 4 6 8 
p<0.001 p<0.001 p=0.009 
170 
 
Table 4.4.8: Cox regression survival analysis for the development of any DR, BDR and RDR
 
 Any DR (773) BDR (729) RDR (44) 
 n Crude hazard ratio 
(95% CI) 
Adjusted hazard 
ratio (95% CI) 
Crude hazard 
ratio (95% CI) 
Adjusted hazard 
ratio (95% CI) 
Crude hazard 
ratio (95% CI) 
Adjusted hazard 
ratio (95% CI) 
Duration of diabetes 
≤10 years 
11-19 years 
≥20 years 
 
1,295 
298 
203 
 
1.00 
1.83 (1.54, 2.17) 
1.86 (1.52, 2.26) 
 
1.00 
1.80 (1.51 2.15) 
2.84 (1.50, 2.24) 
 
1.00 
1.80 (1.51, 2.16) 
1.79 (1.45, 2.19) 
 
1.00 
1.79 (1.49, 2.14) 
1.77 (1.44, 2.18) 
 
1.00 
2.25 (1.05, 4.57) 
2.65 (1.28, 5.51) 
 
1.00 
2.24 (1.10, 4.58) 
2.38 (1.14, 4.97) 
Age at diagnosis of diabetes: 
≤10 years 
11-20 years 
>30 years  
 
371 
491 
934 
 
1.00 
0.70 (0.57, 0.86) 
0.74 (0.62, 0.87) 
 
1.00 
0.73 (0.59, 0.89) 
0.74 (0.62, 0.88) 
 
1.00 
0.69 (0.56, 0.85) 
0.75 (0.63, 0.90) 
 
1.00 
0.71 (0.58, 0.88) 
0.74 (0.61, 0.88) 
 
1.00 
0.69 (0.32, 1.52) 
0.51 (0.25, 1.04) 
 
1.00 
0.74 (0.34, 1.62) 
0.54 (0.27, 1.10) 
Gender: 
Male 
Female 
 
971 
818 
 
0.91 (0.79, 1.05) 
1.00 
 
0.98 (0.85, 1.13) 
1.00 
 
0.94 (0.81, 1.08) 
1.00 
 
1.00 (0.87, 1.16) 
1.00 
 
0.45 (0.24, 0.84) 
1.00 
 
0.51 (0.27, 0.95) 
1.00 
any DR - any diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable diabetic retinopathy; 95% CI - 95% confidence interval; 
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4.4.2.3 Screening intervals 
As duration of diabetes was shown to be the most important putative risk factor for 
DR of the ones available, it was subsequently used to assess the cumulative 
incidence of RDR.  This was done in order to examine the impact of different 
stratifications based on duration of diabetes and differing screening intervals (Figure 
4.4.10).  
 
In persons with a duration of diabetes of ≤10 years there was 1 case of RDR per 
1,000 persons one year after an initial negative screening event which increased to 
5 cases after two years and 15 cases after three years.  When the duration of 
diabetes was 11 to 19 years surprisingly there were no cases of RDR in the first 
year following a negative screening event.  However, two years later there were 19 
cases and the number increased to 40 after three years.  In those persons with a 
duration of diabetes ≥20 years again surprisingly there were no cases of RDR in the 
first year following a negative screening, however this increased to 27 cases after 
two years and 35 cases after three years.  
 
Screening intervals in persons with T1DM could be extended to once every two 
years with only a small increased risk in delaying the diagnosis of RDR (1 case per 
1,000 persons), as there were no cases of RDR in persons with a duration of 
diabetes of 11-19 years of ≥20 years.  If the screening interval was increased to 
once every three years, 6 cases would be at risk of a delay in referral for those with 
a duration of diabetes of ≤10 years.  The risk increased by 3.8 fold for those with a 
duration of diabetes between 11 to 19 years, and 5.8 times for those with diabetes 
≥20 years.  Therefore a screening interval of once every three years could be 
appropriate for those with T1DM with a duration of diabetes ≤10 years, if 6 cases 
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per 1,000 persons was deemed an appropriate level of risk, decreasing to biennial 
once the duration of diabetes exceeded 10 years. 
 
Figure 4.4.10: Incidence of RDR by duration of diabetes over four years in persons 
with T1DM 
 
     Incidence of RDR* 
 Category  Total 
n 
RDR 
cases n 
*1  
year 
*2 
years 
*3 
years 
*4 
years 
 ≤10 years  1295 21 1 5 15 46 
 11-19 
years 
 298 12 0 19 40 78 
 ≥20 years  203 11 0 27 35 72 
 
*Incidence of RDR provided as cases per 1,000 persons.
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4.4.2.4. Summary of main findings 
 During a four year study period involving a population of 1,749 persons with 
T1DM, without evidence of DR at their first screening event by the DRSSW, 
a total of 3 persons developed PDR.  These 3 persons were younger at 
diagnosis of diabetes with a longer duration of diabetes compared to those 
who did not develop PDR. 
 A Surprising finding was that 50% of those who developed RDR had 
maculopathy without evidence of PPDR or PDR. 
 The four year cumulative incidence of any DR, BDR and RDR was 649, 635 
and 56 cases per 1,000 persons. 
 Duration of diabetes, when adjusted for age at diagnosis and gender, was 
the most significant predictor for the incidence of any DR, BDR and RDR. 
 All persons with T1DM without evidence of DR could be placed on a biennial 
screening interval with only 1 case per 1,000 persons at risk of a delay in 
referral to the HES. 
 If the screening interval was adjusted based on duration of diabetes then for 
those persons with a duration of diabetes of ≤10 years 6 cases per 1,000 
persons would be at delayed diagnosis of RDR if the screening interval were 
extended to triennial for this group. However, due to the small population 
size and dropouts these findings should be interpreted with caution. 
 
 
4.5 Discussion 
This study involved a large population of 49,763 persons with T2DM and a smaller 
population of 1,796 persons with T1DM without DR at their first screening event by 
the DRSSW.  The four year cumulative incidence of any DR, BDR and RDR was 
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lower in persons with T2DM 445, 438 and 16 cases respectively per 1,000 persons 
compared to 649, 635 and 56 cases per 1,000 persons with T1DM respectively.  
Surprisingly, 50% of those with T1DM who developed RDR had maculopathy 
without PPDR or PDR.  The proportion was only slightly higher at 57% of persons 
with T2DM.  Maculopathy is usually more prevalent in persons with T2DM with PDR 
more prevalent in T1DM.(Klein et al. 1984)   
 
Direct comparison between our study and that of others reporting incidence rates is 
difficult for reasons stated earlier (see Chapter 3) predominantly due to differences 
in classification of diabetes and DR grading protocols employed and technologies to 
visualise and record the retina image as well as the use of different statistical 
methods to measure and report incidence (i.e. parametric vs. non parametric tests 
and cases per 1,000 persons vs. percentages).  However, some comparison of 
incidence rates can be made with two key studies i.e. the UKPDS, and the 
WESDR.(Klein et al. 1989a, b, Stratton et al. 2001)  The four year cumulative 
incidence of any DR in persons with T2DM was higher in our study at 44.5% 
compared to 38.6% (386 cases per 1,000 persons) in those aged 30 years or more 
at diagnosis of diabetes in the WESDR study.(Klein et al. 1989b)  Similarly the four 
year cumulative incidence of any DR was also higher at 65% in persons with T1DM 
in our study than that seen in the WESDR at 59% (590 cases per 1,000 persons) in 
persons less than 30 years of age.(Klein et al. 1989a)  This may also reflect 
differences in population demographics.  Our four year incidence rate at 44.5% 
were also slightly higher than the 6 year incidence rate of any DR at 41% (410 
cases per 1,000 persons) seen in the newly diagnosed T2DM persons included in 
the UKPDS.(Stratton et al. 2001)   
 
Two studies from screening programmes in the UK (Norfolk and Liverpool) provided 
incidence rates comparable to our study.(Younis et al. 2003a, Younis et al. 2003b, 
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Jones et al. 2012)  The Norfolk screening programme of 16,444 persons 
predominantly with T2DM the four year cumulative incidence of RDR was higher at 
3.7% or 37 cases per 1,000 persons comprising of PPDR 2.6%, maculopathy 0.5% 
and PDR 0.6% which is double the incidence of RDR in our study of persons with 
T2DM.(Jones et al. 2012)  There were a small number of persons with T1DM 
included in the analysis of T2DM in the Norfolk study which may account for some 
of the higher rate seen compared to our study.  In the Liverpool Eye Screening 
programme the four year cumulative incidence of sight-threatening DR was 2.1% in 
3,743 persons with T2DM and 3.2% in 305 persons with T1DM,(Younis et al. 2003a, 
Younis et al. 2003b) which would equate to 21 cases per 1,000 persons with T2DM 
which is higher than the incidence of RDR that we observed.  However, the 32 
cases per 1,000 persons with T1DM was lower than RDR seen in our T1DM 
population.  In addition to the different methods used to calculate the incidence 
rates there were also differences between the definition of RDR and sight-
threatening DR as well as subtle differences in the grading protocols used, which 
could well account for these relatively small differences in the incidence rates 
estimated.  In other population based studies (Chen et al. 1995, Gomes et al. 2000, 
Leske et al. 2003, Looker et al. 2003, Manaviat et al. 2008, Tam et al. 2008, Varma 
et al. 2010, Song et al. 2011) the four year incidence of any DR has mainly been 
reported in populations with T2DM or mixed T2DM and T1DM populations ranging 
from 15.2% in persons with T2DM in Hong Kong (Song et al. 2011) to 47.5% in 
persons with T2DM in Iran (Manaviat et al. 2008).   
 
In our study the annual incidence of any DR and BDR fluctuated over the four years 
which may be due to the population sizes involved and the non-parametric method 
used to estimate the incidence rate.  The Cox regression model assumes a constant 
hazard rate over a full study period, whereas in reality the hazard rates for the 
development of DR would be expected to increase over time which means that the 
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incidence of DR could be underestimated initially and then over estimated in the 
later stages or vice versa.(Kleinbaum et al. 2010)  To illustrate this in the population 
of T2DM examined here using the Weibull regression analysis the four year 
cumulative incidence of any DR was 360 cases per 1,000 persons which was lower 
than calculated in this chapter of 445 cases using the Kaplan Meier 
method.(Thomas et al. 2012)  However, Kaplan Meier and Cox regression analysis 
are more commonly used in health related research.  The reason for this is no 
assumptions about the underlying nature or shape of the survival distribution are 
required and closely approximate the results for the correct parametric model. 
  
The incidence of any DR, BDR and RDR was strongly associated with increasing 
duration of diabetes in persons with T2DM or T1DM after controlling for age at 
diagnosis of diabetes and gender, and treatment of diabetes in only those with 
T2DM.  For those with T2DM for 10 years or more there was a 1.6 fold increased 
risk of any DR and 1.5 fold increased risk of RDR over the study period compared to 
those with diabetes for <5 years.  In comparison those persons with T1DM for 20 
years or more had a 2.8 fold increased risk of any DR and 2.4 fold increased risk of 
RDR compared to those with diabetes for 10 years or less.  Similarly almost all DR 
studies of prevalence and incidence of DR have found duration of diabetes to have 
the strongest association with DR.(Younis et al. 2003b, Tapp et al. 2006, 
Cikamantana et al. 2007, Varma et al. 2007, Zhang et al. 2011)   
 
In persons with T2DM in this study there was also a strong association for insulin 
therapy and the incidence of any DR, BDR and RDR.  Relative to those on diet 
treatment only, those on diet plus OHAs had a 1.3 fold increased risk of any DR and 
BDR and a 1.5 fold increased risk of RDR.  The risk relative to diet only treatment 
increased further for those on insulin therapy to 1.9 fold for any DR and BDR and 
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2.4 fold for RDR.  This increased risk associated with the use of insulin therapy in 
persons with T2DM has been shown in previous incidence studies (Younis et al. 
2003b, Jones et al. 2012) and in studies involving the initiation of insulin therapy in 
T2DM.(Roysarkar et al. 1993, Henricsson et al. 1995, Chantelau et al. 1997, 
Henricsson et al. 1997)  This may reflect the prolonged period of poor glycaemic 
control  prior to the initiation of therapy, with the possibility of the additional impact 
of a rapid improvement in control at the initiation of insulin therapy.(Zhao et al. 
2014)   
 
Although the cumulative incidence of RDR was low in our population over the four 
year study period, the cumulative incidence (cases per 1,000 persons) at 1 and 2 
years preceded by a negative screening event was 0 and 3 cases with T2DM and 1 
and 9 cases with T1DM respectively.  The incidence of RDR varied considerably 
between subgroups, according to duration of diabetes in both T2DM and T1DM and 
treatment modality in persons with T2DM.  In persons with T2DM and a known 
duration of <5 years on diet therapy only, the two year cumulative incidence was 3 
cases rising to 11 cases when known duration increased to ≥10 years and on insulin 
therapy.  In persons with T1DM for ≤10 years the two year cumulative incidence of 
RDR was 5 cases rising to 19 cases when duration increased to 11 to 19 years and 
to 27 cases with duration of ≥ 20.  However, the number of persons with T1DM 
within this study were low especially so for those who developed RDR and so any 
interpretation of these findings should be done with caution. ‘Referable’ disease 
should not be confused with ‘treatable’ disease where numbers would be even 
smaller as the majority of RDR are for changes near the fovea without any macular 
oedema.(Leese 2013)  The potential visual implications of delaying the diagnosis of 
macular oedema are less than delaying the diagnosis of PDR. 
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Therefore, if the screening interval could be extended to once every two years for 
those with T2DM using insulin therapy with a duration of diabetes of ≥10 years and 
once every three years in those on diet only or using OHAs and insulin therapy with 
a duration of diabetes <10 years.  All persons with T1DM could be screened once 
every two years, however the risk may be too high to increase the screening interval 
beyond this..  This is in agreement with other UK screening programmes (Younis et 
al. 2003a, Younis et al. 2003b, Jones et al. 2012, Looker et al. 2013, Stratton et al. 
2013, Looker et al. 2014)  Most recently a report from the 4 Nations committee 
found that in persons with no evidence of DR in both eyes at two consecutive 
annual screening events, an appropriate yield of RDR of 2.5% would allow a 
recommendation for the screening interval to be extended to 2-3 years.(Four 
Nations Study Group 2013)  However, two important caveats within the report were; 
a robust IT system, in order to prevent the loss of patients from the service and 
ensuring accurate and consistent grading without with such a recommendation 
would be unsafe.  This evidence is currently being considered by the UK national 
screening committee.   
 
Screening intervals have already been extended in some programmes across 
Europe and the US, although these countries use ophthalmologists or optometrists 
to conduct detailed evaluations of the retina through slit lamp biomicroscopy or 
digital retinal images.  In Sweden, 1,691 persons with T2DM, good glycaemic 
control (mean HbA1c of 6.4%) and relatively short duration of diabetes (mean 6 
years) without DR were placed on a triennial screening interval.  After 3 years only 
three persons developed maculopathy and none had developed severe non-
proliferative DR or proliferative DR.(Agardh et al. 2011)  In Iceland persons without 
DR are screened biennially and 296 persons (97 T1DM and 199 T2DM) with a 
mean duration of 18 years and HbA1c 8.0% were followed over a period of 10 years.  
No person went from no DR to sight-threatening DR within a two year period.  Of 
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the 33 persons who developed PPDR or worse or CSMO, all had developed mild 
non-PDR first and were therefore on an annual screening protocol prior to sight-
threatening DR developing.(Olafsdottir et al. 2007)  Both of these studies, although 
not providing incidence rates, highlight that it is possible to safely extend screening 
intervals to bi- or triennial without increasing the risk of a delayed diagnosis of DR 
requiring referral to HES in those with no DR at initial screening.  In 2010, the 
American Diabetes Association recommended less frequent than annual screening 
in cases with at least one previous negative screening event.(Lundstrom et al. 2011)  
However, these guidelines were for a detailed evaluation of the retina to be 
conducted by an ophthalmologist or optometrist experienced in diagnosing DR.   
 
In addition to these reports one cost effectiveness study was conducted in Exeter, 
which found that in persons with T2DM without DR an extension of the screening 
interval to once every two years was associated with a 25% reduction in costs 
without increasing the risk of vision loss.(Chalk et al. 2012) 
 
Direct evidence from other UK screening programmes and related clinical trials has 
already been used to revise screening intervals for different types of cancer e.g. 
cervical (Sasieni et al. 2003), breast (The Breast Screening Frequency Trial Group 
2002) and bowel (Mandel et al. 1993) screening programmes.  Our study provides 
strong evidence from a large national screening programme that the annual 
screening interval could be extended in persons without DR, in both T2DM and 
T1DM without causing an increased risk of visual loss and blindness. 
 
The limitations of this study was the restriction to two 45° retinal images per eye, 
and only limited information available on putative risk factors for the development of 
DR.  This study also did not have access to measures of glycaemic control, blood 
pressure, and lipid concentrations.  There was also a high dropout rate experienced 
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of 14.9% of participants who did not have a second screening event despite being 
eligible.  This was especially a problem in the T1DM population, were numbers were 
already small.  Information regarding those persons who did not participate in 
screening was also unobtainable; some may have been excluded for medical 
reasons or because they were already receiving care from an ophthalmologist for 
DR (an exclusion criteria for screening), or they did not attend for other unknown 
reasons.  The use of Cox proportional hazards regression instead of more sensitive 
parametric models such as Weibull may also be a limitation in this study.  However, 
Cox regression is widely used in medical research and its findings are robust and 
closely approximate to the correct parametric model.(Kirkwood et al. 2003)  Using 
the grade of retinopathy from the worst eye only and based on the first screening 
event may also be a limitation of this study.  The use of two consecutive negative 
screening events and based on individual eyes as reported in the four nations 
diabetic retinopathy screening intervals project and in Scotland by Looker et al may 
provide a group at an even lower risk of development of RDR and therefore allow a 
safer extension of the screening interval.(Four Nations Study Group 2013, Looker et 
al. 2013) 
 
4.5.1 Summary of main findings 
 In persons with diabetes without evidence of DR at initial screening there 
was a very low incidence of RDR in persons with both T2DM and T1DM 
after one year. 
 The incidence of RDR varied considerably between subgroups with those 
with T2DM for 10 years or more and using insulin therapy and in persons 
with T1DM for 20 years or more having the highest incidence.   
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 The screening interval could reasonably be extended to once every two 
years for all persons with diabetes who have no evidence of DR at their first 
screening event. 
 Furthermore, it may be possible to extend the screening interval to once 
every three years in those with T2DM of less than 10 years and not receiving 
insulin therapy.  
 
  
 
Chapter 5 
Prevalence of diabetic retinopathy, visual 
impairment and putative risk factors at time 
of first screening event - Centre for Diabetes 
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5.1 Introduction 
The country of South Africa has an estimated population of approximately 52 
million, with the vast majority being indigenous Africans (79.5%) and a much smaller 
minority comprising of mixed races (9%), Caucasians (9%), and Asian Indians 
(2.5%).(U.S. Department of State 2011)  It is located at the southern tip of Africa 
and is divided into 9 provinces.  It is considered an emerging economy, however, 
approximately a quarter of the country’s population are unemployed.(www.gov.za 
2014)  The health care system in South Africa consists of a large and under-
resourced public sector, and a smaller fast growing private sector.  Health care 
varies from basic primary health care, which is provided free by the state for 
approximately 80% of the population, to highly specialised services available in the 
private sector.(www.safric.info 2011)  Approximately 80% of medical doctors 
employed in South Africa work only in the private sector.  
 
It has been estimated that the prevalence of diabetes in South Africa is 8.3% of the 
population (International Diabetes Federation 2014), with only 11% of those with 
diabetes having their eyes routinely examined for DR.(Read et al. 2007)  Diabetes is 
the fourth leading cause of blindness in South Africa (after cataract, glaucoma and 
age related macular degeneration)(Cockburn et al. 2012) and accounts for 8,000 
new cases of visual impairment every year.(Hofman et al. 2014)  There is evidence 
to suggest that the risk of DR and blindness in South Africa varies according to 
ethnicity.(West et al. 1982, Ross et al. 2007, Stolk et al. 2008, Raymond et al. 2009) 
This in part may be due to increased prevalence of diabetes and additional putative 
risk factors for DR or as yet unidentified reasons.  In 2010, the global prevalence of 
DR was estimated to be 55.8% in African Americans, 46.7% in Caucasians, and 
20.9% in Asian Indians.(American Diabetes Association 2010)  In comparison, the 
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reported prevalence of DR in persons with diabetes in South Africa’s public health 
care sector, based on minimal reports, indicate that DR is present in between 14 
and 55% of Indigenous Africans, 41% of Caucasians, and 22 and 37% of Asian 
Indians.(Kalk et al. 1997, Levitt et al. 1997, Carmichael et al. 2005)   
 
In 2002, South Africa signed up to Vision 2020 and published its national guidelines 
for the prevention of blindness.(World Health Organisation 2000, Department of 
Health 2002, World Health Organisation 2007, 2013)  Both documents include 
recommendations for the provision of screening for DR.  However, screening in the 
public sector is difficult in South Africa, as resources are already overstretched, and 
could not cope with the increased demands resulting from the identification of sight-
threatening DR requiring further assessment and treatment by screening.(Mash et 
al. 2007, Cook 2013)  Where screening exists it is adhoc and opportunistic, and 
systematic screening is unlikely in the near future.(Cook et al. 2014)  Those persons 
able to access private health care in South Africa are from a higher socioeconomic 
background than those in the public sector.  The prevalence of DR in the much 
smaller private health care sector (with its different ethnic distribution) has not 
previously been reported prior to this study.(Thomas et al. 2013)  This dataset which 
was provided to us by Dr Larry Distiller (CDE) was an unique opportunity to analyse 
the association between DR and a more extensive range of putative risk factors 
than were available to us at the DRSSW and traditionally collected by screening 
programmes in the UK.  
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5.2 Aims 
The primary aim of this study was 
 to determine the prevalence of any DR, BDR and RDR within the 
population attending the CDE, a private healthcare provider, on the 
occasion of their first screening visit and 
 to determine if the presence of any DR, BDR or RDR varied according to 
ethnicity 
The secondary aims of this study was 
 to investigate the impact of putative risk factors (glycaemic control, 
duration of diabetes, hypertension and dyslipidaemia) on the prevalence 
of any DR, BDR and RDR 
 to determine the prevalence of visual impairment and blindness within 
the CDE at first screening 
 to determine the risk factors associated with visual impairment and 
blindness 
 
5.3 Methods 
Retinal Screening 
All persons with diabetes attending the CDE in Johannesburg, South Africa, 
undergo routine digital retinal photography performed at the time of their first visit 
and annually thereafter.  All details of screening and grading protocols are provided 
in Chapter 2.  In brief, screening consisted of visual acuities recorded using a 3m 
illumined Snellen chart, digital retinal photography using a Canon CR6 non-
mydriatic camera capturing one central 45˚macular image per eye without the use of 
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mydriasis.  All the retinal images were internally graded at the CDE, but were re-
graded by one of three accredited graders according to the DRSSW grading 
protocol. 
 
Clinical laboratory data  
At the time of initial presentation, when the first retinal photographs were taken, 
blood and urine samples were obtained for baseline laboratory investigations 
including HbA1c, fasting lipid analyses (total cholesterol, LDL-cholesterol, HDL-
cholesterol and triglycerides), serum creatinine, urinary albumin excretion.  The 
Albumin:Creatinine ratio (ACR) was estimated and resting supine blood pressure 
and use of anti-hypertensive medication was recorded.  
 
Statistical Methods 
The methods of screening data cleaning and statistical analysis used within this 
chapter are described in detail in Chapter 2.  In this chapter, variables (age at 
diagnosis of diabetes, duration of diabetes, gender, ethnicity, glycaemic control, 
total cholesterol, ACR, smoking status, hypertension, and the use of ACE inhibitors 
or aspirin therapies) were assessed for their association with the presence of any 
DR, BDR and RDR using binary univariate and backwards stepwise multivariate 
logistic regression analyses.  All continuous variables were stratified to avoid 
assumptions of linearity (Table 5.3.1).   
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Table 5.3.1: Stratification of continuous variables 
  T1DM (n) T2DM (n) 
Total Chol 
(mmol/L) 
Low <5 (1,092) <5 (2,666) 
High >5 (417) >5 (1,256) 
ACR 
(mg/mmol) 
Low <3 (1,405) <3 (3,568) 
High >3 (131) >3 (405) 
HbA1c (%)  <7 (310) <6.6 (966) 
 7.0 -7.9 (342) 6.6-7.4 (1,097) 
 8.0-8.9 (322) 7.5 -8.9 (1,008) 
 >9 (563) >9 (907) 
Duration of 
diabetes 
(years) 
 <7 (505) <3 (1,391)  
 7-15 (515) 3-8 (1,360) 
 >15 (517) >8 (1,224) 
Age at 
diagnosis 
(years) 
 <14 (519) <46 (1,403) 
 14-26 (471) 46-55 (1,265) 
 >26 (540) >55 (1,286) 
ACR - albumin creatine ratio; Total chol - total cholesterol 
 
5.4 Results 
5.4.1 Diabetic retinopathy 
Prevalence of diabetic retinopathy within the total population 
A total of 5,565 persons were screened for DR at the CDE in Johannesburg 
between 2001 and 2010.  The majority of persons had T2DM (71.5%) with 27.6% 
having T1DM.  The remaining 0.9% were excluded from all subsequent analysis as 
they had IGT or other forms of diabetes, such as latent autoimmune diabetes of 
adulthood (LADA).  The majority of the total CDE population (5,515) who were 
included in the study were male (63.4%), and Caucasian (71.2%) (Table 5.4.1).  
The mean age of the study population was 51 years, duration of diabetes 9 years 
and they had a mean age at diagnosis of diabetes of 42 years.  The mean HbA1c of 
the population at baseline was 8.0%, total cholesterol 5.0 mg/dl and ACR was 4.3 
mg/mmol.  Almost 20% were smokers, with approximately 40% being hypertensive 
(34% on ACE inhibitors).  
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Table 5.4.1: Characteristics of the study population at fist screening (baseline) 
 
N=5,515 
Age yrs mean (SD) 50.8 (16.1) 
Gender: n (%) 
Male 
Female 
 
3,496 (63.4) 
2,016 (36.6) 
Ethnicity: n (%) 
Caucasian 
Asian Indian 
Indigenous African 
Mixed Race 
 
3,909 (71.2) 
697 (12.7) 
680 (12.4) 
208 (3.8) 
Type of diabetes: n (%) 
T1DM 
T2DM 
 
1,537 (27.9) 
3,978 (72.1) 
Duration of diabetes yrs mean (SD) 8.5 (8.6) 
Age at diagnosis of diabetes yrs mean (SD) 42.3 (17.6) 
HbA1c % mean (SD) 8.2 (2.0) 
Total Cholesterol mmol/L mean (SD) 5.0 (1.2) 
ACR mg/mmol mean (SD) 0.1 (0.3) 
Smoking n (%) 909 (16.5) 
Hypertensive n (%) 2,428 (44.0) 
ACE inhibitors n (%) 1,873 (34.0) 
Aspirin n (%) 787 (14.3) 
yrs - years; SD - standard deviation; n - number; ACR - albumin creatinine ratio; ACE - 
angiotensin converting enzyme inhibitors;  
 
The overall prevalence of any DR within the total study population was 25.9% (95% 
CI 24.7, 27.0) (Figure 5.4.1) with no evidence of DR in 74.2% (95% CI 73.0, 75.3).  
Of those with DR, BDR was evident in 18.3% (95% CI 17.3, 19.4) and RDR in 7.6% 
(95% CI 6.9, 8.3).  RDR comprised of 0.88% (95% CI 0.66, 1.2) with PPDR; 4.1% 
(95% CI 3.6, 4.7) with maculopathy; 1.4% (95% CI 1.1, 1.8) with PPDR and 
maculopathy; 0.44% (95% CI 0.29, 0.66) PDR; and 0.72% (95% CI 0.53, 0.99) with 
PDR and maculopathy.  There were 4.8% (95% CI 4.2, 5.4) with ungradeable 
images predominantly due to media opacification. 
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Figure 5.4.1: Prevalence of DR in persons with diabetes attending the CDE, South 
Africa 
 
NDR - no diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy; PPDR - preproliferative diabetic retinopathy; PDR - proliferative diabetic 
retinopathy 
 
 
5.4.1.1 T2DM 
5.4.1.1.1 Prevalence of DR in persons with T2DM  
There were a total of 3,978 persons with T2DM within the CDE diabetes 
management programme.  The characteristics of the population at baseline (first 
screening event) are represented in Table 5.4.2.  The majority (two thirds) of those 
with T2DM were male and of Caucasian origin.  The mean age was 56.6 years, 
median known duration of diabetes was 5.0 years and the mean HbA1c  level was 
7.5%.  From here on known duration of diabetes in persons with T2DM will be 
referred to as duration. 
 
NDR 
74.2% 
BDR 
18.3% 
Maculopathy 
4.1% 
PPDR± 
Maculopathy 
2.3% 
PDR± 
Maculopathy 
1.2% 
RDR 
7.6% 
 189 
 
Table 5.4.2: Characteristics of persons with T2DMat first screening. 
Characteristics T2DM (n=3,978) 
Age yrs mean (SD) 56.8 (11.8) 
Gender n (%): 
Male 
Female 
 
2,650 (66.6) 
1,326 (33.3) 
Ethnicity n (%): 
Caucasian 
Indigenous African 
Asian Indian 
Mixed Race 
 
2,662 (66.9) 
580 (14.6) 
562 (14.1) 
159 (4.0) 
Duration of diabetes yrs median (IQ) 5.0 (1.0 to 10.0) 
Age at diagnosis diabetes yrs mean (SD) 50.1 (11.8) 
HbA1c % median (IQ) 7.5 (6.6 to 8.9) 
Total Cholesterol mmol/L mean (SD) 5.0 (1.2) 
ACR median (IQ) 1.1 (0.5 to 3.6) 
Other therapies: 
ACE n (%) 
Aspirin n (%) 
Hypertensive n (%) 
 
1,620 (40.7) 
743 (18.7) 
2,441 (53.8) 
Smoker n (%) 607 (15.3) 
ACR - albumin creatinine ratio; ACE - angiotensin converting enzyme; yrs - years; n - 
numbers; IQ - interquartile range; SD - standard deviation 
 
 
Caucasian persons were older at baseline (p<0.001) and at the time of diagnosis of 
diabetes (p<0.001) with a lower HbA1c (p<0.001) than non-Caucasians (Table 
5.4.3).  The duration of diabetes was similar across all the ethnic groups included.  
There were significant differences in gender distribution across the ethnicities with 
more males of Caucasian origin compared to indigenous Africans, Asian Indians 
and those of a Mixed Race (p=0.008) and more females of Mixed Race compared 
to Indigenous Africans, Asian Indians and Caucasians (p<0.013).   
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Table 5.4.3: Baseline characteristics of different ethnic groups in persons with 
T2DM 
 Caucasian 
(n=2,662) 
Indigenous 
African (n=580) 
Asian Indian 
(n=562) 
Mixed Race 
(n=159) 
P 
value 
Age yrs mean (SD) 59.7  
(11.1) 
51.7  
(10.0) 
50.5  
(11.8) 
49.5  
(10.7) 
0.037 
Gender: n (%) 
Male 
 
Female 
 
1,810  
(68.0) 
851  
(32.0) 
 
382  
(65.9) 
197  
(34.0) 
 
362  
(64.4) 
200  
(35.6) 
 
85  
(53.5) 
74  
(46.5) 
 
0.013 
Duration of diabetes yrs 
median (IQ) 
5.0  
(1.0 to 10.0) 
5.0  
(2.0 to 10.0) 
5.0  
(1.0 to 10.0) 
4.0  
(1.0 to 10.0) 
0.173 
Age at diagnosis of 
Diabetes yrs mean (SD) 
53.0  
(11.4) 
44.6  
(9.8) 
43.5  
(11.5) 
43.7  
(10.3) 
0.199 
HbA1c % median (IQ) 7.3 
(6.5 to 8.4) 
8.3  
(7.0 to 10.5) 
7.9  
(6.9 to 9.4) 
8.1 
(7.0 to 10.0) 
0.003 
yrs - years; n - numbers; IQ - interquartile range; SD - standard deviation 
 
 
The prevalence of any DR in those persons with gradeable images was 21.6% 
(95% CI 20.3, 22.9) with no DR detected in 78.4% (95% CI 77.1, 79.7, n = 2,968) 
(Figure 5.4.2).  The majority of DR seen was BDR 14.8% (95% CI 13.7, 15.9, n = 
561) with 6.7% (95% CI 5.9, 7.5, n = 255) having RDR.  The category of RDR 
consisted of 0.7% (95% CI 0.5, 1.0 n = 28) PPDR; 3.7% (95% CI 3.1, 4.3, n = 141) 
maculopathy; 1.4% (95% CI 1.0, 1.8, n = 54) PPDR with maculopathy; 0.2% (95% 
CI 0.1, 0.4, n = 8) PDR; and 0.6% (95% CI 0.4, 0.9, n = 24) PDR with maculopathy.  
There were an additional 4.8% with ungradeable images (95% CI 4.3, 5.6) possibly 
due to media opacifications, the cause of which could not be determined as no 
external images were provided and no details were given by clinician. 
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Figure 5.4.2: Prevalence of DR in persons with T2DM 
 
No DR - no diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy; PPDR - pre-proliferative diabetic retinopathy; PDR - proliferative 
diabetic retinopathy 
 
5.4.1.1.2. Risk Factors for DR 
Ethnicity 
There was a lower proportion of Caucasians than all other ethnic groups in persons 
with any DR compared to those without DR (Table 5.4.4).  The prevalence of any 
DR, BDR and RDR were lowest in Caucasians at 16.8%, 12.4% and 4.4% 
respectively, and whilst the prevalence of any DR and BDR were highest in those of 
Mixed Race at 34.6% and 22.6% the prevalence of RDR was highest in Indigenous 
Africans at 13.1% (Figure 5.4.3).  This difference was significant when compared to 
those without DR (Table 5.4.4). 
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Table 5.4.4: Characteristics of persons with T2DM presenting without or with any DR, BDR and RDR 
 NDR 
(n = 2,968) 
Any DR 
(n=816) 
P Value No DR 
vs. any DR 
BDR 
(n=561) 
RDR 
(n=255) 
P value No DR vs. 
BDR and RDR 
Age yrs mean (SD) 56.1 (11.9) 57.4 (11.0) 0.005 57.7 (11.5) 56.7 (10.0) 0.013 
Gender: n (%) 
Male 
Female 
 
1,967 (66.3) 
1,001 (33.7) 
 
543 (66.7) 
271 (33.2) 
0.816 
 
385 (68.8) 
175 (31.2) 
 
158 (62.2) 
96 (37.8) 
0.182 
Duration of diabetes yrs median (IQ) 3.0 (1.0-7.0) 10.0 (6.0-16.0) <0.001 10.0 (5.0-15.0) 12.0 (8.0-17.0) <0.001 
Age at diagnosis yrs mean (SD) 51.1 (11.9) 45.8 (11.4) <0.001 46.7 (11.8) 43.9 (10.2) <0.001 
Ethnicity: n (%) 
Caucasian 
Indigenous African 
Asian Indian 
Mixed race 
 
2,100 (71.0) 
370 (12.5) 
390 (13.2) 
97 (3.3) 
 
448 (55.1) 
158 (19.4) 
152 (18.7) 
55 (6.7) 
<0.001 
 
331 (59.2) 
82 (14.7) 
110 (19.7) 
36 (6.4) 
 
117 (46.1) 
76 (29.9) 
42 (16.5) 
19 (7.5) 
<0.001 
HbA1c % median (IQ) 7.3 (6.5-8.6) 8.2 (7.1-9.7) <0.001 8.1 (7.0-9.4) 8.7 (7.6-10.4) <0.001 
Total Cholesterol 5.0 (1.2) 5.0 (1.2) 0.330 4.9 (1.1) 5.2 (1.3) 0.029 
ACR 0.95 (0.49-2.7) 2.10 (0.7-7.7) <0.001 1.4 (0.6-5.7) 4.8 (1.5-13.2) <0.001 
Smoker n (%) 463 (15.6) 125 (15.3) 0.844 94 (16.8) 31 (12.2) 0.239 
Hypertensive n (%) 1,540 (51.9) 483 (59.2) <0.001 324 (57.8) 159 (62.4) <0.001 
ACE n (%) 1,153 (38.8) 374 (45.8) <0.001 253 (45.1) 121 (47.5) 0.001 
Aspirin n (%) 569 (19.2) 138 (16.9) 0.143 96 (17.1) 42 (16.5) 0.333 
No DR - no diabetic retinopathy; any DR - any diabetic retinopathy; BDR - Background diabetic retinopathy; RDR - referable diabetic retinopathy; n - number; 
yrs - years; SD - standard deviation; IQ - interquartile range; ACR - albumin creatinine ratio; ACE - angiotensin converting enzyme.
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Figure 5.4.3: Prevalence of DR by ethnicity in persons with T2DM 
 
 
The presence of any DR, BDR and RDR were also associated with ethnicity with 
those of a non-Caucasian origin at an increased risk compared to Caucasians 
(Table 5.4.5).  Indigenous Africans were at a 2.0-fold increased risk of any DR at 
first screening, a 1.4-fold increased risk of BDR and a 3.7-fold increased risk of 
RDR compared to Caucasians.  Asian Indians had an 1.8-, 1.8- and 1.9-fold 
increased risk of having any DR, BDR and RDR whereas those of a Mixed Race 
had a 2.7-, 2.4- and 3.5-fold increased risk respectively when compared to 
Caucasians.  Once adjusted for age at diagnosis, known duration of diabetes and 
HbA1c level those of Mixed Race remained at greatest risk of any DR, BDR and 
RDR at first screening compared to Caucasians with a 2.7-, 2.6- and 3.4-fold 
increased risk respectively (Table 5.4.6). 
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Table 5.4.5: Univariate logistic regression analysis for the presence of any DR, BDR 
and RDR at first screening in persons with T2DM 
 Any DR 
OR (95% CI) n=816 
BDR 
OR (95% CI) N=561 
RDR 
OR (95% CI) n=255 
Age at diagnosis yrs: 
<46 (1,403) 
46-55 (1,265) 
>55 (1,286) 
 
1.00 
0.64 (0.54, 0.77) 
0.33 (0.27, 0.40) 
 
1.00 
0.71 (0.57, 0.87) 
0.40 (0.32, 0.51) 
 
1.00 
0.53 (0.39, 0.71)  
0.20 (0.13, 0.29) 
Male (2,650) 1.02 (0.87, 1.20) 1.12 (0.92, 1.36) 1.19 (0.92, 1.56) 
Ethnicity  
Caucasian (2,662) 
Indigenous African (580) 
Asian Indian (562) 
Mixed Race (159) 
 
1.00 
2.00 (1.62, 2.48) 
1.83 (1.48, 2.26) 
2.66 (1.88, 3.76) 
 
1.00 
1.41 (1.08, 1.83) 
1.79 (1.41, 2.28) 
2.36 (1.58, 3.51) 
 
1.00 
3.69 (2.71, 5.02)  
1.93 (1.34, 2.80)  
3.52 (2.08, 5.95) 
Duration of diabetes yrs 
<3 (1,391) 
3-8 (1,360) 
>8 (1,224) 
 
1.00 
2.61 (2.02, 3.63) 
11.24 (8.84, 14.28) 
 
1.00 
2.68 (2.02, 3.57) 
9.19 (7.00, 12.07) 
 
1.00 
2.36 (1.41, 3.95)  
18.03 (11.47, 29.34) 
HbA1c % 
≤6.5 (966) 
6.6-7.4 (1,097) 
7.5-8.9 (1,008) 
≥9.0 (907) 
 
1.00 
1.61 (1.25, 2.09) 
2.77 (2.16, 3.55) 
3.86 (3.01, 4.95) 
 
1.00 
1.58 (1.18, 2.11) 
2.46 (1.86, 3.27) 
2.99 (2.24, 3.97) 
 
1.00 
1.75 (1.05, 2.94)  
3.84 (2.38, 6.18)  
6.93 (4.37, 10.99) 
Hypertension (2,141) 1.35 (1.15, 1.57) 1.27 (1.06, 1.52) 1.54 (1.18, 2.00) 
Total Cholesterol 
>5mmol/l (1,256) 
 
0.95 (0.81, 1.13) 
 
0.94 (0.78, 1.15) 
 
0.98 (0.74, 1.29) 
ACR >3mg/mmol (405) 1.90 (1.51, 2.30) 1.56 (1.18, 2.07) 2.72 (1.96, 3.79) 
ACE inhibitors (1,620) 1.33 (1.14, 1.56) 1.29 (1.08, 1.55) 1.42 (1.10, 1.84) 
Aspirin (743) 0.86 (0.70, 1.05) 0.87 (0.69, 1.10) 0.83 (0.59, 1.17) 
Smokers (607) 0.98 (0.79, 1.21) 1.09 (0.85, 1.39) 0.75 (0.51, 1.10) 
Any DR - any diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy; OR - odds ratio; 95% CI - 95% confidence interval; yrs - years; ACR - 
albumin creatinine ratio; ACE - angiotensin converting enzyme  
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Table 5.4.6: Multivariate logistic regression analysis for the presence of any DR, 
BDR and RDR at first screening in persons with T2DM 
 
Any DR 
OR (95% CI) 
n=816 
BDR 
OR (95% CI)  
n = 561 
RDR 
OR (95% CI) 
 n=255 
Age at diagnosis yrs 
<46 (n=1,403) 
46-55 (n=1,265) 
>55 (n=1,286) 
 
1.00 
0.88 (0.72, 1.08) 
0.71 (0.56, 0.90) 
 
1.00 
0.91 (0.72, 1.14) 
0.75 (0.57, 0.97) 
 
1.00 
0.78 (0.56, 1.08) 
0.55 (0.35, 0.85) 
Male (n=2,650) 1.04 (0.87, 1.26) 1.11 (0.90, 1.37) 0.85 (0.63, 1.14) 
Ethnicity 
Caucasian (n=2,662) 
Indigenous African (n=580) 
Asian Indians (n=562) 
Mixed Race (n=159) 
 
1.00 
1.78 (1.39, 2.28 
1.60 (1.26, 2.05 
2.68 (1.80, 4.00) 
 
1.00 
1.31 (0.98, 1.75) 
1.60 (1.22, 2.10) 
2.58 (1.65, 4.03) 
 
1.00 
3.08 (2.14, 4.43) 
1.61 (1.07, 2.43) 
3.35 (1.82, 6.16) 
Duration of diabetes yrs 
<3 (n=1,391) 
3-8 (n=1,360) 
>8 (n=1,224) 
 
1.00 
2.33 (1.79, 3.02) 
9.55 (7.43, 12.27) 
 
1.00 
2.42 (1.81, 3.24) 
8.03 (6.05, 10.65) 
 
1.00 
2.05 (1.21, 3.46) 
14.98 (9.37, 23.95) 
HbA1c % 
</=6.5 (n=966) 
6.6-7.4 (n=1,097) 
7.5-8.9% (n=1,008) 
≥9.0 (n=907) 
 
1.00 
1.34 (1.01, 1.77) 
1.85 (1.41, 2.42) 
2.25 (1.71, 2.96) 
 
1.00 
1.31 (0.96, 1.78) 
1.64 (1.22, 2.22) 
1.86 (1.37, 2.54) 
 
1.00 
1.48 (0.86, 2.56) 
2.47 (1.49, 4.09) 
3.73 (2.28, 6.12) 
Any DR - any diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy; OR - odds ratio; 95% CI - 95% confidence interval; yrs - years; 
 
Known duration of diabetes 
The prevalence of any DR, BDR and RDR increased with increasing known duration 
of diabetes (Figure 5.4.4).  In those with relatively newly diagnosed diabetes (known 
duration ≤2 years) the prevalence of any DR and RDR was 7.0%, and 1.6% 
respectively (Table 5.4.7).  This increased to 29.6% and 9.9% respectively in those 
with a known duration of diabetes of 9-10 years.  Once the known duration of 
diabetes had increased to 19-20 years the prevalence of any DR and RDR had 
increased to 57.6% and 17.4% respectively.  Those persons presenting with any 
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DR, BDR or RDR had a significantly longer known duration of diabetes compared to 
those without DR (Table 5.4.4, page189). 
Figure 5.4.4: Prevalence of diabetic retinopathy with increasing known duration of 
diabetes in person with T2DM 
 
Table 5.4.7: The prevalence of any DR, BDR and RDR by known duration of T2DM. 
Known Duration 
of diabetes (yrs) 
n Any DR 
% (95% CI) 
BDR 
% (95% CI) 
RDR 
% (95% CI) 
0-2 1,361 7.0 (5.7, 8.5) 5.4 (4.3, 6.7) 1.6 (1.1, 2.4) 
3-4 516 12.0 (9.5, 15.1) 8.7 (6.6, 11.5) 3.3 (2.1, 5.2) 
5-6 468 16.0 (13.0, 19.6) 13.9 (11.1, 17.3) 2.1 (1.2, 3.9) 
7-8 330 23.6 (19.4, 28.5) 18.2 (14.4, 22.7) 5.5 (3.5, 8.5) 
9-10 335 29.6 (24.9, 34.7) 19.7 (15.8, 24.3) 9.9 (7.1, 13.5) 
11-12 167 47.9 (40.5, 55.4) 29.9 (23.5, 37.3) 18.0 (12.9, 24.5) 
13-14 109 51.4 (42.1, 60.6) 29.4 (21.6, 38.5) 22.0 (5.3, 30.7) 
15-16 175 45.1 (38.0, 52.5) 25.4 (19.3, 32.1) 20.0 (14.8, 26.5) 
17-18 60 66.7 (54.1, 77.3) 41.7 (30.1, 54.3) 25.0 (15.8, 37.2) 
19-20 132 57.6 (49.1, 65.7) 40.2 (32.2, 48.7) 17.4 (11.9, 24.8) 
21-22 26 76.9 (58.0, 89.0) 46.2 (28.8, 64.5) 30.8 (16.5, 50.0) 
23-24 15 60 (35.8, 80.2) 26.7 (10.9, 52.0) 33.3 (15.2, 58.3) 
25-28 34 67.7 (50.8, 80.9) 41.2 (26.4, 57.8) 26.5 (14.6, 43.1) 
29+ 53 45.3 (32.7, 85.6) 34.0 (22.7, 47.4) 11.3 (5.3, 22.6) 
any DR - any diabetic retinopathy; BDR - background diabetic retinopathy; RDR - 
referable diabetic retinopathy; 95% CI - 95% confidence interval; yrs - years 
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Increased known duration of diabetes was strongly associated with the presence of 
any DR, BDR and RDR.  In univariate analysis (Table 5.4.5, page 191), those with 
diabetes for 3-8 years had a 2.6-fold increased risk of having any DR, 2.7-fold for 
BDR and 2.4-fold for RDR, compared to those with diabetes for ≤2 years.  This 
increased to 11.2-, 9.2- and 18.0-fold risk for those with diabetes duration of >8 
years.  Once adjusted for age at diagnosis, ethnicity and HbA1c, level the risk for 
those with diabetes for 3-8 years remained similar to that in the univariate analysis 
at 2.3-, 2.4- and 2.1-fold increased risk of having any DR, BDR and RDR 
respectively compared to those with diabetes for ≤2 years (Table 5.4.6, page 192).  
Whilst the risk decreased slightly in the fully adjusted model for those with diabetes 
for > 8 years to 9.6-, 8.0- and 15-fold increased risk compared to those with 
diabetes for ≤2 years. 
 
Glycaemic Control  
The prevalence of any DR, BDR and RDR increased with increasing HbA1c (Figure 
5.4.5).  The prevalence of any DR was 2.8 times lower in persons with an HbA1c of 
<6.5% at 10.8% compared to those with an HbA1c of ≥9.0% at 31.1%.  The 
prevalence of RDR was 5 times lower in persons with an HbA1c of <6.5% at 2.4% 
compared to an HbA1c ≥9.0% at 12.3%.  Those with any DR, BDR and RDR had a 
significantly higher baseline HbA1c level compared to those presenting without DR 
(Table 5.4.4, page 189). 
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Figure 5.4.5: Prevalence of DR by glycaemic control in persons with T2DM 
 
Higher HbA1c levels at baseline were associated with an increased risk of presenting 
with any DR, BDR and RDR (Table 5.4.5, page 191).  Compared to those with 
HbA1c levels of ≤6.5%, there was a 1.6-, 1.6-, and 1.8-fold increased risk of any DR, 
BDR and RDR at first screening respectively with HbA1c 6.6-7.4%, 2.8-, 2.5- and 
3.8-fold increased risk respectively with HbA1c levels of 7.5-8.9% and a 3.9-, 3.0- 
and 6.9-fold increased risk respectively with HbA1c levels of ≥9.0% in univariate 
analysis.  Once adjusted for age at diagnosis, gender, known duration of diabetes 
and ethnicity these levels of risk decreased slightly in comparison to the univariate 
analysis but still remained significant (Table 5.4.6, page 192).  Those with HbA1c 
levels of 6.6-7.4% had a 1.3-, 1.3- and 1.4-fold increased risk of presenting with any 
DR, BDR and RDR compared to those with HbA1c levels ≤6.5%.  Those with HbA1c 
levels of 7.5-8.9% had a 1.9-, 1.6- and 2.5-fold increased risk and those with HbA1c 
levels of ≥9.0% had a 2.3-, 1.9- and 3.7-fold increased risk of having any DR, BDR 
or RDR respectively compared to those with a HbA1c level ≤6.5%. 
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Other risk factors 
In univariate analysis increasing ACR levels, a younger age at diagnosis, the 
presence of hypertension and the use of ACE inhibitors were associated with an 
increased risk of having any DR, BDR and RDR (Table 5.4.5, page 191).  However, 
these factors were not maintained within the fully adjusted model, with the exception 
of age at diagnosis which was no longer significant. 
 
5.4.1.1.3 Summary of main findings 
In the study population persons with T2DM: 
 The prevalence of any DR was 20.5%, BDR 14.1% and RDR was 6.4% 
 In persons with diabetes duration of ≥20 years, 57.6% had any DR and 
17.4% had RDR 
 At an HbA1c of ≤6.5%, 11.3% had any DR increasing to 33.1% with a HbA1c 
of ≥9.0%.  RDR was 2.5% at an HbA1c of ≤6.5% increasing to 13.2% at the 
higher levels of HbA1c (≥9.0%)  
 Non-Caucasian ethnicity (compared to Caucasians) was independently 
associated with the presence of any DR, BDR and RDR with those of a 
Mixed Race at the greatest risk. 
 Increased known duration of diabetes and an increasing HbA1c were also 
independently associated with the presence of any DR, BDR and RDR 
following adjustment for confounders. 
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5.4.1.2 T1DM 
5.4.1.2.1 Prevalence of DR  
There were 1,537 persons with T1DM within the diabetes management programme 
at the CDE (Table 5.4.8).  The mean age of this population was 35.4 years, the 
majority were male (55.0%) and Caucasian (81.1%).  The median duration of 
diabetes was 11.1 years and HbA1c was 8.4%.  Those of Caucasian ethnicity were 
significantly younger at diagnosis of diabetes compared to the non-Caucasians i.e. 
Indigenous Africans, Asian Indian and those of a Mixed Race (21.6 vs. 28.5, 22.7, 
22.7 years respectively) (Table 5.4.9).  However, no other significant differences 
were seen. 
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Table 5.4.8: Baseline characteristics for all T1DM persons attending the CDE for 
their diabetes care 
Characteristics T1DM (n=1,537) 
Age yrs mean (SD) 35.4 (15.4) 
Gender n (%): 
Male 
Female 
 
846 (55.0) 
690 (44.9) 
Ethnicity n (%): 
Caucasian 
Indigenous African 
Asian Indian 
Mixed Race 
 
1,247 (81.1) 
117 (7.6) 
118 (7.7) 
49 (3.2) 
Duration of diabetes yrs median 
(IQR) 
11.1 (5.0 to 19.0) 
Age at diagnosis diabetes yrs 
mean (SD) 
22.3 (13.8) 
HbA1c % median (IQ) 8.4 (7.3 to 9.8) 
Total Cholesterol mmol/L mean 
(SD) 
5.1 (1.1) 
ACR median (IQ) 0.9 (0.4 to 2.1) 
Other therapies: 
ACE n (%) 
Aspirin n (%) 
Hypertensive n (%) 
 
253 (16.5) 
44 (2.6) 
287 (18.7) 
Smoker n (%) 302 (19.6) 
Key - yrs – years; SD – standard deviation; IQR – interquartile range;  
ACE – angiotensin converting enzyme inhibitors; ACR - albumin creatinine ratio; n - number 
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Table 5.4.9: Ethnic differences in baseline characteristics in persons with T1DM 
 Caucasian 
(n=1,247) 
Indigenous 
African (n=117) 
Asian Indian 
(n=118) 
Mixed Race 
(n=49) 
P 
value 
Age yrs mean (SD) 35.7  
(15.6) 
36.4  
(16.1) 
32.2  
(12.1) 
32.6  
(15.2) 
0.069 
Gender: n (%) 
Male 
 
Female 
 
690  
(55.3) 
556  
(44.6) 
 
66  
(56.4) 
51  
(43.6) 
 
65 
(55.1) 
53  
(44.9) 
 
21  
(42.9) 
28  
(57.1) 
 
0.253 
Duration of diabetes yrs 
median (IQR) 
2.0  
(6.0 to 20.0) 
5.0  
(3.0 to 11.5) 
8.0  
(3.0 to 15.0) 
8.0  
(5.0 to 14.5) 
0.070 
Age at diagnosis of 
diabetes yrs mean (SD) 
21.6  
(13.6) 
28.5  
(15.5) 
22.7  
(11.8) 
22.7  
(14.6) 
0.003 
HbA1c % median (IQR) 8.2  
(7.3 to 9.6) 
9.5  
(7.8 to 11.3) 
8.7  
(7.6 to 10.9) 
9.0  
(7.3 to 11.4) 
0.272 
yrs - years; IQR - interquartile range; n - numbers;  
 
In the T1DM population with gradeable images there were 63.2% (95% CI 60.7, 
65.6) with no evidence of DR, 27.2% (95% CI 25.0, 29.5) with BDR and 9.7% (95% 
CI 8.3, 11.3) with RDR (Figure 5.4.6).  The RDR category consisted of 1.2% (95% 
CI 0.8, 1.9) with PPDR; 5.1% (95% CI 4.1, 6.4) with maculopathy; 1.4% (95% CI 
0.9, 2.1) with PPDR and maculopathy; 1.0% (95% CI 0.6, 1.7) PDR; and 0.95% 
(95% CI 0.57, 0.16) with PDR and maculopathy.  Additionally there were 4.5% (95% 
CI 3.6, 5.6) with ungradeable images due to media opacification (this could not be 
analysed further).  
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Figure 5.4.6: Prevalence of DR in persons with T1DM
 
NDR - no diabetic retinopathy; BDR - background diabetic retinopathy; RDR - referable 
diabetic retinopathy; PPDR - preproliferative diabetic retinopathy; PDR - proliferative diabetic 
retinopathy 
 
5.4.1.2.2 Risk Factors for DR 
Ethnicity  
The prevalence of any DR and BDR was lowest in Indigenous Africans and highest 
in Asian Indians (Figure 5.4.7), whereas the prevalence of RDR was similar across 
the four ethnic groups.  There were no significant differences in ethnicity in those 
presenting with any DR, BDR or RDR when compared to those without DR (Table 
5.4.10, page 197). 
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Figure 5.4.7: Prevalence of DR by ethnicity in persons with T1DM 
  
NDR - no diabetic retinopathy; any DR - any diabetic retinopathy; BDR - background diabetic 
retinopathy; RDR - referable diabetic retinopathy 
 
 
In univariate logistic regression analysis, ethnicity was not significantly associated 
with the presence of any DR, BDR or RDR (Table 5.4.11, page 198).  However, 
ethnicity was retained in the multivariate logistic regression analysis after adjusting 
for gender, age at diagnosis, duration of diabetes, HbA1c, current smoking status 
and the presence of hypertension (Table 5.4.12, page 199).  Asian Indians were at 
an increased risk of any DR (OR 2.01) and BDR (OR 1.93) when compared with 
Caucasians.  Also when compared with Caucasians, Indigenous Africans had an 
increased risk of RDR (OR 3.38).   
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Table 5.4.10: Characteristics of persons with T1DM presenting without DR or with any DR, BDR and RDR 
 No DR 
(N = 927) 
Any DR 
(n = 541) 
P value No 
DR vs. 
Any DR 
BDR 
(n = 399) 
RDR 
(n = 142) 
P value No 
DR vs. BDR 
and RDR 
Age yrs mean (SD) 32.9 (15.6) 38.0 (14.0) <0.001 37.8 (14.0) 38.6 (12.2) <0.001 
Gender: n (%) 
Male 
Female 
 
496 (53.6) 
430 (46.4) 
 
304 (56.2) 
237 (43.8) 
0.329 
 
224 (56.1) 
175 (43.9) 
 
80 (56.3) 
62 (43.7) 
0.363 
Duration of diabetes yrs median (IQ) 6.0 (3.0-12.0) 17.0 (12.0-23.0) <0.001 16.0 (11.0-22.0) 18.0 (14.0-25.0) <0.001 
Age at diagnosis yrs mean (SD) 23.5 (14.4) 19.6 (11.8) <0.001 19.8 (12.0) 19.0 (11.4) <0.001 
Ethnicity: n (%) 
Caucasian 
Indigenous African 
Asian Indian 
Mixed race 
 
749 (81.1) 
76 (8.2) 
69 (7.5) 
30 (3.2) 
 
444 (82.1) 
32 (5.9) 
45 (8.3) 
18 (3.3) 
0.418 
 
330 (82.9) 
21 (5.3) 
34 (8.5) 
13 (3.3) 
 
114 (80.9) 
11 (7.8) 
11 (7.8) 
5 (3.5) 
0.692 
HbA1c % median (IQ) 8.3 (7.1-9.7) 8.5 (7.6-9.9) 0.001 8.4(7.5-9.8) 8.7 (7.8-10.2) 0.001 
Total Cholesterol 5.0 (1.1) 5.3 (1.1) 0.001 5.2 (1.0) 5.7 (1.3) <0.001 
ACR 0.7 (0.4-1.4) 1.2 (0.6-3.8) <0.001 1.02 (0.5-3.0) 2.6 (0.75-10.1) <0.001 
Smoker n (%) 163 (17.6) 124 (22.9) 0.013 92 (23.1) 32 (22.5) 0.045 
Hypertensive n (%) 112 (12.1) 136 (25.1) <0.001 85 (21.3) 51 (35.9) <0.001 
ACE n (%) 98 (10.6) 116 (21.4) <0.001 70 (17.5) 46 (32.4) <0.001 
Aspirin n (%) 16 (1.7) 20 (3.7) 0.019 12* (3.0) 8 (11.6) 0.014 
ACR - albumin creatinine ratio; ACE - angiotensin converting enzyme; yrs - years; n - numbers; SD - standard deviation; IQ - interquartile range
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Table 5.4.11: Univariate logistic regression analysis for the presence of any DR, 
BDR and RDR in persons with T1DM 
 Any DR  
OR (95% CI)  
n=541 
BDR 
OR (95%CI)  
n=399 
RDR 
OR (95% CI) 
 n=142 
Age at diagnosis: yrs  
< 14 (n=519) 
14-26 (n=515) 
>26 (n=540) 
 
1.00 
1.01 (0.78, 1.30) 
0.57 (0.44, 0.74) 
 
1.00 
1.06 (0.80, 1.40) 
0.56 (0.42, 0.75) 
 
1.00 
0.86 (0.56, 1.32)  
0.59 (0.38, 0.90) 
Male (n=846) 1.11 (0.90, 1.38) 1.11 (0.88, 1.41) 1.12 (0.78, 1.60) 
Ethnicity:  
Caucasian (n=1,247) 
Indigenous African (n=117) 
Asian Indian (n=118) 
Mixed Race (n=49) 
 
1.00 
0.71 (0.46. 1.09) 
1.10 (0.74, 1.63) 
1.01 (0.56, 1.84) 
 
1.00 
0.63 (0.38, 1.03) 
1.12 (0.73, 1.72) 
0.98 (0.51, 1.91) 
 
1.00 
0.95 (0.49, 1.84)  
1.05 (0.54, 2.04)  
1.10 (0.42, 2.88) 
Duration of diabetes: yrs 
<7 (n=505) 
7-15 (n=515) 
>15 (n=517) 
 
1.00 
8.89 (6.01, 13.15) 
26.20 (17.62, 38.95) 
 
1.00 
7.92 (5.21, 12.01) 
20.53 (13.46, 31.30) 
 
1.00 
16.19 (5.75, 45.60) 
68.74 (24.89, 189.88) 
HbA1c: % 
<7.0 (n=310) 
7.0-7.9 (n=342) 
8.0-8.9 (n=322) 
≥9.0 (n=563) 
 
1.00 
1.78 (1.26, 2.52) 
2.15 (1.52, 3.04) 
2.05 (1.50, 2.81) 
 
1.00 
2.05, (1.39, 3.02) 
2.30 (1.56, 3.39) 
2.05 (1.43, 2.93) 
 
1.00 
1.15 (0.62, 2.12)  
1.79 (1.01, 3.19)  
2.06 (1.23, 3.44) 
Total Cholesterol >5mmol/l 
(n=417) 
1.72 (1.36, 2.18) 1.57 (1.21, 2.04) 2.19 (1.51, 3.18) 
ACR >3mg/mmol (n=131) 2.91 (1.99, 4.25) 2.51 (1.65, 3.82) 4.11 (2.45, 6.87) 
ACE inhibitors (n=253) 2.31 (1.72, 3.10) 1.80 (1.29, 2.51) 4.05 (2.69, 6.10) 
Aspirin (n=44) 2.19 (1.12, 4.26) 1.77 (0.83, 3.77) 3.40 (1.43, 8.10) 
Smokers (n=302) 1.39 (1.07, 1.81) 1.41 (1.05, 1.87) 1.36 (0.89, 2.09) 
Hypertension (n=287) 2.44 (1.85, 3.22) 1.97 (1.44, 2.69) 4.08 (2.75, 6.06) 
ACR - albumin creatinine ratio; ACE - angiotensin converting enzyme; yrs - years; n - 
numbers; OR - odds ration; 95% CI - 95% confidence interval 
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Table 5.4.12: Multivariate logistic regression analysis for the presence of any DR 
and referable DR in persons with T1DM 
 
Any DR  
OR (95% CI) 
 n=541 
BDR 
OR (95% CI)  
n = 399 
RDR 
OR (95% CI)  
n=142 
Age at diagnosis: yrs 
< 14 (n=519) 
14-26 (n=515) 
>26 (n=540) 
 
1.00 
1.05 (0.77,1.44) 
0.75 (0.54, 1.04) 
 
1.00 
1.12 (0.80, 1.55) 
0.76 (0.54, 1.09) 
 
1.00 
0.71 (0.42,1.19) 
0.68 (0.39, 1.16) 
Male: (n=846) 1.19 (0.92, 1.54) 1.16 (0.88, 1.52) 1.44 (0.94, 2.21) 
Ethnicity: 
Caucasian (n=1,247) 
Indigenous African (n=117) 
Asian Indian (n=118) 
Mixed Race (n=49) 
 
1.00 
1.75 (1.02, 3.04) 
2.01 (1.23, 3.28) 
1.29 (0.61, 2.70) 
 
1.00 
1.48 (0.81, 2.70) 
1.93 (1.15, 3.23) 
1.17 (0.53, 2.60) 
 
1.00 
3.38 (1.39, 8.22) 
2.11 (0.92, 4.84) 
1.06 (0.36, 3.17) 
Duration of diabetes: yrs 
<7 (n=505) 
7-15 (n=515) 
>15 (n=517) 
 
1.00 
10.35 (6.81, 15.75) 
37.64 (23.85, 59.40) 
 
1.00 
9.19 (5.90, 14.30) 
29.04 (17.95, 46.98) 
 
1.00 
20.80 (7.05, 61.37) 
127.61 (41.71, 390.41) 
HbA1c: % 
<7.0 (n=310) 
7.0-7.9 (n=342) 
8.0-8.9 (n=322) 
>/=9.0 (n=563) 
 
1.00 
1.33 (0.89, 1.99) 
2.17 (1.44, 3.27) 
3.26 (2.21, 4.81) 
 
1.00 
1.47 (0.96, 2.28) 
2.25 (1.44, 3.51) 
3.07 (2.01, 4.70) 
 
1.00 
0.94 (0.47, 1.88) 
2.03 (1.03, 3.97) 
4.14 (2.22, 7.39) 
Smoker (n=302) 1.75 (1.26, 2.43) 1.72 (1.21, 2.43) 2.17 (1.27, 3.70) 
Hypertensive (n=287) 1.45 (1.03, 2.04) 1.19 (0.81, 1.73) 2.30 (1.40, 3.75) 
ACR - albumin creatinine ratio; ACE - angiotensin converting enzyme; yrs - years; n - 
numbers; OR - odds ration; 95% CI - 95% confidence interval 
 
Duration of diabetes 
The prevalence of any DR, BDR and RDR increased with increasing duration of 
diabetes (Figure 5.4.8).  In newly diagnosed persons with a duration of diabetes of 
≤2 years the prevalence of any DR and RDR was 3.0% and 0.5% respectively 
(Table 5.4.13).  In those with a duration of diabetes of 9-10 years this had increased 
to 34.1% with any DR and to 3.1% with RDR.  Once duration of diabetes reached 
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19-20 years the prevalence of any DR, and RDR had increased to 73.6% and 
25.0% respectively.  When compared to those without DR those presenting with any 
DR, BDR or RDR had a significantly increased duration of diabetes (Table 5.4.10, 
page 202).  
 
 
Figure 5.4.8: Prevalence of diabetic retinopathy by duration of T1DM  
  
Table 5.4.13: The prevalence of any DR, BDR and RDR by duration of T1DM 
Duration of 
diabetes 
(yrs) 
n Any DR 
% (95% CI) 
BDR 
% (95% CI) 
RDR 
% (95% CI) 
0-2 203 3.0 (1.4, 6.3) 2.5 (1.1, 5.6) 0.49 (0.1, 2.7) 
3-4 124 7.3 (3.9, 13.2) 5.7 (2.8, 11.2) 1.6 (0.4, 6.0) 
5-6 171 11.1 (7.2, 16.7) 10.5 (6.8, 16.0) 0.58 (0.1, 3.2) 
7-8 125 16.0 (10.6, 23.4) 12.8 (8.0, 19.8) 3.2 (1.3, 7.9) 
9-10 129 34.1 (26.5, 42.6) 31.0 (23.7, 39.4) 3.1 (1.2, 7.7) 
11-12 90 47.8 (37.8, 58.0) 38.9 (29.5, 49.2) 8.9 (4.6, 16.6) 
13-14 96 57.3 (47.3, 66.7) 37.5 (28.5, 47.5) 19.8 (13.1, 28.9) 
15-16 100 61.0 (51.2, 70.0) 46.0 (36.6, 55.7) 15.0 (9.3, 23.3) 
17-18 74 70.3 (59.1, 79.5) 44.6 (33.8, 55.9) 25.7 (17.1, 36.7) 
19-20 72 73.6 (62.4, 82.4) 48.6 (37.4, 59.9) 25.0 (16.4, 36.1) 
21-22 64 67.2 (55.0, 77.4) 45.3 (33.7, 57.4) 21.9 (13.5, 33.4) 
23-24 40 57.5 (42.2, 71.5) 55.0 (39.8, 69.3) 2.5 (4.4, 12.9) 
25-28 57 70.2 (57.3, 80.5) 42.1 (30.2, 55.0) 28.1 (18.1, 40.8) 
29+ 123 59.4 (50.5, 67.6) 43.1 (34.7, 51.9) 16.3 (10.8, 23.8) 
n - number; Any DR - any diabetic retinopathy; BDR - background diabetic; RDR - referable 
diabetic retinopathy; yrs - years 
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The findings in this population when subjected to univariate logistic regression 
analysis demonstrated that increasing duration of diabetes was the strongest risk 
factor for the presence of any DR (Table 5.4.11, page 203).  Those with a duration 
of diabetes of 7-15 years had an 8.9-fold increased risk of having any DR, 7.9-fold 
of having BDR, and 16.2-fold of having RDR compared to those who had diabetes 
for <7 years.  As the duration of diabetes increased to >15 years so did the risk of 
developing any DR, BDR and RDR increasing to a 26.2-, 20.5- and 68.7-fold risk 
respectively.  After adjusting for age at diagnosis, gender, ethnicity, HbA1c, smoking 
and hypertension increasing duration of diabetes remained the strongest risk factor 
for the presence of any DR, BDR and RDR (Table 5.4.12, page 204).  Those with a 
duration of diabetes of 7-15 years had a 10.4-fold increased risk of having any DR, 
9.2-fold of having BDR and 20-fold of developing RDR compared to those with 
diabetes for <7 years.  When the duration of diabetes increased to >15 years the 
risk of having any DR, BDR and RDR increased to 37.6-, 29.0- and 127.6-fold.   
 
Glycaemic control 
The prevalence of any DR, BDR and RDR increased with increasing HbA1c at the 
time of first screening (Figure 5.4.9).  Those with any DR, BDR or RDR when 
compared to those without DR had a significantly higher HbA1c level (Table 5.4.10, 
page 202).  Increasing HbA1c level increased the risk of presenting with any DR, 
BDR and RDR.  In univariate analysis those with HbA1c levels ≥9.0% had a 2.1-fold 
increased risk of presenting with any DR, BDR and RDR compared to those with a 
HbA1c <7.0% (Table 5.4.11, page 203). After adjusting for age at diagnosis, gender, 
ethnicity, duration of diabetes, smoking and hypertension those with a HbA1c of 7.0-
7.9% had a 1.3- and 1.5-fold increased risk of having any DR and BDR respectively 
compared to those with a HbA1c <7.0% (Table 5.4.12, page 204).  However, there 
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was no significant increased risk of having RDR between those with a HbA1c of 7.0-
7.9% and <7.0%.  As the HbA1c level increased to 8.0-8.9% the risk of having any 
DR, BDR and RDR increased to 2.2-, 2.3- and 2.0-fold respectively compared to 
those with a HbA1c of <7.0%.  Once the HbA1c was ≥9.0% the risk of having any DR, 
BDR or RDR increased to 3.3-, 3.1- and 4.1-fold respectively compared to those 
with a HbA1c of <7.0%. 
 
 
Figure 5.4.9: Prevalence of diabetic retinopathy by glycaemic control in persons with 
T1DM 
 
Other risk factors 
The risk factors significantly associated with the presence of any DR in univariate 
regression analysis were a high ACR, presence of hypertension, the use of ACE 
inhibitors, aspirin therapy, the habit of smoking, and total cholesterol levels (Table 
5.4.11, page 203).  The same significant associations were seen for the presence of 
BDR and RDR with the exception of the use of aspirin therapy for BDR and smoking 
for RDR.  Although there was a significant association between ACR and any DR, 
BDR and RDR these data were not included in the subsequent stepwise 
multivariate analyses as data was missing for many of the persons screened.  In 
multivariate analysis, risk factors independently associated with any DR were the 
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presence of hypertension and the habit of smoking, both of which increased the risk 
of any DR (Table 5.4.12, page 204).  The presence of hypertension and smoking 
also significantly increased the risk of any DR and RDR, with the exception of 
hypertension which was no longer significant for the presence of BDR. 
 
5.4.1.2.3 Summary of main findings 
In the study population with T1DM: 
 The prevalence of any DR was 36.9%, BDR 27.2% and RDR was 9.7%  
 After having diabetes for≥ 20 years, 73.6% had evidence of any DR and 
25.0% had RDR 
 At HbA1c of ≤7.0%, 24.8% had any DR increasing to 40.6% with a HbA1c of 
≥9.0%, whilst for RDR the prevalence increased from 7.3% to 12.2% for the 
same HbA1c levels respectively 
 Increasing duration of diabetes and baseline HbA1c levels were the strongest 
risk factors for the presence of any DR, BDR and RDR after adjusting for 
confounders 
 Other risk factors independently associated with any DR, BDR and RDR 
were ethnicity with Asian Indian's at higher risk of any DR and BDR and 
Indigenous Africans at a higher risk of RDR, compared to Caucasians after 
adjusting for confounders. 
 Those with hypertension and those who smoked were also at an increased 
risk of any DR, BDR and RDR after adjusting for confounders. 
 
 212 
 
5.4.2 Visual acuity 
5.4.2.1 T2DM 
5.4.2.1.1 Prevalence of visual impairment and blindness 
There were 74.1% (2,946) with a recorded visual acuity at the time of screening.  
Reasons for not recording visual acuity were not provided.  The majority (96.2%) of 
those who had visual acuity testing, had normal vision at first screening (Figure 
5.4.10), 3.5% had visual impairment (6/12-6/36) and 0.3% were blind (6/60 or 
worse) in their better seeing eye. 
 
Figure 5.4.10: Prevalence of normal vision, visual impairment and blindness in 
persons with T2DM at first screening 
 
 
The prevalence of DR and ungradeable images (due to media opacification) 
increased in line with worsening visual acuity.  The prevalence of RDR increased 
from 5.8% in those with normal vision to 12.5% in those with visual impairment, and 
20% in those who were blind.  The prevalence of ungradeable images increased 
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from 3.6% in those with normal vision to 20.2% in those with visual impairment, and 
30% in those who were blind (Figure 5.4.11a).  The proportion of persons with 
relatively newly diagnosed T2DM (≤2 years) decreased as visual acuity worsened.  
Of those persons with normal vision, 40.1% had had diabetes for <3 years with the 
proportion decreasing to 26% for those with visual impairment, and down to 20% for 
those who were blind (Figure 5.4.11b).  Even though the proportion of persons with 
visual impairment (50%) was highest in those with T2DM for ≥9 years, the 
proportion of persons who were blind (40%) had had T2DM for 3-8 years.  The 
proportion of persons aged ≥63 years with normal vision increased from 27.7%, to 
69.2% with visual impairment and 70% in persons who were blind (Figure 5.4.11c). 
 
Figure 5.4.11: Prevalence of normal vision, visual impairment and blindness with a) 
DR status, b) duration of diabetes c) age, in persons with T2DM 
a) 
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c) 
 
 
5.4.2.2 T1DM 
5.4.2.2.1 Prevalence of visual impairment and blindness 
Only 57.8% (889) of persons with T1DM had a recorded visual acuity at the time of 
screening.  Reasons for not recording visual acuity were not recorded.  Almost all of 
those tested (98.0%, n = 889) had a visual acuity of better than 6/12 (normal vision) 
in their better seeing eye (Figure 5.4.7), 1.8% (16) had a visual acuity of 6/12-6/36 
(visual impairment) and 0.2% (2) had a visual acuity of 6/60 or worse (blind) (Figure 
5.4.12).  
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Figure 5.4.12: Visual acuity in persons with T1DM at first screening 
 
There was a slight increase in the prevalence of visual impairment and blindness in 
those who had RDR at first screening compared to those without DR (Figure 
5.4.13a).  As duration of diabetes increased the prevalence of normal vision 
decreased and visual impairment increased, whilst the prevalence of blindness 
remained unchanged (Figure 5.4.13b).  However, the largest increase in the 
prevalence of visual impairment and blindness occurred in those subjects whose 
images were ungradeable.  The prevalence of normal vision decreased slightly with 
increasing age (Figure 5.4.13c).   
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Figure 5.4.13: Prevalence of normal vision, visual impairment and blindness with a) 
DR status, b) duration of diabetes and c) age in persons with T1DM 
a) 
 
b) 
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5.4.2.3 Summary of main findings 
 The prevalence of visual impairment and blindness was low in persons with 
T2DM at 3.5% and 0.3% respectively, and was low in those with T1DM at 
1.8% and 0.2% respectively. 
 The prevalence of visual impairment and blindness was higher in persons 
with RDR compared to those without DR and highest in those with 
ungradeable images in persons with either T2DM or T1DM. 
 
 
5.5 Discussion 
Within this special but limited sub-study of a cohort of persons with T2DM and 
T1DM undergoing retinal photography within a private diabetes management 
programme in South Africa, at the time of their first screening visit the prevalence of 
any DR was 20.5%, BDR was 14.1% and RDR was 6.4% in T2DM, and 36.9%, 
27.2% and 9.7% respectively in T1DM.  Two other studies, (Mash et al. 2007, Read 
et al. 2007) have previously reported the prevalence of DR in people with diabetes 
attending community clinics in Cape Town, South Africa.  Mash et al evaluated the 
implementation of a pilot screening service utilising a mobile screening NM digital 
camera in primary care.  In 400 patients screened the prevalence of any DR was 
63% (combined T2DM and T1DM),and RDR 43%.(Mash et al. 2007)  Read et al 
evaluated the level of DR in 248 consecutive persons with T2DM attending a 
primary care clinic, the prevalence of DR was 32.3% and 8.9% had RDR.(Read et 
al. 2007)  However the assessment of DR was by undilated direct ophthalmoscope 
with dilation used only if DR lesions were seen.  As the sensitivity and specificity of 
direct ophthalmoscopy is inferior to retinal photography this may be a reason for the 
difference in prevalence of DR reported.(Harding et al. 1995)  In a further study 
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using a 60° mydriatic fundus camera the prevalence of any DR was 33.4% as 
assessed by endocrinologists, and 26.5% when assessed by ophthalmologists with 
severe DR at 11.7%, and 12.6% respectively.(Joannou et al. 1996)  In a third and 
similar study comparing 60° colour photography versus clinicians’ fundus 
examinations the prevalence of any DR was 30.6%, with severe DR in 12.3% as 
determined by the reference standard.(Carmichael et al. 2005)  Therefore, the 
prevalence of DR in persons with T2DM reported in this study of patients attending 
a private clinic was lower than previously seen from community based studies in 
South Africa.  This may be due to the differences in the ethnicity and socio-
demographics of the populations accessing private and public health care services 
in South Africa.  In comparison to this study, where the majority were Caucasian's 
(71%), Read et al had a majority of Indigenous African (50%) with only 2% 
Caucasian, (Read et al. 2007) Levitt et al had all Indigenous Africans, (Levitt et al. 
1997) Carmichael et al had 49% Caucasians, 39% Indigenous Africans, 
(Carmichael et al. 2005) whilst Joannou et al had a population of 30% Indigenous 
African/Indian.(Joannou et al. 1996) 
  
Ethnic differences in the prevalence of any DR have previously been reported to be 
higher in non-Caucasian persons when compared to Caucasians or Europeans, 
(West et al. 1982, Stolk et al. 2008, Raymond et al. 2009) and similarly for 
severe/referable stages of DR.(Ross et al. 2007, Stolk et al. 2008)  Only two 
previous studies of persons with diabetes, with relative small numbers of patients, 
have examined differences between ethnic groups in South Africa.(Kalk et al. 1997, 
Read et al. 2007)  One study did not report any significant associations between 
ethnicity (Indigenous Africans, Mixed Race and Caucasians) and DR(Read et al. 
2007); whilst another study found that those of an African and Indian origin had a 
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significantly higher prevalence of severe DR than Caucasians.(Kalk et al. 1997)  
However a small sample size (248 patients) and method of DR detection being 
direct ophthalmoscopy may have limited the findings by Read et al.(Read et al. 
2007)  In contrast, we observed clear differences in the risk of DR between the 
ethnic groups we studied in the cohort of subjects attending the CDE in 
Johannesburg during 2001 to 2010.  Whilst the risk of any DR was increased in 
Asian Indians, RDR was higher in Indigenous Africans with T1DM when compared 
to Caucasians.  The risk of both any DR and RDR was increased for all non-
Caucasian populations, with those of Mixed Race at the greatest risk compared to 
Caucasians with T2DM.  These differences seen between Caucasians and non-
Caucasians remained after correction for other risk factors, including HbA1c at 
baseline and age at diagnosis of diabetes.  Possible explanations include 
differences in tissue response to chronic glycaemia due to ethnicity, as well as 
unrelated factors, such as erythrocyte turnover or the rate of protein glycation, 
presence of anaemia (especially haemolytic anaemia, thalassaemia and sickle cell 
anaemia).(Hare et al. 2012)  There is also some evidence that HbA1c may vary 
independently of glycaemia among people of different ethnicities.(Ziemer et al. 
2010, Chapp-Jumbo et al. 2012, Hare et al. 2012)  Those of black origin were found 
to have higher HbA1c levels than Caucasians after adjusting for confounders in 
persons without diabetes, impaired glucose tolerance and with known diabetes.  
Previous studies have also found associations between polymorphisms of specific 
genes, for example the endothelial nitric oxide synthase gene, and DR in different 
ethnicities, including African populations.(Chen et al. 2007)  Therefore, whether the 
increased risk in prevalence of RDR in non-Caucasians is due to differences in the 
presence and/or response to putative risk factors or some unknown gene or genes 
are still unclear.(Burgess et al. 2013)  
 
 220 
 
In our cohort Increasing duration of diabetes was the most significant risk factor 
associated with the presence of any DR, BDR and RDR in both T2DM and T1DM, 
which has also been consistently shown in almost all studies of prevalence,(Klein et 
al. 1984a, b, Kristinsson et al. 1994a, Kristinsson et al. 1994b, Henricsson et al. 
1996, Dowse et al. 1998, Younis et al. 2002, Misra et al. 2009, American Diabetes 
Association 2010b, Zhang et al. 2010, Yau et al. 2012) including the DRSSW 
population reported in Chapter 3.(Thomas et al. 2014)  
 
In both persons with T2DM and T1DM the risk of any DR, BDR and RDR increased 
with increasing HbA1c at time of initial screening.  Those with T1DM with an HbA1c 
above 8.0% had a 2 to 4 fold increased odds of having any DR, BDR and RDR 
compared to those with a HbA1c of 7.0% or less.  There was no significant difference 
comparing T1DM subjects with an HbA1c between 7.0% and 7.9% and those with a 
HbA1c of less than 7.0%.  In T2DM there was an increased risk of any DR, BDR and 
RDR associated with each incremental quartile of HbA1c compared to those with a 
HbA1c of 6.5% or less.  Previous clinical trials (The Diabetes Control and 
Complications Trial Research Group 1993, 1995, UK Prospective diabetes study 
group 1998a, The ADVANCE Collaborative Group. 2008, Duckworth et al. 2009) 
have reported that for every 1% decrease in HbA1c the risk of DR is reduced by 
37%, with the progression to sight-threatening DR reduced by 25%, the need for 
laser therapy by 25% and blindness by 15%.(Cheung et al. 2010)  The effect of 
early intensive therapy to achieve good glycaemic control appears to be long lasting 
and referred to as ‘metabolic memory’.(White et al. 2008)  However, a glycaemic 
threshold below which no apparent benefits in risk reduction is controversial, with a 
meta-analysis finding reductions in the frequency of DR below the diagnostic criteria 
for diabetes.(Wong et al. 2008)  However, clinical trials have not found any 
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additional benefit in aggressive glycaemic control, HbA1c <6.5%, on the 
development or progression of DR,(Gerstein et al. 2008, The ADVANCE 
Collaborative Group. 2008) with further findings suggesting a possible increase in 
mortality at the lower HbA1c range due to hypoglycaemia.(Liew et al. 2009)  
Therefore, the increased risk of hypoglycaemia with aggressive glycaemic targets 
should also be kept in mind in arriving at the best efficacy: adverse effect balance 
for each individual person. 
 
Hypertension was shown to be a significant risk factor for DR only in persons with 
T1DM.  Previous epidemiological studies and clinical trials have shown 
hypertension as an important modifiable risk factor for DR,(Mohamed et al. 2007, 
Gallego et al. 2008, Klein et al. 2008) but not in all studies.(ACCORD study group et 
al. 2010)  The UKPDS (UK Prospective diabetes study group 1998b, Matthews et 
al. 2004) demonstrated that for every 10mmHg decrease in systolic blood pressure 
the risk of DR progression was reduced by 35%, the need for laser therapy by 35% 
and visual loss by 50%,(Cheung et al. 2010) but these benefits have not been 
sustainable without continued long-term maintenance of blood pressure 
control.(Holman et al. 2008)  Some clinical trials (Chaturvedi et al. 1998, Chaturvedi 
et al. 2008, Mitchell et al. 2008, Sjolie et al. 2008, Mauer et al. 2009) investigating 
the effects of a RAS inhibitors have reported benefits for DR.  The DIRECT study 
investigating the effects of Candesartan in T2DM and T1DM have found reductions 
in the risk and progression of DR in persons with T1DM, (Chaturvedi et al. 2008) 
and increased regression of DR in persons with T2DM,(Sjolie et al. 2008) 
independent of changes in blood pressure.  However, the ADVANCE study did not 
show any beneficial effects of the combination of perindopril and indapamide on DR 
in persons with T2DM.(Patel et al. 2007)  A reason for the lack of an effect for 
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persons with T2DM, in contrast to the UKPDS,(UK Prospective diabetes study 
group 1998b) may be due to the more aggressive treatment of hypertension and 
lower blood pressure targets in this patient group.  In this study, the use of ACE 
inhibitors was associated with an increased risk of DR in both T2DM and T1DM.  
However, the use of aspirin therapy was only associated with an increased risk of 
any DR and RDR in T1DM, and not at all in T2DM.  Yet having adjusted for 
confounders, the use of ACE inhibitors and aspirin were no longer significant and 
were removed from the analysis.  Previously, the ETDRS found that aspirin had no 
beneficial effects on the progression of DR in persons with mild to severe non-PDR 
or early PDR.(Early Treatment Diabetic Retinopathy Study Research Group 1991)  
However, in the early stages of DR aspirin has been shown to slow the progression 
of microaneurysms by more than 50% over 3 years.(The DAMAD Study Group 
1989) 
 
The relevance of smoking as a risk factor for DR is inconclusive and controversial, 
with some studies showing a positive association,(Anonymous 1977, Klein et al. 
1983, UKPDS group 1990, Kohner et al. 1998) with others showing no 
association,(Klein et al. 1983, Kohner et al. 1998) whilst others suggest that 
smoking may be protective against the development of DR.(Stratton et al. 2001)  
Interestingly in our study, smoking was also inconclusive as a risk factor, with 
associations shown only for the development of RDR and only in persons with 
T1DM after adjusting for confounders.   
 
In our study population there was a low level of visual impairment and blindness in 
both T2DM and T1DM.  The prevalence of visual impairment was higher in persons 
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with T2DM compared to that of T1DM at 3.5% versus 1.8% respectively, although 
the prevalence of blindness was similar in both at 0.3% and 0.2% respectively.  This 
difference may be explained by the older age of theT2DM population.  Two studies 
have reported the prevalence of visual impairment in the African region at 8.5% and 
severely visually impaired or blindness at 3.6% (Glover et al. 2012) and 28.8% and 
11.4% respectively.(Mash et al. 2007) however, these studies did not report visual 
acuity separately for T2DM and T1DM.  Even so the prevalence of visual 
impairment and blindness in the CDE cohort were much lower than that previously 
reported, which may again be accounted for by differences in the population 
characteristics and socioeconomic status and/or genetic makeup. 
 
As DR is one of the major causes of blindness and visual impairment in people with 
diabetes, it is reasonable to assume that risk factors for DR would also be 
associated with visual impairment and blindness.(Deckert et al. 1967, Nielsen 
1984a, b, Rand et al. 1985, Agardh et al. 1993, Reichard 1995)  In the CDE cohort, 
the prevalence of visual impairment and blindness was highest in those with 
ungradeable images.  The most common cause of ungradeable images in screening 
programmes is cataract, media opacity and poor pupil dilation.(Thomas et al. 2014)  
Information on other eye conditions found during the screening process was not 
available for analysis in this study, and so could not be investigated further. 
 
Compared to previous population based studies in Africa and South Africa the 
strength of this study was the relatively larger sample size, although still small in 
epidemiological terms, and that all the data (i.e. retinal images and the putative risk 
factors) were collected at a single centre utilising standard protocols.  However, as 
most of the diabetes population in South Africa utilise the public health system and 
are of Indigenous African descent, the population studied here utilising the private 
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health system and being predominantly Caucasian is therefore not representative of 
the majority of persons with diabetes in South Africa.  Whilst the use of standardised 
digital retinal photography and grading protocol are strengths within this study, the 
lack of dilation may have led to a higher proportion of ungradeable images and the 
availability of only one 45° fields per eye may have resulted in under reporting of 
DR.  
 
5.5.1 Summary of main findings 
 In this population of persons with diabetes entering a private diabetes 
management programme in Johannesburg, SA, there was a low prevalence 
of DR.   
 Ethnicity was independently associated with the presence of DR and RDR at 
the time of first screening in both T2DM and T1DM.   
 Increasing duration of diabetes and poor glycaemic control were the 
strongest risk factors associated any DR and RDR in persons in both T2DM 
and T1DM.   
 In T1DM hypertension and smoking were additional risk factors for the 
presence of any DR and RDR. 
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6.1 Introduction 
The incidence of DR within South Africa, has not previously been adequately 
reported.  It has been estimated that diabetes, because of DR and cataracts 
accounts for 8,000 new cases of vision impairment every year.(Hofman et al. 2014) 
 
Previous studies in Europe have assessed the risk of developing DR, for the 
purpose of defining the most appropriate screening interval for individual patients, 
based on a minimal number of risk factors for DR available for analysis i.e. age, 
gender, duration of diabetes, type of diabetes and treatment for diabetes.(Younis et 
al. 2003a, Younis et al. 2003b, Olafsdottir et al. 2007, Agardh et al. 2011, Jones et 
al. 2012, Thomas et al. 2012)  The availability of additional putative risk factors 
including glycaemic control, blood pressure and cholesterol should make it possible 
to better individualise the screening interval.  There is also additional evidence 
which suggests that the risk of DR could vary with ethnicity.(West et al. 1982, Ross 
et al. 2007, Stolk et al. 2008, Raymond et al. 2009)  Therefore, the CDE dataset 
which was provided afforded me an unique opportunity to assess appropriate 
screening intervals with these additional putative risk factors available, although 
relatively small in numbers. 
 
6.2 Aims 
The primary aim of this chapter was to determine: 
 whether an annual screening interval is necessary in all persons with 
diabetes without any evidence of DR at initial screening based on a single 
45 degree central field (posterior pole) digital image acquired without 
mydriasis 
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In order to determine the appropriate screening intervals the secondary aims of this 
chapter were to determine: 
 the seven year cumulative incidence of any DR, BDR and RDR in persons 
with T2DM and T1DM in the stated population in Johannesburg, South 
Africa 
 the risk factors associated with the incidence of any DR, BDR and RDR in 
both T2DM and T1DM over the study period 
 
6.3 Methods 
At entry into the disease management programme retinal photographs are taken 
alongside measures of HbA1c, ACR and total cholesterol as well as recording the 
presence and/or treatment for hypertension and the habit of smoking (see Methods 
Chapter 2).  These assessments are then repeated on at least an annual basis if not 
more frequently.  The study population was followed up over a period of seven 
years from 2001-2010.   
 
To allow analysis of ethnic origin, due to the relatively small population sizes of both 
T2DM and T1DM ethnicity was grouped as Caucasian and non-Caucasians which  
comprised of Indigenous Africans, Asian Indians and persons of Mixed Race.  
Details of the statistical methods used in this chapter are described in Chapter 2.  In 
addition to the basic descriptive analyses used throughout, survival analyses, 
Kaplan Meier and Cox proportional hazards methods were also employed to 
estimate the incidence of any DR, BDR and RDR, as well as to examine the 
putative risk factors collected and their association with the development and or 
progression of DR.  Using the available risk factors associated with the incidence of 
RDR, incidence rates according to glycaemic control, duration of diabetes and 
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ethnicity were estimated to elucidate the impact of different screening intervals 
within this population.   
 
The subsets investigated were: 
for T2DM: 
A) Glycaemic control and known duration of diabetes sub-grouped as follows: 
 HbA1c ≤7.0% with a known duration of diabetes ≤10 years 
 HbA1c ≤7.0% with a known duration of diabetes >10 years 
 HbA1c >7.0% with a known duration of diabetes ≤10 years 
 HbA1c >7.0% with a known duration of diabetes >10 years 
and for T1DM: 
A) Ethnicity and glycaemic control sub-grouped as follows 
 Caucasians with an HbA1c ≤7.0% 
 Non-Caucasians with an HbA1c ≤7.0% 
 Caucasian with an HbA1c >7.0% 
 Non-Caucasians with an HbA1c >7.0% 
 
B) Ethnicity and duration of diabetes sub-grouped as follows: 
 Caucasians with a duration of diabetes ≤10 years 
 non-Caucasians with a duration of diabetes ≤10 years 
 Caucasians with a duration of diabetes >10 years 
 non-Caucasians with a duration of diabetes >10 years 
 
C) Glycaemic control and duration of diabetes sub-grouped as follows: 
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 HbA1c ≤7.0% with a duration of diabetes ≤10 years 
 HbA1c ≤7.0% with a duration of diabetes >10 years 
 HbA1c >7.0% with a duration of diabetes ≤10 years 
 HbA1c >7.0% with a duration of diabetes >10 years 
 
6.4 Results  
Of the 3,941 persons with diabetes without evidence of DR at initial screening, 
60.2% (2,371) had at least 1 further screening event within the study period and 
were included in the following analysis.  Reasons for not having a second screening 
event included: non-attendance, cancellation of medical aid, emigration or death.  
Due to the anonymisation of the data, this could not be investigated further. 
 
6.4.1. T2DM 
6.4.1.1 Incident DR in persons with T2DM  
There were 2,968 persons with T2DM without DR at their first DR screening event 
at the CDE, Johannesburg, South Africa.  57.3% (1,702) underwent at least 1 
further screening episode and 42.7% (1,266) did
 
not.  Of those who did not have 
any further screening within the time period of the study 22.6% (286) were deemed 
not eligible as a second screening event would have occurred before 12 months of 
the end of the study period.  The remaining 77.2% (977) although eligible 
unfortunately did not receive and or attend for a further screening episode.  Those 
who did have a second screening event were significantly older, with a lower HbA1c 
level and contained a higher proportion of Caucasians (Table 6.4.1) compared to 
those who did not have a repeat screening event. 
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Of those included in the analysis, the majority were Caucasian with a mean age 
56.8 years and a median known duration of diabetes of 4.0 years (Table 6.4.1).  The 
majority (74.7%) were Caucasian, with only 10.9% Indigenous Africans, 11.3% 
Indian Asians and 2.7% of Mixed Race.  The mean age at diagnosis of diabetes 
was 51.5 years and the median HbA1c at first screening was 7.2%.  
 
Tables 6.4.1: Baseline characteristics between persons with T2DM who attended for 
a second screening event and therefore included in the study and those who were 
eligible but did not. 
 No second screening 
(977) 
Included  
(1,702) 
P value 
Age years mean (SD) 55.5 (12.2) 56.8 (11.5) 0.008 
Gender: n (%) 
Male 
Female 
 
652 (66.7) 
325 (33.3) 
 
1,136 (66.7) 
566 (33.3 
0.996 
Ethnicity: n (%) 
Caucasian 
Indigenous African 
Indian Asian 
Mixed Race 
 
648 (66.3) 
143 (14.6) 
142 (14.5) 
40 (4.1) 
 
1,271 (74.7) 
186 (10.9) 
192 (11.3) 
46 (2.7) 
<0.001 
Known duration of 
diabetes years median 
(IQ) 
3.0 (1.0-7.0) 4.0 (1.0-8.0) 0.082 
Age at diagnosis years 
mean (SD) 
50.6 (11.9) 51.5 (11.5) 0.050 
HbA1c % median (IQ) 7.6 (6.6-9.0) 7.2 (6.5-8.3) <0.001 
Total Cholesterol  
(mmol/l) mean (SD) 
5.1 (1.3) 4.9 (1.1) 0.022 
ACR median (IQ) 1.0 (0.52-3.0) 0.91 (0.48-2.5) 0.246 
Other therapies: n (%) 
Aspirin 
ACE 
 
794 (81.3) 
183 (18.7) 
 
1,416 (83.2) 
286 (16.8) 
 
0.206 
0.027 
Hypertension n (%) 491 (50.3) 896 (52.6) 0.234 
Smokers n (%) 185 (18.9) 229 (13.5) <0.001 
Key: ACR - Albumin:Creatinine ratio; ACE - Angiotensin Converting Enzyme inhibitors; 
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Of the 2,968 persons with T2DM without DR at first screening, 1,710 (57.6%) 
persons underwent a second screening event, 1,121(37.8%) underwent a third 
screening event, 734 (24.7%) a fourth, 440 (14.8%) a fifth , 231 (7.8%) a sixth, 96 
(3.2%) a seventh, 28 (0.9%) an eighth and 2 (0.07%) a ninth screening event.  The 
average screening intervals ranged from 1.0 (0.9) year between the first and second 
screening events to 0.6 (0.5) years between the seventh and eighth screening 
events.  Over the study period, 15.3% (262) developed DR, of which, 13.8% (236) 
had BDR and 1.5% (26) RDR (Figure 6.4.1).  The RDR group consisted of 1.4% 
(24) who developed maculopathy, 0.06% developed PPDR with maculopathy and 
0.06% developed PDR alone without maculopathy.  Only one person developed 
PDR, however images at their second screening event were ungradeable.  
Therefore, the PDR was only visible at the third screening event which was 2.8 
years after the initial negative screen.  This person was a 59 year old male, 
Caucasian with a 4 year history of diabetes at the first screening event and an 
HbA1c of 7.1%.  He was a non-smoker, did not have hypertension and was not 
receiving aspirin or an ACE inhibitor.  At the third screening event when the PDR 
was seen the HbA1c had only slightly worsened to 7.6%, hypertension had 
developed and he was being treated with ACE inhibitors and aspirin. 
 
6.4.1: Incidence of DR during the 7 year study period in persons with T2DM 
 
No DR 
84.7% 
BDR 
13.8% 
Maculopathy 
1.4% 
PPDR + 
Maculopathy 
0.06% 
PDR 
0.06% 
RDR 
1.5% 
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The overall incidence of any DR, BDR and RDR over the course of the seven year 
study period is shown in Table 6.4.2 and Figure 6.4.2.  The annual incidence (cases 
per 1,000 persons) of any DR increased from 18 cases in the first year to 83 cases 
in the seventh year.  The annual incidence of RDR increased from 1 case in the first 
year to 20 cases in the sixth year and an additional 10 cases in the seventh year.  
The seven year cumulative incidence of any DR, BDR and RDR was 351 (35.1%), 
331 (33.1%) and 47 (4.7%) cases respectively. 
 
Table 6.4.2: Annual and cumulative incidence of any DR, BDR and RDR in persons 
with T2DM 
 Any DR 
Time (yrs) Number Annual 
incidence 
Cum incidence  
(95% CI) 
1 1,545 18.0 18.0 (17.98, 18.02) 
2 1,132 59.0 77.0 (76.9, 77.1) 
3 798 62.0 139.0 (138.7, 139.3 
4 543 39.0 178.0 (177.5, 178.5) 
5 350 35.0 213.0 (212.1, 213.9) 
6 182 55.0 268.0 (265.9, 270.1) 
7 46 83.0 351.0 (341.3, 360.7) 
 BDR 
Time (yrs) Number Annual 
incidence 
Cum incidence  
(95% CI) 
1 1,522 17.0 17.0 (16.98,17.02) 
2 1,119 56.0 69.0 (68.9, 69.1) 
3 792 59.0 126.0 (125.7, 126.3) 
4 541 40.0 160.0 (159.5, 160.5) 
5 349 36.0 195.0 (194.1, 195.9) 
6 181 54.0 251.0 (249.0, 253.0) 
7 46 89.0 331.0 (321.6, 340.4) 
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Table 6.4.2 continued 
 
 RDR 
Time (yrs) Number Annual 
incidence 
Cum incidence 
 (95% CI) 
1 1,561 1.0 1.0 (0.99, 1.0) 
2 1,192 4.0 5.0 (4.99, 5.01) 
3 876 6.0 11.0 (10.98, 11.02) 
4 624 2.0 13.0 (12.96, 13.04) 
5 421 5.0 17.0 (16.9, 17.1) 
6 228 20.0 37.0 (36.7, 37.3) 
7 61 10.0 47.0 (45.6, 48.4) 
 
Number - Number remaining at risk; cum incidence - cumulative incidence; Any DR - any 
diabetic retinopathy; BDR background diabetic retinopathy; RDR - referable diabetic 
retinopathy; yrs - years; Incidence is number of cases per 1,000 persons 
 
Figure 6.4.2: a) Annual and b) cumulative incidence of any DR, BDR and RDR in 
persons with T2DM 
a) 
 
b) 
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6.4.1.2 Risk factors for incident DR 
The characteristics at first screening of those who developed any DR, BDR and 
RDR and those who remained free of DR over the course of the seven year study 
period are shown in table 6.4.3.  There were no significant differences between 
those who developed any DR and those who remained free from DR for age, 
gender, total cholesterol, ACR, smoking status, hypertension and the use of ACE 
inhibitors.  There were also no significant differences between the Kaplan Meier 
curves for gender, total cholesterol, ACR, smoking status and the use of aspirin.  
These risk factors were also not significant between those who developed BDR and 
RDR and those who remained free of DR with the exception of gender for the 
development of BDR, were females were at a decreased risk compared to males, 
and the use of ACE inhibitors which decreased the risk of development of RDR 
(Table 6.4.4, page 234). 
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Table 6.4.3: Characteristics at first screening for persons with T2DM who remained free of DR and those who developed any DR, BDR and 
RDR during the course of the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No DR – no diabetic retinopathy; Any DR – any diabetic retinopathy; BDR – background diabetic retinopathy;  RDR – referable diabetic retinopathy; SD – 
standard deviation; IQ – Interquartile range; ACR – albumin: creatinine ratio; ACE – angiotensin converting enzyme inhibitors
 
NDR  
(1,448) 
Any DR 
(262) 
p 
value 
BDR 
 (236) 
p value RDR 
 (26) 
p 
value 
Age years mean (SD) 56.9 (11.4) 56.3 (12.4) 0.472 56.5 (12.7) 0.689 54.1 (9.7) 0.233 
Gender: n (%) 
Male 
Female 
 
954 (65.9) 
494 (34.1) 
 
187 (71.4) 
75 (28.6) 
0.083 
 
172 (72.9) 
64 (27.1) 
0.034 
 
15 (57.7) 
11 (42.3) 
0.325 
Known duration years mean (SD) 3.0 (1.0-7.0) 6.0 (3.0-10.0) <0.001 6.0 (2.3-10.0) <0.001 6.0 (4.8 – 10.0) 0.088 
Age at diagnosis years mean (SD) 52.0 (11.4) 48.7 (12.0) <0.001 48.9 (12.3) <0.001 47.0 (9.0) 0.042 
Ethnicity: n (%) 
Caucasian 
Indigenous African 
Asian 
Mixed race 
 
1,097 (76.0) 
149 (10.3) 
162 (11.2) 
35 (2.4) 
 
180 (68.7) 
38 (14.5) 
31 (11.8) 
11 (4.2) 
0.050 
 
164 (69.8) 
33 (14.0) 
28 (11.9) 
10 (4.3) 
0.101 
 
16 (64.0) 
5 (20.0) 
3 (12.0) 
1 (4.0) 
0.483 
HbA1c % median (IQ) 7.1 (6.5-8.1) 8.0 (7.0-9.3) <0.001 7.9 (7.0-9.2) <0.001 8.7 (71-11.3) 0.002 
Total Cholesterol  
(mmol/l) mean (SD) 
4.9 (1.1) 4.9 (1.1) 0.791 4.9 (1.0) 0.508 5.3 (1.5) 0.250 
ACR median (IQ) 0.88 (0.47-2.45) 1.1 (0.56-3.2) 0.191 1.1 (0.58-3.8) 0.137 0.72 (0.40-1.1) 0.396 
ACE n (%) 586 (40.5) 105 (40.1) 0.905 101 (42.8) 0.500 4 (15.4) 0.009 
Aspirin n (%) 256 (17.7) 32 (12.2) 0.030 30 (12.7) 0.059 2 (7.7) 0.209 
Smoker n (%) 195 (13.5) 34 (13.0) 0.830 30 (12.7) 0.752 4 (15.4) 0.764 
Hypertensive n (%) 761 (52.6) 140 (53.4) 0.793 130 (55.1) 0.470 10 (38.5) 0.143 
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Known duration of diabetes 
Those who developed any DR and BDR were significantly younger at diagnosis of 
diabetes.  However, whilst they had a longer known duration of diabetes those who 
developed RDR did not differ statistically from those who remained free of DR, may 
be due to the small numbers within this group (Table 6.4.3, page 231).  There was a 
significant difference in the survival curves for the incidence of any DR and BDR in 
respects to the known duration of diabetes, subdivided as <5 years, 5-9 years and 
≥10 years (Figure 6.4.3).  Those with the longest known duration of diabetes i.e. 
>10 years, had the poorest prognosis with the survival curves for the incidence of 
any DR and BDR, with those with the shortest duration having the best 
prognosis.(Figure 6.4.3a,b).  For the incidence of RDR those with a duration of 
diabetes of 5-9 years and ≥ 10 years had a similar prognosis, with those with a 
duration of diabetes <5 years having the best prognosis (Figure 6.4.3c).  In the Cox 
regression analysis, after adjusting for age at diagnosis, gender, ethnicity, and 
baseline HbA1c level, increased known duration of diabetes was significantly 
associated with the development of any DR, BDR and RDR (Table 6.4.4, page 234).  
Those persons with a known duration of diabetes of 5-9 years had a 2.9-fold 
increased risk of developing RDR when compared to those with a duration of 
diabetes of <5 years.  This risk however decreased to 2.4-fold for the development 
of RDR in persons with a known duration of diabetes of ≥10 years compared to <5 
years again this may be due to the small numbers within this group.
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Figure 6.4.3: Kaplan-Meier survival curves for the development of a) any DR, b) BDR and c) RDR by known duration of diabetes in persons 
with T2DM 
a)       b)       c) 
 
 
 Any DR BDR RDR 
 
 1 2  3 4 5 6  7 1 2 3 4 5 6 7 1 2  3 4 5 6  7 
<
5 
ye
a
rs
 Number at risk 843 614 419 278 171 82 20 839 612 418 297 171 82 20 851 633 442 303 192 97 26 
Number of 
cases 
14 37 60 72 82 87 92 12 33 55 66 76 81 86 2 2 3 4 4 5 6 
5-
10
 
ye
a
rs
 Number at risk 400 309 225 156 102 60 12 387 303 223 156 102 57 12 402 330 251 184 127 71 16 
Number of 
cases 
8 35 56 65 69 74 77 8 28 45 52 56 61 64 0 3 7 7 9 12 12 
>
10
 
ye
a
rs
 
Number at risk 301 208 153 108 76 42 14 295 203 150 106 75 41 14 307 228 182 136 101 59 19 
Number of 
cases 
8 39 62 72 78 87 90 7 37 58 67 72 81 83 0 2 3 4 4 6 7 
p<0.001 p<0.001 p=0.021 
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6.4.4: Univariate and Multivariate Cox regression analysis for the incidence of any DR, BDR and RDR in persons with T2DM. 
 
Any DR BDR RDR 
 Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Crude 
HR (95% CI) 
Adjusted 
HR (95% CI) 
Age at diagnosis of diabetes: 
<45 (459) 
45-50 (337) 
51-60 (520) 
>60 (379) 
 
1.81 (1.25, 2.62) 
1.23 (0.81, 1.86) 
1.13 (0.77, 1.67) 
1.00 
 
0.79 (0.55, 1.13) 
0.82 (0.59, 1.15) 
0.93 (0.61, 1.41) 
1.00 
 
1.70 (1.16, 2.50) 
1.14 (0.74, 1.76) 
1.07 (0.72, 1.61) 
1.00 
 
0.77 (0.52, 1.13) 
0.82 (0.57, 1.16) 
0.98 (0.63, 1.52) 
1.00 
 
3.39 (0.75, 15.35) 
2.46 (0.49, 12.23) 
1.97 (0.41, 9.47) 
1.00 
 
0.82 (0.30, 2.25) 
0.84 (0.31, 2.24) 
0.56 (0.11, 2.72) 
1.00 
Female 0.83 (0.64, 1.09) 0.79 (0.55, 1.13) 0.79 (0.58, 1.04) 0.72 (0.53, 0.97) 1.62 (0.74, 3.53) 1.30 (0.59, 2.89) 
Non-Caucasians (433) 1.53 (1.17, 1.99) 1.26 (0.94, 1.69) 1.49 (1.13, 1.97) 1.23 (0.90, 1.69) 2.17 (0.98, 4.78) 1.51 (0.66, 3.49) 
Known duration of diabetes  
<5 (953) 
5-10 (531) 
>10 (225) 
 
1.00 
1.82 (1.37, 2.40) 
2.63 (1.91, 3.63) 
 
1.00 
1.60 (1.19, 2.15) 
2.27 (1.60, 3.22) 
 
1.00 
1.68 (1.25, 2.26) 
2.63 (1.88, 3.68) 
 
1.00 
1.49 (1.09, 2.03) 
2.27 (1.58, 3.28) 
 
1.00 
3.55 (1.38, 9.17) 
2.63 (0.80, 8.66) 
 
1.00 
2.94 (1.12, 7.70) 
2.38 (0.70, 8.05) 
HbA1c (%) 
≤6.70 (550) 
6.71-7.80 (530) 
>7.80 (533) 
 
1.00 
1.33 (0.91, 1.94) 
3.31 (2.37, 4.64) 
 
1.00 
1.24 (0.85, 1.82) 
2.94 (2.08, 4.16) 
 
1.00 
1.40 (0.94, 2.08) 
3.32 (2.32, 4.75) 
 
1.00 
1.32 (0.88, 1.97) 
3.03 (2.10, 4.37) 
 
1.00 
0.77 (0.21, 2.85) 
3.79 (1.40, 10.28) 
 
1.00 
0.65 (0.17, 2.45) 
2.62 (0.93, 7.40) 
Total Cholesterol  
 (≥4.90) (454) 
0.77 (0.54, 1.09) N/A 0.77 (0.53, 1.11) N/A 0.70 (0.24, 2.01) N/A 
ACE inhibitors (691) 1.02 (0.80, 1.31)  1.14 (0.88, 1.48)  0.28 (0.10, 0.80)  
ACR 1.02 (1.00, 1.04)  1.02 (1.00, 1.04)  0.92 (0.74, 1.14)  
Hypertension (901) 1.04 (0.81, 1.33) N/A 1.11 (0.86, 1.44) N/A 0.55 (0.25, 1.22) N/A 
Smoker (229) 0.98 (0.68, 1.41) N/A 0.97 (0.66, 1.43) N/A 1.18 (0.41, 3.41) N/A 
Aspirin (288) 1.20 (0.83, 1.75)  1.27 (0.86, 1.88)  1.07 (0.24, 4.74)  
N/A - variables were not included in the multivariate analysis
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Glycaemic control 
Those developing DR (any, BDR and RDR) had a significantly higher HbA1c at the 
time of first screening than those who remained free of DR (Table 6.4.3, page 231).  
There was a significant difference in the survival curves for the incidence of any DR, 
BDR and RDR according to baseline HbA1c level with those with an HbA1c, of >7.8% 
had much worse survival curves compared to those with an HbA1c of 6.7-7.8 and 
≤6.7% (Figure 6.4.4).  Increased HbA1c levels were also significantly associated with 
the incidence of any DR, BDR and RDR in the Cox regression analysis after 
adjusting for age at diagnosis, gender, ethnicity and known duration of diabetes 
(Table 6.4.4, page 234).  Those persons with a baseline HbA1c of 6.7-7.8% did not 
have a significantly increased risk of developing any DR, BDR or RDR compared to 
those with an HbA1c of <6.7%.  In comparison, those persons with an HbA1c of 
>7.8% had a 2.9-, 3.0- and 2.6-fold increased risk of developing any DR, BDR and 
RDR respectively compared to those with a HbA1c level of <6.7%. 
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Figure 6.4.4: Kaplan-Meier survival curves for the development of a) any DR, b) BDR and c) RDR by HbA1c level at first screening in persons 
with T2DM 
a)        b)      c) 
 
 
 Any DR BDR RDR 
 
 1 2  3 4 5 6  7 1 2 3 4 5 6 7 1 2  3 4 5 6  7 
≤6
.7%
 Number at risk 499 360 262 185 121 66 15 495 359 262 185 121 66 15 502 368 275 198 136 78 18 
Number of 
cases 
5 23 32 35 41 45 46 4 19 27 30 36 40 41 1 2 2 2 2 3 4 
6.
71
-
7.
80
%
 Number at risk 486 380 273 185 122 71 17 483 377 272 184 122 71 17 488 394 293 205 139 82 21 
Number of 
cases 
5 20 41 48 51 55 62 4 19 38 45 47 51 58 1 1 3 3 3 4 4 
>
7.
81 %
 
Number at risk 483 336 222 142 87 36 10 467 327 217 141 102 35 10 493 369 260 186 122 55 17 
Number of 
cases 
13 57 90 109 118 127 130 12 49 78 93 86 111 113 0 4 8 10 12 16 17 
p<0.001 
p<0.001 
p<0.001 
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Ethnicity 
There were significantly more non-Caucasians who developed any DR compared to 
those who remained free of DR.  However, there was no significant difference 
between those who remained free of DR and those who developed BDR or RDR 
(Table 6.4.3, page 231).  Over the duration of the study, there was a significant 
difference between the survival curves of Caucasians and non-Caucasians for the 
incidence of any DR and BDR with non-Caucasians having a worse prognosis 
(Figure 6.4.5).  For the incidence of RDR, non-Caucasians again appeared to have 
the worst prognosis but the difference just failed to reach significance.  In the Cox 
regression analysis, after adjusting for age at diagnosis, gender, known duration of 
diabetes and baseline HbA1c level, there was a trend for non-Caucasians to be at an 
increased risk of developing any DR, BDR and RDR however this did not reach 
significance (Table 6.4.5, 234).
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Figure 6.4.5: Kaplan-Meier survival curves for the development of a) any DR, b) BDR and c) RDR by ethnicity in persons with T2DM 
a)       b)       c) 
 
 
 Any DR BDR RDR 
 
 1 2  3 4 5 6  7 1 2  3 4 5 6  7 1 2  3 4 5 6  7 
Ca
uc
as
i
a
n 
Number at risk 1160 875 621 419 278 148 36 1147 868 618 417 277 147 36 1172 920 678 477 330 185 44 
Number of 
cases 
19 80 125 147 158 170 178 16 71 112 133 143 155 162 2 6 9 10 10 14 16 
N
on
-
Ca
uc
as
ia
n
 
Number at risk 385 257 177 124 752 34 10 375 251 174 124 72 34 10 389 272 199 147 91 43 17 
Number of 
cases 
11 31 53 62 71 78 81 11 27 46 52 61 68 71 0 1 4 5 7 9 9 
p=0.001 p=0.005 p=0.050 
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6.4.1.3 Screening intervals for persons with T2DM 
In view of the findings above, which indicate that an increasing known duration of 
diabetes and a higher HbA1c at first screening appears to be the most important 
explanatory variables for predicting the development of DR.  These factors were 
then used to assess the cumulative incidence of RDR over the study.  Known 
duration of diabetes was stratified into the following subgroups ≤10 years (short 
duration) and >10 years (long duration).  HbA1c was stratified into ≤7.0% (low HbA1c) 
and >7.0% (high HbA1c) (Figure 6.4.6). 
 
Known duration of diabetes and glycaemic control 
Those persons with a high HbA1c level and long known duration of diabetes at 
baseline had the highest seven year cumulative incidence of RDR (cases per 1,000 
persons) at 97 cases (95% CI 79.8, 114.2) compared to 34 cases (95% CI 31.6, 
36.4) with a low HbA1c and short duration of diabetes and 21 cases (95% CI 16.0, 
26.0) with a low HbA1c and a long duration and 62 cases with a high HbA1c and a 
short duration of diabetes (Figure 6.4.6) The one and two year cumulative incidence 
of RDR in those with a low HbA1c level was 2 (95% CI 1.99, 2.01) and 4 cases (95% 
CI 3.98, 4.01) respectively with a short duration.  There was no new cases of RDR 
in those with a low HbA1c level and a long duration before 3 years.  In those with a 
high HbA1c, the one and two year cumulative incidence of RDR was 1 (95% CI 0.99, 
1.00) and 7 cases (95% CI 6.97, 7.02) respectively with a short duration and 0 and 
9 cases (95% CI 8.8, 9.2) respectively in those with a long duration.  Therefore, it 
may be safe to screen persons with a low baseline HbA1c level and a short known 
duration of diabetes once every 5 years, those with a low HbA1c and a long known 
duration of diabetes once every three years, and those with a high HbA1c level 
irrespective of duration of diabetes once every 2 years. 
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Figure 6.4.6: Cumulative incidence of RDR sub-grouped by HbA1c level at first 
screening and known duration of diabetes in persons with T2DM 
 
*Incidence is cases per 1,000 persons
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Category 
Total 
n 
cases 
n 
*1 
year 
*2 
year 
*3 
year 
*4 
year 
*5 
year 
*6 
year 
*7 
year 
 ≤7.Ϭ% ≤10 
years 644 5 
 
2 4 4 4 
 
4 
 
12 
 
34 
 >7.Ϭ% ≤ϭϬ 
years 71 1 
 
1 7 15 18 
 
27 
 
62 
 
62 
 ≤7.Ϭ% >ϭϬ 
years 745 15 
 
0 0 21 21 
 
21 
 
21 
 
21 
 >7.0% >10 
yea 140 4 
 
0 9 9 26 
 
26 
 
50 
 
97 
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6.4.1.4 Summary of Main Findings for persons with T2DM 
 Only one person with T2DM without DR at first screening developed PDR during 
the course of the seven year study period. 
 The seven year cumulative incidence of any DR, BDR and RDR was 351, 331 
and 47 cases. 
 After adjusting for age at diagnosis of diabetes, gender and ethnicity, increased 
duration (known) of diabetes and deteriorating glycaemic control (HbA1c ) were 
both associated with increasing incidence of any DR, BDR and RDR. 
 Ethnicity was not independently associated with the incidence of RDR when 
adjusted for HbA1c and known duration of diabetes.  However, the numbers of 
non-Caucasians within this group were very small. 
 The screening interval in persons with T2DM was stratified based on known 
duration of diabetes and glycaemic control. 
 Those with a HbA1c ≤7.0% and a duration of diabetes of ≤10 years could have a 
screening interval of once every two or three years with 2 or 4 cases per 1,000 
persons respectively at risk of a delayed diagnosis of RDR. 
 Those with a HbA1c ≤7% and a duration of diabetes >10 years could have a 
screening interval of once every three years as there were no cases of RDR 
until 3 years after a negative screening. 
 Those with a HbA1c >7% irrespective of duration of diabetes could have a 
screening interval of once every two years with only 1 case per 1,000 persons at 
risk of a delayed diagnosis of RDR. 
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6.4.2 T1DM 
6.4.2.1 Incident DR in persons with T1DM 
927 (39.1%) persons with T1DM did not have DR at first screening.  O these 31.3% 
(290) did not undergo a repeat screening within the seven year study period.  14.1% 
(41) were not eligible for a repeat screening, as this would have been within 12 
months of the first event, and for an additional 2 persons the date of first screening 
was unavailable.  The remainder 85.9% (247) although eligible for repeat screening 
and were within the defined time frame screening, unfortunately did not occur for 
unknown reasons.  Those who did not undergo a second screening event had a 
significantly shorter duration of diabetes and a higher HbA1c level compared to those 
who did have a second screening event.  No other significant differences were seen 
as outlined in Table 6.4.5. Of those included in the analysis (637) the majority were 
male (54%), Caucasian (81.8%), with a mean age at diagnosis of 23.5 years, 
median duration of diabetes of 7 years and a median HbA1c of 8.1% at entry into the 
study (Table 6.4.5).  
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Table 6.4.5: Baseline characteristics between persons with T1DM who did undergo 
a repeat screening event and those who were otherwise eligible but did not.   
 No Second 
screening (247) 
Included (637) p value 
Age years mean (SD) 31.9 (16.9) 33.5 (15.3) 0.261 
Gender: n (%) 
Male 
Female 
 
127 (51.4) 
119 (48.2) 
 
344 (54.0) 
293 (46.0) 
0.526 
Ethnicity: n (%) 
Caucasian 
Indigenous African 
Asian 
Mixed Race 
 
192 (77.7) 
22 (8.9) 
19  (7.7) 
13 (5.3) 
 
521 (81.8) 
51 (8.0) 
47 (7.4) 
16 (2.5) 
0.198 
Duration yrs median 
(IQR) 
5.0 (2.0-9.0) 7.0 (4.0-13.0) <0.001 
Age at diagnosis yrs 
mean (SD) 
24.0 (15.7) 23.5 (14.0) 0.624 
HbA1c % median (IQR) 8.7 (7.5-10.6) 8.1 (7.0-9.5) <0.001 
Total Cholesterol mmol/L 
mean (SD) 
5.2 (1.4) 5.0 (1.0) 0.166 
ACR median (IQR) 0.91 (0.42-1.58) 0.68 (0.37-1.4) 0.088 
Other therapies: n (%) 
Aspirin 
ACE 
 
5 (2.0) 
20 (8.1) 
 
10 (1.6) 
73 (11.5) 
 
0.639 
0.144 
Hypertension n (%) 24 (9.7) 84 (13.2) 0.157 
Current Smokers n (%) 47 (19.0) 107 (16.8) 0.433 
SD – Standard Deviation; n – total number; IQR – Interquartile range; ACR – 
albumin:creatinine ratio; ACE – angiotension converting enzymes; yrs - years 
 
During the seven year study period a total of 454 (71.3%) persons had three 
screening events, 323 (50.9%) had four, 228 (36.0%) had five, 159 (25.1%) had six, 
82 (12.9%) had seven, 23 (3.6%) had eight, 4 (0.7%) had nine and only 1 (0.2%) 
had ten screening events.  The mean (SD) screening interval during the study 
period ranged from 1.2 (1.2) years between the first and second screening event to 
0.6 (0.5) years between the seventh and eighth.  During the study period, 34.8% 
(224) developed any DR, 31.6% (203) BDR and 3.3% (21) RDR (Figure 6.4.7).  The 
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categories of RDR consisted of 0.6% (4) PPDR, 2.2% (14) maculopathy and 0.5% 
(3) PPDR with maculopathy.  Noone developed PDR.  Therefore, 65.2% (419) 
remained free of DR at their final screening event.  
 
Figure 6.4.7: Incident DR during the seven year study period in persons with T1DM 
 
No DR - No diabetic retinopathy; BDR - Background diabetic retinopathy, RDR - Referable 
diabetic retinopathy; PPDR  - Pre-proliferative diabetic retinopathy;  
 
The annual and cumulative incidence of any DR, BDR and RDR over the seven 
year study period is represented in Table 6.4.6.  The annual incidence (cases per 
1,000 persons) of any DR increased from 29 cases in the first year to 63 cases in 
the seventh year.  The annual incidence of RDR increased from 2 cases in the first 
year to 5 cases in the seventh year.  The seven year cumulative incidence of any 
DR was 536 cases, BDR 511 cases and RDR 50 cases.
No DR 
65.2% 
BDR 
31.6% 
PPDR 
0.6% 
maculopathy 
2.2% 
PPDR + 
Maculopathy 
0.5% 
RDR 
3.3% 
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Table 6.4.6: Incidence of any DR, BDR and RDR over the seven year study period 
in persons with T1DM 
 Any DR 
Time 
(yrs) 
Number Annual 
Incidence 
Cum. Incidence 
(95% CI) 
1 589 29.0 29.0 (28.9, 29.1) 
2 427 134.0 163.0 (162.4, 163.6) 
3 350 91.0 254.0 (252.9, 255.1) 
4 257 65.0 319.0 (317.3, 320.7) 
5 178 77.0 396.0 (393.4, 398.6) 
6 113 77.0 473.0 (468.7, 477.3) 
7 29 63.0 536.0 (518.6, 553.4) 
 BDR 
Time 
(yrs) 
Number Annual 
Incidence 
Cum. Incidence 
(95% CI) 
1 570 28.0 28.0 (27.9, 28.1) 
2 416 124.0 152.0 (151.4, 152.6) 
3 322 88.0 240.0 (238.9, 241.1) 
4 253 66.0 299.0 (269.4, 300.6_ 
5 176 73.0 372.0 (369.4, 374.6) 
6 113 73.0 445.0 (440.7, 449.3) 
7 29 66.0 511.0 (493.5, 528.5) 
 RDR 
Time 
(yrs) 
Number Annual 
Incidence 
Cum. Incidence 
(95% CI) 
1 602 2.0 2.0 (1.99, 2.01*) 
2 497 7.0 9.0 (8.96, 9.03*) 
3 422 9.0 18.0 (17.9, 18.1) 
4 357 7.0 25.0 (24.9, 25.1) 
5 275 6.0 31.0 (30.8, 31.2) 
6 186 14.0 45.0 (44.6, 45.5) 
7 60 5.0 50.0 (48.8, 51.2) 
Number - Number of persons at risk; Number of cases per 1,000 persons; Any DR – any 
diabetic retinopathy ; BDR – background diabetic retinopathy ; RDR – referable diabetic 
retinopathy ; cum incidence – cumulative incidence; Time - time since first negative 
screening event; Number - Number of cases remaining at risk; 95% CI – 95% confidence 
interval; yrs - years;* two decimal places provided due to the small difference in value 
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6.4.2.2 Risk factors for incident DR 
The characteristics of those who developed any DR, BDR and RDR compared to 
those who remained free of DR are shown in Table 6.4.7.  There were no significant 
differences between those without DR and those who developed any DR, BDR or 
RDR for age, gender, ACR, smoking status, hypertension, and ACE inhibitors or 
aspirin use.  These were also not significant in Kaplan Meier and Cox regression 
analysis (Table 6.4.8, page 246).  There were also no significant differences or 
associations between those without DR and those who developed BDR and RDR 
for total cholesterol.
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Table 6.4.7: Baseline Characteristics of persons with T1DM who developed DR and those who remained free of DR 
 No DR (419) Any DR (224) p value No DR 
vs. Any DR 
BDR (203) p value No 
DR vs. BDR 
RDR (21) p value No 
DR vs. RDR 
Age years mean (SD) 33.9 (15.8) 32.9 (14.3) 0.475 32.4 (14.0) 0.275 38.2 (16.1) 0.164 
Gender: n (%) 
Male 
Female 
 
217 (51.8) 
202 (48.2) 
 
130 (58.0) 
94 (42.0) 
0.130 
 
119 (58.6) 
84 (41.4) 
0.109 
 
11 (52.4) 
10 (47.6) 
0.882 
Ethnicity: n (%) 
Caucasian 
Indigenous African 
Asian Indian 
Mixed Race 
 
347 (82.8) 
33 (7.9) 
29 (6.9) 
10 (2.4) 
 
177 (79.7) 
19 (8.6) 
18 (8.1) 
8 (3.6) 
0.730 
 
165 (82.1) 
16 (8.0) 
15 (7.5) 
5 (2.5) 
0.995 
 
12 (57.1) 
3 (14.3) 
3 (14.3) 
3 (14.3) 
0.003 
Duration years median (IQ) 6.0 (3.0-12.0) 10.0 (6.0-17.0) <0.001 10.0 (6.0-17.0) <0.001 8.0 (5.5-15.5) 0.758 
Age at diagnosis years mean 
(SD) 
25.0 (14.5) 20.5 (12.4) <0.001 19.8 (12.2) <0.001 27.0 (13.2) 0.250 
HbA1c % median (IQ) 7.9 (6.9-9.4) 8.4 (7.4-9.9) 0.032 8.3  (7.3-9.6) 0.190 10.1 (7.9-11.6) <0.001 
Total Cholesterol mmol/l 
mean (SD)  
4.9 (1.0) 5.2 (1.1) 0.030 5.1 (0.9) 0.096 5.9 (1.9) 0.200 
ACR median (IQ) 0.71 (0.37-1.4) 0.63 (0.34-1.3) 0.830 0.62 (0.37-1.3) 0.820 1.2 (0.27-2.6) 0.956 
ACE n (%) 42 (10.0) 33 (14.7) 0.076 29 (14.3) 0.117 4 (19.0) 0.284 
Aspirin n (%) 7 (1.7) 3 (1.3) 0.746 3 (1.5) 0.858 0 0.558 
Hypertensive n (%) 49 (11.7) 37 (16.5) 0.087 30 (14.8) 0.279 7 (33.3) 0.006 
Smoker n (%) 69 (16.5) 38 (17.0) 0.872 34 (16.7) 0.930 4 (19.0) 0.763 
No DR - no diabetic retinopathy; any DR - any diabetic retinopathy; BDR – background diabetic retinopathy; RDR – referable diabetic retinopathy; SD – 
standard deviation; IQ Interquartile range; ACR – albumin:creatinine ratio; ACE – angiotensin converting enzyme inhibitor
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Duration of diabetes 
Those who developed any DR and BDR compared to those without DR had a 
significantly longer duration of diabetes (Table 6.4.7, page 243).  Although those 
with RDR had a longer duration of diabetes compared to those without DR, this did 
not reach significance.  There were significant differences in the survival curves for 
the incidence of any DR, and BDR according to the duration of diabetes, but not 
RDR (Figure 6.4.8).  Those with a duration of diabetes of ≥12 years had the poorest 
prognosis compared to those with a duration of diabetes of ≤ 5 years in respect to 
the development of any DR or BDR.  There was no significant differences in the 
survival curves for duration of diabetes and the time until RDR developed, however, 
the numbers in this group were limited.  Increased duration of diabetes had the 
strongest association with the incidence of any DR, BDR and RDR in Cox 
regression analysis after adjusting for age at diagnosis of diabetes, gender, 
ethnicity, HbA1c and hypertension (Table 6.4.8, page 246).  Those persons with a 
duration of diabetes of 6-11 years had a 1.5 fold increased risk of developing any 
DR and BDR and a 3.6 fold increased risk of developing RDR compared to those 
with a duration of diabetes of ≤5 years.  Those persons with a duration of diabetes 
of ≥12 years had a 2.3, 2.2 and 4.9 fold increased risk of developing any DR, BDR 
and RDR respectively compared to those with a duration of diabetes of ≤5 years.
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Figure 6.4.8: : Kaplan-Meier survival curves for the development of a) any DR, b) BDR and c) RDR by duration of diabetes in persons with 
T1DM 
a)         b)       c) 
 
 
 Any DR BDR RDR 
 
 1 2  3  4 5  6  7 1 2  3  4 5  6  7 1 2  3  4 5  6  7 
≤5
 
ye
a
rs
 Number at risk 221 158 121 91 54 31 5 217 155 109 90 54 31 4 221 171 136 105 70 42 11 
Number of cases 1 16 27 29 38 45 49 1 15 25 26 34 41 45 0 0 3 3 4 4 4 
6-
11
 
ye
a
r
s 
Number at risk 187 137 110 88 64 41 13 178 132 105 85 62 41 13 188 157 140 120 98 70 27 
Number of cases 1 25 40 52 64 71 73 1 21 36 46 57 62 64 0 2 2 4 5 7 8 
≥1
2 
ye
a
rs
 
Number at risk 181 132 99 81 60 41 12 175 129 97 78 60 41 12 194 169 146 132 107 74 22 
Number of cases 16 51 68 78 86 92 95 15 47 63 74 79 85 88 1 3 5 6 6 7 7 
p=0.496 
p<0.001 p<0.001 
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Table 6.4.8: Multivariate Cox regression for the development of any DR, BDR and RDR in persons with T1DM 
 
Any DR (224) BDR (213) RDR (21) 
 Crude Adjusted Crude Adjusted Crude Adjusted 
Female (296) 0.89 (0.68, 1.16) 0.87 (0.66, 1.15) 0.87 (0.66, 1.15) 0.84 (0.63, 1.12) 1.23 (0.51, 2.96) 1.71 (0.68, 4.29) 
Non-Caucasians (117) 1.44 (1.04, 2.00) 1.68 (1.20, 2.35) 1.31 (0.92, 1.86) 1.59 (1.10, 2.30) 4.47 (1.85, 10.80) 4.67 (1.73, 12.60) 
Age at diagnosis: 
≤12 (179) 
13-22 (144) 
23-33 (164) 
≥34 (153) 
 
2.37 (1.59, 3.53) 
1.68 (1.09, 2.58) 
1.72 (1.13, 2.62) 
1.00 
 
2.40 (1.55, 3.71) 
1.73 (1.10, 2.73) 
1.93 (1.25, 2.98) 
1.00 
 
2.80 (1.81, 4.34) 
1.93 (1.21, 3.09) 
1.93 (1.22, 3.05) 
1.00 
 
2.73 (1.70, 4.37) 
1.91 (1.17, 3.12) 
2.05 (1.28, 3.30) 
1.00 
 
0.46 (0.14, 1.59) 
0.42 (0.11, 1.63) 
0.75 (0.25, 2.24) 
1.00 
 
0.46 (0.11, 1.84) 
0.57 (1.34, 2.40) 
0.95 (0.31, 2.93) 
1.00 
Duration of diabetes 
≤5 (242) 
6-11 (199) 
≥12 (202 
 
1.00 
1.62 (1.13, 2.31) 
2.11 (1.50, 2.98) 
 
1.00 
1.53 (1.05, 2.23) 
2.28 (2.56, 3.33) 
 
1.00 
1.59 (1.09, 2.32) 
2.14 (1.49, 3.05) 
 
1.00 
1.49 (1.01, 2.21) 
2.24 (1.51, 3.32) 
 
1.00 
2.01 (0.61, 6.55) 
1.48 (0.43, 5.08) 
 
1.00 
3.62 (1.02, 12.82) 
4.88 (1.09, 21.75) 
HbA1c 
≤7.40 (208) 
7.41-8.90 (207) 
>8.90 (201) 
 
1.00 
1.35 (0.96, 1.90) 
1.69 (1.21, 2.37) 
 
1.00 
1.18 (0.84, 1.68) 
1.75 (1.22, 2.50) 
 
1.00 
1.40 (0.98, 1.98) 
1.61 (1.13, 2.31) 
 
1.00 
1.22 (0.85, 1.75) 
1.67 (1.14, 2.43) 
 
1.00 
0.75 (0.17, 3.34) 
4.17 (1.36, 12.84) 
 
1.00 
0.55 (0.12, 2.58) 
5.02 (1.48, 16.98) 
Total Cholesterol  
≤4.43 (83) 
4.44-5.38 (83) 
≥5.39 (82) 
 
1.00 
1.80 (1.02, 3.17) 
1.61 (0.92, 2.83) 
 
n/a 
 
1.00 
1.96 (1.09, 3.53) 
1.56 (0.85, 2.84) 
 
n/a 
 
1.00 
0.47 (0.04, 5.20) 
2.25 (0.44, 11.60) 
 
n/a 
ACR ratio 1.03 (0.99, 1.08)  1.04 (0.99, 1.08)  1.02 (0.83, 1.24)  
ACE inhibitors (75) 1.48 (1.02, 2.15) n/a 1.43 (0.96, 2.12) n/a 2.00 (0.67, 6.00) n/a 
Hypertensive (86) 1.42 (1.00, 2.02) 1.56 (1.06, 2.30) 1.26 (0.86, 1.86) 1.41 (0.93, 2.15) 3.81 (1.52, 9.55) 3.30 (1.17, 9.31) 
Smoking status (107) 1.06 (0.75, 1.51) n/a 1.04 (0.72, 1.51) n/a 1.31 (0.44, 3.92) n/a 
n/a - variables were excluded from the multivariate analysis
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Glycaemic control 
Those who developed any DR and RDR had a significantly higher HbA1c at first 
screening (8.4% and 10.1% respectively) than those who remained free of DR 
(7.8%) (Table 6.4.7, page 243).  There was also a significant difference in the 
survival curves for any DR, BDR and RDR according to baseline HbA1c (Figure 
6.4.9).  Those with an HbA1c  of >8.9% had the worst ‘survival’ curves for the 
incidence of any DR, BDR and RDR compared to those with an HbA1c of 7.41-8.9% 
or ≤7.4.  However, the survival rates for those with an HbA1c of 7.41-8.9% and >8.9 
were similar until approximately 4 years for any DR, and 4.8 years for BDR.  This 
separation in survival curves appeared earlier after approximately 2.8 years for the 
incidence of RDR.  Increasing HbA1c levels at first screening were associated with 
an increased risk of developing any DR, BDR and RDR in the Cox regression 
analysis after adjusting for age at diagnosis of diabetes, gender, ethnicity, duration 
of diabetes and hypertension (Table 6.4.8, page 246).  Those persons with a 
baseline HbA1c level of 7.4-8.9% did not differ significantly in their risk of developing 
any DR, BDR or RDR compared to those with a HbA1c ≤7.4%.  However, those with 
an initial HbA1c >8.9% had a 1.8-fold  increased risk of developing any DR, a 1.7-
fold increased risk of developing BDR and a 5-fold increased risk of developing 
RDR compared to those with a baseline HbA1c level of ≤7.4%.
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Figure 6.4.9: Kaplan-Meier survival curves for the development of a) any DR, b) BDR and c) RDR by HbA1c level at first screening in persons 
with T1DM 
a)               b)                   c) 
 
 
 Any DR BDR RDR 
 
 1 2  3 4 5 6  7 1 2 3 4 5 6 7 1 2  3 4 5 6  7 
≤7
.4 % 
Number at risk 193 144 117 95 69 47 7 190 144 117 95 69 47 7 199 166 142 123 99 74 20 
Number of cases 7 30 37 44 51 57 58 6 26 33 40 47 53 54 1 3 4 4 4 4 4 
7.
41
-
8.
9%
 Number at risk 192 132 103 87 64 41 14 189 130 101 87 64 41 14 196 159 143 131 105 64 23 
Number of cases 5 33 49 57 65 71 74 5 32 48 54 62 68 71 0 1 1 2 2 3 3 
>
8.
9
%
 
Number at risk 183 135 96 66 37 20 4 170 126 90 60 36 20 4 187 155 123 92 63 42 13 
Number of cases 6 28 47 56 67 75 79 6 24 40 48 56 62 66 0 1 5 7 9 11 12 
p=0.009 p=0.028 
p=0.001 
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Ethnicity 
Significantly more non-Caucasians developed RDR than any other ethnic group 
(Table 6.4.7, page 243).  There was a significant difference between the survival 
curves for ethnicity and the incidence of any DR and RDR, but not for the incidence 
of BDR (Figure 6.4.10).  Non-Caucasians had the worst prognosis for the incidence 
of any DR, BDR and RDR.  Non-Caucasians were at 1.7-, 1.6- and 4.7-fold 
increased risk of developing any DR, BDR and RDR respectively compared to 
Caucasians based on the Cox regression analysis after adjusting for age at 
diagnosis of diabetes, gender, duration of diabetes, HbA1c and hypertension (Table 
6.4.8, page 246). 
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Figure 6.4.10: Kaplan-Meier survival curves for the development of a) any DR, b) BDR and c) RDR by Ethnicity in persons with T1DM 
a)       b)       c) 
 
 
 Any DR BDR RDR 
 
 1 2  3 4 5 6  7 1 2  3 4 5 6  7 1 2  3 4 5 6  7 
Ca
uc
as
i
a
n 
Number at risk 483 356 280 224 156 102 26 473 351 275 221 155 102 26 496 415 357 307 237 161 53 
Number of 
cases 
15 75 105 126 147 164 171 14 69 99 118 137 153 16
0 
1 3 4 6 8 9 10 
N
on
-
Ca
uc
as
ia
n
 
Number at risk 106 71 50 33 22 11 3 97 65 47 32 21 11 3 107 82 65 50 38 25 7 
Number of 
cases 
3 17 30 36 41 44 46 3 14 24 28 33 35 37 0 2 6 7 7 9 9 
p=0.025 p=0.136 p<0.001 
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6.4.2.3 Screening intervals for persons with T1DM 
As the risk factors duration of diabetes, HbA1c and ethnicity were the most important 
explanatory variables for predicting the development of DR these were then used to 
assess the cumulative incidence of RDR.  Caucasians and non-Caucasians were 
stratified into low HbA1c (≤7.0%) and high HbA1c (>7.0%) groups at first screening 
(Figure 6.4.11), and also according to the duration of diabetes i.e. short (≤10 years) 
and long (>10 years) duration of diabetes (Figure 6.4.12).  Low and high HbA1c level 
were  further stratified according to short and long duration of diabetes i.e. 10 years 
and below and over 10 years respectively (Figure 6.4.13).   
 
Ethnicity and glycaemic control 
The seven year cumulative incidence of RDR (cases per 1,000 persons) in those 
with a high HbA1c was 176 cases (95% CI 128.6, 223.4) in non-Caucasian persons 
compared to a much lower incidence in Caucasians at 46 cases (95% CI 43.5, 48.5) 
(Figure 6.4.11).  The one and two year cumulative incidence in those persons with a 
low HbA1c was 0 and 7 cases (95% CI 6.9, 7.1) respectively for Caucasians and 
was 0 and 40 cases (95% CI 35.3, 44.7) in non-Caucasians respectively.  In those 
with a high HbA1c the one and two year incidence of RDR was 3 (95% CI 2.98, 3.02) 
and 6 cases (95% CI 5.95, 6.04) respectively in Caucasians and surprisingly 0 and 
15 cases (95% CI 14.6, 15.4) in non-Caucasians respectively.  The lower incidence 
of RDR in non-Caucasians with a high HbA1c may be due to the small number of 
persons who developed RDR as well as the small numbers of non-Caucasians.  
Therefore, both Caucasians and non-Caucasians could undergo screening once 
every two years with minimal risk of 3 cases per 1,000 persons, irrespective of 
glycaemic control.   
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Figure 6.4.11: Cumulative incidence of RDR for low and high HbA1c levels and 
ethnicity in persons with T1DM 
 
Key: C - Caucasian; NC - Non-Caucasian; *incidence if cases per 1,000 persons 
 
Ethnicity and duration of diabetes 
The seven year cumulative incidence of RDR in those with a long duration of 
diabetes was lower in Caucasians at 24 (95% CI 22.5, 25.5) compared to non-
Caucasians at 264 (95%CI 137.1, 390.9) (Figure 6.4.12).  The one and two year 
cumulative incidence of RDR in those with a short duration of diabetes was 0 and 3 
cases (95% CI 2.98, 3.02) in Caucasians and 0 and 15 cases (95% CI 14.6, 15.4) in 
non-Caucasian.  In those with a long duration of diabetes the one and two year 
incidence of RDR was 5 (95% CI 4.95, 5.05) and 11 cases (95% CI 10.9, 11.1) in 
Caucasians and 0 and 56 cases (95% CI 48.0, 64.0) in non-Caucasian.  Therefore, 
Caucasians with a long duration of diabetes, and non-Caucasians irrespective of 
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Total 
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RDR 
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*1 
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*2 
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*3 
years 
*4 
years 
*5 
years 
*6 
years 
*7 
years 
 C ≤7.Ϭ% 132 1 0 7 7 7 7 7 7 
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duration of diabetes, could be screened once every two years with only 5 cases at 
risk of a delayed diagnosis of RDR.  Caucasians with a short duration of diabetes 
could be screened once every three years with 3 cases at an risk of a delayed 
diagnosis of RDR. 
 
Figure 6.4.12: Cumulative incidence of RDR by duration of diabetes and ethnicity in 
persons with T1DM 
 
Key: C - Caucasian; NC - Non-Caucasian; *Incidence of DR is cases per 1,000 persons
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 C ≤10 years 327 7 0 3 3 9 22 32 44 
 C >10 years 191 4 5 11 17 24 24 24 24 
 NC ≤10 years 93 5 0 15 48 67 67 112 112 
 NC >10 years 21 3 0 56 141 141 141 264 264 
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Duration of diabetes and glycaemic control 
If duration of diabetes and baseline HbA1c were combined then those with a long 
duration of diabetes and high HbA1c level had the highest incidence of RDR initially 
with a 1 year incidence of RDR at 7 cases per 1,000 persons.  However, the 7 year 
cumulative incidence of RDR was highest in those with a high HbA1c level and short 
duration of diabetes at 73 cases per 1,000 persons (Figure 6.4.13).  The seven year 
cumulative incidence of RDR in those with a low HbA1c level with a short duration of 
diabetes was 13 cases (95% CI 10.2, 15.8) and 16 cases (95% CI 13.4, 18.6) with a 
long duration of diabetes.  This increased to 73 cases (95% CI 68.9, 77.1) in those 
with a high HbA1c and short duration of diabetes and 57 cases (95% CI 51.1, 62.9) 
with a high HbA1c and long duration of diabetes.  This lower incidence of RDR in 
those with a high HbA1c and long duration of diabetes, compared to those with a 
short duration of diabetes may again be due to small numbers.   
 
The one and two year cumulative incidence of RDR in those with a low HbA1c level 
with a short duration of diabetes was 0 and 13 cases (95% CI 12.6, 13.4) and in 
those with a long duration of diabetes 0 and 16 cases (95% CI 15.4, 16.6).  In those 
with a high HbA1c, the one and two year cumulative incidence of RDR was 0 and 4 
cases (95% CI 3.97, 4.03) with a short duration of diabetes and 7 (95% CI 6.9, 7.1) 
and 15 cases (95% CI 14.8, 15.2) with a long duration.  Therefore, those with a low 
HbA1c irrespective of duration of diabetes could be screened once every two years.  
Those with a high HbA1c and a short duration of diabetes could be screened once 
every three years; and those with a high HbA1c level and long duration of diabetes 
should undergo annual screening with the possibly of once every two years. 
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Figure 6.4.13: Cumulative incidence of RDR by HbA1c at first screening and duration 
of diabetes in persons with T1DM 
 
*Incidence is cases per 1,000 persons
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6.4.2.4 Summary of main findings for persons with T1DM 
 Nobody with T1DM with no evidence of DR at baseline developed PDR 
during the seven year study period. 
 The seven year cumulative incidence (cases per 1,000 persons) of any DR, 
BDR and RDR was 536, 511 and 50 cases respectively. 
 Duration of diabetes, glycaemic control, ethnicity and the presence of 
hypertension were significantly associated with a higher incidence of any 
DR, BDR and RDR after adjustment for age at diagnosis and gender. 
 If screening intervals were stratified based on: 
 Ethnicity and glycaemic control then: 
o Both Caucasians and non-Caucasians could be screened once every 
two years, irrespective of glycaemic control. 
 Ethnicity and duration of diabetes then: 
o Caucasians with a short duration of diabetes could be screened once 
every three years. 
o Caucasians with a long duration of diabetes could be screened once 
every two years. 
o Non-Caucasians, irrespective of duration of diabetes could be 
screened once every two years. 
 Glycaemic control and duration of diabetes then: 
o Low HbA1c, irrespective of duration of diabetes, could be screened 
once every two years.   
o High HbA1c and a short duration of diabetes could be screened once 
every three years. 
o Long duration of diabetes and high HbA1c continue annual screening 
with the possibly of once every two years. 
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 However these findings should be interpreted with caution due to the 
small sample size and high dropout rate. 
 
6.5
 
Discussion 
The one year incidence of any DR, BDR and RDR in persons with T2DM or T1DM 
attending the CDE in Johannesburg, South Africa was relatively low at 18, 17 and 1 
cases per 1,000 persons respectively in persons with T2DM and 28, 18 and 2 cases 
per 1,000 persons respectively in persons with T1DM.  However, the seven year 
cumulative incidence of any DR and BDR in persons with T2DM was 351 and 331 
cases per 1,000 persons respectively.  Whilst in persons with T1DM the seven year 
cumulative incidence of any DR and BDR was higher at 536 and 517 cases per 
1,000 persons respectively.  Over the study period, the one year incidence of RDR 
increased for T2DM from 1 case per 1,000 persons to a seven year cumulative 
incidence of 47 cases  and in T1DM from 2 cases per 1,000 persons to 50 cases 
per 1,000 persons respectively.  The higher incidence of all levels of DR seen in 
persons with T1DM compared to those with T2DM may be due to differences in the 
population characteristics e.g. those with T1DM were younger, had a longer 
duration of diabetes and a higher HbA1c level compared to persons with T2DM at 
first screening.   
 
To date, no previous studies have reported on the incidence of DR in the African 
region including South Africa and only one study has reported incidence rates in 
Mauritius.(Tapp et al. 2006)  This study reported the six year cumulative incidence 
rates in a multi-ethnic population of persons with T2DM based on retinal 
photographs of one eye only.  The six year cumulative incidence of any DR was 
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23.8% and PDR was 0.4%.  These incidence rates may be underestimated as 
retinal photography was restricted to one eye only, which may also result in some 
sight-threatening lesions being missed.  However,  the incidence of any DR was 
similar to what was seen in our study of 268 cases per 1,000 persons (26.8%). 
 
The incidence of any DR, BDR and RDR was higher in non-Caucasians compared 
to Caucasians in our study in Johannesburg.  Based on multivariate survival 
analysis after adjusting for confounding factors, non-Caucasians had a greater risk 
for incident DR in T1DM only.  To date the incidence rates of DR worldwide have 
mainly been reported in Caucasian populations and the influence of ethnicity has 
only been looked at in relatively few studies.  One study in America noted that black 
persons with T2DM were more likely to develop DR over a four year period than 
white persons (50% vs. 19% p=0.002), and even after adjusting for all other risk 
factors (glycaemic control, systolic blood pressure, type of diabetes treatment and 
gender) black persons were still at an increased risk compared to whites (OR 2.96 
95% CI 1.00-8.78).(Harris et al. 1999)  In a population of T1DM, the four year 
incidence of any DR was similar at 51% in African Americans and Caucasians, 
however, when controlling for other known risk factors, (time between examinations, 
glycaemic control, serum creatinine and duration of diabetes) African Americans 
had a lower risk of both development and progression of DR than Caucasians (both 
OR 2.62).(Arfken et al. 1994)  The authors were not able to explore the reason for 
this lower risk.  Whether these differences represent a genetic predisposition to 
microvascular damage remains unknown. 
 
Increased HbA1c level at baseline in our study was independently associated with 
the incidence of DR in both persons with T2DM and T1DM.  Glycaemic control has 
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similarly been found in other studies to be strongly associated with both the 
development and progression of DR.  The WESDR study found that each 
successively higher quartile of glycosolated haemoglobin at baseline, in both older 
and younger onset groups, was associated with an increasing incidence of 
DR.(Klein et al. 1994)  The DCCT found in T1DM that intensive treatment reduced 
the incidence of DR by 76% and the progression of DR by 54%.  They also 
discovered a residual protective effect on DR of this early tight control.(The 
Diabetes Control and Complications Trial Research Group 1993)  A much lower 
(17%) risk of progression of DR was seen in the UKPDS for intensive glycaemic 
control in newly diagnosed persons with T2DM.(UK Prospective diabetes study 
group 1998b)  However, in the DCCT there were also 10% of persons with 
good glycaemic control who developed DR (mean HbA1c ≤6.9%) additionally 
40% of those with poor metabolic control remained without evidence of DR 
(mean HbA1c ≥9.5%).(Zhang et al. 2001) 
 
In my study, increasing the duration of diabetes had the strongest association with 
the incidence of any DR, BDR and RDR after adjusting for age at diagnosis of 
diabetes, gender, ethnicity, HbA1c and hypertension in both T2DM and T1DM.  In 
persons with T2DM, the risk of developing RDR was 2.9 fold greater in those with a 
known duration of 5-10 years, with the risk essentially similar at 2.4 fold in those 
with a known duration of diabetes of >10 years compared to those with a known 
duration of <5 years. This unexpected finding may be a consequence of small 
numbers of persons developing RDR.  The risk of developing RDR was 3.6 fold and 
4.6 fold greater in persons with T1DM duration of 6-11 years and ≥12 years 
respectively compared to those with a duration of diabetes of ≤5 years.  Similar 
findings have been reported in many studies as discussed in chapters 3-5. 
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In our study the presence of hypertension was also found to be associated with the 
development of DR but only in persons with T1DM.  This was also the case in the 
WESDR study where diastolic blood pressure was a significant predictor of the 
progression of DR and the incidence of PDR in persons with younger onset 
diabetes,(Klein et al. 1998) but no association was seen for persons with older 
onset diabetes.(Klein et al. 1995)  In the ACCORD study, there was also no 
beneficial effect of intensive versus conventional anti-hypertensive treatment, nor in 
the ABCD trial comparing moderate with tight blood pressure control, on the 
progression of DR in persons with T2DM.(Estacio et al. 2000, ACCORD study group 
et al. 2010)  In contrast, the UKPDS found in persons with T2DM that for each 
10mm Hg decrease in mean systolic blood pressure there was a 13% reduction in 
for microvascular endpoints. (UK prospective diabetes study group et al. 2000)  The 
effects of blood pressure lowering treatments such as ACE inhibitors and β-blockers 
have found reductions in the risk of progression of retinopathy of 50% in persons 
with T1DM over 2 years (Chaturvedi et al. 1998) and 34% in persons with T2DM 
over 7 years.(UK Prospective diabetes study group 1998a)  These effects were 
seen even after adjustment for glycaemic control.  Therefore, there may be a 
threshold for blood pressure below which no additional benefit on the progression of 
DR can be seen. Unfortunately the systolic and diastolic blood pressure 
measurements were not available for assessment in our study as only the presence 
or absence of hypertension was available. 
 
There was no association seen between total cholesterol levels and the incidence of 
any DR, BDR and RDR in our study with respect T1DM or T2DM.  Unfortunately a 
large number of values for total cholesterol were missing which may account for this 
finding and therefore this was not retained within the adjusted Cox regression 
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models.  The effect of cholesterol lowering has been investigated by studies 
previously with mixed results.  Two trials have found positive associations between 
serum lipids and DR (Chew et al. 1996) or maculopathy,(Klein et al. 1991) with 
other studies finding beneficial effects of fibrates on hard exudates and macular 
oedema.(Harrold et al. 1969, Dorne 1977, Rencova et al. 1992, Freyberger et al. 
1994, Keech et al. 2007, ACCORD study group et al. 2010, Morgan et al. 2013)  
This reduction in the onset of DR did not appear to be attributable to the lipid 
lowering effects of fibrates.  Other non-lipid-related mechanisms that may explain 
the effect of fibrates on DR are the anti-inflammatory and antioxidant properties of 
fibrates.(Poynter et al. 1998, Delerive et al. 1999)  However other studies have 
found no association.(Duncan et al. 1968, Sjolie et al. 1997, Colhoun et al. 2004, 
Thomason et al. 2004) 
 
In our study there was a low one and two year cumulative incidence of RDR for 
persons with either T2DM or T1DM who had no evidence of DR at first screening 
event.  Therefore, extending the screening interval in this population from annual to 
biennial in persons with T2DM would mean 1 case, and in T1DM 2 cases would be 
at risk of a delay in the detection of RDR.  If the interval was extended to triennial 
this would increase to 5 and 7 cases in persons with T2DM and T1DM respectively.  
This is a similar risk to that seen in the DRSSW population (chapter 4).  Both of 
these studies add to the increasing body of evidence which suggests that it would 
be safe to increase the screening interval beyond annual screening to biennial in 
those persons with T1DM or T2DM who had screened negative for DR.(Younis et 
al. 2003a, Younis et al. 2003b, Olafsdottir et al. 2007, Agardh et al. 2011, Aspelund 
et al. 2011, Jones et al. 2012, Looker et al. 2013, Porta et al. 2013, Stratton et al. 
2013) 
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The multivariate analysis conducted demonstrated that the incidence of RDR was 
not uniform across the range of persons with diabetes and that certain subgroups 
may be at a higher or lower risk of DR.  Due to the strong association between 
HbA1c ,duration of diabetes and the effects of ethnicity on the incidence of DR 
shown in this study in South Africa, these risk factors were used to further assess 
the cumulative incidence of DR.  The various subgroup analyses demonstrated that 
persons with T2DM with good glycaemic control (HbA1c ≤7.0%), and with T1DM of 
Caucasian origin with a duration of diabetes of 10 years or less could be safely 
screened beyond annual to once every two years or even three years.  The 
increased incidence of RDR seen in non-Caucasians especially those with T1DM 
indicates that the screening interval should not be extended beyond once every two 
years.  However, the numbers within the groups were small and therefore caution 
should be applied when interpreting these findings and recommendations.  This is 
evidenced by some unexpected findings in the T1DM population of non-Caucasian 
origin with an HbA1c level >7.0% having a lower 2 year cumulative incidence of RDR 
compare to those with an HbA1c level ≤7.0%.  Also those with an HbA1c level >7.0% 
and a duration of diabetes of >10 years had a higher incidence of RDR until 5 years 
after a negative screening event at which point those with a duration of diabetes of 
<10 years had a higher incidence of RDR. 
 
Almost all of the current evidence regarding optimal screening intervals based on 
data collected by DR screening programmes strongly suggest that it would be safe 
to extend screening intervals to at least biennial in persons without DR at first 
screening.(Younis et al. 2003a, Younis et al. 2003b, Olafsdottir et al. 2007, Misra et 
al. 2009, Agardh et al. 2011, Aspelund et al. 2011, Jones et al. 2012, Thomas et al. 
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2012, Four Nations Study Group 2013, Looker et al. 2013, Porta et al. 2013, 
Stratton et al. 2013)  Two European screening programmes have assessed the 
effect of extending the screening interval from annual to biennial in Iceland and 
triennial in Sweden in persons with T2DM without previous evidence of DR within 
their respective programmes.(Olafsdottir et al. 2007, Agardh et al. 2011)  In Iceland 
biennial screening intervals has been adopted as over a 10 year period of 
observation no patients without prior DR developed RDR.  Annual screening was 
conducted following the detection of BDR.(Olafsdottir et al. 2007).  In the Swedish 
programme a total of only three people developed maculopathy after three years of 
which only one person required laser therapy and none developed PDR.(Agardh et 
al. 2011).  The latest evidence from the UK, i.e. the four nations diabetic retinopathy 
screening intervals project study group report has also suggested the possibility of 
an extension of the screening interval in persons without evidence of DR in both 
eyes at two consecutive annual screening events to once every two or three 
years.(Four Nations Study Group 2013) 
 
Screening for DR although shown to be cost-effective is still expensive.  Any cost-
effectiveness savings made from re-organising screening programmes without an 
appreciably increased risk to patients are required especially in the current financial 
climate.  An increase in the screening interval from annual to biennial has been 
estimated to achieve a 25% reduction in costs.(Chalk et al. 2012)  However, 
individualising the screening interval based on a person's constellation of risk 
factors could further improve the cost effectiveness of screening.  This allows 
screening to be conducted according to risk, avoiding unnecessary screening in the 
majority and possibly increased screening in those at risk resulting in less screening 
for the majority affording the possibility of more frequent screening in those at 
greatest risk. 
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The limitations of this study in Johannesburg, were previously stated in chapter 5, 
i.e. not representative of the majority of people in South Africa with diabetes, lack of 
dilation, and capture of only one macular centre 45o retinal image per eye, a high 
dropout rate of 31.4% (1,224) of persons who did not attend a second screening 
event despite being eligible.  We unfortunately were not able to obtain information 
on those persons who did not participate in a second screening event.  In addition to 
these using the Cox proportional hazards regression analysis instead of more 
sensitive parametric models such as Weibull (Akaike H 1974) may also be a limiting 
factor for the interpretation of the findings obtained in this study.  In addition there is 
the issue of the small sample size especially for those with T1DM and those of non-
Caucasian ethnicity which means some of the findings need to be interpreted with 
caution.  The addition of other putative risk factors such as HbA1c ,ethnicity and the 
presence of hypertension, estimation of ACR, cholesterol levels and smoking habit 
were of added value in this study in addressing the risk of development of DR. 
 
6.5.1 Summary of main findings 
 The seven year cumulative incidence of any DR, BDR and RDR were lower in 
persons with T2DM compared to those with T1DM. 
 After adjusting for confounders the incidence of any DR, BDR and RDR was 
associated with duration of diabetes, glycaemic control in T2DM with the 
addition of ethnicity and hypertension in persons with T1DM. 
 The screening interval could be safely extended from annual to biennial in 
persons with both T2DM and T1DM where there is no evidence of DR at 
screening. 
 There is also the possibility of extending the screening interval to triennial in 
persons with T2DM under good glycaemic control (HbA1c ≤7.0%), and in 
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persons with T1DM, of Caucasian ethnicity and a short duration of diabetes (≤10 
years) with no prior DR.  However, due to the small study population, the low 
rate of RDR development and the dropout rate these findings should be 
interpreted with caution. 
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7.1 General discussion 
This thesis set out to describe the epidemiology of DR in persons with diabetes both 
T2DM and T1DM, attending the community based National DR Screening Service 
for Wales, (DRSSW) during the period of 2005-2009 and the Centre for Diabetes 
and Endocrinology in Johannesburg, South Africa.  The reported prevalence and 
incidence of DR has varied considerably  between the many different population 
groups studied globally, dependent on the type, according to differing 
classifications, and duration of diabetes, methods of detection and characteristics of 
the population studied.(Bodansky et al. 1982, Klein et al. 1985, Kristinsson et al. 
1994a, Kristinsson et al. 1994b, Younis et al. 2002, Younis et al. 2003b, Younis et 
al. 2003a, Misra et al. 2009, Jones et al. 2012, Yau et al. 2012, Stratton et al. 2013)  
This thesis determined the prevalence and incidence of DR in persons with diabetes 
over the age of 12 years in the above populations and also explored the risk factors 
associated with the development of DR over a period of four to 7 years respectively 
in those without evidence of DR at initial screening.  However, due to the number of 
people who did not attend for further screening the incidence rates beyond 3 years 
should be interpreted with caution.  The incidence of DR and the associated risk 
factors were then utilised to assess  a safe screening interval based on a limited 
number of risk factors which included type of diabetes, duration of diabetes and 
treatment modality for those with T2DM from Wales and a more expansive risk 
profile including glycaemic control, the presence of hypertension, dyslipidaemia and 
ethnicity, for the population from Johannesburg.  In addition visual acuity was 
assessed in both populations as it forms part of the screening process.   
 
As mentioned above the prevalence and incidence of DR in a population of persons 
with diabetes living in Wales was derived from the National DR Screening Service in 
Wales, (DRSSW) UK which during 2005 and 2009 screened a total of 135,152 
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persons.  The service employs standardised and quality assured protocols for 
image capture and grading.  Following the assessment of visual acuity,  digital 
retinal images were captured (2x45o) using Canon Dgi non-mydriatic cameras.  
Image grading was then conducted by trained and accredited retinal graders 
utilising an enriched version of the UK national screening protocol.  Quality 
assurance was undertaken on a monthly basis. 
 
The prevalence and incidence of DR has not previously been estimated in such a 
large community based population undergoing routine annual retinal screening with 
standardised quality assured protocols for image capture and grading and therefore 
this dataset represents an unique opportunity to ascertain the prevalence of DR in 
the defined population and the development of DR over a period of four years in 
those with no DR at a single initial screening event.  Based on the development of 
RDR over the study period it was estimated if the screening interval could be 
extended beyond the current annual screening. 
 
91,393 (67.2%) of the 135,152 persons screened by the DRSSW between 2005 and 
2009 were included for analysis.  Reasons for excluding 43,759 (32.4%) were 
T2DM with an age at diagnosis of <30 years and T1DM with an age at diagnosis of 
≥30 years (without confirmation from the patients GP).  Of the 91,393 included 
86,390 (94.5%) had T2DM and 5,003 (5.5%) had T1DM.  The overall prevalence of 
any DR was 32.3%, BDR 27.3% and RDR 5.0%.  The prevalence of any DR within 
the DRSSW population was lower in persons with T2DM compared to T1DM at 
31.0% and 56.2% respectively.  The majority of DR was BDR at 26.6% and 39.8% 
in T2DM and T1DM respectively with 4.4% and 16.4% respectively having RDR.  
The prevalence of any DR (31.0%) in persons with T2DM was similar to that 
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previously reported in other UK screening services using digital images both in 
Liverpool at 25.3% (Younis et al. 2002) and Norwich at 25.3% (Misra et al. 2009). A 
recent worldwide systematic review of studies involving retinal photography reported 
a similar prevalence at 25.2%.(Yau et al. 2012)  In this study the prevalence of any 
DR (56.2%) in persons with T1DM was slightly higher than that reported earlier by 
Younis et al at 45.7%.(Younis et al. 2002) both being considerably lower than that 
reported in the global review at 77.3% (Yau et al. 2012) The Liverpool study  
observed  slightly higher prevalence of RDR in T2DM compared to my findings at 
6.0% vs. 4.0% respectively, although it was the same in persons with T1DM at 
16.4%.(Younis et al. 2002) The prevalence of RDR that I observed in both T2DM 
and T1DM was much lower than that reported in the global review at 6.9% and 
38.5% respectively.(Yau et al. 2012)   
 
The cumulative incidence of DR within the DRSSW over the four year study period 
in persons with T2DM was 44.5% (445 cases per 1,000 persons) with any DR, 
43.8% (438 cases per 1,000 persons) of BDR and 1.6% (16 cases per 1,000 
persons) of RDR the annual incidence was higher in persons with T1DM at 64.9% 
(649 cases per 1,000 persons), 63.5% (635 cases per 1,000 persons) and 5.6% (56 
cases per 1,000 persons), respectively.  Interestingly 50% of those with T1DM who 
developed RDR had maculopathy without co-existing PPDR or PDR.    Similarly, 
56.6% of persons with T2DM who developed RDR also had maculopathy without 
co-existing PPDR or PDR.  Only 6.8% of those with T1DM who developed RDR had 
PDR and 8.1% had PDR in T2DM.  The four year cumulative incidence of RDR in 
persons with T2DM was lower in our study at 1.6% compared to the four year 
incidence of sight-threatening DR observed in the Liverpool DR screening 
programme at 2.1% (21 cases per 1,000 persons) (Younis et al. 2003a) and the five 
year cumulative incidence of RDR in the Norwich screening programme at 5.3% (53 
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cases per 1,000 persons).(Jones et al. 2012)  However, in T1DM the incidence of 
sight-threatening DR in Liverpool was lower at 3.2% (32 cases per 1,000 persons) 
compared to the incidence of RDR seen in my study at 5.6%.(Younis et al. 2003b)  
Possible reasons for these differences include the different statistical methods used 
to calculate incidence rates, as well as differences between our classification of 
RDR and sight-threatening DR plus possible differences in population demography. 
 
In this study there were no cases of RDR in persons with T2DM at the end of the 
first year following a single negative screening event.  The two year incidence of 
RDR in persons with T2DM was 0.3% (3 cases per 1,000 persons).  Therefore, the 
annual screening interval could safely be extended to once every two years for 
persons with T2DM without DR at their initial screening event.  If the annual 
screening interval was further extended to once every three years 150 out of 
~50,000 (0.3%) people, without evidence of DR at first screening would have had a 
delayed diagnosis of RDR.  In comparison, the one year cumulative incidence of 
RDR in persons with T1DM was 0.1% (1 case per 1,000 persons) and at two years 
was 0.9% (9 cases per 1,000 persons).  Therefore, if the screening interval was 
extended to once every two years then 2 people out of ~2,000 would have had a 
delayed diagnosis of RDR and if extended to once every three years then this would 
have increased to18 people.  
 
It was then considered that a safe screening interval maybe better defined if 
putative risk factors for the development of DR were employed to estimate the risk 
of developing RDR. In this study the increased duration of diabetes was 
independently associated with increased prevalence and incidence of any DR, BDR 
and RDR for both T2DM and T1DM.  Similarly almost all DR epidemiological type 
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studies have found duration of diabetes to have a strong association with 
DR.(Younis et al. 2003a, Tapp et al. 2006, Cikamantana et al. 2007, Varma et al. 
2007, Zhang et al. 2011)  We also observed that insulin treatment  in T2DM was 
significantly associated with the prevalence and incidence of any DR, BDR and 
RDR as has been shown in previous studies (Younis et al. 2003a, Jones et al. 
2012). Studies involving the initiation of insulin therapy in T2DM (Roysarkar et al. 
1993, Henricsson et al. 1995, Chantelau et al. 1997, Henricsson et al. 1997) have 
recorded a rapid progression of DR in poorly controlled persons.    The association 
with insulin therapy could also be a reflexion  of long term poor glycaemic control 
necessitating the use of insulin, with the possibility of an additional impact resulting 
from a rapid reduction in glucose levels especially in those with the poorest 
control.(Zhao et al. 2014) 
 
The positive association of duration of diabetes in both T2DM and T1DM and type 
of treatment of diabetes in T2DM with the incidence of DR allowed us to examine 
further the impact of different risk stratification strategies.  There were no cases of 
RDR with T2DM within the first year following a negative screening event.  The two 
year incidence in those with T2DM treated with either diet alone, OHAs or insulin 
with a duration of diabetes of <5 years was 0.3% (3 cases per 1,000 persons) for 
both diet and OHAs and 0.1% (1 case per 1,000 persons) using insulin therapy.  In 
those with a duration of diabetes of 5-9 years the two year incidence of RDR was 
0.2% (2 cases per 1,000 persons) in those treated through diet alone, 0.4% (4 
cases per 1,000 persons)in those on OHAs and 0.3% (3 cases per 1,000 persons) 
in those using insulin.  Once the duration of diabetes was ≥10 years the two year 
incidence of RDR was 0.1% (1 case per 1,000 persons) for those on diet only, 0.3% 
(3 cases per 1,000 persons) in those taking OHAs and 1.1% (11 cases per 1,000 
persons) for those requiring the addition of insulin.  Therefore, the screening interval 
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could be extended to once every two years for those with T2DM and once every 
three years in those on diet only or using OHAs with a known duration of diabetes 
<10 years.   
 
In persons with T1DM with a duration of diabetes of ≤10 years the incidence of RDR 
one year following a negative screening event was 0.1% (1 case per 1,000 persons) 
increasing to 0.5% (5 cases per 1,000 persons) after 2 years.  Interestingly, those 
with T1DM for 11-19 years duration there were no cases of RDR one year after a 
negative screening, however there were 1.9% (19 cases per 1,000 persons) after 
two years.  For those with T1DM for ≥20 years duration again there were no cases 
of RDR within the first year however, 2 years after there were 2.7% (27 cases of 
RDR per 1,000 persons).  Therefore, all persons with T1DM should be screened at 
least once every two years especially those with a duration of diabetes in excess of 
10 years and treated with either OHAs and/or insulin.  If the duration of T1DM was 
≤10 years then the screening interval could be further extended. 
 
The main question to answer when trying to assess the optimal screening intervals 
is what amount of interval disease (number of people at risk of a delayed diagnosis 
of RDR) is acceptable and this will need to be balanced against the cost of 
screening and take into consideration the costs relating to visual impairment and 
blindness.(Looker et al. 2014)  Other UK screening programmes have also 
recommended that screening intervals in those without DR could safely be extended 
beyond the current annual screening interval.(Younis et al. 2003b, Younis et al. 
2003a, Jones et al. 2012, Looker et al. 2013, Stratton et al. 2013, Leese et al. 2015)  
The Liverpool screening programme calculated that the mean screening interval 
with a 95% probability of not missing sight-threatening DR was 5.4 years in persons 
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with T2DM and 5.7 years in those with T1DM.(Younis et al. 2003b, Younis et al. 
2003a)  However, they recognised the potential administrative difficulties and the 
risk of non-compliance with overly long screening intervals without a robust IT 
system support and therefore, recommended a screening interval of 2-3 years.  The 
one and two year cumulative incidence of sight-threatening DR within the Liverpool 
screening programme was 0.3% and 0.8% in persons with T2DM and 0.3% and 
0.8% in those with T1DM who would be at risk of a delayed diagnosis of sight-
threatening DR.(Younis et al. 2003b, Younis et al. 2003a)  In Norwich the annual 
incidence of RDR was calculated at <0.5% in persons with T2DM.(Jones et al. 
2012)  However, in Scotland it was estimated that in persons with 2 consecutive 
negative screening events the risk of progression to RDR within a 2 year screening 
interval was very low at ≤0.15% in T2DM.(Looker et al. 2013)  Most recently a report 
from the four Nations DR study group found that in persons with no evidence of DR 
in either eye at two consecutive  screening events at least 12 months apart, 
between 0.3% and 1.3% progressed to RDR at 2 years with <0.3% requiring 
treatment..(Four Nations Study Group 2013, Leese et al. 2015)  However, two 
important caveats within the report were; a robust IT system, in order to prevent the 
loss of patients from the service and ensuring accurate and consistent grading 
without with such a recommendation would be unsafe.  This evidence is currently 
being considered by the UK national screening committee.  Both of these caveats 
are met by the DRSSW with both a robust IT system and a quality assured call and 
recall system and grading.  This study has also taken into consideration the impact 
of duration and type of diabetes in assessing risk of developing RDR.   
 
In parallel my study explored the prevalence of visual impairment and blindness 
which were low at 6.6% and 0.4% in T2DM respectively and 2.8% and 0.1% 
respectively in T1DM.  The limitation in interpreting this data is that it was either 
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attributable to DR or other conditions and it was not possible to distinguish between 
them  as this information was not available then. The reason for the low prevalence 
of blindness within the DRSSW is likely due to the exclusion of persons who were 
registered blind as they would have difficulties following the screening procedures, 
or are under regular care of HES and therefore excluded from screening.  No 
previous community based studies of screening programmes have reported the 
level of visual impairment and blindness in persons with T2DM and T1DM 
separately. 
 
A second smaller dataset of persons with diabetes undergoing photographic based 
screening was provided from a diabetes management programme in Johannesburg, 
South Africa involving 5,515 persons screened between 2001 and 2010.  This data 
promised an unique opportunity to further examine the epidemiology of DR in a 
different population with the additional information on more putative risk factors than 
were available to us in Wales at the time this analysis, such as glycaemic control, 
the presence of hypertension and dyslipidaemia.  As part of its diabetes 
management programme at the Centre for Diabetes and Endocrinology (CDE), 
Johannesburg, South Africa, offers annual screening based on one macula centred 
retinal image taken through undilated pupils using the Canon CR6 non-mydriatic 
camera following the assessment of visual acuity .  Images were graded by a local 
diabetologist according to a standard DR grading protocol.  However, due to 
differences between the grading protocol and that used in the DRSSW all images 
having DR were re-graded according to the DRSSW grading protocol by one of 
three trained retinal graders employed by the DRSSW.   Despite the availability of 
more putative risk factors for this population the study was limited, due to its 
relatively small population size and therefore, findings should be interpreted with 
caution. 
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In the cohort of patients enrolled at the CDE there were 3,978 persons with T2DM 
and 1,537 persons with T1DM who underwent screening between 2001 and 2009.  
The combined (T2DM and T1DM) prevalence of DR reported in this study was: any 
DR 25.9% and RDR 7.6%, which is lower than previously seen from community 
based studies in South Africa who observed a prevalence of  62.2% with any DR 
and 44.5% with RDR,(Mash et al. 2007) 32.3% and 8.9% respectively (Read et al. 
2007), and 33.4% and 11.7% respectively.(Carmichael et al. 2005)  This may be 
due to the differences in the ethnicity and socio-demographics of persons with 
diabetes cared for in the private and public health care sectors in South Africa.  The 
prevalence of DR was lower in persons with T2DM compared with T1DM (20.5% in 
T2DM versus 36.9% in , T1DM).  The majority of DR was BDR  at 14.1% with 6.4% 
RDR in T2DM and 27.2% and 9.7% respectively in T1DM.   
 
The seven year cumulative incidence of DR was 35.1% (351 case per 1,000 
persons), 33.1% (331 cases per 1,000 persons) and 4.7% (47 cases per 1,000 
persons) for T2DM and 53.6% (536 cases per 1,000 persons), 51.1% (511 cases 
per 1,000 persons) and 5.0 (50 cases per 1,000 persons) for T1DM.    The one year 
cumulative incidence of RDR was low at 0.1% (1 case per 1,000 persons) with 
T2DM and 0.2% (2 cases per 1,000 persons) with T1DM.  Therefore, if the annual 
screening interval was extended in the CDE then of the ~3,000 persons followed up 
without evidence of DR then 9 persons (3 with T2DM and 6 with T1DM) would have 
had a delayed diagnosis of RDR.  Unfortunately none of the previous studies have 
reported the incidence rates of DR in Africa which limits any comparisons that could 
be made. 
 
Increased HbA1c and duration of diabetes were seen to be significantly associated 
with the prevalence and incidence of any DR, BDR and RDR in both T2DM and 
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T1DM.  Similarly glycaemic control has been consistently found in other studies to 
be strongly associated with both the development and progression of DR.(The 
Diabetes Control and Complications Trial Research Group 1993, UK Prospective 
Diabetes Study group 1998a, b, Gaede et al. 2003, ACCORD study group et al. 
2010)  Some studies have also discovered a residual protective effect (legacy 
effect) on DR of early tight glycaemic control.(The Diabetes Control and 
Complications Trial Research Group 1993, Holman et al. 2008, White et al. 2010, 
Aiello et al. 2014)  However, in the DCCT 10% of persons developed DR despite 
good metabolic control (mean HbA1c ≤6.9%) and 40% of those with poor metabolic 
control remained without evidence of DR (mean HbA1c ≥9.5%).(Zhang et al. 2001) 
 
In the CDE population a non-Caucasian ethnicity was significantly associated with 
the prevalence of DR in both T2DM and T1DM but only associated with the 
incidence of DR in T1DM.  To date on a worldwide basis the incidence rates of DR 
have mainly been reported for Caucasian populations, although two studies have 
reported higher incidence rates in African Americans with both T2DM and T1DM 
when compared to Caucasians.(West et al. 1982, Kalk et al. 1997)  Whether these 
differences represent a genetic predisposition to microvascular damage and/or 
other risk factors remains unknown. 
 
In the cohort from Johannesburg, South Africa the presence of hypertension was 
also found to be associated with the development of DR, but only in persons with 
T1DM.  This was also seen in the WESDR study where diastolic blood pressure 
was a significant predictor for  progression of DR and the incidence of proliferative 
DR in persons with younger onset diabetes,(Klein et al. 1998) but no association 
was seen in persons with older onset diabetes.(Klein et al. 1995)  However, the 
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UKPDS and ABCD trials both demonstrated the importance of hypertension as a 
risk factor for micro- and macro-vascular complications in type 2 diabetes.  
However, the more recent ACCORD and ADVANCE trials did not find a beneficial 
effect of lowering blood pressure on DR.(Beulens et al. 2009, ACCORD study group 
et al. 2010)  A reason for the non-beneficial effect for lowing blood pressure on DR 
found in the ACCORD and ADVANCE trials compared with the UKPDS study may 
be due to much higher initial BP and greater reduction on treatment seen in the  
UKPDS study. 
 
The risk factors found to be associated with the incidence of RDR within the CDE 
population i.e.; duration of diabetes and HbA1c in both T2DM and T1DM and 
ethnicity and hypertension in T1DM were incorporated into risk analysis to 
determine the impact of different screening stratifications.  Due to the small 
population size the analyses had to be conducted for a combination of two risk 
factors.  For persons with T2DM this was HbA1c  and duration of diabetes and for 
T1DM these were: ethnicity and HbA1c, ethnicity and duration of diabetes and HbA1c 
with duration of diabetes.  In persons with T2DM and an HbA1c ≤7.0% and a known 
duration of diabetes ≤10 years the incidence of RDR one year after a negative 
screening was 0.2% (2 cases per 1,000 persons) rising to 0.4% (4 cases per 1,000 
persons) 2 years after a negative screen (Table 7.1).  Surprisingly once the known 
duration of diabetes increased to >10 years there were no cases of RDR one or two 
year after a negative screen.  For those with an HbA1c >7.0% and a duration of 
diabetes ≤10 years the one year incidence of RDR was  0.1% (1 case per 1,000 
persons) increasing to 0.7% (7 cases per 1,000 persons) after 2 years.  Once the 
known duration of diabetes had increased to >10 years there were no cases of RDR 
on year following a negative screening event however two years after this was 0.9% 
(9 cases per 1,000 persons)  Therefore, those persons with an HbA1c of ≤7.0% 
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regardless of known duration could undergo screening once every three years 
whilst those with an HbA1c of >7.0% would need to be screened once every two 
years.    
 
Table 7.1: The one and two year incidence of RDR in persons with T2DM 
 Duration of diabetes 
 
 
HbA1c 
 
≤7.0% 
≤10 years 
1 year 2 cases 
2 years 4 cases 
>10 years 
1 year 0 cases 
2 years 0 cases 
>7.0% 1 year 1 case 
2 years 7 cases 
1 year 0 cases 
2 years 9 cases 
Incidence is cases per 1,000 persons 
 
For persons with T1DM the one and two year incidence of RDR is shown in Table 
7.2.  For Caucasians the one and two year incidence of RDR was 0% and 0.7% (7 
cases per 1,000 persons) with an HbA1c ≤7.0% and 0.3% and 0.6% (3 and 6 cases 
per 1,000 person) respectively with an HbA1c >7.0%.  For non-Caucasians the one 
and two year incidence of RDR was 0 and 4.0% (40 cases per 1,000 persons) 
respectively with an HbA1c ≤7.0% and 0.7% and 1.5% (7 and 15 cases per 1,000 
persons) respectively with an HbA1c >7.0%.  In Caucasians with a duration of 
diabetes ≤10 years the incidence of RDR one and two years after a negative 
screening event was 0 and 0.3% (3 cases per 1,000 persons) respectively and with 
a duration of diabetes >10 years was 0.5% and 1.1% (5 and 11 cases per 1,000 
persons) respectively.  In non-Caucasians with a duration of diabetes ≤10 years the 
one and two year incidence of RDR was 0 and 1.5% (15 cases per 1,000 persons) 
respectively and with a duration of diabetes >10 years was 0 and 5.6% (56 cases 
per 1,000 persons) respectively.  Excluding ethnicity from the stratification in those 
with an HbA1c ≤7.0% the one and two year incidence of RDR was 0 and 1.3% (13 
cases per 1,000 persons) respectively and in those with a duration of diabetes ≤10 
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years and 0 and 1.6% (16 cases per 1,000 persons) respectively with a duration of 
diabetes >10 years.  Once HbA1c was >7.0 the one and two year incidence of RDR 
was 0 and 0.4% (4 cases per 1,000 persons) respectively with a duration of ≤10 
years and 0.7% and 1.5% (7 and 15 cases per 1,000 persons) respectively with a 
duration of >10 years.  Therefore those persons of Caucasian ethnicity with a 
duration of diabetes ≤10 years the two year incidence of RDR was sufficiently low 
(0.3%) to allow an extension of the screening interval to once every three years.  
With the exception of non-Caucasians with an HbA1c >7.0% or Caucasians with a 
duration of diabetes of >10 years or an HbA1c >7.0% and a duration of diabetes >10 
years whose one year incidence of RDR was sufficiently high to recommend 
maintaining annual screening intervals all other groups could undergo screening 
once every two years.  However this analysis should be interpreted with caution as 
the population size was small and further larger scale studies are required before 
the screening interval can safely be modified.  In addition those persons enrolled in 
the CDE cannot be regarded as representative of the majority of the population of 
persons with diabetes in South Africa. 
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Table 7.2: One and Two year incidence of RDR in persons with T1DM by ethnicity 
and HbA1c, ethnicity and duration of diabetes and duration of diabetes and HbA1c 
 
 
 
HbA1c 
 Ethnicity 
 Caucasian Non Caucasian 
≤7.0% 1 year 0 cases 
2 years 7 cases 
1 year 0 cases 
2 years 40 cases 
>7.0% 1 year 3 cases 
2 years 6 cases 
1 year 7 cases 
2 years 15 cases 
 
 
 
Duration 
 Ethnicity 
 Caucasian Non Caucasian 
≤10 
years 
1 year 0 cases 
2 years 3 cases 
1 year 0 cases 
2 years 15 cases 
>10 
years 
1 year 5 cases 
2 years 11 cases 
1 year 0 cases 
2 years 56 cases 
 
 
 
Duration 
 HbA1c 
 ≤7.0% >7.0% 
≤10 
years 
1 year 0 cases 
2 years 13 cases 
1 year 0 cases 
2 years 4 cases 
>10 
years 
1 year 0 cases 
2 years 16 cases 
1 year 7 cases 
2 years 15 cases 
Incidence is cases per 1,000 persons 
 
The prevalence of visual impairment and blindness were low in this cohort of 
persons with diabetes at 3.5% and 0.3% respectively for persons with T2DM and 
1.8% and 0.2% respectively for those with T1DM.  The prevalence of visual 
impairment and blindness in populations in South Africa have not previously been 
reported. 
 
This study shows that information on additional putative risk factors for the 
development of DR could be useful in better ensuring the safety of extended 
screening intervals.  In the future it may be beneficial to consider individualising the 
screening interval based on the level of DR observed together with the available risk 
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factors.  A study in Demark developed an algorithm to calculate a persons' 
screening interval based on the presence of retinopathy, type of diabetes, duration 
of diabetes, HbA1c, systolic blood pressure and gender.(Aspelund et al. 2011)  The 
study imposed a minimum screening interval of 6 months and maximum of 60 
months.  Using this approach they found the mean recommended screening interval 
to be 29 months.  This corresponds to a 59% reduction in screening frequency 
compared to annual screening with 2.9% developing sigh-threatening DR before the 
next screening visit.  The algorithm was tested on a database containing 5,199 
patients over a period of 20 years.  This study showed that individualising the 
screening interval based on putative risk factor information could make screening 
more efficient.  However, whether additional risk factors for DR such as treatment of 
diabetes and cholesterol levels would provide a more sensitive algorithm needs to 
be investigated.  The main barrier to introducing such an algorithm in UK screening 
programmes is that they don't collect such information on the putative risk factors.  
Therefore, capturing this information possibly through improved IT links with GP's or 
Laboratories or collection at the point of screening, would need to be carefully 
considered before individual risk based screening could be introduced. 
 
Due consideration should also be given to service user views / opinions before any 
adjustments to screening intervals are introduced.  We have conducted two earlier 
studies exploring patient perceptions of extending beyond the current annual 
screening interval.  One study involved a patient questionnaire which revealed that 
85% of those who responded think that they should have their eyes screened every 
year.  65% stated that they would except an extended screening interval as long as 
medical evidence proved it was safe.(Yeo et al. 2012b) Therefore, If any changes 
are to be made in the future the concerns of those 35% who did not agree needs to 
be taken into consideration.  The second study utilised a discrete choice experiment 
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in an attempt to understand the preferences of persons with diabetes for screening 
provisions.  The findings were that although the frequency of screening was a 
valued attribute they would be willing to have the screening interval extended if 
other preferences for service provision, such as the ability to detect other changes 
in the eyes, were taken into account.(Yeo et al. 2012a)   
 
Underprovided education/information about DR, resulting in a lack of awareness of 
the seriousness of the detrimental effects of DR on visual acuity, is cited to be one 
of the main barriers to attendance.(Van Eijk et al. 2012, Shepple et al. 2014)  This 
coupled with the evidence that those persons who do not attend for screening are at 
3.78 fold increased risk of developing RDR compared to those who do attend is of 
concern when considering extending screening intervals.(Leese G P et al. 2008)  
Therefore, a patient education/awareness programme should be implemented in 
conjunction with the planning allied to modifying the screening interval according to 
risk to ensure attendance.  Additional measures to improve attendance should be 
investigated e.g. offering out-of-hour screening and weekends.  In addition a text 
message reminder system could be implemented. 
 
7.2 Study Limitations and Strengths 
There were a number of limitations within this thesis for both study populations as 
there are for all retrospective observational studies especially when attempting to 
estimate the impact of changing the screening interval beyond annual screening.  
The DRSSW excluded persons under the care of ophthalmology, registered blind or 
under the age of 12 years from screening and therefore they could not be included 
in the analysis.  Other exclusions were also made to ensure the quality of the data 
to be analysed within this thesis i.e. persons with T2DM with an age at diagnosis of 
289 
 
diabetes <30 years or T1DM with an age at diagnosis of ≥30 years.  The main 
limitations of the DRSSW cohort were the number of exclusions and the limited 
number of risk factors available for analysis.  In the South African cohort  persons 
with a diagnosis of diabetes other than T2DM or T1DM were excluded.  The main 
limitation of the South African dataset was the small sample size which limited the 
conclusions that could be drawn from the analysis.  Also the population examined 
from South Africa was from a private healthcare sector of the population and 
therefore  not representative of the majority of persons with diabetes in South Africa.  
The study dropout rate observed beyond the second screening event was also a 
limitation in both studies.  In the T2DM population in  DRSSW 38% did not undergo 
a third screening event, which increased to 79% for a fourth screening event.  For 
the T1DM population 37% did not undergo a third screening event, increasing to 
76% at the fourth screening event.  In the South Africa study for the T2DM 
population the dropout rate at the third screening event was 35% increasing to 76% 
at the fourth screening event.  For the T1DM population this was 29% and 49% 
respectively.  The reasons for the dropouts could not be investigated, due to the 
anonymous nature of the data sets, could bias the findings.  These limit the 
conclusions that can be drawn from these studies especially beyond the third 
screening event and in the South African dataset. 
 
Another study limitation was that the best corrected visual acuity was not measured 
and current acuity was used instead.  Although if the current visual acuity was lower 
than 6/9 a pinhole measurement was recorded.  Additionally the visual impairment 
and blindness found within these studies could not be attributed to DR as recordings 
of other lesions were not present within the datasets. 
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A possible limitation of this study and its analysis was to rely on  only one negative 
screening event on which to stratify screening intervals, however, the risk of 
developing RDR was similar to that described by the Four Nations diabetic 
retinopathy screening interval study group in those with no retinopathy detected at 
two screening episodes one year apart where the four year incidence of RDR 
ranged from 0.3% and 1.3% over the seven programmes included in the study  
 
However, the strengths of this study were the large population size of the Welsh 
cohort and the utilisation of standardised screening methodologies employed to 
both capture and grade digital retinal images within each programme.  Visual acuity 
was also recorded by trained healthcare assistants using 3m illuminated Snellen 
charts..  Grading was performed by accredited graders in a structured 3 tiered 
process using a modified version of the NSC grading protocol.  In the CDE visual 
acuity and image capture was performed by diabetes nurses educators also using a 
3m illuminated Snellen chart, but capturing only one macular centred image without 
mydriasis.  Grading was performed initially by one local diabetologist using the 
CDE’s standard grading protocol, although all images with DR lesions were re-
graded by one of three (including myself) accredited graders according to the Welsh 
grading protocol.  Those images with no DR were not included in the re-grading 
process.  In addition was the availability of a greater number of risk factors. 
 
7.3 Future Research 
Future research should continue to focus on individualising screening intervals 
using more detailed risk factor analysis in a prospective study in order to define low, 
medium and high risk individuals and corresponding safe screening intervals.  For 
this purpose it will be necessary to include the following putative risk factors: type of 
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diabetes (according to an agreed classification), duration of diabetes (accepting the 
difficulty with type 2 diabetes), blood pressure, lipid profile, ethnicity and 
concomitant medication.  Standardised protocols for the acquisition of images and 
grading is essential along with quality assurance procedures as was adopted in this 
thesis.  It is also essential to ensure a validated register of the population under 
study and well defined inclusion and exclusion criteria.  A patient centred approach 
is a main future requirement.  This could be achieved by a prospective randomised 
controlled trial to compare annual screening and risk-based screening intervals 
varying between 6 months for high risk individuals, 12-24 months for medium risk 
and 36 months for low risk individuals.  This would need to be accompanied by cost-
effectiveness analysis across the different screening intervals.   
 
Further comparison between the need for one versus two successive annual screen 
negative episodes would be of additional value.  Additionally screening intervals for 
persons with pre-existing BDR and possibly more advanced DR such as PPDR 
should be further investigated along with health economics.   
 
Studies should also consider assessing the outcomes of those persons referred for 
DR to the HES.  Consideration should be given to whether the referrals were 
appropriate, whether treatment was given and if so was it carried out in timely 
manner. 
 
The impact of changing the screening intervals on the attitudes of patients towards 
DR screening should be carefully assessed.  Qualitative Research needs to assess 
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how best to communicate these changes and the reasons behind them to the 
patients to ensure up take of screening remains unaffected. 
 
Beyond screening intervals other ways to ensure the cost effectiveness of screening 
programmes for DR should be investigated such as improving the uptake rate for 
screening and the adoption of new or emerging technologies into screening 
programmes such as automated grading and the role of optical coherence 
tomography (OCT) for the detection of macular oedema which is difficult with the 
current 2-D images obtained with the non-mydriatic cameras.  
 
Additional research should also focus on the mechanisms involved in the 
development and progression of DR thereby developing better less destructive 
treatments such as the anti-VEGF treatments and other medications such as the 
fibrates. 
 
7.4 Summary 
The evidence emanating from my analysis in this thesis in conjunction with previous 
studies from diabetic retinopathy screening programmes in the UK,(Younis et al. 
2003b, Younis et al. 2003a, Jones et al. 2012, Looker et al. 2013, Stratton et al. 
2013, Leese et al. 2015) and in Europe (Olafsdottir et al. 2007, Agardh et al. 2011, 
Aspelund et al. 2011, Porta et al. 2013) provide an increasing evidence base for the 
extension of screening intervals in a low-risk population.  Additional studies have 
also demonstrated that extending the screening interval would also be cost-effective 
with as much as a 25% reduction in the costs of screening.(Chalk et al. 2012)  
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The high prevalence of DR at entry into both of the programmes examined in this 
thesis emphasises the importance of such programmes in an attempt to eliminate 
the incidence of sight-threatening DR, in persons with diabetes.  Progress has been 
made over the years with changes in diabetes care with earlier diagnosis, lower 
glycaemic, blood pressure and cholesterol targets lowering the prevalence of 
DR.(Vallance  et al. 2008, Kyto et al. 2011)  Other recent evidence shows that DR is 
for the first time no longer a leading cause of blindness in the working age 
population in England and Wales.(Liew et al. 2014)  The authors suggested that this 
may in part be due to screening programmes for DR as well as improved diabetes 
care.  However, more needs to be done to further reduce the incidence of blindness 
from DR through understanding its pathophysiology and development of new 
treatments in light of the ongoing global diabetes epidemic, with an estimated 387 
million persons affected in 2014 which is expected to rise to 592 million persons 
with diabetes by 2035, especially in low or middle income countries (International 
Diabetes Federation 2014) with the accompanying risk of sight-threatening DR. 
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Abstract
Objectives To determine the incidence of any and referable diabetic
retinopathy in people with type 2 diabetes mellitus attending an annual
screening service for retinopathy and whose first screening episode
indicated no evidence of retinopathy.
Design Retrospective four year analysis.
Setting Screenings at the community based Diabetic Retinopathy
Screening Service for Wales, United Kingdom.
Participants 57 199 people with type 2 diabetes mellitus, who were
diagnosed at age 30 years or older and who had no evidence of diabetic
retinopathy at their first screening event between 2005 and 2009. 49
763 (87%) had at least one further screening event within the study
period and were included in the analysis.
Main outcome measures Annual incidence and cumulative incidence
after four years of any and referable diabetic retinopathy. Relations
between available putative risk factors and the onset and progression
of retinopathy.
Results Cumulative incidence of any and referable retinopathy at four
years was 360.27 and 11.64 per 1000 people, respectively. From the
first to fourth year, the annual incidence of any retinopathy fell from
124.94 to 66.59 per 1000 people, compared with referable retinopathy,
which increased slightly from 2.02 to 3.54 per 1000 people. Incidence
of referable retinopathy was independently associated with known
duration of diabetes, age at diagnosis, and use of insulin treatment. For
participants needing insulin treatment with a duration of diabetes of 10
years or more, cumulative incidence of referable retinopathy at one and
four years was 9.61 and 30.99 per 1000 people, respectively.
Conclusions Our analysis supports the extension of the screening
interval for people with type 2 diabetes mellitus beyond the currently
recommended 12 months, with the possible exception of those with
diabetes duration of 10 years or more and on insulin treatment.
Introduction
Diabetic retinopathy remains amajor cause of visual impairment
and blindness in the United Kingdom,1 with its early detection
and timely treatment2-4 capable of reducing the risk of visual
loss. The evidence that screening for diabetic retinopathy is cost
effective5 6 has led to the establishment, over the past 20 years,
of several screening programmes at local, regional, and national
levels throughout the UK and elsewhere, varying in size, design,
and complexity.7 8
Various methods have been used to screen for diabetic
retinopathy, including ophthalmoscopy (direct and indirect);9
obtaining retinal images (for example, Polaroid images),9-11 35
mm transparencies,12 and more recently digital images with13 or
without mydriasis;14 15 as well as combining ophthalmoscopy
with retinal photography.16 17 In 1999, the National Screening
Committee for England and Wales recommended the use of
digital photography through dilated pupils to screen people for
diabetic retinopathy18 19 from the age of 12 years. A national
consensus protocol for grading and disease management, based
on annual screening,20 was also developed as part of the yearly
review for every person with diabetes. In 2003, the Diabetic
Retinopathy Screening Service for Wales was established and
is currently responsible for the annual screening of 150 000
people registered with diabetes mellitus in Wales (about 5% of
the population).
Despite the increase in diabetes mellitus worldwide,21 some
evidence has suggested a decline during the past few decades
in the prevalence and incidence of diabetic retinopathy,
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especially sight threatening retinopathy. This reduction is
attributed not only to improved care but also to the earlier
detection of both diabetes and diabetic retinopathy.22-24 Evidence
from screening programmes of relatively small numbers of
patients with type 2 diabetes has also suggested that an extension
of the screening interval—beyond the currently recommended
12 months—would be safe for those without evidence of
retinopathy at first screening.25-29 Such a change in policy could
substantially reduce heath service expenditure while allowing
reinvestment into the screening service. This reinvestment could
provide more frequent screening for people with early exudative
maculopathy and early diabetic retinopathy, and allow earlier
discharge of patients at the hospital eye service as a result of
more frequent follow-up being available at the screening service.
Our study reviewed data for a large population of people with
type 2 diabetes mellitus who had shown no evidence of diabetic
retinopathy at their first screen. We estimated the annual and
cumulative incidence of retinopathy over a four year period,
and explored the association between the development of
retinopathy and its putative risk factors.
Methods
Study population
Every person known to have diabetes mellitus over the age of
12 years and registered with a general practice in Wales must
be referred to the Diabetic Retinopathy Screening Service for
Wales by their doctor, apart from those excluded on medical
grounds (for example, those unable to attend screening owing
to infirmity or comorbidity)30 or those already attending hospital
based ophthalmology services because of retinopathy. Our four
year retrospective analysis included data for all patients
classified as having type 2 diabetes mellitus, diagnosed over
the age of 30 years, andwho attended screening between January
2005 and November 2009. Exclusion criteria included: a
diagnosis, on referral to the screening service, of type 1 diabetes
mellitus; a diagnosis of type 2 diabetes mellitus but at age
younger than 30 years; or no type of diabetes mellitus recorded
on the referral notification (predominantly from primary care).
Data were anonymised before undergoing statistical analysis.
Screening procedure
After registration with the Diabetic Retinopathy Screening
Service for Wales, each patient is invited to attend screening at
a location closest to them (with an appointment date and time).
Screening is undertaken at a variety of venues throughoutWales,
including general practice surgeries and local hospitals or
community centres. A trained healthcare assistant assesses
patients’ current visual acuity in both eyes (achieved with or
without glasses or with pinhole reading), using an illuminated
3 m Snellen chart. Tropicamide (1%) is then applied to each
eye, and after about 15 minutes, a trained photographer takes
two 45° digital retinal images per eye (one macular centred, and
one nasal field) using a non-mydriatic Canon DGi camera (with
a 30D or 40D camera back). The retinal images are transferred
to a central reading centre for grading. The photographers can
also take additional images of the retina, lens, or iris if deemed
necessary.
Diabetic retinopathy grading
Trained staff use a standardised protocol to grade diabetic
retinopathy, which is an enriched version of the English National
Screening Protocol,20 and take the worst grade for either eye as
the final grading level.We used the following grading categories
of retinopathy: none present, background, preproliferative or
proliferative, and maculopathy (based on surrogate markers
such as exudates within 1 disc diameter of the fovea).
For the statistical analysis, we defined referable retinopathy as
participants with preproliferative or proliferative retinopathy
(with or without maculopathy), or maculopathywith background
retinopathy. This category relates to those whowould, according
to guidelines, need referral to the hospital eye service for further
assessment or treatment. Digital retinal images were not
considered gradable if the retina of both eyes could not be
visualised adequately—that is, retinal vessels were not visible
within 1 disc diameter of the centre of the fovea and fine vessels
were not visible across the surface of the optic disc.
Ethical approval
We sought advice from the South East Wales research ethics
committee, as well as from the Cardiff and Vale University
Health Board (previously the Cardiff and Vale National Health
Service trust), the host organisation for the Diabetic Retinopathy
Screening Service for Wales, on behalf of the Welsh Assembly
Government. In their considered opinion, this study was a
service evaluation and therefore did not require ethical approval.
Individual patients provided written informed consent at each
screening event for their anonymised data to be used in research.
Statistical analysis
We used descriptive analyses to characterise the study
population and patterns of diabetic retinopathy, and used t tests
and χ2 tests to explore differences between patients without any
retinopathy and those who developed any, background, or
referable retinopathy. Parametric survival analysis with
covariates identified those factors associated with the
development of referable retinopathy.
The presence or absence of diabetic retinopathy was determined
after each screening event during the study period. Although
intended to occur annually, screening took place at variable
times during the four year period. For people who developed
retinopathy between two screening events, the time to
development lay between the two episodes, and therefore the
data were interval censored; for those who did not develop the
disorder by the final screening event, the data were right
censored. We therefore modelled the time to development of
retinopathy using survival analysis to allow for these two types
of censoring.
We used a parametric approach, implemented by the routine
INTCENS program in Stata. From the estimated parameters,
the survival function was calculated to derive the annual and
cumulative incidence of any and referable diabetic retinopathy.
We used bootstrapping to calculate confidence intervals, because
we could not obtain the standard errors easily.31 Different
distributions were considered for the underlying survival times,
including Weibull, exponential, Gompertz, log normal, and
inverse Gaussian. We chose the distribution on the basis of the
Akaike information criterion.32
We explored the effect of putative risk factors with available
information (that is, age, sex, age at diagnosis, duration of
diabetes mellitus, and treatment types) by incorporating them
into this survival analysis. To avoid assumptions of linearity,
we used the following categories for the duration of diabetes:
less than five years, five to nine years, and 10 years or more.
Age categories were: 30-49 years, 50-59 years, and 70 years or
older. The risk factors were examined individually and then
re-examined in a multivariate analysis with all variables
included.We did statistical analyses using SPSS version 16 and
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Stata version 10; evidence of significance was taken as P<0.05
unless otherwise stated.
Results
A total of 85 214 individuals with type 2 diabetes mellitus
underwent screening for diabetic retinopathy between January
2005 and November 2009; 57 199 (67.1%) had no evidence of
retinopathy and were therefore eligible for inclusion in this
study. At the initial screening event, 22 501 (26.4%) had
evidence of background retinopathy and 3723 (4.4%) had
referable retinopathy. Those with referable retinopathy consisted
of: 1169 (1.4%) with maculopathy, 1279 (1.5%) preproliferative
retinopathy, and 262 (0.3%) proliferative retinopathy (817
(1.0%) preproliferative retinopathy andmaculopathy, 196 (0.2%)
proliferative retinopathy and maculopathy). We excluded 1791
(2.1%) participants who had images that could not be graded,
as well as those with evidence of existing retinopathy.
Of 57 199 people without evidence of diabetic retinopathy at
the first screening event, 7436 (13.0%) did not attend another
screening during the study period, 449 (6.0%) of whom were
not eligible for a second screen (which would have occurred
within 12 months). We do not know why the remaining 6987
(94.0%) people did not attend a second screening event, because
anonymisation of the records prevented further investigation;
however, this group was older and had a longer known duration
of diabetes than the group attending at least one additional
screening event (table 1⇓). We did not observe a significant
difference in the proportions of male participants between these
two groups.
We found that 49 763 participants had a second screening event,
31 924 (64.2%) a third, 10 615 (21.3%) a fourth, and 767 (1.5%)
a fifth (total of 93 069 events). Although screening was intended
to occur annually, the screening intervals were generally longer
than one year, with a mean (standard deviation) interval of 17.8
(6.3) months between the first and second screening events,
15.3 (4.4) months between the second and third, 13.2 (2.7)
months between the third and fourth, and 12.0 (1.9) months
between the fourth and fifth. Only 4479 (9%) participants had
an interval of 12 (1) months between screening events.
During the study, 12 922 (26.0%) participants with type 2
diabetes mellitus developed diabetic retinopathy, of whom the
vast majority (12 574 (97.3%)) developed background
retinopathy. Of 348 (0.7%) people who developed referable
retinopathy, 197 (56.6%) had evidence of maculopathy, 107
(30.7%) had preproliferative retinopathy, and 25 (7.2%)
proliferative retinopathy. Sixteen (4.6%) people had
preproliferative retinopathy andmaculopathy, and three (0.9%)
had proliferative retinopathy and maculopathy.
Of 28 participants who developed proliferative diabetic
retinopathy (with or without maculopathy), 14 (50.0%) did so
between 12 and 24 months after the first screening event, three
(10.7%) after 24-36 months, 10 (35.7%) after 36-48 months,
and one (3.6%) after 48 months. Duration of diabetes was less
than five years in 19 (68%) participants, and 27 (96%) received
diet and oral treatment, with only one receiving insulin. Of
participants who developed proliferative retinopathy within 12
to 24 months, none were on insulin treatment and only two
(14%) had had diabetes longer than 10 years.
In the survival analysis, we selected the Weibull distribution as
best fitting the data. Tables 2⇓ and 3⇓ show the estimated annual
and cumulative incidence of any and referable diabetic
retinopathy. The annual incidence of any retinopathy at one
year was 124.94 per 1000 people, decreasing to 66.59 per 1000
at four years, with a cumulative incidence of 360.27 per 1000
people at four years. By contrast, the annual incidence of
referable retinopathy increased from 2.02 to 3.54 per 1000
people, with a cumulative incidence of 11.64 at four years. The
cumulative incidence of each retinopathy group was about twice
as high in participants who received insulin treatment (tables 2
and 3).
Table 4⇓ summarises the baseline characteristics of the three
groups according to outcome—that is, participants who did not
develop diabetic retinopathy and those who developed any or
referable retinopathy. The mean known duration of diabetes
mellitus and the proportion of participants requiring insulin
treatment were significantly greater in those who developed
referable retinopathy than in those who remained free of
retinopathy. Mean ages at diagnosis of diabetes and at first
screening were lowest in the group that developed referable
retinopathy and highest in the group that did not develop any
retinopathy. Sex distribution did not differ between the groups.
Table 5⇓ shows the effects of putative risk factors on the risk
of participants developing diabetic retinopathy. A significantly
raised risk of referable retinopathy was associated with an
increased duration of diabetes mellitus. Risk was highest in
participants diagnosed at age 30-49 years, with significantly
reduced risks in those aged up to 70 years at diagnosis. The risk
of any or referable retinopathy varied greatly between different
types of diabetes treatment. Age, duration of diabetes, and
treatment had similar effects on the risk of developing
background retinopathy, although age at diagnosis of more than
70 years was associated with a significantly increased risk.
The incidence of referable retinopathy varied considerably
between subgroups. For example, for participants given diet
treatment only with a known duration of diabetes of less than
five years, the cumulative incidence of retinopathy at one, two,
and three years from the first negative screen was 1.83, 3.66,
and 5.45 per 1000 people, respectively. Corresponding values
for participants receiving insulin treatment with a duration of
diabetes of less than 10 years were 0.71, 3.80, and 10.10 per
1000 people, respectively. For participants with a duration of
diabetes of 10 years or more, the use of insulin treatment
increased cumulative incidence greatly (with insulin treatment
2.24, 5.86, and 10.33 per 1000 people; without insulin treatment
9.61, 17.10, and 24.26 per 1000 people).
Discussion
In our study relating to people with type 2 diabetes mellitus
enrolled in the national Diabetic Retinopathy Screening Service
for Wales from 2005 to 2009 with no evidence of diabetic
retinopathy at initial screening, the annual incidence of any
retinopathy per 1000 people was 124.94 (12.5%) in the first
year, falling each year to 66.59 (6.7%) in the fourth year. The
cumulative incidence at four years was 360.27 per 1000 people
(36.0%). The annual incidence of referable retinopathy per 1000
people was low at 2.02 (0.2%) in the first year, with a small
increase to 3.54 (0.4%) in the fourth year; the cumulative
incidence at four years was 11.64 (1.2%).
The incidence of referable retinopathy was positively and
independently associated with the known duration of type 2
diabetes and the need for insulin treatment, and inversely related
to age at diagnosis. For participants on diet treatment with a
duration of diabetes of less than five years, the cumulative
incidence of referable diabetic retinopathy at one, two, and three
years was 1.83, 3.66, and 5.45 per 1000 people, respectively.
By contrast, the corresponding values for participants using
insulin treatment with a duration of diabetes of more than 10
years were 9.61, 17.10, and 24.26 per 1000 people, respectively,
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an approximately fivefold increase. For participants not using
insulin with a duration of diabetes of more than 10 years, the
corresponding values were 2.24, 5.86, and 10.33 per 1000
people, respectively, and 0.71, 3.80, and 10.10 per 1000 people,
respectively, for those using insulin treatment with a duration
of diabetes of less than 10 years.
The results suggest that for people with type 2 diabetes mellitus
and no evidence of retinopathy at screening, the interval of
screening could be extended beyond the 12 months currently
(but rarely) adopted. Patients on insulin treatment with a history
of diabetes of 10 years or more should continue to be screened
annually.
Strengths and weaknesses of the study
The large sample size was one of the main strengths of this
study. Furthermore, all participants were screened for the
presence of retinopathy by a standardised protocol of digital
retinal imaging and subsequent grading by trained staff.
However, screening was restricted to two 45° retinal images
per eye, and only limited information was available on putative
risk factors for the development of diabetic retinopathy (we
could not obtain measures of glycaemic control, blood pressure,
and lipid concentrations).We recorded a high dropout rate (12%)
of participants who did not have a second screening event
despite being eligible. We were not able to obtain information
for those people who did not participate in screening; somemay
have been excluded for medical reasons, because they were
already receiving care from an ophthalmologist for diabetic
retinopathy, or they did not attend for other unknown reasons.
Comparison with other studies
The annual incidence of referable diabetic retinopathy observed
in our study was similar to that previously reported by Younis
and colleagues from the Liverpool Diabetic Eye screening
programme for sight threatening retinopathy (equivalent to our
category of referable retinopathy)—0.2% in the first year, with
a cumulative incidence of 1.7% at four years.26 The authors
recommended an extension of the screening interval to triennial
screening, based on the 95% probability of people remaining
free from sight threatening retinopathy with a mean screening
interval of 5.4 years.
Data from the annual screening programme in Norfolk28 and
the biennial screening programme in Iceland25 also concluded
that biennial screening intervals would be safe in those people
without evidence of diabetic retinopathy at screening. The
Icelandic screening programme reported that people who
developed sight threatening retinopathy were placed on annual
screening once they were identified as having background
retinopathy. Therefore, these patients had no undue delay in the
diagnosis or treatment of sight threatening retinopathy over the
10 year period of observation.25
A study of the Swedish screening programme used a three year
screening interval in a cohort of well controlled participants
(mean HbA1c 6.4% at baseline) with type 2 diabetes mellitus,who showed no evidence of retinopathy and had a mean known
duration of diabetes of six years.29 The researchers observed
that 28% of participants developedmild tomoderate retinopathy,
but did not develop sight threatening or referable retinopathy
in the form of severe preproliferative or proliferative retinopathy
during the three year study period. However, they did identify
macular oedema in three people, one of whom needed laser
treatment.
Several studies, including the Liverpool Diabetic Eye Study,26
similarly found that the incidence of diabetic retinopathy was
associated with the duration of diabetes and the use of insulin
treatment.33-36 A younger age at diagnosis of diabetes has also
been linked with increased incidence of retinopathy,33 although
this association was not found in the UK Prospective Diabetes
Study.37 In agreement with previous studies,26 37 we found no
relation between the incidence of retinopathy and participants’
sex, but we found a strong association between incidence and
the use of insulin treatment, presumably indicating the stage of
the disease.
Therefore, on the present evidence, annual screening is not
necessary for people with type 2 diabetes with no lesions of
diabetic retinopathy seen on digital images. Exceptions would
include people with a duration of diabetes of 10 years or more
and on insulin treatment, who should be retained on annual
screening. If the screening service used a screening interval
longer than 1 year, it would need to use safeguards to ensure
that if patients changed risk groups within the year, a new
appropriate interval would apply. Safeguards would include the
education of patients and professionals to be aware of signs or
symptoms suggestive of sight threatening retinopathy, and robust
communication between healthcare professionals and the
screening service. As electronic patient records become more
widespread, these objectives could be more readily achievable.
Not all people classified as having referable diabetic retinopathy,
for the purpose of screening, need urgent treatment at the first
ophthalmological review. This is because most of these referrals
are for isolated exudates (exudative maculopathy) without
associated leakage (macular oedema) and early preproliferative
retinopathy that need further investigations with fluorescein
angiography or optical coherence tomography to determine high
risk features. Laser treatment for such changes is not indicated,
according to the Early Treatment of Diabetic Retinopathy
Study,3 although focal laser treatment is considered for clinically
important macular oedema. Early preproliferative retinopathy
is also generally not treated in the first instance, since such cases
are monitored for progression to high risk features and
sometimes these retinal signs can resolve with improvement of
glycaemic control.
The decision to treat is based on various factors, such as severity
and status of the fellow eye, diabetes control, blood pressure,
and lipid status. Clearly, if proliferative diabetic retinopathy is
evident, early treatment with pan retinal photocoagulation can
prevent the loss of vision.2A delay in diagnosing early exudative
maculopathy or preproliferative retinopathy should not
necessarily result in a poor outcome, since most diagnosed
patients would enter a period of observation by the
ophthalmologist after referral.
Future research
Our future research will explore the implications of varying the
screening interval using risk stratification. To better predict the
development of retinopathy, further research should investigate
additional risk factors (for example, the individual and collective
effects of glycaemic control (HbA1c), blood pressure, albuminexcretion, and lipid status, as well as possible treatments). These
findings could improve risk stratification by better defining safe
screening intervals on an individual basis. Another important
area to investigate further includes the economic effect of the
different screening intervals.
Conclusion and implications for policymakers
Other screening programmes have been able to revise their
screening intervals based on evidence—that is, cervical,38
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e874 doi: 10.1136/bmj.e874 (Published 22 February 2012) Page 4 of 11
RESEARCH
breast,39 and bowel40 screening programmes in the UK. The
original recommendation to undertake annual screening for
diabetic retinopathy was based on a consensus view of experts
and the over-riding wish to include such findings as part of the
annual review for people with diabetes. Much debate has
surrounded the appropriate screening interval for retinopathy
screening, and although the American Diabetes Association
recently recommended yearly screening, it suggested less
frequent screening in people with at least one previous negative
screen.41
Our study shows that the annual incidence of referable diabetic
retinopathy is low in people with type 2 diabetes mellitus and
without evidence of retinopathy at initial screening. These results
lend further support to the suggestion of an extension to the
screening interval beyond the 12 months currently adopted
(although rarely achieved), with the possible exception of
patients with a known duration of diabetes of longer than 10
years and on insulin treatment, who should continue to be
screened annually. People who develop background retinopathy
should also continue annual screening to avoid any delay in
referral to ophthalmology services should sight threatening
retinopathy develop, as adopted by the Icelandic screening
service.25
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What is already known on this topic
Screening for diabetic retinopathy is cost effective
Diabetic retinopathy remains the leading cause of blindness in the working age population
Previous studies have questioned the need for annual screening
What this study adds
For people with type 2 diabetes mellitus with no evidence of diabetic retinopathy at initial screening, the interval of screening could be
extended beyond the 12 months currently adopted, but rarely achieved. Possible exceptions are patients with a history of diabetes of
10 years or more and on insulin treatment, who should continue to be screened annually
Future research should focus on a more comprehensive risk stratification as a basis for defining safe screening intervals
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Tables
Table 1| Baseline characteristics of study participants
P
Participants without evidence of diabetic retinopathy at initial screening
Characteristics
Attended at least one further screening event
(n=49 763)
Did not attend a further screening event
(n=6897)*
<0.00164.4 (11.3)66.9 (13.5)Age (years)†
<0.0014.2 (4.4)4.6 (4.8)Known duration of diabetes mellitus
(years)†
<0.00160.2 (11.3)62.3 (13.2)Age at diagnosis of diabetes mellitus
(years)†
Sex‡
0.08727 529 (55.3)3794 (55.0)Male
21 975 (44.2)3175 (46.0)Female
259 (0.5)18 (0.3)Unknown
Treatment for diabetes mellitus‡
<0.00117 236 (34.6)2684 (38.9)Diet
29 049 (58.4)3787 (54.9)Oral hypoglycaemic agents
2669 (5.4)394 (5.7)Insulin
809 (1.6)122 (1.8)Unknown
*Group includes eligible participants only. †Mean (standard deviation). ‡Number (%).
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Table 2| Yearly incidence of any and referable diabetic retinopathy in participants without retinopathy at baseline
Referable retinopathyAny retinopathyTime from last negative
screen Cumulative incidenceAnnual incidenceCumulative incidenceAnnual incidence
2.02 (1.63 to 2.44)2.02 (1.63 to 2.44)124.94 (120.62 to 128.32)124.94 (120.62 to 128.32)1 year
4.85 (4.29 to 5.43)2.82 (2.51 to 3.12)216.81 (211.50 to 220.04)91.68 (89.67 to 93.66)2 years
8.09 (7.20 to 8.93)3.24 (2.76 to 3.68)293.80 (287.34 to 297.76)76.96 (74.96 to 79.30)3 years
11.64 (10.27 to 13.00)3.54 (2.89 to 4.21)360.27 (352.98 to 366.06)66.59 (64.67 to 68.92)4 years
Data are incidence (95% confidence interval) per 1000 people. Incidence of background retinopathy is the difference between the incidences of any and referable
retinopathy.
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Table 3| Yearly incidence of any and referable diabetic retinopathy in participants using insulin treatment and without retinopathy at baseline
Referable retinopathyAny retinopathyTime from last negative
screen Cumulative incidenceAnnual incidenceCumulative incidenceAnnual incidence
2.56 (1.13 to 4.70)2.56 (1.13 to 4.70)192.43 (177.70 to 206.50)192.43 (177.70 to 206.50)1 year
7.67 (4.78 to 10.71)5.00 (3.33 to 6.50)320.64 (304.86 to 334.53)128.03 (120.00 to 136.85)2 years
14.48 (9.68 to 18.66)6.84 (4.23 to 9.43)421.62 (403.10 to 437.67)100.19 (92.02 to 109.50)3 years
22.81 (15.20 to 30.30)8.41 (4.40 to 12.90)502.95 (482.26 to 525.51)81.69 (74.32 to 89.49)4 years
Data are incidence (95% confidence interval) per 1000 people. Incidence of background retinopathy is the difference between the incidences of any and referable
retinopathy.
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Table 4| Baseline characteristics of participants according to outcome
PReferable retinopathy (n=348)PAny retinopathy (n=12 922)No retinopathy (n=36 841)*
0.00562.9 (11.3)0.00264.9 (11.3)64.2 (11.3)Age (years)†
<0.0015.6 (5.4)<0.0015.1 (4.9)3.9 (4.2)Known duration of diabetes mellitus (years)†
<0.00157.3 (11.8)<0.00159.8 (11.5)60.3 (11.3)Age at diagnosis of diabetes mellitus (years)†
Sex‡
0.786195 (56.2)0.2327183 (55.9)20 346 (55.5)Male
152 (43.8)5659 (44.1)16 316 (44.5)Female
Treatment for diabetes mellitus‡
<0.00172 (20.7)<0.0013318 (26.0)13 918 (38.5)Diet
234 (67.2)8326 (64.4)20 723 (57.3)Oral hypoglycaemic agents
42 (12.1)1114 (8.6)1555 (4.3)Insulin
*Reference group. †Mean (standard deviation). ‡Number (%).
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e874 doi: 10.1136/bmj.e874 (Published 22 February 2012) Page 10 of 11
RESEARCH
Table 5| Parametric survival analysis with covariates in participants who developed diabetic retinopathy, according to grading category
Referable retinopathyBackground retinopathyAny retinopathy
Putative risk
factor
Adjusted hazard
ratio (95% CI)
Crude hazard ratio
(95% CI)
Adjusted hazard
ratio (95% CI)
Crude hazard ratio
(95% CI)
Adjusted hazard
ratio (95% CI)
Crude hazard ratio
(95% CI)
Known duration of diabetes mellitus
1.001.001.001.001.001.00<5 years
1.35 (1.05 to 1.73)1.54 (1.21 to 1.96)1.29 (1.23 to 1.34)1.39 (1.34 to 1.45)1.29 (1.23 to 1.34)1.39 (1.34 to 1.45)5-9 years
1.61 (1.19 to 2.19)1.99 (1.49 to 2.66)1.67 (1.58 to 1.76)1.82 (1.73 to 1.92)1.68 (1.59 to 1.77)1.92 (1.74 to 1.93)≥10 years
Age at diagnosis
1.001.001.001.001.001.0030-49 years
0.75 (0.57 to 0.99)0.71 (0.54 to 0.94)0.97 (0.92 to 1.02)0.94 (0.89 to 0.99)0.97 (0.92 to 1.02)0.93 (0.89 to 0.98)50-59 years
0.57 (0.42 to 0.77)0.50 (0.37 to 0.67)1.00 (0.95 to 1.06)0.91 (0.87 to 0.96)0.99 (0.94 to 1.05)0.90 (0.86 to 0.95)60-69 years
0.83 (0.60 to 1.16)0.64 (0.47 to 0.88)1.20 (1.13 to 1.27)0.98 (0.93 to 1.04)1.20 (1.13 to 1.27)0.98 (0.03 to 1.03)≥70 years
Treatment for diabetes mellitus
1.001.001.001.001.001.00Diet
1.61 (1.22 to 2.12)1.78 (1.36 to 2.32)1.42 (1.36 to 1.48)1.48 (1.43 to 1.55)1.41 (1.36 to 1.47)1.48 (1.43 to 1.55)Oral
hypoglycaemic
agents
2.60 (1.73 to 3.90)3.39 (2.32 to 4.97)2.03 (1.89 to 2.18)2.34 (2.19 to 2.51)2.03 (1.89 to 2.18)2.35 (2.19 to 2.51)Insulin
All factors were significant at P<0.001.
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Incidence of diabetic retinopathy in people with type2 diabetes mellitus attending the Diabetic RetinopathyScreening Service for Wales: retrospective analysis
In the online version of this paper (BMJ 2012;344:e874, doi:10.
1136/bmj.e874) by Rebecca L Thomas and colleagues, the last
sentence in the Results section should have been: “For
participants with a duration of diabetes of 10 years or more, the
use of insulin treatment increased cumulative incidence greatly
(without insulin treatment 2.24, 5.86, and 10.33 per 1000 people;
with insulin treatment 9.61, 17.10, and 24.26 per 1000 people).”
Cite this as: BMJ 2012;344:e2205
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Ethnic Differences in the Prevalence of
Diabetic Retinopathy in PersonsWith
DiabetesWhen First Presenting at a
Diabetes Clinic in South Africa
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OBJECTIVEdTo describe the prevalence and associated risk factors for diabetic retinopathy
(DR) within a multiethnic population at presentation to a diabetes clinic in South Africa.
RESEARCH DESIGN AND METHODSdRetinal photography was conducted using a
nonmydriatic digital camera without mydriasis and graded by one of three senior graders.
Logistic regression analyses were used to assess the association between any DR, referable DR,
and clinical risk factors.
RESULTSdA total of 1,537 persons with type 1 and 3,978 with type 2 diabetes were included.
Prevalence of any DR in type 1 diabetes was 35.2% (background DR 26% and referable DR 9.2%)
and in type 2 diabetes was 20.5% (14.1 and 6.4%, respectively). In type 1 diabetes, there was an
increased risk of any DR in Asian Indians, whereas the risk of referable DR was increased for
indigenous Africans compared with Caucasians. In type 2 diabetes, the risk was increased for all
non-Caucasians compared with Caucasians. Longer duration of diabetes and elevated HbA1c
were independently associated with any and referable DR in both type 1 and type 2 diabetes, with
the addition of hypertension and smoking in type 1 diabetes when adjusted for age at diagnosis of
diabetes, sex, and ethnicity.
CONCLUSIONSdThe prevalence of DR in this population from South Africa was similar to
that reported globally; however, ethnic differences were observed. Increasing duration of di-
abetes and poor glycemic control were the strongest risk factors associated with any and referable
DR in both type 1 and type 2 diabetes.
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S
outh Africa has an estimated pop-
ulation of ;50 million inhabitants,
the majority being indigenous Afri-
cans (79.5%) with a minority comprising
Caucasian (9%), mixed race (9%), and
Asian Indians (2.5%) (1). The health
care provider system in South Africa con-
sists of a large and under-resourced pub-
lic sector and a smaller, fast-growing
private health care sector. Health care var-
ies from the most basic primary health
care, which is provided free by the state
to ;80% of the population, to highly
specialized services available in the pri-
vate sector (2). It has been estimated
that the prevalence of diabetes in South
Africa is 5–10% of the population (3),
with only ;11% of those with diabetes
having their eyes routinely examined for
diabetic retinopathy (DR) (4).
There is some evidence to suggest that
the risk of DR and blindness in South
Africa can vary with ethnicity (5–8). This
in part may be due to increased preva-
lence and impact of additional putative
risk factors for DR or as yet unidentiﬁed
risk factors for DR. Recently, the global
prevalence of DR has been reported to
be 55.8% in African Americans, 46.7%
in Caucasians, and 20.9% in Asians (9).
To date, the reported prevalence of DR in
South Africa’s public sector has ranged
between 14 and 55% in indigenous Afri-
cans, 41% in Caucasians, and 22 and 37%
in Asian Indians with diabetes (10–12).
The aim of this study was to describe
the prevalence of DR within a deﬁned
population with diabetes attending, for
the ﬁrst time, a private diabetes clinic,
the Centre for Diabetes and Endocrinol-
ogy (CDE) in Johannesburg, South Africa,
and to identify the associated risk factors
as well as explore any ethnic variations in
the prevalence of DR. Prevalence ﬁgures
are essential in order to estimate current
and future burden of disease and beneﬁts
that may result from the implementation
of a DR-screening service.
RESEARCH DESIGN AND
METHODS
Setting
The CDE is a private multispecialist
center based in Johannesburg, South Af-
rica, established in 1994. It serves as the
principal center in a network of 262
smaller urban and rural centers providing
diabetes care services in underdeveloped
communities in South Africa. Details of
the diabetes management program of
the CDE have been described in detail
previously (13).
Methods
All persons with diabetes attending the
CDE undergo routine digital retinal pho-
tography performed at the time of their
ﬁrst visit and annually thereafter. Digital
retinal photography was conducted in a
darkened room using a nonmydriatic
digital camera (Canon CR6–45NM;
Canon) capturing one macular centered
image per eye without the use of mydriasis
by one of two trained technicians, one of
whom is a diabetes nurse educator. All
retinal images from the patient’s ﬁrst
c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c c
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screening event obtained from 2001–
2010 were independently reviewed and
graded by one of three senior retinal grad-
ers according to a modiﬁed U.K. standard
DR-grading protocol used by the DR
Screening Service for Wales (14). Levels
of DR were classiﬁed as no DR (NDR) if
no lesions were detected, any DR when at
least one microaneurysm and/or a blot
hemorrhage were detected, and referable
DR (RDR), which included preprolifer-
ative and proliferative lesions of DR as
well as exudative maculopathy. RDR is
the level at which further assessment by
an ophthalmologist is deemed necessary.
Subjects included in this analysis
were classiﬁed as having type 1 or type
2 diabetes on clinical assessment accord-
ing to the American Diabetes Association
classiﬁcation of diabetes (9). Those indi-
viduals who did not clinically clearly ﬁt
into this classiﬁcation were excluded
from the analysis.
At the time of initial presentation,
when the ﬁrst retinal photographs were
taken, blood was obtained for baseline
laboratory investigations including HbA1c,
lipid analyses, and serum creatinine, and
urine was collected for the assessment of
the microalbumin/creatinine ratio. This
initial HbA1c was regarded as the baseline
value and used in the analysis. The HbA1c
was initially analyzed as Diabetes Control
and Complications Trial (DCCT) percent
values and then converted to International
Federation of Clinical Chemistry and Lab-
oratory Medicine (IFCC) mmol/mol units
using the formula: [DCCTpercent22.15]3
10.929. Both DCCT and IFCC units are
dually reported throughout. Subjects
were considered to have hypertension if
their blood pressure was found to be
.140/90 mmHg taken in the right arm
seated after 5-min rest and/or if they
were already on antihypertensive therapy.
Other variables such as BMI were not
available for analysis in this study.
Statistical analysis was conducted us-
ing SPSS version 16 (SPSS) and the
population characteristics described us-
ing means and SDs for normally distrib-
uted and medians and interquartile
ranges (IQ) for nonnormally distributed
continuous variables and percentages for
categorical variables. Signiﬁcance testing
used: t tests and Mann-Whitney U tests
for continuous variables and x2 for cate-
gorical variables. Stepwise logistic regres-
sion analysis was used to assess the
association of clinical risk factors and
the presence of any DR and RDR for per-
sons with type 1 and type 2 diabetes
separately. Odds ratios (OR) and 95%
CI were calculated for each. The continu-
ous variables (HbA1c and duration of dia-
betes) were stratiﬁed to avoid assumptions
of linearity (i.e., for type 1 diabetes): HbA1c
,7.0 (,53), 7.0–7.9% (53–63), 8.0–
8.9% (64–74), and $9.0% ($75 mmol/
mol) and duration of diabetes ,7, 7–15,
and .15 years; and for type 2 diabetes:
HbA1c ,6.6 (,49), 6.6–7.4 (49–57),
7.5–8.9 (58–74) and $9.0% ($75
mmol/mol) and known duration of diabe-
tes,3, 3–8, and.8 years. Different strat-
iﬁcations were used in those with type 1
and type 2 diabetes for HbA1c and dura-
tion of diabetes to ensure an equal distri-
bution among the strata for both diabetes
types. Associations were considered sig-
niﬁcant if the P value was ,0.05.
RESULTSdA total of 5,565 subjects
were seen at the CDE in Johannesburg
during 2001 and 2010. The majority of
people had type 2 diabetes (71.5%), with
27.6% having type 1 diabetes. The remain-
ing 0.9% had other forms of diabetes
and were excluded from the analysis. The
baseline characteristics of the population
studied are listed in Table 1.
Type 1 diabetes
In persons with type 1 diabetes, those of
Caucasian origin had a longer duration of
diabetes (P , 0.001), were younger at di-
agnosis (P , 0.001), and had a lower
HbA1c at presentation (P , 0.001) com-
pared with the non-Caucasian population.
Among the non-Caucasians, indigenous
Africans had a shorter duration of diabetes
compared with those of mixed race (P =
0.026) and were older at diagnosis than
either the Asian Indians (P = 0.004) or
those of mixed race (P = 0.004) (Table 2).
There was no evidence of DR in 60.3%
(95% CI 57.8–62.7; n = 927), background
DR was detected in 26% (95% CI 23.8–
28.2; n = 399), and RDR in 9.2% (95% CI
7.9–10.8; n = 142). The RDR category
consisted of 1.2% (95% CI 0.7–1.8; n =
18) with preproliferative DR, 4.9% (95%
CI 3.9–6.1; n = 75) had exudative macu-
lopathy, 1.3% (95% CI 0.8–2.0; n = 20)
preproliferative DR with exudative mac-
ulopathy, 1.0% (95% CI 0.6–1.6; n = 15)
Table 1dBaseline* characteristics for persons with diabetes
Characteristics
Type 1 diabetes
(n = 1,537)
Type 2 diabetes
(n = 3,978)
All subjects
(n = 5,515)
Age (years) [mean (SD)] 35.4 (15.4) 56.8 (11.8) 50.8 (16.1)
Sex [n (%)]
Male 846 (55.0) 2,650 (66.6) 3,496 (63.4)
Female 690 (44.9) 1,326 (33.3) 2,016 (36.6)
Unknown 1 (0.1) 2 (0.1) 3 (0.1)
Ethnicity [n (%)]
Caucasian 1,247 (81.1) 2,662 (66.9) 3,909 (70.9)
Indigenous African 117 (7.6) 580 (14.6) 697 (12.6)
Asian 118 (7.7) 562 (14.1) 680 (12.3)
Mixed race 49 (3.2) 159 (4.0) 208 (3.8)
Unknown 6 (0.4) 15 (0.4) 21 (0.4)
Duration of DM (years) [median (IQ)] 11.0 (5.0–19.0) 5.0 (1.0–10.0) 6.0 (2.0–12.0)
Age at diagnosis DM (years) [mean (SD)] 22.3 (13.8) 50.1 (11.9) 42.3 (17.6)
HbA1c (%) [median (IQ)] 8.4 (7.3–9.8) 7.5 (6.6–8.9) 7.7 (6.8–9.2)
HbA1c (mmol/mol) [median (IQ)] 68 (56–84) 58 (49–74) 61 (51–77)
Total cholesterol (mmol/L) [mean (SD)] 5.1 (1.1) 5.0 (1.2) 5.0 (1.2)
Albumin/creatinine ratio [median (IQ)] 0.9 (0.4–2.1) 1.1 (0.5–3.6) 1.0 (0.5–3.0)
Other therapies [n (%)]
ACE 253 (16.5) 1,620 (40.7) 1,873 (34.0)
Aspirin 44 (2.9) 743 (18.7) 787 (14.3)
Hypertensive [n (%)] 287 (18.7) 2,141 (53.8) 2,428 (44.0)
Smoker [n (%)] 302 (19.6) 607 (15.3) 909 (16.5)
Retinopathy [n (%)]
Unassessable 69 (4.5) 194 (4.9) 263 (4.8)
NDR 927 (63.1) 2,968 (78.4) 3,895 (74.2)
Any DR 541 (36.9) 816 (21.4) 1,357 (25.8)
RDR 142 (9.7) 255 (6.6) 397 (7.5)
*At presentation to CDE.
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proliferative DR, and 0.9% (95% CI 0.5–
1.5; n = 14) proliferative DR with exuda-
tive maculopathy. There were 4.5% (95%
CI 3.6–5.6; n = 69) unassessable images
mainly due to the presence of lens opaci-
ﬁcation.
Thosewho presented with any or RDR
comparedwith those withNDRwere older
[mean (SD)]: 38.0 (13.6) and 38.6 (12.2)
years versus 32.9 (15.6) years, respectively
(P, 0.001); and were younger at diagno-
sis of diabetes: 19.6 (11.8) and 19.0 (11.4)
years versus 23.5 (14.4) years, respectively
(P, 0.001), with a longer duration of di-
abetes [median (IQ)]: 17.0 (12.0–23.0)
and 18.0 (14.0–25.0) years versus 6.0
(3.0–12.0) years, respectively (P , 0.001).
Those presenting with any or referable lev-
els of DR compared with those without DR
also had a higher HbA1c level: 8.5 (7.6–
9.9)% (69 [60–85] mmol/mol]), 8.7 (7.8–
10.2)% (72 [62–88] mmol/mol) versus 8.3
(7.1–9.7)% (67 [54–83] mol/mol), respec-
tively (any DR vs. NDR, P = 0.033; RDR vs.
NDR, P = 0.013) and had a higher preva-
lence of hypertension (25.1 and 35.9%
RDR versus 12.1%, respectively; P ,
0.001). There were also more cigarette
smokers with any DR or RDR compared
with thosewithoutDR (22.9 and22.5%ver-
sus 17.6%, respectively; P = 0.013). (Only
one P value is shown in the text, as the P
value is similar for the comparison between
any DR versus NDR and RDR versus NDR.)
In logistic regression analyses, the
presence of any DR and RDR was signif-
icantly associated with ethnicity (Table 3).
Asian Indians were at an increased risk of
any DR (OR 1.78) when compared with
Caucasians and adjusted for age at diagno-
sis, sex, duration of diabetes, HbA1c, hy-
pertension, and smoking status. In
comparison, indigenous Africans had an
increased risk of RDR (OR 3.36). There
was no signiﬁcant difference for any DR
or RDR comparing those of mixed race
with Caucasians. Other risk factors inde-
pendently associated with any DR (Table
3) were a longer duration of diabetes (OR
10.28, 7–15 years; 37.31, .15 years; ref-
erence group ,7 years), an increased
HbA1c (OR 1.32, ,7.0% [,53 mmol/
mol]; 2.15, 8.0–8.9% [64–74 mmol/mol];
and 3.20,$9.0% [$75 mmol/mol]; refer-
ence group.7.0% [.53 mmol/mol]), the
presence of hypertension (OR 1.44), and
the habit of smoking (OR 1.78). The pres-
ence of RDR was also signiﬁcantly associ-
ated with duration of diabetes, HbA1c,
hypertension, and smoking. There was a
weak but signiﬁcant association between
albumin/creatinine ratio and any DR and
RDR in univariate analysis; however, these
data were missing for many of the persons
with diabetes and were therefore removed
from the stepwise multivariate analyses.
Type 2 diabetes
Caucasian subjects with type 2 diabetes
were older at baseline and at the time of
diagnosis (P , 0.001) and had a lower
HbA1c (P , 0.001) than non-Caucasians
(Table 2). The known duration of diabe-
tes was similar across all ethnicities. There
were differences in sex distribution, with
more males of Caucasian ethnicity com-
pared with non-Caucasians (P = 0.008)
and more females of mixed race compared
Table 2dBaseline* characteristics for the different ethnic groups for persons with type 1 and type 2 diabetes
Caucasian Non-Caucasians P value†
Indigenous
African Asian Mixed race P value‡
Type 1 diabetes
n 1,247 284 117 118 49
Age (years) [mean (SD)] 35.7 (15.6) 34.0 (14.5) 0.075 36.3 (16.1) 32.2 (12.1) 32.6 (15.2) 0.069
Sex [n (%)] 0.570 0.253
Male 690 (55.3) 152 (53.5) 66 (56.4) 65 (55.1) 21 (42.9)
Female 556 (44.6) 132 (46.5) 51 (43.6) 53 (44.9) 28 (57.1)
Unknown 1 (0.1) 0 0 0 0
Duration of DM (years)
[median (IQ)] 12.0 (6.0–20.0) 7.0 (3.0–13.0) ,0.001 5.0 (3.0–11.5) 8.0 (3.0–15.0) 8.0 (5.0–14.5) 0.070
Age at diagnosis (years)
[mean (SD)] 21.6 (13.6) 25.0 (14.2) ,0.001 28.5 (15.5) 22.7 (11.8) 22.7 (14.6) 0.003
HbA1c (%) [median (IQ)] 8.2 (7.3–9.6) 9.0 (7.7–11.2) ,0.001 9.5 (7.8–11.3) 8.7 (7.6 to 10.9) 9.0 (7.3–11.4) 0.272
HbA1c (mmol/mol)
[median (IQ)] 66 (56–81) 75 (61–99) ,0.001 80 (62–100) 72 (60–96) 75 (56–101) 0.272
Type 2 diabetes
n 2,662 1,296 580 562 159
Age (years) [mean (SD)] 59.7 (11.1) 50.9 (10.9) ,0.001 51.7 (10.0) 50.5 (11.8) 49.5 (10.7) 0.037
Sex [n (%)] 0.008 0.013
Male 1,810 (68.0) 829 (63.7) 382 (65.9) 362 (64.4) 85 (53.5)
Female 851 (32.0) 471 (36.2) 197 (34.0) 200 (35.6) 74 (46.5)
Unknown 1 (0.0) 1 (0.1) 1 (0.2) 0 0
Duration of DM (years)
[median (IQ)] 5.0 (1.0–10.0) 5.0 (2.0–10.0) 0.073 5.0 (2.0–10.0) 5.0 (1.0–10.0) 4.0 (1.0–10.0) 0.173
Age at diagnosis (years)
[mean (SD)] 53.0 (11.4) 44.0 (10.7) ,0.001 44.6 (9.8) 43.5 (11.5) 43.7 (10.3) 0.199
HbA1c (%) [median (IQ)] 7.3 (6.5–8.4) 8.1 (6.9–10.0) ,0.001 8.3 (7.0–10.5) 7.9 (6.9–9.4) 8.1 (7.0–10.0) 0.003
HbA1c (mmol/mol)
[median (IQ)] 56 (48–68) 65 (52–86) ,0.001 67 (53–91) 63(52–79) 65 (53–86) 0.003
*At presentation to CDE. †P value differences between Caucasians and non-Caucasians. ‡P value for differences across the non-Caucasian groups. DM, diabetes.
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with indigenous Africans and Asian Indi-
ans (P , 0.013). There was also a differ-
ence in age and HbA1c levels between
those of non-Caucasian ethnicity with
those indigenous Africans who were older
(P = 0.037) and with higher HbA1c levels
(P = 0.003) compared with Asian Indians
and mixed races (Table 2).
In the entire cohort of subjects with
type 2 diabetes, the prevalence of any DR
was 20.5% (95%CI 19.3–21.8), withNDR
detected in 74.6% (95% CI 73.2–75.9;
n = 2,968). The majority of DR seen was
background DR: 14.1% (95% CI 13.1–
15.2; n = 561), with 6.4% (95% CI 5.7–7.2;
n = 255) having RDR. The category of
RDR consisted of 0.7% (95% CI 0.5–1.0;
n = 28) preproliferative DR, 3.5% (95% CI
3.0–4.2, n = 141) exudative maculopathy,
1.4% (95% CI 1.0–1.8; n = 54) preprolif-
erative DR with exudative maculopathy,
0.2% (95% CI 0.1–0.4; n = 8) proliferative
DR, and 0.6% (95% CI 0.4–0.9; n = 24)
proliferative DR with exudative macu-
lopathy. There was a similar proportion
with unassessable images (4.8%; 95% CI
4.3–5.6) with type 2 diabetes as seen in the
subjects with type 1 diabetes.
Those presenting with any or RDR
compared with those without DR were
younger at diagnosis of diabetes (mean
[SD]) (45.8 [11.4] years for any DR or
43.9 [10.2] years RDR vs. 51.1 [11.7]
years NDR; P , 0.001), had a longer
known duration of diabetes (median
[IQ]) (10.0 [6.0–16.0] years for any DR
or 12.0 [8.0–17.0] years RDR vs. 3.0
[1.0–7.0] years NDR; P , 0.001), and
had a higher HbA1c level (8.2 [7.1–9.7]%;
66 [54–83] mmol/mol for any DR; or 8.7
[7.6–8.7]%; 72 [60–72] mmol/mol RDR
vs. 7.3 [6.5–8.6]%; 56 [48–70] NDR; P ,
0.001). There was also a higher propor-
tion of persons with hypertension (59.2%
any DR or 62.4% RDR vs. 51.9% NDR;
Table 3dMultivariate logistic regression analysis of independent risk factors for any and RDR in persons with type 1 and type 2
diabetes (adjusted for age at diagnosis of diabetes and sex)
Any DR (n = 541) RDR (n = 142)
Crude OR (95% CI) Adjusted OR (95% CI) Crude OR (95% CI) Adjusted OR (95% CI)
Type 1 diabetes
Ethnicity (n)
Caucasian (1,247) 1.00 1.00 1.00 1.00
Indigenous African (117) 0.71 (0.46–1.09) 1.72 (1.00–2.97) 0.95 (0.49–1.84) 3.40 (1.40–8.26)
Asian (118) 1.10 (0.74–1.63) 2.02 (1.23–3.29) 1.05 (0.54–2.04) 2.07 (0.90–4.75)
Mixed race (49) 1.01 (0.56–1.84) 1.29 (0.62–2.69) 1.10 (0.42–2.88) 1.06 (0.36–3.18)
Duration of DM (years) (n)
,7 (505) 1.00 1.00 1.00 1.00
7–15 (515) 8.89 (6.01–13.15) 10.28 (6.75–15.65) 16.19 (5.75–45.60) 20.08 (6.81–59.18)
.15 (517) 26.20 (17.62–38.95) 37.31 (23.57–59.07) 68.74 (24.89–189.88) 116.06 (38.00–354.43)
HbA1c (%) (n)
,7.0a (310) 1.00 1.00 1.00 1.00
7.0–7.9b (342) 1.78 (1.26–2.52) 1.32 (0.88–1.97) 1.15 (0.62–2.12) 0.95 (0.47–1.89)
8.0–8.9c (322) 2.15 (1.52–3.04) 2.15 (1.43–3.25) 1.79 (1.01–3.19) 1.99 (1.02–3.90)
$9.0d (563) 2.05 (1.50–2.81) 3.20 (2.17–4.71) 2.06 (1.23–3.44) 4.07 (2.18–7.62)
Albumin/creatinine ratio (n = 647) 1.06 (1.03–1.09) 1.08 (1.04–1.01)
Hypertension (n = 302) 2.44 (1.85–3.22) 1.44 (1.02–2.03) 4.08 (2.75–6.06) 2.41 (1.47–3.96)
Smoking (n = 287) 1.39 (1.07–1.81) 1.78 (1.28–2.47) 1.36 (0.89–2.09) 2.15 (1.27–3.65)
Any DR (n = 816) RDR (n = 255)
Type 2 diabetes
Ethnicity (n)
Caucasian (2,662) 1.00 1.00 1.00 1.00
Indigenous African (580) 2.00 (1.62–2.48) 1.79 (1.40–2.30) 3.69 (2.71–5.02) 3.08 (2.14–4.43)
Asian (562) 1.83 (1.48–2.26) 1.59 (1.24–2.04) 1.93 (1.34–2.80) 1.57 (1.04–2.39)
Mixed race (159) 2.66 (1.88–3.76) 2.69 (1.80–4.02) 3.52 (2.08–5.95) 3.27 (1.78–6.04)
Known duration of DM (years) (n)
,3 (1,391) 1.00 1.00 1.00 1.00
3–8 (1,360) 2.61 (2.02–3.36) 2.33 (1.80–3.03) 2.36 (1.41–3.95) 2.05 (1.21–3.46)
.8 (1,224) 11.24 (8.8–14.28) 9.59 (7.46–12.32) 18.03 (11.47–28.34) 14.98 (9.37–23.95)
HbA1c (%) (n)
,6.5e (966) 1.00 1.00 1.00 1.00
6.5–7.4f (1,097) 1.61 (1.25–2.09) 1.32 (1.00–1.75) 1.75 (1.05–2.94) 1.46 (0.85–2.51)
7.5–8.9g (1,008) 2.77 (2.16–3.55) 1.84 (1.40–2.41) 3.84 (2.38–6.18) 2.43 (1.47–4.03)
$9.0h (97) 3.86 (3.01–4.95) 2.25 (1.71–2.96) 6.93 (4.37–10.99) 3.68 (2.25–6.03)
Albumin/creatinine ratio (n = 1,483) 1.03 (1.02–1.05) 1.04 (1.02–1.05)
Hypertension (n = 607) 1.35 (1.15–1.57) 1.54 (1.18–2.00)
Smoking (n = 2,141) 0.98 (0.79–1.21) 0.75 (0.51–1.10)
a
,53 mmol/mol. b53–66 mmol/mol. c64–74 mmol/mol. d$75 mmol/mol. e,48 mmol/mol. f48–57 mmol/mol. g58–74 mmol/mol. h75 mmol/mol. DM, diabetes.
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P, 0.001). There was a (P, 0.001) lower
proportion ofCaucasians than all other eth-
nic groups in those with any or RDR (16.8
and 4.4% Caucasians, 27.2 and 13.1% in-
digenous Africans, 27.0 and 7.5%Asian In-
dians, and 34.6 and 11.9% mixed race,
respectively) compared with those without
DR (78.9% Caucasian, 63.8% indigenous
Africans, 69.4% Asian Indians, and 61.0%
mixed race; Fig. 1). (Only one P value is
shown in the text, as the P value is similar
for the comparison between any DR versus
NDR and RDR versus NDR.)
When compared with the Caucasian
population, non-Caucasians had an in-
creased risk of any DR (indigenous Afri-
cans 1.90, Asian 1.74, and mixed race
2.95) when adjusted for age at diagnosis of
diabetes, sex, known duration of diabetes,
and HbA1c (Table 3). Other risk factors in-
dependently associated with any DR
included a longer known duration of dia-
betes (OR 2.33, 3–8 years; 9.59,.8 years;
reference group,3 years) and an increased
HbA1c (OR 1.32 6.6–7.4% [49–57 mmol/
mol]; 1.84, 7.5–8.9% [58–74 mmol/mol];
and 2.25,$9.0% [$75 mmol/mol]; refer-
ence group,6.6% [49 mmol/mol]). Non-
Caucasian ethnicity increased known
duration of diabetes and increased HbA1c
were also associated with RDR. Smoking
was not associated with an increased risk
of any DR or RDR. Although hypertension
was associated with any DR and RDR in
univariate analysis, it was not included in
the results of stepwise multivariate analy-
ses. Although there was a weak signiﬁcant
association between albumin/creatinine ra-
tio and any DR and RDR in univariate anal-
ysis, these data were missing for the
majority of patients and therefore removed
from the stepwise analysis.
CONCLUSIONSdIn a large cohort of
persons with type 1 and type 2 diabetes
undergoing retinal photography when
ﬁrst presenting at the CDE, the overall
prevalence of DR and RDR at the time of
the ﬁrst visit was 24.6 and 7.2%, respec-
tively. The prevalence of anyDRwas lower
than in the recent survey of the global
prevalence of any DR of 34.6% (9). This is
the ﬁrst study to be conducted in the pri-
vately funded sector in South Africa,
which may account for this difference.
Ethnic differences in the prevalence
and associations with the presence of any
DR (5,7,8) and also severe/referable stages
of DR (6,7) have previously been reported
to be higher in non-Caucasian persons
when compared with Caucasians or Euro-
peans. Only two previous studies, in rel-
ative numbers of persons with diabetes,
have examined differences between eth-
nic groups in South Africa (4,10). One
study did not report any signiﬁcant asso-
ciations between ethnicity and DR (4),
and the other found that those of an Afri-
can and Indian origin had a signiﬁcantly
higher prevalence of severe DR than Euro-
peans (10). In contrast, we observed clear
differences in the risk of DR between the
ethnic groups studied. Although the risk
of any DR was increased in Asian Indians,
RDR was increased for indigenous Afri-
cans with type 1 diabetes when compared
with Caucasians, and the risk of both any
DR and RDR was increased for all non-
Caucasian populations compared with
Caucasians with type 2 diabetes. These
differences remained after correction for
other risk factors, which include the fact
that those of African and mixed-race ori-
gin had higher HbA1c levels at baseline
and type 2 diabetes starting at a younger
age than in the non-Caucasian popula-
tion. Kalk et al. (10) also reported a higher
prevalence of microalbuminuria in pa-
tients of indigenous African decent
when compared with a Caucasian popu-
lation. This suggests that ethnic differen-
ces exist in the propensity to develop
microvascular complications such as DR.
Our study demonstrated that the pres-
ence of any DR and RDR were strongly
associated with increasing duration of di-
abetes and a higher HbA1c level in persons
with both type 1 and type 2 diabetes, thus
conﬁrming earlier epidemiological studies
(15,16). Previous epidemiological studies
and clinical trials also indicate that hyper-
tension is an important modiﬁable risk
factor for DR (17–19). In this study how-
ever, hypertension was shown to be a sig-
niﬁcant risk factor only in persons with
type 1 diabetes. A reason for the lack of
an association for persons with type 2 di-
abetes may be due to the more aggressiveFigure 1dFrequency of DR by ethnic groups in persons with type 1 (A) and type 2 (B) diabetes.
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treatment of hypertension and lower
blood pressure targets in this patient
group. The importance of smoking as a
risk factor for DR is inconclusive, with
some studies showing either an associa-
tion (20–23) or even suggesting that
smoking may be protective against the de-
velopment of DR (24). In our study, smok-
ing had a clear association with the
development of referable retinopathy in
patientswith type 1 diabetes, but not those
with type 2 diabetes.
Compared with previous population-
based studies in Africa and South Africa,
the strength of this study was the larger
sample size and that all the data (i.e., retinal
images and the putative risk factors) were
derived from a single center (CDE). How-
ever, as most of the population in South
Africa with diabetes uses the public health
system, the population studied in this
paper may not therefore be representative
of this majority. Although the use of stan-
dardized digital retinal photography and
grading protocol are strengths within this
study, the lack of dilation may have led to a
higher proportion of ungradeable images,
and the availability of only one 458 ﬁeld per
eye may have resulted in underreporting
of DR.
Long-term follow-up of the majority
of the participants in this study, involving
intensive diabetes and risk factor man-
agement, is underway at the CDE. This
will allow assessment of the incidence of
both newly developing DR and the pro-
gression of DR in this cohort of subjects
with both type 1 and type 2 diabetes and
will be the subject of a future report.
In this large population sample of
individuals with diabetes entering a diabe-
tes management program, there was a low
prevalence of DR. Ethnicity was indepen-
dently associated with the presence of DR
andRDR inboth type 1 and type 2diabetes.
Increasing duration of diabetes and poor
glycemic control were the strongest risk
factors associated with the presence of any
and RDR in persons with both type 1 and
type 2 diabetes. In type 1 diabetes, hyper-
tension and smoking were additional risk
factors for the presence of any and RDR.
AcknowledgmentsdNo potential conﬂicts of
interest relevant to this article were reported.
R.L.T., L.D., S.D.L., S.R.C., V.J.M., B.K.,
and D.R.O. contributed to the writing of this
article and approved the ﬁnal version of the
manuscript. R.L.T. processed and analyzed
data. L.D. was the lead for this study with the
support of B.K. and D.R.O. L.D., S.D.L., B.K.,
and D.R.O. contributed to the concept, study
design, and interpretation of data. S.R.C.
contributed to the processing of data. V.J.M.
collated all data. D.R.O. is the guarantor of this
work and, as such, had full access to all the
data in the study and takes responsibility for
the integrity of the data and the accuracy of the
data analysis.
Parts of this studywere presented in abstract
form at the 71st Scientiﬁc Sessions of the
American Diabetes Association, San Diego,
California, 24–28 June 2011.
References
1. U.S. Department of State. Background note:
SouthAfrica [Internet]. Available fromhttp://
www.state.gov/r/pa/ei/bgn/2898.htm.
Accessed 25 November 2011
2. SouthAfrica.info. Health care in South
Africa [Internet]. Available from http://
www.southafrica.info/about/health/
health.htm. Accessed 25 November 2011
3. Levy J, Jotkowitz AB. Diabetes in Africa:
screening for diabetic retinopathy. Eur J
Intern Med 2010;21:145–146
4. Read O, Cook C. Retinopathy in diabetic
patients evaluated at a primary care clinic
in Cape Town. S Afr Med J 2007;97:941–
942, 944
5. Raymond NT, Varadhan L, Reynold DR,
et al.; UK Asian Diabetes Study Retinop-
athy Study Group. Higher prevalence of
retinopathy in diabetic patients of South
Asian ethnicity compared with white Eu-
ropeans in the community: a cross-sectional
study. Diabetes Care 2009;32:410–415
6. Ross SA, McKenna A, Mozejko S, Fick
GH. Diabetic retinopathy in native and
nonnative Canadians. Exp Diab Res 2007;
2007:76271
7. StolkRP, van SchooneveldMJ,Cruickshank
JK, et al.; AdRem Project Team and
ADVANCE Management Committee. Reti-
nal vascular lesions in patients of Caucasian
and Asian origin with type 2 diabetes: base-
line results from the ADVANCE Retinal
Measurements (AdRem) study. Diabetes
Care 2008;31:708–713
8. West KM, Ahuja MM, Bennett PH, et al.
Interrelationships of microangiopathy,
plasma glucose and other risk factors in
3583 diabetic patients: a multinational
study. Diabetologia 1982;22:412–420
9. American Diabetes Association. Standards
of medical care in diabetesd2010. Di-
abetes Care 2010;33(Suppl. 1):S11–S61
10. Kalk WJ, Joannou J, Ntsepo S, Mahomed
I, Mahanlal P, Becker PJ. Ethnic differ-
ences in the clinical and laboratory asso-
ciations with retinopathy in adult onset
diabetes: studies in patients of African,
European and Indian origins. J InternMed
1997;241:31–37
11. Carmichael TR, Carp GI, Welsh ND, Kalk
WJ. Effective and accurate screening for
diabetic retinopathy using a 60 degree
mydriatic fundus camera. S Afr Med J
2005;95:57–61
12. Levitt NS, Bradshaw D, Zwarenstein MF,
Bawa AA, Maphumolo S. Audit of public
sector primary diabetes care in Cape Town,
South Africa: high prevalence of complica-
tions, uncontrolled hyperglycaemia, and hy-
pertension. DiabetMed 1997;14:1073–1077
13. Distiller LA, Brown MA, Joffe BI, Kramer
BD. Striving for the impossible dream:
a community-based multi-practice col-
laborativemodel of diabetes management.
Diabet Med 2010;27:197–202
14. Zheng B, Li T, Chen H, Xu X, Zheng Z.
Correlation between ﬁcolin-3 and vascu-
lar endothelial growth factor-to-pigment
epithelium-derived factor ratio in the vit-
reous of eyes with proliferative diabetic
retinopathy. Am J Ophthalmol 2011;152:
1039–1043
15. Klein R, Klein BE, Moss SE, Davis MD,
DeMets DL. The Wisconsin Epidemiologic
Study of Diabetic Retinopathy. III. Preva-
lence and risk of diabetic retinopathy when
age at diagnosis is 30 or more years. Arch
Ophthalmol 1984;102:527–532
16. Klein R, Klein BE, Moss SE, Davis MD,
DeMets DL. TheWisconsin epidemiologic
study of diabetic retinopathy. II. Preva-
lence and risk of diabetic retinopathy
when age at diagnosis is less than 30 years.
Arch Ophthalmol 1984;102:520–526
17. Mohamed Q, Gillies MC, Wong TY.
Management of diabetic retinopathy:
a systematic review. JAMA 2007;298:
902–916
18. Klein R, Knudtson MD, Lee KE, Gangnon
R, Klein BE. The Wisconsin Epidemio-
logic Study of Diabetic Retinopathy: XXII
the twenty-ﬁve-year progression of reti-
nopathy in persons with type 1 diabetes.
Ophthalmology 2008;115:1859–1868
19. Gallego PH, Craig ME, Hing S, Donaghue
KC. Role of blood pressure in development
of early retinopathy in adolescents with
type 1 diabetes: prospective cohort study.
BMJ 2008;337:a918
20. UKPDS group. UK Prospective Diabetes
Study 6. Complications in newly di-
agnosed type 2 diabetic patients and their
association with different clinical and
biochemical risk factors. Diabetes Res
1990;13:1–11
21. Anonymous. Cigarette smoking and di-
abetic retinopathy. Lancet 1977;1:841–842
22. Klein R, Klein BE, Davis MD. Is cigarette
smoking associated with diabetic reti-
nopathy? Am J Epidemiol 1983;118:
228–238
23. Kohner EM, Aldington SJ, Stratton IM,
et al. United Kingdom Prospective Di-
abetes Study, 30: diabetic retinopathy at
diagnosis of non-insulin-dependent di-
abetes mellitus and associated risk factors.
Arch Ophthalmol 1998;116:297–303
24. Stratton IM, Kohner EM, Aldington SJ,
et al. UKPDS 50: risk factors for incidence
and progression of retinopathy in type II
diabetes over 6 years from diagnosis. Di-
abetologia 2001;44:156–163
care.diabetesjournals.org DIABETES CARE, VOLUME 36, FEBRUARY 2013 341
Thomas and Associates
Prevalence of diabetic retinopathy within a national
diabetic retinopathy screening service
Rebecca L Thomas,1 Frank D Dunstan,2 Stephen D Luzio,1
Sharmistha Roy Chowdhury,3 Rachel V North,4 Sarah L Hale,5 Robert L Gibbins,6
David R Owens1
▸ Additional material is
published online only. To view
please visit the journal online
(http://dx.doi.org/10.1136/
bjophthalmol-2013-304017).
For numbered afﬁliations see
end of article.
Correspondence to
Prof David R Owens, Diabetes
Research Group, Institute of
Life Sciences, College of
Medicine, Swansea University,
Singleton Park, Swansea,
SA2 8PP, UK;
owensdr@cardiff.ac.uk
Received 16 July 2013
Revised 21 November 2013
Accepted 8 July 2014
To cite: Thomas RL,
Dunstan FD, Luzio SD, et al.
Br J Ophthalmol Published
Online First: [please include
Day Month Year]
doi:10.1136/bjophthalmol-
2013-304017
ABSTRACT
Aims Determine the prevalence and severity of diabetic
retinopathy (DR) and risk factors in a large community
based screening programme, in order to accurately
estimate the future burden of this speciﬁc and
debilitating complication of diabetes.
Methods A cross-sectional analysis of 91 393 persons
with diabetes, 5003 type 1 diabetes and 86 390 type 2
diabetes, at their ﬁrst screening by the community based
National Diabetic Retinopathy Screening Service for
Wales from 2005 to 2009. Image capture used 2×45°
digital images per eye following mydriasis, classiﬁed by
qualiﬁed retinal graders with ﬁnal grading based on the
worst eye.
Results The prevalence of any DR and sight-
threatening DR in those with type 1 diabetes was
56.0% and 11.2%, respectively, and in type 2 diabetes
was 30.3% and 2.9%, respectively. The presence of DR,
non-sight-threatening and sight-threatening, was
strongly associated with increasing duration of diabetes
for either type 1 or type 2 diabetes and also associated
with insulin therapy in those with type 2 diabetes.
Conclusions Prevalence of DR within the largest
reported community-based, quality assured, DR screening
programme, was higher in persons with type 1 diabetes;
however, the major burden is represented by type 2
diabetes which is 94% of the screened population.
INTRODUCTION
Diabetic retinopathy (DR) continues to be an
important microvascular complication in type 1
and type 2 diabetes. Previous evidence suggests that
DR is evident in approximately 50% of persons
with type 1 diabetes for 28 years and advanced DR
after 39 years.1 In contrast about 12–19%,2 3 of
persons with type 2 diabetes have some DR already
at the time of diagnosis,4 with 4% developing pro-
liferative DR after 20 years or more of diabetes.2 In
the UK and USA, DR unfortunately remains among
the leading causes of blindness and low vision,
along with age related macular degeneration and
glaucoma.5–8
The St Vincent Declaration (1989) recommended
that new onset blindness arising from DR should
be reduced by a third within 5 years.9 However, it
is only in the last decade that signiﬁcant progress
has been made in implementing screening pro-
grammes to detect and monitor DR. To date many
different DR screening models have been intro-
duced worldwide.10–19 In the UK the National
Screening Committee for England and Wales
(1999) produced guidelines for DR screening
programmes to ensure standardisation and quality
assurance. The recommended screening procedure
includes assessment of visual acuity and obtaining
digital fundal photographs following mydriasis,20
in persons aged 12 years and older.21 The recom-
mendation of screening beginning from the age of
12 years reﬂects the low incidence of DR, and espe-
cially proliferative DR, in younger children.22 In
Scotland a three tiered screening approach has been
implemented which involves obtaining only one
macular centred digital fundal photograph per eye
without mydriasis (tier 1) and if unsuccessful then
mydriasis is used (tier 2) and ﬁnally biomicroscopy
with a slit lamp if photography remains unsuccess-
ful (tier 3).23
Wales currently has a population of 3.06 million
which is predominantly Caucasian, with the major-
ity situated in the industrial south (∼60%) with the
remainder of the country generally regarded as
rural.24 The prevalence of diabetes in Wales is cur-
rently estimated at approximately 5%, with
160 000 people affected.25 Following a pilot
regional programme,26 a national DR screening
programme, the Diabetic Retinopathy Screening
Service for Wales (DRSSW) was commissioned in
2002. The aim of the service was initially to iden-
tify all undiagnosed sight-threatening DR and facili-
tate timely onwards referral to hospital eye services
(HES). The secondary aim was to identify the pres-
ence of any DR so that improvements in glycaemic
control, hypertension and dyslipidaemia could be
implemented where necessary.20
The prevalence of DR has previously been
described for several populations,8 27 using differ-
ent methods for the detection and classiﬁcation of
DR which accounts in part for the broad variations
observed. A recent systematic review,27 conducted
an individual participant analysis to estimate the
global prevalence of DR and also to determine the
major risk factors by pooling a total 35 studies
(22 896 people) conducted between 1980 and
2008 in the USA, Australia, Europe and Asia. The
studies obtained retinal photographs using a
mixture of 35 mm ﬁlm and digital images, through
dilated and undilated pupils capturing between one
and nine ﬁelds per eye with a minority photograph-
ing one eye only. There were also several different
grading protocols used to ascertain the prevalence
and severity of DR.
The objective of our study was to accurately
determine the prevalence of DR at entry into a
national screening programme using standardised
protocols and quality-assured methodology for
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photography and grading and also to explore the relationship
between certain putative risk factors with the presence of any
lesions of DR and also the presence of sight-threatening DR in
persons with type 1 and type 2 diabetes.
MATERIALS AND METHODS
DRSSW is a community-based mobile screening service.
Habitual Visual acuity (VA) is recorded (with or without glasses
or with pinhole) using a 3 m illuminated Snellen chart and two
45° ﬁelds (one macula centred and one nasal) digital fundal
photographs are captured following mydriasis (1% tropicamide)
followed by grading by accredited retinal graders. Images are
stored on laptop computers and then downloaded daily onto a
central server, either directly or via a secure internet connection.
DRSSW employs 30 photographic teams consisting of a health-
care professional and an accredited photographer who conduct
the screening at 220 locations throughout Wales. The Canon
DGi digital camera is used to acquire the digital images which
are centrally graded using a standardised grading protocol
(table 1). All the key elements are subject to quality control pro-
cedures. At the time of screening all persons are asked to sign a
two part consent form. The ﬁrst part is to give consent for
mydriasis to be instilled and for retinal photographs to be taken.
The second part is for consent for their anonymised data and
images to be used for teaching and research purposes. Only the
data for those individuals who provided both consents were
included in this study.
Persons with diabetes aged 12 years or above who are regis-
tered with a general practitioner (GP) in Wales and not already
under the care of HES for DR related reasons, are required to
be referred to DRSSW accompanied by demographic and diag-
nostic information. These referrals from GP’s form the single
collated list of persons for screening. On a monthly basis the
lists are compiled and sent to each GP practice for validation.
Of those known to have diabetes in Wales 8.4% were ineligible
for screening as 6.5% were already under the care of HES for
DR related reasons, 1.6% were excluded due to medical reasons
and 0.4% were under the age of 12 years (19.3% of those who
were eligible for screening did not attend appointments). All
persons invited for screening are sent an appointment letter
with a date, time and venue for screening. All letters have a
reminder that all appointments and venues can be changed to a
time and place more suitable for the individual. DRSSW cur-
rently (2013) has an uptake rate of 80% for screening. Those
who do not attend screening appointments are sent additional
appointments within 3 months and their GPs are informed of
their non-attendance and are asked to remind their patients of
the importance of attending screening.
DRSSW uses a grading protocol which evolved from the
European handbook for screening9 and all subsequent changes
were made by consensus with ophthalmologists across Wales as
part of the All Wales Ophthalmology group who provide advice
and guidance to DRSSW on DR and referrals to HES. Subjects
with DR were subdivided into two groups: non-sight-
threatening DR (NSTDR) which included those with background
DR and preproliferative DR (PPDR); and sight-threatening DR
(STDR), that is, maculopathy and/or proliferative DR (table 1).
As retinal thickening or clinically signiﬁcant macular oedema is
not discernible on non-stereoscopic images, maculopathy was
deﬁned as deﬁnite exudates or haemorrhages (with an unex-
plained VA of worse than 6/12) within one disc diameter of the
fovea. Both eyes were assessed for DR and the worse grade from
the two eyes used in the analysis. All persons with unassessable
images in one or both eyes that had not previously been seen by
an ophthalmologist were referred to HES for assessment. Where
only one eye was assessable the presence or absence of DR relied
on this eye as was the grading of DR if present. The National
Screening Committee deﬁnition of unassessable images is used by
DRSSW.30
Characteristics of the study population were described using
means (SD) for continuous variables with percentages for cat-
egorical variables. For comparisons, T tests and χ2 tests were
used, respectively, with a p value of <0.05 used to indicate stat-
istical signiﬁcance. Logistic regression analyses were performed
to assess the association of the routinely collected variables with
retinopathy status, separately for each type of diabetes. The con-
tinuous variables of age at diagnosis of diabetes and duration of
diabetes were categorised to avoid assuming linearity, with dif-
ferent categories used for type 1 and type 2 diabetes to ensure
equal distribution among the groups. For type 1 diabetes, age at
diagnosis was divided into subgroups ≤12 yrs, 13–23 yrs and
≥24 yrs and diabetes duration into subgroups <10 yrs, 10–19
yrs and ≥20 years. For type 2 diabetes the subgroups for age at
diagnosis were ≤55 yrs, 56–66 yrs and ≥67 yrs and for diabetes
duration were <5 years, 5–9 years and ≥10 years, respectively.
OR and 95% CI for each were calculated.
RESULTS
From January 2005 to November 2009, 91 393 persons with
type 1 or type 2 diabetes were screened by DRSSW. The demo-
graphic characteristics of the participants are included in
table 2. The overall prevalence of any DR within this popula-
tion was 32.4% (95% CI 32.1% to 32.7%), NSTDR 29.0%
(95% CI 28.7% to 29.3%) and STDR 3.4% (95% CI 3.3% to
3.5%). The prevalence of any DR was 56.3% in persons with
type 1 diabetes and 30.9% in persons with type 2 diabetes.
NSTDR prevalence was 45.1% in type 1 diabetes and 28.1% in
type 2 diabetes. For STDR the prevalence in type 1 diabetes was
11.2% and in type 2 diabetes was 2.9%. The prevalence of the
different categories of DR are shown in table 2.
The characteristics of subjects with and without DR at initial
screening are compared in table 3, with the former group
divided into NSTDR and STDR. In subjects with type 1 dia-
betes, those with STDR were more likely to be male, younger at
the time of diagnosis, with a longer duration of diabetes and
therefore older at ﬁrst screening compared with those without
Table 1 A comparison of grading protocols for DR
ETDRS scale28 NSC29 DRSSW
10 No DR RO No DR RO No DR
20–35 Very mild—mild
non-proliferative DR
R1 Background DR R1.1 Minimal
background DR
R1.2 Moderate
background DR
43–53 Moderate—severe
non-proliferative
diabetic retinopathy
R2 Preproliferative
DR
R2 Preproliferative
DR
≥61 Proliferative DR R3 Proliferative DR R3 Proliferative DR
M0 No
maculopathy
M0 No maculopathy
M1 Maculopathy M1 Possible
maculopathy
M2 Definite
maculopathy
DR, diabetic retinopathy; DRSSW, Diabetic Retinopathy Screening Service for Wales;
ETDRS, Early Treatment of Diabetic Retinopathy Study; NSC, National Screening
Committee (UK).
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DR. Participants with type 2 diabetes and STDR were also more
likely to be male, younger at the screening event and with a
longer duration of diabetes, and in addition were more likely to
be receiving insulin therapy compared with those without DR.
The results of the logistic regression analysis are shown in
table 4. For subjects with type 1 diabetes the OR for each type
of DR was signiﬁcantly higher in those aged 12–23 years at
diagnosis and signiﬁcantly lower in those aged over 23 years
when compared with those aged below 12 years at diagnosis.
Men also had increased odds of all severities of DR compared
with women. The OR of all severity grades of DR increased
sharply with duration of diabetes. There was a 7.90-fold and
20.60-fold increased odds of any DR associated with a duration
of diabetes of 10–19 years and ≥20 years compared with
<10 years and a 28.22-fold and 85.84-fold increased odds of
STDR in the same subgroups, respectively. For type 2 diabetes
the ORs of any DR and NSTDR were signiﬁcantly higher (1.18
and 1.24, respectively) in those aged over 66 years at diagnosis
of diabetes than in subjects aged 55 years or less at diagnosis.
However the OR of STDR decreased (0.60 and 0.58) with
increasing age at diagnosis of diabetes. Men had increased odds
of all grades of DR compared with women. The odds of all
grades of DR increased with increasing duration of diabetes. For
any DR the odds increased by a factor of 1.60 with a known
duration of diabetes of 5–9 years and almost 3.71-fold for a
known duration of diabetes of 10 years or more compared with
less than 5 years and for STDR the odds increased from
1.83-fold to 6.76-fold in the same subgroups, respectively. The
use of insulin had ORs of 2.77 for any DR and 7.24 for STDR
compared with those using diet alone.
DISCUSSION
This study provides estimates of the baseline prevalence of DR
for subjects over the age of 12 years and not receiving care at
the HES for DR related reasons, when attending for the ﬁrst
time at DRSSW. In the population studied the prevalence of any
DR, NSTDR and STDR in subjects with type 1 diabetes were
56.3%, 45.0% and 11.2%, respectively, and in type 2 diabetes
were 30.9%, 27.7% and 2.9%, respectively. The presence of
NSTDR and STDR was strongly associated with increasing dur-
ation of diabetes with either type 1 or type 2 diabetes and was
also associated with insulin therapy in those with type 2
diabetes.
The strength of this study is the large population size that
underwent systematic screening using standardised quality
assured procedures and equipment for photography and
grading. Graders and photographers were accredited. The
Table 3 Characteristics for subjects with type 1 and type 2 diabetes presenting either without DR, with any DR, NSTDR or STDR
Type 1 diabetes Type 2 diabetes
NDR (Reference) Any DR NSTDR STDR NDR (Reference) Any DR NSTDR STDR
n 2,177 2,802 2,243 559 58 389 26 216 23 763 2,453
Age years 34.5 (19.2) 37.9 (13.5)* 37.5 (14.0)* 39.1 (11.5)* 64.6 (11.7) 66.3 (11.4)* 66.6 (11.5)* 64.0 (10.9)*
Gender * * *
Male 1182 (54.5) 1524 (54.7) 1170 (52.5) 354 (63.4)* 32 162(55.4) 15 425(59.1) 13 908(58.8) 1517 (62.0)
Female 985 (45.5) 1264 (45.3) 1060 (47.5) 204 (36.6) 25 886(44.6) 10 684(40.9) 9753 (41.2) 931 (38.0)
Duration of diabetes years 9.4 (10.5) 22.3 (12.2)* 21.9 (12.6)* 24.2 (10.5)* 4.3 (4.5) 7.6 (6.8)* 7.4 (6.6)* 10.4 (7.5)*
Treatment of diabetes * * * *
Diet only N/A N/A N/A N/A 20 379(35.3) 5078 (19.6) 4873 (20.8) 205 (8.5)
OHA N/A N/A N/A N/A 33 578(58.2) 16 446(63.6) 14 941(63.7) 1505 (62.0)
Insulin N/A N/A N/A N/A 3744 (6.5) 4339 (16.8) 3625 (15.5) 714 (29.5)
Age at diagnosis of diabetes years 25.2 (17.2) 15.5 (7.9)* 15.7 (7.9)* 14.9 (7.9)* 60.3 (11.7)* 58.7 (12.1)* 59.2 (12.0)* 53.5 (11.8)*
Numbers are mean (±SD) or n (%).
*p Values <0.0001.
Any DR, any diabetic retinopathy; diabetes, diabetes mellitus; N/A, not applicable; NDR, no evidence of diabetic retinopathy; NSTDR, non-sight-threatening diabetic retinopathy;
OHA, oral hypoglycaemic agent; STDR, sight-threatening diabetic retinopathy.
Table 2 Characteristics of study participants at the occasion of
first screening event.
Type 1 diabetes Type 2 diabetes
n 5,003 86 390
Age, years 36.5 (16.4) 65.3 (11.7)
Gender n (%)
Male 2721 (54.7) 48 490 (56.4)
Female 2257 (45.3) 37 446 (43.6)
Known duration of diabetes,
years
16.7 (13.2) 5.3 (5.6)
Treatment of diabetes
Diet only 0 26 025 (30.5)
OHA 0 51 071 (59.9)
Insulin 5003 (100) 8226 (9.5)
Age at diagnosis of diabetes,
years
19.7 (13.7) 60.0 (11.9)
Unassessable images
% (95% CI)
0.5 (0.3 to 0.7) 2.1 (2.0 to 2.2)
DR status: % (95% CI)
No DR 43.8 (42.4 to 45.1) 69.0 (68.7 to 69.3)
BDR 39.8 (38.4 to 41.2) 26.5 (26.3 to 26.9)
PPDR only 5.2 (4.6 to 5.9) 1.5 (1.4 to 1.6)
NSTDR 45.1 (43.7 to 46.4) 28.1 (27.8 to 28.4)
Maculopathy (with BDR) 4.2 (3.7 to 4.8) 1.4 (1.3 to 1.5)
PPDR with maculopathy 2.9 (2.5 to 3.4) 0.97 (0.91 to 1.04)
PDR only 2.6 (2.2 to 3.1) 0.31 (0.28 to 0.35)
PDR with maculopathy 1.5 (1.2 to 1.9) 0.23 (0.20 to 0.27)
STDR 11.2 (10.4 to 12.1) 2.9 (2.8 to 3.0)
Some subjects had missing values for gender and treatment. Numbers are mean
(±SD) or n (%) unless otherwise stated.
BDR, background diabetic retinopathy; diabetes, diabetes mellitus; No DR, no
evidence of diabetic retinopathy; NSTDR, non-sight-threatening diabetic retinopathy;
OHA, oral hypoglycaemic agent; PDR, proliferative diabetic retinopathy; PDR with
maculopathy, proliferative diabetic retinopathy with exudates within 1 disc diameter
of the fovea; PPDR, preproliferative diabetic retinopathy; PPDR with maculopathy,
preproliferative diabetic retinopathy with exudates less than 1 disc diameter from the
fovea; STDR, Sight-threatening diabetic retinopathy.
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exclusion of subjects who did not participate in screening is a
limitation. The exclusion of those persons with diabetes under
the care of HES because of DR is likely to lead to an underesti-
mation, however currently the extent of this difference is not
known. Although PPDR is the level at which referral to HES is
required by screening programmes in the UK, it was excluded
from the category of STDR in this study so that it was more
comparable with the category of STDR reported in previous
studies. Also the limited availability of putative risk factors
which included only duration and treatment of diabetes with
glycaemic control, blood pressure and lipid status not collected
by the DRSSW is a limitation and will be addressed in future
studies.
The comparison of the prevalence rates for DR between
studies is inherently difﬁcult due to the changing classiﬁcation
of diabetes over time and the different grading protocols
employed, as well as differences in population character-
istics.8 27 31–34 Web appendix 1 shows the prevalence rates
found in previous studies worldwide. In other UK screening
programmes the prevalence of any DR has been reported at
53.5% for type 1diabetes,33 and 19.2–25.3% for type 2 dia-
betes,3 32 33 which were lower than that seen in our study popu-
lation at 56.0% and 30.3%, respectively. Also in comparison, in
Iceland the prevalence of DR was slightly lower in type 1 dia-
betes and higher in type 2 diabetes at 51.7%34 and 41.0%,31
respectively. A recent meta-analysis found a much higher preva-
lence of DR in type 1 diabetes at 77.3%27 and a slightly lower
prevalence in type 2 diabetes at 25.2%.27 Retinal image capture
(number of images and the use or not of mydriasis) may con-
tribute to some of these differences as well as duration of dia-
betes. Our study clearly demonstrates that increased duration of
diabetes is associated with a higher prevalence of DR. The
prevalence of STDR previously reported in the UK has been
16.4% in type 1 diabetes and 1.9% and 6.0% in type 2 dia-
betes.3 32 33 In our study the prevalence of STDR was a little
lower in persons with type 1 diabetes at 11.2%. Differences in
the classiﬁcation of STDR such as the inclusion or exclusion of
PPDR and deﬁnitions of maculopathy may explain the differ-
ences.32 33 We had essentially similar prevalence of STDR at
2.9% in type 2 diabetes. The Scottish screening programme
reported the prevalence in 47 090 newly diagnosed type 2 dia-
betes and this short duration is likely to be the reason for the
low prevalence of DR reported at 19.3% for any DR and 1.9%
for RDR.3
Increasing duration of diabetes was the most signiﬁcant risk
factor for the presence of any DR, NSTDR and STDR in sub-
jects with type 1 and type 2 diabetes. The ORs were much
higher in type 1 diabetes compared with type 2 diabetes,
however the duration of diabetes was also longer with sub-
groups of <10 years, 10–19 years and ≥20 years compared
with <5 years, 5–9 years and ≥10 years, respectively. The risk
of all grades of DR increased with duration of diabetes being
particularly high in those with diabetes duration of 20 years or
more for type 1 diabetes and 10 years or more for type 2
diabetes.
In our study we observed an increased risk of all severities
of DR associated with the use of insulin after adjusting for
all other confounders. For type 2 diabetes this may reﬂect a
more advanced disease state and we interpret this as likely to
be an epiphenomenon and not a direct result of insulin
therapy. Glycaemia and duration of diabetes have previously
been shown to be highly associated with the presence of DR
along with elevated blood pressure and cholesterol
levels.4 8 33 35–38
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To date this study represents the largest reported community-
based national DR screening programme for detecting the pres-
ence of DR, especially STDR. The ﬁndings will provide our
policy makers with important information for planning eye care
services, with the proviso that the prevalence of STDR may be
underestimated because of those already within HES. The
strong association with disease duration demonstrates the
importance of early detection and referral to a screening pro-
gramme. The detection of STDR at an early stage is essential to
ensure timely onward referral for further assessment and pos-
sible treatment to improved outcome. Detection of NSTDR pro-
vides the physician with an opportunity to improve, where
necessary, glycaemic and blood pressure control to prevent the
progression of DR. A structured screening programme is
expected to reduce blindness by 40% within 4 years.29
Addressing issues of non-attendance currently at approximately
20% will contribute greatly to the success of such programmes
to ensure optimal cost beneﬁt of any DR screening service, espe-
cially poignant in times of austerity.
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June 2010 
American Diabetes Association (ADA) 70th Scientific Sessions (Poster) 
Determining a safe screening interval for subjects without diabetic retinopathy 
Thomas R.L, Roy Chowdhury S., Luzio S.D., Hale S.L., North R.V., Owens D.R.  
 
Diabetic Retinopathy status at First Screening Visit in a National Screening 
Program, Wales UK  
Roy Chowdhury S., Thomas R.L., Luzio S.D., Hale S.L., North R.V., Owens D.R. 
 
September 2010 
European Association of the Study of Diabetes (EASD) 46th Annual Meeting 
(Poster) 
Prevalence of Diabetic Retinopathy at first screening event in a National screening 
programme in Wales UK: 2005-2009 
Roy Chowdhury S., Thomas R.L., Luzio S.D., Hale S.L., North R.V., Owens D.R. 
 
November 2010 
South Western Ophthalmological Society (Poster) 
Determining a safe screening interval for subjects without diabetic retinopathy 
Thomas R.L., Roy Chowdhury S., Luzio S.D., Hale S.L., North R.V., Owens D.R. 
Awarded Best poster prize 
 
Diabetic Retinopathy status at First Screening Visit in a National Screening 
Program, Wales UK 
Roy Chowdhury S., Thomas R.L., Luzio S.D., Hale S.L., North R.V., Owens D.R. 
 
June 2011 
American Diabetes Association 71st Scientific Sessions (Publication only) 
Prevalence of Diabetic Retinopathy in a Diabetes and Endocrinology Centre (CDE) 
in South Africa (SA) 
Roy Chowdhury S., Thomas R.L., Distiller L.A, Brown V., Kramer B.D., Luzio S.D., 
Owens D.R. 
 
Development of Diabetic Retinopathy in subjects attending a Diabetes and 
Endocrinology clinic in Johannesburg- South Africa 
Thomas R.L., Roy Chowdury S., Distiller L.A., Brown V., Kramer B.D., Luzio S.D., 
Owens D.R. 
 
March 2011 
Diabetes UK annual professional conference (Oral) 
Prevalence of Diabetic Retinopathy and Distribution of Visual Acuities across 
Wales: 2005-2009 
Thomas R.L., Roy Chowdhury S., Luzio S.D., Hale S.L., North R.V., Owens D.R., 
 
September 2014 
Annual Wales Public Health Conference (Poster) 
Incidence of Diabetic Retinopathy within the Diabetic Retinopathy Screening 
Service for Wales (DRSSW) - Determining safe screening intervals 
Thomas R.L, Dunstan F.D., Luzio S.D., Owens D.R., 
 
 
 
 
 
